Carbofuran; Order Denying FMC's Objections and Requests for Hearing, 59608-59686 [E9-27261]
Download as PDF
59608
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
I. General Information
ENVIRONMENTAL PROTECTION
AGENCY
40 CFR Part 180
[EPA–HQ–OPP–2005–0162; FRL–8797–6]
Carbofuran; Order Denying FMC’s
Objections and Requests for Hearing
pwalker on DSK8KYBLC1PROD with RULES2
AGENCY: Environmental Protection
Agency (EPA).
ACTION: Order.
SUMMARY: In this order, EPA denies
objections to, and requests for hearing
on, a final rule revoking all pesticide
tolerances for carbofuran under section
408(d) of the Federal Food, Drug, and
Cosmetic Act (FFDCA). The objections
and hearing requests were filed on June
30, 2009, by the National Corn Growers
Association, National Sunflower
Association, National Potato Council,
and FMC Corporation (‘‘Petitioners’’).
DATES: This final order is effective
November 18, 2009.
ADDRESSES: EPA has established a
docket for this action under docket
identification (ID) number EPA–HQ–
OPP–2005–0162. To access the
electronic docket, go to https://
www.regulations.gov, and search for the
docket number. Follow the instructions
on the regulations.gov Web site to view
the docket index or access available
documents. All documents in the docket
are listed in the docket index available
in regulations.gov. Although listed in
the index, some information is not
publicly available, e.g., Confidential
Business Information (CBI) or other
information whose disclosure is
restricted by statute. Certain other
material, such as copyrighted material,
is not placed on the Internet and will be
publicly available only in hard copy
form. Publicly available docket
materials are available in the electronic
docket at https://www.regulations.gov,
or, if only available in hard copy, at the
OPP Regulatory Public Docket in Rm. S–
4400, One Potomac Yard (South Bldg.),
2777 S. Crystal Dr., Arlington, VA. The
Docket Facility is open from 8:30 a.m.
to 4 p.m., Monday through Friday,
excluding legal holidays. The Docket
Facility telephone number is (703) 305–
5805.
FOR FURTHER INFORMATION CONTACT: Jude
Andreasen, Pesticide Re-evaluation
Division (7508P), Office of Pesticide
Programs, Environmental Protection
Agency, 1200 Pennsylvania Ave., NW.,
Washington, DC 20460–0001; telephone
number: (703) 308–9342; e-mail address:
andreasen.jude@epa.gov.
SUPPLEMENTARY INFORMATION:
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
A. Does this Action Apply to Me?
In this document EPA denies
objections and hearing requests by the
National Corn Growers Association,
National Sunflower Association,
National Potato Council, and FMC
Corporation (‘‘Petitioners’’) concerning
EPA’s final rule revoking all pesticide
tolerances for carbofuran. This action
may also be of interest to agricultural
producers, food manufacturers, or
pesticide manufacturers. Potentially
affected entities may include, but are
not limited to:
• Crop production (NAICS code 111).
• Animal production (NAICS code
112).
• Food manufacturing (NAICS code
311).
• Pesticide manufacturing (NAICS
code 32532).
This listing is not intended to be
exhaustive, but rather provides a guide
for readers regarding entities likely to be
affected by this action. Other types of
entities not listed in this unit could also
be affected. The North American
Industrial Classification System
(NAICS) codes have been provided to
assist you and others in determining
whether this action might apply to
certain entities. If you have any
questions regarding the applicability of
this action to a particular entity, consult
the person listed under FOR FURTHER
INFORMATION CONTACT.
B. How Can I Access Electronic Copies
of this Document?
In addition to accessing an electronic
copy of this Federal Register document
through the electronic docket at https://
www.regulations.gov, you may access
this Federal Register document
electronically through the EPA Internet
under the Federal Register listings at
https://www.epa.gov/fedrgstr. You may
also access a frequently updated
electronic version of EPA’s tolerance
regulations at 40 CFR part 180 through
the Government Printing Office’s pilot
e-CFR site at https://www.gpoaccess.gov/
ecfr.
C. Acronyms
The following is a list of acronyms
used in this order:
AChE—Acetylcholinesterase
aPAD—Acute Population Adjusted Dose
BMD—Bench Mark Dose
BMDL—Bench Mark Dose Level
CCA—Comparative Cholinesterase
Assay
CNS—Central Nervous System
CRA—Cumulative Risk Assessment
CSFII—Continuing Survey of Food
Intakes by Individuals
PO 00000
Frm 00002
Fmt 4701
Sfmt 4700
CWA—Clean Water Act
CWS—Community Water System
DEEM–FCID—Dietary Exposure
Evaluation Model-Food Commodity
Intake Database
ECG—Electrocardiogram
EDWC—Estimated Drinking Water
Concentration
EPA—Environmental Protection Agency
FACA—Federal Advisory Committee
Act
FDA—Food and Drug Administration
FIFRA—Federal Insecticide, Fungicide,
and Rodenticide Act
FFDCA—Federal Food, Drug, and
Cosmetic Act
FQPA—Food Quality Protection Act of
1996
HSRB—Human Studies Review Board
HUC–8—8-digit hydrologic unit code
IRED—Interim Reregistration Eligibility
Decision
LD50—Lethal Dose for 50% of a
population
LOAEL—Lowest Observable Adverse
Effect Level
NAWQA—National Water Quality
Assessment Program
NHEERL—National Health and
Environmental Effects Laboratory
NMC CRA—N-Methyl Carbamate
Cumulative Risk Assessment
NOAEL—No Observable Adverse Effect
Level
NOIC—Notice of Intent to Cancel
NRDC—National Resources Defense
Council
OP—Organophosphate
ORD—Office of Research and
Development
PAD—Population Adjusted Dose
PCA—Percent Cropped Area
PCT—Percent Crop Treated
PDP—Pesticide Data Program
PND—Post-Natal Day
PNS—Peripheral Nervous System
PoD—Point of Departure
ppb—parts per billion
ppm—parts per million
PRZM–EXAMS—Pesticide Root Zone
Model-Exposure Analysis Model
System
RBC—red blood cell
RED—Reregistration Eligibility Decision
RfD—Reference Dose
SAP—Scientific Advisory Panel
SDWA—Safe Drinking Water Act
USDA—United States Department of
Agriculture
USGS—United States Geological Survey
WARP—Watershed Regression for
Pesticides
II. Introduction
A. What Action Is the Agency Taking?
Exposure to the pesticide carbofuran
resulting from existing legal uses is
unsafe—unsafe for the general
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
population, and particularly unsafe for
infants and children. EPA reached this
conclusion in 2006 after an exhaustive
multi-year review of the data on
carbofuran as part of its effort to
determine whether carbofuran should
be reregistered under the Federal
Insecticide, Fungicide, and Rodenticide
Act (‘‘FIFRA’’), and whether the
tolerances allowing carbofuran residues
on certain foods met the revised safety
standard in section 408 of the FFDCA.
This multi-year review included
multiple opportunities for public
participation, including no less than
four formal public comment periods.
Following EPA review of yet more
carbofuran data submitted by FMC, the
carbofuran registrant, and the review of
EPA’s science findings by the FIFRA
Scientific Advisory Panel (SAP)—an
independent scientific peer review
panel—EPA again reached the same
conclusion in its July 31, 2008 proposal
to revoke the carbofuran tolerances (73
FR 44864 (July 31, 2008)). In response
to this proposed revocation, FMC
submitted comments challenging many
of EPA’s science findings and also
requesting the cancellation of the
registration of carbofuran on several
crops and the restriction of where, and
the manner in which, carbofuran could
be used in the United States on its
remaining registered crop sites. Finding
FMC’s science arguments to be flawed
and its proposed amendments to the
carbofuran registration to be
insufficient, EPA finalized the rule
revoking carbofuran tolerances on May
15, 2009 (74 FR 23046 (May 15, 2009)).
Pursuant to the procedures of the
FFDCA, on June 29, 2009 objections to
the final revocation rule were filed by
the National Corn Growers Association,
National Sunflower Association,
National Potato Council, and FMC
Corporation (‘‘Petitioners’’). The
Petitioners also requested a hearing on
their objections. Coupled with these
objections, FMC filed on the same day
yet another series of proposed
amendments to its carbofuran
registration. These proposed
modifications contained new
application and geographic restrictions
as well as an unprecedented nongovernmental scheme for preventing the
use of carbofuran in any one area of the
country above a small percentage of that
area’s agricultural acreage. The
Petitioners relied on these proposed
carbofuran registration amendments as
central to, and inextricably intertwined
with, their objection to EPA’s prior
determination in the final rule that
carbofuran tolerances are unsafe.
Specific challenges raised by the
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
Petitioners involved EPA’s decision on
the appropriate level of the additional
safety factor to protect infants and
children, EPA’s estimate of carbofuran
levels in drinking water, EPA’s
consideration of the time needed to
recover from exposure to carbofuran,
and EPA’s refusal to consider a human
toxicity study conducted with
carbofuran.
Today’s order denies all of the
Petitioners’ objections and requests for
hearing. A principal flaw in the
Petitioners’ objections is that they have
objected to EPA’s determination in the
final rule on the safety of carbofuran
based on the FIFRA registration
amendments that FMC filed with EPA
45 days after the safety determination
was made. As such, the Petitioners’
objections are irrelevant, and thus
immaterial, to the determination EPA
made in the final rule. FMC has the
statutory right under FIFRA to request
amendment of its carbofuran
registration. What Petitioners may not
do is prolong the FFDCA tolerance
revocation process by challenging EPA’s
safety determination based on proposed
FIFRA registration changes not before
EPA at the time of its final revocation
decision.
It should be noted that EPA’s decision
on the carbofuran tolerances is not a
determination on FMC’s proposed
registration amendments. FMC may
continue to pursue these amendments
and also the re-establishment of
carbofuran tolerances in light of the
amendments. Further, FMC may seek
administrative review, and potentially
an administrative hearing, with regard
to any adverse decision issued by EPA
on its proposed amendments. But that
process must be played out in the
future, a future in which any decision
about the safety of carbofuran is made
prior to the re-introduction of
carbofuran residues in food and water,
rather than concurrent with the
continued exposure of infants and
children to levels of carbofuran residues
that EPA has found to be unsafe.
Despite the fact that a central aspect
of the Petitioners’ objections is based on
a flawed conception of the objection
process (i.e., the notion that the
objection process presents the
opportunity for a complete
reformulation of the matter in dispute,
rather than a chance for a review of the
accuracy of EPA’s earlier
determination), EPA has undertaken a
comprehensive analysis of the merits of
each of the Petitioners’ objections and
hearing requests. That analysis shows,
as is exhaustively set out in Unit VI, that
none of the Petitioners’ requests for
hearing meets the regulatory standard
PO 00000
Frm 00003
Fmt 4701
Sfmt 4700
59609
for granting a hearing and none of the
Petitioners’ objections has merit. There
are numerous reasons for these
conclusions, but two related themes
running throughout EPA’s analysis are
the Petitioners’ failure to timely raise
issues or submit supporting documents
during the public comment process on
the proposed rule and the Petitioners’
failure to object to how EPA, in the final
rule, resolved the issues the Petitioners
did raise in the comment process. EPA
considers issues untimely raised to be
waived—as EPA clearly warned at the
proposal stage—and finds recycled
comments on the proposed rule to be
irrelevant to the detailed determinations
made in the final rule. The rulemaking
phase of the revocation process has a
purpose, and parties treat it lightly at
their peril. Finally, EPA notes that an
additional problem with the Petitioners’
objections is that once the newly
proposed registration amendments are
stripped from the objections, it is not at
all clear that any remaining issues, even
if concluded in the Petitioners’ favor,
would result in lowering carbofuran’s
estimated risks—which EPA has
estimated as far exceeding the safety
standard—to an acceptable level. For all
of these reasons, the Petitioners’
objections and hearing requests are
denied.
B. What Is the Agency’s Authority for
Taking This Action?
EPA is taking this action pursuant to
the authority in FFDCA section
408(g)(2)(C), which requires the Agency
to issue a final order resolving the
objections to its final rule, issued
pursuant to 408(b)(1)(b), 408(b)(2)(A),
and 408(e)(1)(A). 21 U.S.C.
346a(b)(1)(b), (b)(2)(A), (e)(1)(A),
(g)(2)(C).)
III. Statutory and Regulatory
Background
In this Unit, EPA provides
background on the relevant statutes and
regulations governing the Petitioners’
objections and requests for hearing as
well as on pertinent Agency policies
and practices.
A. FFDCA/FIFRA and Applicable
Regulations
1. In general. EPA establishes
maximum residue limits, or
‘‘tolerances,’’ for pesticide residues in
food under section 408 of the FFDCA
(21 U.S.C. 346a). Without such a
tolerance or an exemption from the
requirement of a tolerance, a food
containing a pesticide residue is
‘‘adulterated’’ under section 402 of the
FFDCA and may not be legally moved
in interstate commerce (21 U.S.C. 331,
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59610
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
342). Monitoring and enforcement of
pesticide tolerances are carried out by
the U.S. Food and Drug Administration
(‘‘FDA’’) and the U.S. Department of
Agriculture (‘‘USDA’’). Section 408 was
substantially rewritten by the Food
Quality Protection Act of 1996
(‘‘FQPA’’), which added the provisions
discussed below establishing a detailed
safety standard for pesticides, additional
protections for infants and children, and
the process for establishing or revoking
tolerances (Pub. L. 104–170, 110 Stat.
1489 (1996)).
EPA also regulates pesticides under
the Federal Insecticide, Fungicide, and
Rodenticide Act (‘‘FIFRA’’) (7 U.S.C.
136 et seq.). While the FFDCA
authorizes the establishment of legal
limits for pesticide residues in food,
FIFRA requires the approval of
pesticides prior to their sale and
distribution (7 U.S.C. 136a(a)), and
establishes a registration regime for
regulating the use of pesticides. FIFRA
regulates pesticide use in conjunction
with its registration scheme by requiring
EPA review and approval of pesticide
labels and specifying that use of a
pesticide inconsistent with its label is a
violation of federal law (7 U.S.C.
136j(a)(2)(G)). In the FQPA, Congress
integrated action under the two statutes
by requiring that the safety standard
under the FFDCA be used as a criterion
in FIFRA registration actions as to
pesticide uses that result in dietary risk
from residues in or on food (7 U.S.C.
136(bb)), and directing that EPA
coordinate, to the extent practicable,
revocations of tolerances with pesticide
cancellations under FIFRA. (21 U.S.C.
346a(l)(1)).
2. Safety standard for pesticide
tolerances. Section 408(b)(2)(A)(i) of the
FFDCA requires EPA to modify or
revoke a tolerance if EPA determines
that the tolerance is not ‘‘safe’’ (21
U.S.C. 346a(b)(2)(A)(ii)). Section
408(b)(2)(A)(ii) of the FFDCA defines
‘‘safe’’ to mean that ‘‘there is a
reasonable certainty that no harm will
result from aggregate exposure to the
pesticide chemical residue, including
all anticipated dietary exposures and all
other exposures for which there is
reliable information.’’ This includes
exposure through drinking water and in
residential settings, but does not include
occupational exposure. Section
408(b)(2)(D) directs EPA, in making a
safety determination, to:
Consider, among other relevant
factors—* * *
(vi) Available information concerning
the aggregate exposure levels of
consumers (and major identifiable
subgroups of consumers) to the
pesticide chemical residue and to other
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
related substances, including dietary
exposure under the tolerance and all
other tolerances in effect for the
pesticide chemical residue, and
exposure from other non-occupational
sources;
EPA must also consider, in evaluating
the safety of tolerances, ‘‘safety factors
which * * * are generally recognized as
appropriate for the use of animal
experimentation data.’’ (21 U.S.C.
346a(b)(2)(D)(ix).)
Risks to infants and children are given
special consideration. Specifically,
section 408(b)(2)(C) states that EPA:
Shall assess the risk of the pesticide
chemical based on—* * *
(II) Available information concerning the
special susceptibility of infants and children
to the pesticide chemical residues, including
neurological differences between infants and
children and adults, and effects of in utero
exposure to pesticide chemicals;
(21 U.S.C. 346a(b)(2)(C)(i)(II) and
(III)). This provision also creates a
presumptive additional safety factor for
the protection of infants and children.
Specifically, it directs that ‘‘[i]n the case
of threshold effects, * * * an additional
tenfold margin of safety for the pesticide
chemical residue and other sources of
exposure shall be applied for infants
and children to take into account
potential pre- and post-natal toxicity
and completeness of the data with
respect to exposure and toxicity to
infants and children’’ (21 U.S.C.
346a(b)(2)(C)). EPA is permitted to ‘‘use
a different margin of safety for the
pesticide chemical residue only if, on
the basis of reliable data, such margin
will be safe for infants and children’’
(Id.). The additional safety margin for
infants and children is referred to
throughout this order as the ‘‘children’s
safety factor.’’
3. Procedures for establishing,
amending, or revoking tolerances.
Tolerances are revoked by rulemaking
under the unique procedural framework
set forth in the FFDCA. Section 408(e)
of the FFDCA, 21 U.S.C. 346a(e),
authorizes EPA to modify or revoke
tolerances on its own initiative.
In issuing a regulation on its own
initiative, EPA must first publish a
notice of proposed rulemaking, and
must generally provide at least 60 days
to allow the public to comment on the
proposed regulation. After considering
comments submitted during this
comment period, EPA issues a final
rule.
Once EPA issues a final rule, any
person may file objections with EPA
and, if desired, request an evidentiary
hearing on those objections (21 U.S.C.
346a(g)(2)). Objections must specify
PO 00000
Frm 00004
Fmt 4701
Sfmt 4700
‘‘with particularity the provisions of the
regulation * * * deemed objectionable
and stating reasonable grounds
therefore’’ (21 U.S.C. 346a(g)(2)(A); 40
CFR 178.25(a)). Objections and hearing
requests must be filed within 60 days
(Id.). The statute provides that EPA shall
‘‘hold a public evidentiary hearing if
and to the extent the Administrator
determines that such a public hearing is
necessary to receive factual evidence
relevant to material issues of fact raised
by the objections’’ (21 U.S.C.
346a(g)(2)(B)). EPA regulations make
clear that hearings will only be granted
where it is shown that there is ‘‘a
genuine and substantial issue of fact;’’
the requestor has identified evidence
‘‘which, if established, will resolve one
or more of such issues in favor of the
requestor,’’ and the issue is
‘‘determinative’’ with regard to the relief
requested (40 CFR 178.32(b)). After
consideration of any objections, EPA
must issue a final order stating the
action taken in response to each
objection, including a determination as
to whether any hearing is appropriate
(21 U.S.C. 346a(g)(2)(C)). The final order
also establishes any revisions to the
final regulation EPA deems to be
warranted based on the objections. Id.
EPA’s final order on the objections is
subject to judicial review in the Court of
Appeals, within 60 days of the
publication of the order (21 U.S.C.
346a(h)(1)).
4. Tolerance reassessment and FIFRA
reregistration. EPA revoked the
carbfuran tolerances to implement the
Agency’s findings made during the
reregistration and tolerance
reassessment processes.
The FQPA required that EPA reassess
the safety of all pesticide tolerances
existing at the time of its enactment. (21
U.S.C. 346a(q)). EPA was given 10 years
to reassess the approximately 10,000
tolerances in existence in 1996. In this
reassessment, EPA was required to
review existing pesticide tolerances
under the new ‘‘reasonable certainty
that no harm will result’’ standard set
forth in section 408(b)(2)(A)(i). (21
U.S.C. 346a(b)(2)(A)(i)). This
reassessment was substantially
completed by the August 3, 2006
deadline. Tolerance reassessment was
generally handled in conjunction with a
similar program involving reregistration
of pesticides under FIFRA. (7 U.S.C.
136a–1). Reassessment and
reregistration decisions were generally
combined in a document labeled a
Reregistration Eligibility Decision
(RED).
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
B. EPA’s Human Research Rule
EPA decisions regarding the use of
human studies in pesticide regulatory
decisions are governed by the Protection
for Subjects in Human Research final
rule (‘‘Human Research rule’’), which
significantly strengthened and
expanded protections for subjects of
human research (71 FR 6138 (February
6, 2006)). The framework of the Human
Research rule rests on the basic
principle that EPA will not, in its
actions, rely on data derived from
unethical research. The rule divides
studies involving intentional dosing of
human subjects into two groups: ‘‘new’’
studies—those initiated after April 7,
2006 (the effective date of the rule)—
and ‘‘old’’ studies—those initiated
before April 7, 2006. The Human
Research Rule forbids EPA from relying
on data from any ‘‘new’’ study, unless
EPA has adequate information to
determine that the research was
conducted in substantial compliance
with the ethical requirements contained
therein (40 CFR 26.1705). These ethical
rules are derived primarily from the
‘‘Common Rule,’’ (40 CFR part 26), a
rule setting ethical parameters for
studies conducted or supported by the
federal government. In addition to
requiring informed consent and
protection of the safety of the subjects,
among other things, the rule specifies
that ‘‘[r]isks to subjects [must be]
reasonable in relation to * * * the
importance of the knowledge that may
reasonably be expected to result [from
the study].’’ (40 CFR 26.1111(a)(2)). In
other words, a study would be judged
unethical if it did not have scientific
value outweighing any risks to the test
subjects.
As to ‘‘old’’ studies, the Human
Research Rule forbids EPA from relying
on such data if there is clear and
convincing evidence that the conduct of
the research was fundamentally
unethical or significantly deficient with
respect to the ethical standards
prevailing at the time the research was
conducted (40 CFR 26.1704). EPA has
indicated that in evaluating ‘‘the ethical
standards prevailing at the time the
research was conducted’’ it will
consider the Nuremburg Code, various
editions of the Declaration of Helsinki,
the Belmont Report, and the Common
Rule, as among the standards that may
be applicable to any particular study (71
FR at 6161). Further, reflecting the
concern that scientifically invalid data
are ‘‘always unethical,’’ (71 FR at 6160),
the rule limits the human research that
can be relied upon by EPA to
‘‘scientifically valid and relevant data’’
(40 CFR 26.1701).
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
Whether the data are ‘‘new’’ or ‘‘old,’’
the Human Research rule forbids EPA
from relying on data from any study
involving intentional exposure of
pregnant women, fetuses, or children
subject to a very limited exception (40
CFR 26.1703, 1706).
To aid EPA in making scientific and
ethical determinations under the
Human Research rule, the rule
established an independent Human
Studies Review Board (HSRB) to review
both proposals for new research (new
studies) and reports of completed
human research (old studies) on which
EPA proposes to rely (40 CFR 26.1603).
The rule directs that the HSRB shall be
comprised of non-EPA employees ‘‘who
have expertise in fields appropriate for
the scientific and ethical review of
human research, including research
ethics, biostatistics, and human
toxicology’’ (40 CFR 26.1603(a)). If EPA
decides to rely on the results from ‘‘old’’
research conducted to identify or
measure a toxic effect, EPA must submit
the results of its assessment to the HSRB
for evaluation of the ethical and
scientific merit of the research (40 CFR
26.1602(b)(2)).
EPA has established the HSRB as a
federal advisory committee under the
Federal Advisory Committee Act
(FACA) to take advantage of ‘‘the
benefits of the transparency and
opportunities for public participation’’
that accompany a FACA committee (71
FR at 6156). The HSRB, as appointed by
EPA, contains approximately 16
distinguished experts in the fields of
bioethics, biostatistics, human health
risk assessment and human toxicology,
primarily from academia (Ref. 10).
IV. EPA’s Approach to Dietary Risk
Assessment
EPA performs a number of analyses to
determine the risks from aggregate
exposure to pesticide residues. A short
summary is provided below to aid the
reader. For further discussion of the
regulatory requirements of section 408
of the FFDCA and a complete
description of the risk assessment
process, see https://www.epa.gov/
fedrgstr/EPA-PEST/1999/January/Day04/p34736.htm.
To assess the risk of a pesticide
tolerance, EPA combines information on
pesticide toxicity with information
regarding the route, magnitude, and
duration of exposure to the pesticide.
The risk assessment process involves
four distinct steps: (1) Identification of
the toxicological hazards posed by a
pesticide; (2) determination of the
exposure ‘‘level of concern’’ for humans;
(3) estimation of human exposure; and
(4) characterization of human risk based
PO 00000
Frm 00005
Fmt 4701
Sfmt 4700
59611
on comparison of human exposure to
the level of concern.
A. Hazard Identification and Selection
of Toxicological Endpoint
1. In General. Any risk assessment
begins with an evaluation of a
chemical’s inherent properties, and
whether those properties have the
potential to cause adverse effects (i.e.,
hazard identification). EPA then
evaluates the hazards to determine the
most sensitive and appropriate adverse
effect of concern, based on factors such
as the effect’s relevance to humans and
the likely routes of exposure.
Once a pesticide’s potential hazards
are identified, EPA determines a
toxicological level of concern for
evaluating the risk posed by human
exposure to the pesticide. In this step of
the risk assessment process, EPA
essentially evaluates the levels of
exposure to the pesticide at which
effects might occur. An important aspect
of this determination is assessing the
relationship between exposure (dose)
and response (often referred to as the
dose-response analysis). In evaluating a
chemical’s dietary risks EPA uses a
reference dose (RfD) approach, which
involves a number of considerations
including:
• A ‘point of departure’ (PoD)—the
value from a dose-response curve that is
at the low end of the observable data
and that is the dose that serves as the
‘starting point’ in extrapolating a risk to
the human population;
• An uncertainty factor to address the
potential for a difference in toxic
response between humans and animals
used in toxicity tests (i.e., interspecies
extrapolation);
• An uncertainty factor to address the
potential for differences in sensitivity in
the toxic response across the human
population (i.e., intraspecies
variability); and
• The need for an additional safety
factor to protect infants and children, as
specified in FFDCA section 408(b)(2)(C).
EPA uses the chosen PoD to calculate
a safe dose or RfD. The RfD is calculated
by dividing the chosen PoD by all
applicable safety or uncertainty factors.
Typically in EPA risk assessments, a
combination of safety or uncertainty
factors providing at least a hundredfold
(100X) margin of safety is used: 10X to
account for interspecies extrapolation
and 10X to account for intraspecies
variability. Further, as required by
FFDCA section 408(b)(2)(C), in
evaluating the dietary risks for pesticide
chemicals, an additional safety factor of
10X is presumptively applied to protect
infants and children, unless reliable
data support selection of a different
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59612
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
factor. In implementing FFDCA section
408, EPA also calculates a variant of the
RfD referred to as a Population Adjusted
Dose (PAD). A PAD is the RfD divided
by any portion of the children’s safety
factor that does not correspond to one
of the traditional additional uncertainty/
safety factors used in general Agency
risk assessment. The reason for
calculating PADs is so that other parts
of the Agency, which are not governed
by FFDCA section 408, can, when
evaluating the same or similar
substances, easily identify which
aspects of a pesticide risk assessment
are a function of the particular statutory
commands in FFDCA section 408. For
acute assessments, the risk is expressed
as a percentage of a maximum
acceptable dose or the acute PAD (i.e.,
the acute dose which EPA has
concluded will be ‘‘safe’’). As discussed
below in Unit V.C., dietary exposures
greater than 100 percent of the acute
PAD are generally cause for concern and
would be considered ‘‘unsafe’’ within
the meaning of FFDCA section
408(b)(2)(B). Throughout this document
general references to EPA’s calculated
safe dose are denoted as an acute PAD,
or aPAD, because the relevant point of
departure for carbofuran is based on an
acute risk endpoint.
2. Acetylcholinesterase Inhibition.
Carbofuran is a member of the class of
pesticides called N-methyl carbamates
(NMCs). The primary toxic effect caused
by NMCs, including carbofuran, is
neurotoxicity resulting from inhibition
of the enzyme acetylcholinesterase
(AChE). The toxicity profile of these
pesticides is characterized by rapid time
to onset of effects followed by rapid
recovery (minutes to hours). Consistent
with its mechanism of action, toxicity
data on AChE inhibition from laboratory
rats provide the basis for deriving the
PoD for carbofuran.
AChE inhibition is a disruption of the
normal process in the body by which
the nervous system chemically
communicates with muscles and glands.
Communication between nerve cells
and a target cell (i.e., another nerve cell,
a muscle fiber, or a gland) is facilitated
by the chemical, acetylcholine. When a
nerve cell is stimulated it releases
acetylcholine into the synapse (or space)
between the nerve cell and the target
cell. The released acetylcholine binds to
receptors in the target cell, stimulating
the target cell in turn. As EPA has
explained, ‘‘the end result of the
stimulation of cholinergic pathway(s)
includes, for example, the contraction of
smooth (e.g., in the gastrointestinal
tract) or skeletal muscle, changes in
heart rate or glandular secretion (e.g.,
sweat glands) or communication
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
between nerve cells in the brain or in
the autonomic ganglia of the peripheral
nervous system.’’ (Ref. 78 at 10).
AChE is an enzyme that breaks down
acetylcholine and terminates its
stimulating action in the synapse
between nerve cells and target cells.
When AChE is inhibited, acetylcholine
builds up prolonging the stimulation of
the target cell. This excessive
stimulation potentially results in a
broad range of adverse effects on many
bodily functions including muscle
cramping or paralysis, excessive
glandular secretions, or effects on
learning, memory, or other behavioral
parameters. Depending on the degree of
inhibition these effects can be serious,
even fatal.
EPA’s cholinesterase inhibition policy
statement explains EPA’s approach to
evaluating the risks posed by AChEinhibiting pesticides such as carbofuran
(Ref. 78 at 10). The policy focuses on
three types of effects associated with
AChE-inhibiting pesticides that may be
assessed in animal and human
toxicological studies: (1) Physiological
and behavioral/functional effects; (2)
AChE inhibition in the central and
peripheral nervous system; and (3)
AChE inhibition in red blood cells and
blood plasma. The policy discusses how
such data should be integrated in
deriving an acceptable dose (RfD/PAD)
for a AChE-inhibiting pesticide.
After clinical signs or symptoms,
AChE inhibition in the nervous system
provides the next most important
endpoint for evaluating AChE-inhibiting
pesticides. Although AChE inhibition in
the nervous system is not itself regarded
as a direct adverse effect, it is ‘‘generally
accepted as a key component of the
mechanism of toxicity leading to
adverse cholinergic effects’’ (Id. at 25).
As such, the policy states that it should
be treated as ‘‘direct evidence of
potential adverse effects’’ and ‘‘data
showing this response provide valuable
information in assessing potential
hazards posed by antiAChE pesticides’’
(Id.). Unfortunately, useful data
measuring AChE inhibition in the
peripheral nervous system tissues has
only been relatively rarely captured by
standard toxicology testing, particularly
for the NMC compounds. For central
nervous system effects, however, more
recent neurotoxicity studies ‘‘have
sought to characterize the time course of
inhibition in * * * [the] brain,
including brain regions, after acute and
90-day exposures’’ (Id. at 27).
AChE inhibition in the blood is one
step further removed from the direct
harmful consequences of AChEinhibiting pesticides. According to the
policy, inhibition of blood AChEs ‘‘is
PO 00000
Frm 00006
Fmt 4701
Sfmt 4700
not an adverse effect, but may indicate
a potential for adverse effects on the
nervous system’’ (Id. at 28). The policy
states that ‘‘[a]s a matter of science
policy, blood AChE data are considered
appropriate surrogate measures of
potential effects on peripheral nervous
system AChE activity in animals, for
central nervous system (‘‘CNS’’) AChE
activity in animals when CNS data are
lacking and for both peripheral and
central nervous system AChE in
humans’’ (Id. at 29). The policy notes
that ‘‘there is often a direct relationship
between a greater magnitude of
exposure [to a AChE-inhibiting
pesticide] and an increase in incidence
and severity of clinical signs and
symptoms as well as blood AChE
inhibition’’ (Id. at 30). Thus, the policy
regards blood AChE data as
‘‘appropriate endpoints for derivation of
reference doses or concentrations when
considered in a weight-of-the-evidence
analysis of the entire database * * *’’
(Id. at 29). Between AChE inhibition
measured in red blood cell (‘‘RBC’’) or
blood plasma, the policy states a
preference for reliance on RBC AChE
measurements because plasma is
composed of a mixture of
acetylcholinesterase and
butyrylcholinesterase, and inhibition of
the latter is less clearly tied to inhibition
of acetylcholinesterase in the nervous
system (Id. at 29, 32).
EPA has relied on a benchmark dose
(BMD) approach for deriving the PoD
from the available rat toxicity studies. A
BMD is a point estimate along a doseresponse curve that corresponds to a
specific response level. For example, a
BMD10 represents a 10% change from
the background; 10% is often used as a
typical value for the response of concern
(Ref. 76). Generically, the direction of
change from background can be an
increase or a decrease depending on the
biological parameter and the chemical
of interest. In the case of carbofuran,
inhibition of AChE is the toxic effect of
concern. Following exposure to
carbofuran, the normal biological
activity of the AChE enzyme is
decreased (i.e., the enzyme is inhibited).
Thus, when evaluating BMDs for
carbofuran, the Agency is interested in
a decrease in AChE activity compared to
normal activity levels, which are also
termed ‘‘background’’ levels.
Measurements of ‘‘background’’ AChE
activity levels are usually obtained from
animals in experimental studies that are
not treated with the pesticide of interest
(i.e., ‘‘negative control’’ animals).
In addition to the BMD, a confidence
limit was also calculated. Confidence
limits express the uncertainty in a BMD
that may be due to sampling and/or
E:\FR\FM\18NOR2.SGM
18NOR2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
pwalker on DSK8KYBLC1PROD with RULES2
experimental error. The lower
confidence limit on the dose used as the
BMD is termed the BMDL, which the
Agency uses as the PoD. Use of the
BMDL for deriving the PoD rewards
better experimental design and
procedures that provide more precise
estimates of the BMD, resulting in
tighter confidence intervals. Use of the
BMDL also helps ensure with high
confidence (e.g., 95% confidence) that
the selected percentage of AChE
inhibition is not exceeded. From the
PoD, EPA calculates the RfD and aPAD.
Specific to carbofuran and the other
NMCs, EPA the FIFRA SAP has
reviewed and supported the statistical
methods used to derive the BMD and
BMDLs on multiple occasions (Refs. 34,
35, 36).
In the Agency’s BMD analysis for
carbofuran, EPA used a response level
of 10% brain AChE inhibition; this
value represents the estimated dose
where AChE is inhibited by 10%,
compared to untreated animals. For the
last several years EPA has used the 10%
value to regulate AChE inhibiting
pesticides, including
organophosphorous pesticides (OPs)
and NMCs. For a variety of toxicological
and statistical reasons, EPA chose 10%
brain AChE inhibition as the response
level for use in BMD calculations. EPA
analyses have demonstrated that 10% is
a level that can be reliably measured in
the majority of rat toxicity studies; is
generally at or near the limit of
sensitivity for discerning a statistically
significant decrease in AChE activity
across the brain compartment; and is a
response level close to the background
(Refs. 34, 35).
B. Estimating Human Dietary Exposure
Levels
Pursuant to section 408(b) of the
FFDCA, EPA has evaluated carbofuran’s
dietary risks based on ‘‘aggregate
exposure’’ to carbofuran. By ‘‘aggregate
exposure,’’ EPA is referring to exposure
to carbofuran by multiple pathways of
exposure. EPA uses available data and
standard analytical methods, together
with assumptions designed to be
protective of public health, to produce
separate estimates of exposure for a
highly exposed subgroup of the general
population, for each potential pathway
and route of exposure. For acute risks,
EPA then calculates potential aggregate
exposure and risk by using
probabalistic 1 techniques to combine
1 Probabilistic analysis is used to predict the
frequency with which variations of a given event
will occur. By taking into account the actual
distribution of possible consumption and pesticide
residue values, probabilistic analysis for pesticide
exposure assessments ‘‘provides more accurate
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
distributions of potential exposures in
the population for each route or
pathway. For dietary analyses, the
relevant sources of potential exposure to
carbofuran are from the ingestion of
residues in food and drinking water.
The Agency uses a combination of
monitoring data and predictive models
to evaluate environmental exposure of
humans to carbofuran.
1. Exposure from Food. The level of
human exposure to pesticide residues in
food is a function of both the pesticide
residues in food and the amount of food
consumed. Data on the residues of
carbofuran in foods are available from a
variety of sources. One of the primary
sources of data comes from federallyconducted surveys, including the
Pesticide Data Program (PDP) conducted
by the USDA. Further, market basket
surveys, which are typically performed
by registrants, can provide additional
residue data. These data generally
provide a characterization of pesticide
residues in or on foods consumed by the
U.S. population that closely
approximates real world exposures
because they are sampled closer to the
point of consumption in the chain of
commerce than field trial data, which
are generated to establish the maximum
level of legal residues that could result
from maximum permissible use of the
pesticide. In certain circumstances,
when EPA believes the information will
provide more accurate exposure
estimates, EPA will rely on field trial
data (see below in Unit VI.E.1).
EPA relies on USDA’s Continuing
Survey of Food Intake by Individuals
(CSFII) for information on food
consumption by the US population as
well as 32 subgroups based on age,
gender, ethnicity, and region. The latest
CSFII was conducted in 1994–1996 and
1998. The 1998 survey was a special
survey required by the FQPA to
supplement the number of children
survey participants. DEEM–FCID also
contains ‘‘recipes’’ that convert foods as
consumed (e.g., pizza) back into their
component raw agricultural
commodities (e.g., wheat from flour, or
tomatoes from sauce, etc.). This is
necessary because residue data are
generally gathered on raw agricultural
commodities rather than on finished
ready-to-eat food. Data on residue
information on the range and probability of possible
exposure and their associated risk values’’ (Ref. 77).
In capsule, a probabilistic pesticide exposure
analysis constructs a distribution of potential
exposures based on data on consumption patterns
and residue levels and provides a ranking of the
probability that each potential exposure will occur.
People consume differing amounts of the same
foods, including none at all, and a food will contain
differing amounts of a pesticide residue, including
none at all.
PO 00000
Frm 00007
Fmt 4701
Sfmt 4700
59613
values for a particular pesticide and the
RfD or PADs for that pesticide are
inputs to the DEEM–FCID computer
program to estimate exposure and risk.
The DEEM–FCID computer program
estimates exposure by combining data
on human consumption amounts with
residue values in food commodities.
DEEM–FCID also compares exposure
estimates to appropriate RfD or PAD
values to estimate risk. EPA uses
DEEM–FCID to estimate exposure for
the general U.S. population as well as
for 32 subgroups based on age, sex,
ethnicity, and region. DEEM–FCID
allows EPA to process extensive
volumes of data on human consumption
amounts and residue levels in making
risk estimates. Matching consumption
and residue data, as well as managing
the thousands of repeated analyses of
the consumption database conducted
under probabilistic risk assessment
techniques, requires the use of a
computer.
For carbofuran’s assessment, EPA
used DEEM–FCID to calculate risk
estimates based on a probabilistic
distribution. DEEM–FCID combines the
full range of residue values for each
food with the full range of data on
individual consumption amounts to
create a distribution of exposure and
risk levels. More specifically, DEEM–
FCID creates this distribution by
calculating an exposure value for each
reported day of consumption per person
(‘‘person/day’’) in CSFII, assuming that
all foods potentially bearing the
pesticide residue contain such residue
at a value selected randomly from the
exposure data sets. The exposure
amounts for the thousands of person/
days in the CSFII are then collected in
a frequency distribution. EPA also uses
DEEM–FCID to compute a distribution
taking into account both the full range
of data on consumption levels and the
full range of data on potential residue
levels in food. Combining consumption
and residue levels into a distribution of
potential exposures and risk requires
use of probabilistic techniques.
The probabilistic technique that
DEEM–FCID uses to combine differing
levels of consumption and residues
involves the following steps:
(1) Identification of any food(s) that
could bear the residue in question for
each person/day in the CSFII;
(2) Calculation of an exposure level
for each of the thousands of person/days
in the CSFII database, based on the
foods identified in Step #1 by randomly
selecting residue values for the foods
from the residue database;
(3) Repetition of Step #2 one thousand
times for each person/day; and
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59614
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
(4) Collection of all of the hundreds
of thousands of potential exposures
estimated in Steps ##2 and 3 in a
frequency distribution.
The resulting probabilistic assessment
presents a range of exposure/risk
estimates.
2. Exposure from water. EPA may use
field monitoring data and/or simulation
water exposure models to generate
pesticide concentration estimates in
drinking water. Monitoring and
modeling are both important tools for
estimating pesticide concentrations in
water and can provide different types of
information. Monitoring data can
provide estimates of pesticide
concentrations in water that are
representative of the specific
agricultural or residential pesticide
practices in specific locations, under the
environmental conditions associated
with a sampling design (i.e., the
locations of sampling, the times of the
year samples were taken, and the
frequency by which samples were
collected). Although monitoring data
can provide a direct measure of the
concentration of a pesticide in water, it
does not always provide a reliable basis
for estimating spatial and temporal
variability in exposures because
sampling may not occur in areas with
the highest pesticide use, and/or when
the pesticides are being used and/or at
an appropriate sampling frequency to
detect high concentrations of a pesticide
that occur over the period of a day to
several days.
Because of the limitations in most
monitoring studies, EPA’s standard
approach is to use simulation water
exposure models as the primary means
to estimate pesticide exposure levels in
drinking water. Modeling is a useful
tool for characterizing vulnerable sites,
and can be used to estimate peak
pesticide water concentrations from
infrequent, large rain events. EPA’s
computer models use detailed
information on soil properties, crop
characteristics, and weather patterns to
estimate water concentrations in
vulnerable locations where the pesticide
could be used according to its label (69
FR 30042, 30058–30065 (May 26,
2004)). These models calculate
estimated water concentrations of
pesticides using laboratory data that
describe how fast the pesticide breaks
down to other chemicals and how it
moves in the environment at these
vulnerable locations. The modeling
provides an estimate of pesticide
concentrations in ground and surface
water. Depending on the modeling
algorithm (e.g., surface water modeling
scenarios), daily concentrations can be
estimated continuously over long
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
periods of time, and for places that are
of most interest for any particular
pesticide.
EPA relies on models it has developed
for estimating pesticide concentrations
in both surface water and ground water.
Typically EPA uses a two-tiered
approach to modeling pesticide
concentrations in surface and ground
water. If the first tier model suggests
that pesticide levels in water may be
unacceptably high, a more refined
model is used as a second tier
assessment. The second tier model for
surface water is actually a combination
of two models: The Pesticide Root Zone
Model (PRZM) and the Exposure
Analysis Model System (EXAMS). The
second tier model for ground water uses
PRZM alone.
A detailed description of the models
routinely used for exposure assessment
is available from the EPA OPP Water
Models Web site: https://www.epa.gov/
oppefed1/models/water/index.htm.
These models provide a means for EPA
to estimate daily pesticide
concentrations in surface water sources
of drinking water (a reservoir) using
local soil, site, hydrology, and weather
characteristics along with pesticide
application and agricultural
management practices, and pesticide
environmental fate and transport
properties. Consistent with the
recommendations of the FIFRA SAP,
EPA also considers regional percent
cropped area factors (PCA) which take
into account the potential extent of
cropped areas that could be treated with
pesticides in a particular area. The
PRZM and EXAMS models used by EPA
were developed by EPA’s Office of
Research and Development (ORD), and
are used by many international
pesticide regulatory agencies to estimate
pesticide exposure in surface water.
EPA’s use of the percent cropped area
factors and the Index Reservoir scenario
was reviewed and approved by the
FIFRA SAP in 1999 and 1998,
respectively (Refs. 30, 31).
In modeling potential surface water
concentrations, EPA attempts to model
areas of the country that are vulnerable
to surface water contamination rather
than simply model ‘‘typical’’
concentrations occurring across the
nation. Consequently, EPA models
exposures occurring in small, highly
agricultural watersheds in different
growing areas throughout the country,
over a 30-year period. The scenarios are
designed to capture residue levels in
drinking water from reservoirs with
small watersheds with a large
percentage of land use in agricultural
production. EPA’s models take into
account that pesticide residues in water
PO 00000
Frm 00008
Fmt 4701
Sfmt 4700
fluctuate daily, seasonally, and yearly as
a result of the timing of pesticide
applications, the vulnerability of the
water supply to pesticide loading
through runoff, spray drift and/or
leaching, and changes in the weather.
Concentrations are also affected by the
method of application, the location and
characteristics of the sites where a
pesticide is used, the climate, and the
type and degree of pest pressure.
EPA uses the output of daily
concentration values from tier two
modeling as an input to DEEM–FCID,
which combines water concentrations
with drinking water consumption
information in the daily diet to generate
a distribution of exposures from
consumption of drinking water
contaminated with pesticides. These
results are then used to calculate a
probabilistic assessment of the aggregate
human exposure and risk from residues
in food and drinking water.
3. Aggregate Exposure Analyses.
Using probabilistic analyses, EPA
combines the national food exposures
with the exposures derived for
individual region and crop-specific
drinking water scenarios to derive
estimates of aggregate exposure.
Although food is distributed nationally,
and exposures to pesticide residues are
therefore not expected to vary
substantially throughout the country,
drinking water is locally derived and
consumed and there can be significant
variations in pesticide levels in local
watersheds due to geographic, climatic,
and other factors. To be protective of all
population subgroups, EPA uses
modeled estimates from vulnerable
watersheds in calculating aggregate
exposure.
EPA’s standard acute dietary exposure
assessment calculates total dietary
exposure over a 24-hour period; that is
consumption over 24 hours is summed
and no account is taken of the fact that
eating and drinking occasions may
spread out exposures over a day. This
total daily exposure generally provides
reasonable estimates of the risks from
acute dietary exposures, given the
nature of most chemical endpoints. Due
to the rapid recovery associated with
carbofuran toxicity (AChE inhibition),
24-hour exposure periods may or may
not be appropriate. To the extent that a
day’s eating or drinking occasions
leading to high total daily exposure
might be found close together in time,
or to occur from a single eating event,
minimal AChE recovery would occur
between eating occasions (i.e., exposure
events). In that case, the ‘‘24-hour sum’’
approach, which sums eating events
over a 24-hour period, would provide
reasonable estimates of risk from food
E:\FR\FM\18NOR2.SGM
18NOR2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
pwalker on DSK8KYBLC1PROD with RULES2
and drinking water. Conversely, to the
extent that eating occasions leading to
high total daily exposures are widely
separated in time (within one day) such
that substantial AChE recovery occurs
between eating occasions, then the
estimated risks under any 24-hour sum
approach may be overstated. In that
case, a more sophisticated approach—
one that accounts for intra-day eating
and drinking patterns and the recovery
of AChE between exposure events—may
be more appropriate. This approach is
referred to as the ‘‘Eating Occasions
Analysis’’ and it takes into account the
fact that the toxicological effect of a first
dose may be reduced or tempered prior
to a second (or subsequent) dose.
Thus, rather than treating a full day’s
exposure as a one-time ‘‘bolus’’ dose, as
is typically done in the Agency’s
assessments, the Eating Occasion
analysis uses the actual time of eating or
drinking occasion, and amounts
consumed as reported by individuals to
the USDA CSFII. The actual CSFIIrecorded time of each eating event is
used to ‘‘separate out’’ the exposures
due to each eating occasion; in doing so,
this ‘‘separation’’ allows the Agency to
distinguish between each intake event
and account for the fact that at least
some partial recovery of AChE
inhibition attributable to the first
(earlier) exposure occurs before the
second exposure event. For chemicals
for which the toxic effect is rapidly
reversible, the time between two (or
more) exposure events permits partial to
full recovery from the toxic effect from
the first exposure and it is this ‘‘partial
recovery’’ that is specifically accounted
for by the Eating Occasion Analysis.
More specifically, an estimated
‘‘persisting dose’’ from the first
exposure event is added to the second
exposure event to account for the partial
recovery of AChE inhibition that occurs
over the time between the first and
second exposures. The ‘persisting dose’
terminology, and this general approach
were originally suggested by the FIFRA
SAP in the context of assessing AChE
inhibition from cumulative exposures to
OP pesticides (Ref. 33).
C. Selection of Acute Dietary Exposure
Level of Concern
Because probabilistic assessments
generally are based on a realistic range
of residue values to which the
population may be exposed, EPA’s
starting point for estimating exposure
and risk for such aggregate assessments
is the 99.9th percentile of the
population under evaluation, which
represents one person out of every 1000
persons. When using a probabilistic
method of estimating acute dietary
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
exposure, EPA typically assumes that,
when the 99.9th percentile of acute
exposure is equal to or less than the
aPAD, the level of concern for acute risk
has not been exceeded. By contrast,
where the analysis indicates that
estimated exposure at the 99.9th
percentile exceeds the aPAD, EPA
would generally conduct one or more
sensitivity analyses to determine the
extent to which the estimated exposures
at the high-end percentiles may be
affected by unusually high food
consumption or residue values. To the
extent that one or a few values seem to
‘‘drive’’ the exposure estimates at the
high end of exposure, EPA would
consider whether these values are
reasonable and should be used as the
primary basis for regulatory decision
making (Ref. 77).
V. Carbofuran Background and
Regulatory History
A. Tolerance Reassessment and
Pesticide Reregistration
In July 2006, EPA completed a refined
acute probabilistic dietary risk
assessment for carbofuran as part of the
tolerance reassessment program under
section 408(q) of the FFDCA and
pesticide reregistration under section 4
of FIFRA. The assessment was
conducted using Dietary Exposure
Evaluation Model-Food Commodity
Intake Database (DEEM–FCIDTM,
Version 200–2.02), which incorporates
consumption data from the United
States Department of Agriculture’s
(USDA’s) Nationwide Continuing
Surveys of Food Intake by Individuals
(CSFII), 1994–1996 and 1998, as well as
carbofuran monitoring data from
USDA’s Pesticide Data Program 2 (PDP),
estimated percent crop treated
information, and processing/cooking
factors, where applicable. The
assessment was conducted applying an
additional 500-fold safety factor that
included a 5X children’s safety factor,
pursuant to section 408(b)(2)(C). That
refined assessment showed acute
dietary risks from carbofuran residues in
food significantly above EPA’s level of
concern (Ref. 14). Based in part on the
results of that assessment, EPA
concluded that carbofuran failed to meet
the revised safety standard in FFDCA
section 408(b) and the standard for
FIFRA reregistration.3
2 USDA’s Pesticide Data Program monitors for
pesticides in certain foods at the distribution points
just before release to supermarkets and grocery
stores.
3 Although not relevant to this proceeding, in
addition to determining that use of carbofuran
resulted in unacceptable dietary risks, EPA
concluded that use of carbofuran did not meet the
PO 00000
Frm 00009
Fmt 4701
Sfmt 4700
59615
The tolerance reassessment and
FIFRA reregistration process for
carbofuran contained numerous
opportunities for public participation.
These included public comment periods
on the preliminary ecological risk
assessment (June–August 2005), the
preliminary human health risk
assessment (September–November
2005), the revised combined risk
assessment (March–May 2006), and the
interim Registration Eligibility
Document (RED) (August–November
2006). EPA received over 200 comments
(plus a letter campaign supporting
carbofuran with 2,896 signatories) to the
2006 RED. FMC submitted extensive
comments throughout the process
(including, but not limited to, a
comment of 62 pages plus 13
attachments totaling over 900 pages on
August 23, 2005, a letter with 20
attachments on November 11, 2005, 46
pages of comments on January 26, 2006,
78 pages of comments on February 17,
2006, a 15-page letter with 8
attachments on May 22, 2006, over 200
pages on May 24, 2006, and other
submissions. Following issuance of the
RED in August 2006, FMC stated that
they would be submitting new data to
refute EPA’s ecological and human
health risk concerns, as well as EPA’s
benefits assessments. Twenty-three
submissions with studies and analyses
were submitted in 2007, all of which
EPA reviewed. FMC submitted 175
pages of comments to the proposed
tolerance revocations jointly with the
NPC, NCGA, NCC, and NSA on 9/29/09.
The Agency has also met numerous
times with FMC, growers, and other
stakeholders regarding carbofuran.
One particular aspect of the risk
assessment process that involved
substantial public participation
opportunities was EPA’s review of the
human toxicology studies performed
with carbofuran. In making a
determination on whether these studies
met the standards of the Human
Research rule, EPA, as required, sought
the advice of the HSRB. The HSRB
review process includes the opportunity
for the public both to submit written
comments and to make an oral
presentation to the HSRB. FMC gave
both written and oral comments at the
HSRB meeting, which was held May 2–
4, 2006. FMC also submitted written
comments on the final HSRB report on
the meeting.
standard for FIFRA registration based on
unacceptable occupational and ecological risks.
E:\FR\FM\18NOR2.SGM
18NOR2
59616
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
pwalker on DSK8KYBLC1PROD with RULES2
B. Draft Notice of Intent to Cancel
Carbofuran Registrations
In January 2008, EPA published a
draft Notice of Intent to Cancel (NOIC)
all carbofuran registrations, based in
part on carbofuran’s dietary risks. As
mandated by FIFRA, EPA solicited
comments from the FIFRA Scientific
Advisory Panel (SAP) on its draft
NOIC.4 As part of that process, EPA
presented its dietary risk assessment of
carbofuran to the FIFRA SAP, and
requested comment on key issues in the
risk assessment: The Agency’s approach
to selecting the point of departure and
the children’s safety factor. FMC and the
remaining Petitioners participated in
this meeting, making substantial
presentations to the SAP. As described
in the proposal, the Agency believes
that the Panel’s responses
unambiguously support the Agency’s
approach with regard to carbofuran’s
hazard identification and hazard
characterization (73 FR 44875 (July 31,
2008)). In addition, EPA believes that,
on balance, the application of a 4X
children’s safety factor is consistent
with the SAP’s advice. Additional detail
on the SAP’s advice and EPA’s
responses can be found at Ref. 83.
C. Proposed Revocation of Carbofuran
Tolerances
Having considered the comments
from the SAP, EPA initiated the process
to revoke all carbofuran tolerances,
publishing a proposed revocation on
July 31, 2008 (73 FR 44,864 (July 31,
2008) (FRL–8378–8)). EPA proposed to
revoke all of the existing tolerances for
residues of carbofuran on the grounds
that aggregate exposure from all uses of
carbofuran fails to meet the FFDCA
section 408 safety standard (Id). Based
on the contribution from food alone,
EPA calculated dietary exposures to
carbofuran exceed EPA’s level of
concern for all of the more sensitive
subpopulations of infants and children.
At the 99.9th percentile, aggregate
carbofuran dietary exposure from food
and drinking water from contaminated
ground water was estimated to range
from 1100% of the aPAD for adults, to
greater than 10,000% of the aPAD for
infants, the population subgroup with
the highest estimated dietary exposure
(Ref. 12). Similarly, aggregate dietary
exposures from food and drinking water
from surface water, based on
contamination from use on corn in
4 The draft NOIC was based on all of carbofuran’s
combined risks—dietary, occupational, and
ecological. Because some non-food use registrations
remain, EPA anticipates issuing the NOIC
subsequent to undertaking the activities required to
revoke the carbofuran tolerances to cancel these
remaining uses.
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
Nebraska, ranged from 340% of the
aPAD for adults, to 3,900% aPAD for
infants. EPA also determined that, based
on actual residue levels measured in
food in commerce, individual children
consuming typical amounts of a single
food item received unsafe levels of
carbofuran. For example, based on the
level of residues detected on in the food
supply, a child between 3–5 years, who
consumed 1⁄2 cup of cantaloupe, would
receive a dose ranging between 180%
and 7,200% of the aPAD. Finally, the
proposal discussed a number of
sensitivity analyses the Agency had
calculated in order to further
characterize the potential risks to
children. Every one of these sensitivity
analyses determined that estimated
exposures significantly exceeded EPA’s
level of concern for children.
EPA held a 60-day comment period
on the proposed revocation rule. In the
proposed rule, EPA made clear that if
any person had concerns with EPA’s
proposed revocation, those concerns
must be raised during the comment
period to be preserved. Specifically,
EPA stated:
prohibited on much of the Eastern US
to protect vulnerable sources of
groundwater; use restrictions were
imposed in other areas of the country,
preventing use within set distances to
prevent runoff into sources of surface
water drinking water supplies.
On November 7, 2008, the Petitioners
submitted additional information as a
supplement to their September
comments. Specifically, they submitted
carbofuran use data that the Petitioners
used in preparing its surface water
assessments. The information consisted
of a spreadsheet that contained all of the
data provided to the Water Panel by
FMC, and a document that explained
the materials, methods, and procedures
employed by the Panel to utilize this
data.
On December 24, 2008, FMC
submitted a petition requesting that EPA
stay the effective date of the tolerance
revocations, and that EPA consider
additional information, including
further risk mitigation measure that the
registrant intended to implement, as
well as additional analyses that the
Petitioners’ experts were developing.
In addition to submitting comments in
response to this proposal, you may also
submit an objection at the time of the final
rule. If you anticipate that you may wish to
file objections to the final rule, you must
raise those issues in your comments on this
proposal. EPA will treat as waived, any issue
not originally raised in comments on this
proposal. Similarly, if you fail to file an
objection to the final rule within the time
period specified, you will have waived the
right to raise any issues resolved in the final
rule. After the specified time, issues resolved
in the final rule cannot be raised again in any
subsequent proceedings on this rule.
E. Final Rule Revoking Carbofuran
Tolerances
(73 FR at 44865).
D. Petitioners’ Comments on the
Proposed Rule
The comment period for the proposed
rule closed on September 29, 2008.
During the comment period, the
Petitioners submitted comments
challenging particular aspects of EPA’s
risk assessment. For example, the
Petitioners challenged the basis for
EPA’s 4X children’s safety factor, and
the method and assumptions on which
EPA relied to estimate drinking water
concentrations. In addition, the
registrant, FMC Corporation, requested
that EPA cancel the use on 22 of the
crops on which it was registered,
including many of the foods posing the
highest risks to children. FMC also
requested that EPA modify its labels to
include a number of additional
restrictions intended to mitigate the
risks identified in EPA’s risk
assessment. For example, use was
PO 00000
Frm 00010
Fmt 4701
Sfmt 4700
On May 15, 2009, EPA published its
final rule, based on a revised risk
assessment that addressed the voluntary
cancellations and label restrictions
submitted by the close of the September
29 comment period. The only food uses
that remained registered after the
voluntary cancellations were
sunflowers, corn, potatoes, and
pumpkins. In response to the changes
made on the labels, EPA revised its risk
assessment to account for the reduced
number of crops, the altered geographic
restrictions, and the additional risk
mitigation measures proposed as part of
FMC’s comments.
Having considered all comments
received by the close of the comment
period, and based on its revised
analyses, EPA concluded that aggregate
exposures from all remaining uses of
carbofuran were still unsafe for infants
and children, and that revocation of the
remaining tolerances was warranted.
The final rule explained that, although
the recent cancellation of several
registered uses reduced the dietary risks
to children, EPA’s analyses still showed
that estimated exposures significantly
exceed EPA’s level of concern for
children. For example, EPA determined
that the estimated risks could be as high
as 9,400% of the aPAD for infants. A
detailed description of the risk
assessment supporting the final rule
follows.
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
1. Toxicity. AChE inhibition in brain
and the PNS is the initial adverse
biological event which results from
exposure to carbofuran, and with
sufficient levels of inhibition leads to
other effects such as tremors, dizziness,
as well as gastrointestinal and
cardiovascular effects, including
bradycardia (Ref. 15). Thus, AChE
inhibition provides the most
appropriate effect to use in risk
extrapolation for derivation of RfDs and
PADs. Protecting against AChE
inhibition ensures that the other adverse
effects associated with cholinergic
toxicity, mentioned above, do not occur.
There are three studies available that
compare the effects of carbofuran on
eleven-day-old rats (i.e., post-natal day
11 or PND11) rats with those in young
adult rats (herein called comparative
AChE studies) (Refs. 1, 2, 4, and 66).
Two of these studies were submitted by
FMC, the registrant, and one was
performed by EPA–ORD. An additional
study conducted by EPA–ORD involved
PND17 rats (Ref. 63). Although it is not
possible to directly correlate ages of
juvenile rats to humans, PND11 rats are
believed to be close in development to
newborn humans. PND17 rats are
believed to be closer developmentally to
human toddlers (Refs. 10, 22, and 23).
Other studies in adult rats used in the
Agency’s analysis included additional
data from EPA–ORD (Refs. 54, 62, and
66).
The studies in juvenile rats show a
consistent pattern that juvenile rats are
more sensitive than adult rats to the
effects of carbofuran. These effects
include inhibition in AChE in addition
to incidence of clinical signs of
neurotoxicity such as tremors. This
pattern has also been observed for other
NMC pesticides, which exhibit the same
mechanism of toxicity as carbofuran
(Ref. 81). It is not unusual for juvenile
rats, or indeed, for infants or young
children, to be more sensitive to
chemical exposures as metabolic
detoxification processes in the young
are still developing. Because juvenile
rats, called ‘pups’ herein, are more
sensitive than adult rats, data from pups
provide the most relevant information
for evaluating risk to infants and young
children and are thus used to derive the
PoD. In addition, typically (and this is
the case for carbofuran) young children
(ages 0–5 years) tend to be the age
groups most exposed to carbofuran
because they tend to ingest larger
amounts of food and water per their
body weight than do teenagers or adults.
As such, the focus of EPA’s analysis of
carbofuran’s dietary risk from residues
in food and water is on young children
(ages 0 to 5 years). Since these age
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
groups experience the highest levels of
dietary risk, protecting these groups
against the effects of carbofuran will, in
turn, also protect other age groups.
The Agency used a meta-analysis to
calculate the BMD10 and BMDL10 for
pups and adults; this analysis includes
brain data from studies where either
adult or juvenile rats or both were
exposed to a single oral dose of
carbofuran. The Agency used a dosetime-response exponential model where
benchmark dose and half-life to
recovery can be estimated together. This
model and the statistical approach to
deriving the BMD10 s, BMDL10 s, and
half-life to recovery have been reviewed
and supported by the FIFRA SAP (Refs.
34, 35, and 36). The meta-analysis
approach offers the advantage over
using single studies by combining
information across multiple studies and
thus provides a robust PoD.
For AChE-inhibiting pesticides, EPA
generally evaluates the effects of the
pesticide on both brain and RBC AChE.
RBC AChE is used as a surrogate for
effects on the PNS because data directly
measuring effects on the PNS are
difficult to obtain.
Using quality brain AChE data from
the three studies (two FMC, one EPA–
ORD) conducted with PND11 rats, in
combination, provides data to describe
both low and high doses. By combining
the three studies in PND11 animals
together in a meta-analysis, the entire
dose-response range is covered. The
results of the BMD analysis for PND11
pup brain AChE data provide a BMD10
of 0.04 mg/kg/day and BMDL10 of 0.03
mg/kg/day—this BMDL10 of 0.03 mg/kg/
day provides the PoD (Ref. 70).
EPA, however, lacked adequate data
on carbofuran’s effects on RBC AChE.
Two studies required from FMC were
rejected as flawed. To account for the
lack of data in the PNS and/or a
surrogate (i.e., RBC AChE inhibition
data) in pups at the low end of the
response curve, and for the fact that
RBC AChE inhibition appears to be a
more sensitive point of departure
compared to brain AChE inhibition,
EPA determined that, consistent with
the statutory mandate, some portion of
the statutory default 10X children’s
safety factor needed to be retained.
Because there are some carbofuran data
that characterize the toxicity in
juveniles, EPA concluded that the
weight-of-the-evidence supports
reducing the statutory factor of 10X to
a value lower than 10X. This results in
a children’s safety factor that is less than
10 but more than 1.
The modified children’s safety factor
takes into account the greater sensitivity
of the RBC AChE. The preferred
PO 00000
Frm 00011
Fmt 4701
Sfmt 4700
59617
approach to comparing the relative
sensitivity of brain and RBC AChE
inhibition would be to compare the
BMD10 estimates. However, BMD10
estimates from the available RBC AChE
inhibition data are not reliable due to
lack of data at the low end of the dose
response curve. As an alternative
approach, EPA used the ratio of brain to
RBC AChE inhibition at the BMD50,
since there are quality data at or near
the 50% response level such that a
reliable estimate can be calculated. EPA
estimated the RBC BMD50 to brain
BMD50 potency ratio using EPA’s data
for RBC (the only reliable RBC data in
PND11 animals for carbofuran) and all
available data in PND11 animals for
brain. There is, however, an assumption
associated with using the 50% response
level—namely that the magnitude of
difference between RBC and brain AChE
inhibition is constant across dose. In
other words, EPA is assuming the RBC
and brain AChE dose response curves
are parallel. There are currently no data
to test this assumption for carbofuran.
Comparing RBC BMD50 and brain
BMD50 AChE inhibition, EPA calculated
a BMD50 ratio of 4.1X. Accordingly, EPA
concluded that a children’s safety factor
of 4X would be protective of infants and
children.
Using the BMDL10 of 0.03 mg/kg/day,
combined with the default 10X
interspecies and intraspecies factors,
along with the 4X children’s safety
factor results in an aPAD = 0.000075
mg/kg/day for infants and children. The
aPAD for youths and adults is
calculated in the same manner, but EPA
does not apply the 4X children’s safety
factor, resulting in an aPAD of 0.0002
mg/kg/day.
2. Acute Exposures from Food. The
estimated acute dietary exposure from
carbofuran residues in food alone (i.e.,
assuming no additional carbofuran
exposure from drinking water), is below
EPA’s level of concern for the U.S.
Population and all population
subgroups. Children 1 to 2 years of age
(78% aPAD) were the most highly
exposed population subgroup when
food only was included. The major
driver of the acute dietary exposure risk
(food only) for Children 1 to 2 years is
milk, at greater than 90% of the
exposure.
3. Acute Exposures from Drinking
Water. EPA’s analyses show that those
individuals-both adults as well as
children—who receive their drinking
water from vulnerable sources are
exposed to levels that exceed EPA’s
level of concern—in some cases by
orders of magnitude. This primarily
includes those populations consuming
drinking water from ground water from
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59618
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
shallow wells in acidic aquifers overlaid
with sandy soils that have had crops
treated with carbofuran. It could also
include those populations that obtain
their drinking water from reservoirs
located in small agricultural watersheds,
prone to runoff, and predominated by
crops that are treated with carbofuran,
although there is more uncertainty
associated with these exposure
estimates.
a. Ground Water. In EPA’s revised
assessment, ground water
concentrations were estimated for all
remaining crops on carbofuran labels,
and used two new Tier 2 scenarios.
Based on a new corn scenario,
representative of potentially vulnerable
areas in the upper Midwest, EPA
estimated 1-in-10-year concentrations
for ground water source drinking water
of 16 to 1.6 × 10¥3 μg/L, for pH 6.5 and
7, respectively. A potato scenario
representing use in the Northwest
estimated no measurable concentrations
of carbofuran in ground water. Other
remaining uses were modeled using a
Tier 1 ground water model (Screening
Concentration in Groundwater) with
estimated peak 90-day concentrations of
48–178 μg/L, depending on application
rate. Well setback prohibitions of 50 feet
were proposed on the September 2008
label for the flowable and granular
formulations in select counties in
Kentucky (seven counties), Louisiana
(one county), Minnesota (one county),
and Tennessee (one county). Analysis of
the impact of these setbacks for the use
on corn indicated that the setbacks
would not reduce concentrations
significantly at locations where
exposure to carbofuran in ground water
is of concern because at acid pHs,
carbofuran does not degrade sufficiently
during the travel time from the
application site to the well to
substantially reduce the concentration.
Exposure estimates for this
assessment are drawn primarily from
EPA’s modeling. To conduct its
modeling, EPA examined readily
available data with respect to ground
water and soil pH to evaluate the spatial
variability of pH. Ground water pH
values can span a wide range; this is
especially true for shallow ground water
systems, where local conditions can
greatly affect the quality and
characteristics of the water (higher or
lower pHs compared to average values).
The ground water simulations reflect
variability in pH by modeling
carbofuran leaching in four different pH
conditions (pH 5.25, 6.5, 7.0, and 8.7),
representing the range in the Wisconsin
aquifer system. The upper and lower
bound of pH values that EPA chose for
this assessment were measured values
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
from the aquifer, and the remaining two
values were chosen to reflect common
pH values between the measured values.
Based on EPA’s assessment, the
maximum 1-in-10-year peak carbofuran
concentrations in vulnerable ground
water for a single application on corn in
Wisconsin, at a rate of 1 pound per acre
were estimated to range from a low of
less than 1 ppb based on a pH of 7 or
higher, to a high of 16 ppb, based on a
pH of 6.5.
The results of EPA’s revised corn
modeling, based on a scenario in
Wisconsin, are consistent with the
results of the PGW study developed by
FMC in Maryland in the early 1980s.
Using higher use rates than currently
permitted, the peak concentration
measured in the PGW study was 65 ppb;
when scaled to current use rates, the
estimated peak concentration was 11
ppb. EPA’s modeling is also consistent
with a number of other targeted ground
water studies conducted in the 1980s
showing that high concentrations of
carbofuran can occur in vulnerable
areas; the results of these studies as well
as the PGW study are summarized in
References 13 and 67.
While there have been additional
ground water monitoring studies that
included carbofuran as an analyte since
that time, there has been no additional
monitoring targeted to carbofuran use in
areas where aquifers are vulnerable.
However, data compiled in 2002 by
EPA’s Office of Water show that
carbofuran was detected in treated
drinking water at a few locations. Based
on samples collected from 12,531
ground water supplies in 16 states,
carbofuran was found at one public
ground water system at a concentration
of greater than 7 ppb and in two ground
water systems at concentrations greater
than 4 ppb (measurements below this
limit were not reported). An infant
receiving these concentrations would
receive doses equivalent to 220% of the
aPAD or 130% aPAD, respectively,
based on a single 8 ounce serving of
water. As this monitoring was not
targeted to carbofuran, the likelihood is
low that these samples capture peak
concentrations. Given the lack of
targeted monitoring, EPA has primarily
relied on modeling to develop estimates
of carbofuran residues in ground water
sources of drinking water.
EPA compiled a distribution of
estimated carbofuran concentrations in
water based on these estimates, which
was used to generate probabilistic
assessments of the potential exposures
from drinking water derived from
vulnerable ground water sources. Based
on these assessments, estimated
PO 00000
Frm 00012
Fmt 4701
Sfmt 4700
exposures ranged between 770% aPAD
for adults to 9400% aPAD for infants.
b. Surface Water. For the final rule,
EPA conducted additional refined
modeling based on the September 2008
label submitted by FMC. The modeling
addressed all of the domestic uses that
remain registered, and included certain
refinements to better understand the
impacts of varying pH. EPA also
conducted modeling to assess the
impact of the proposed spray drift buffer
requirements and other spray drift
measures included on the September
label.
EPA estimated carbofuran
concentrations resulting from the use on
pumpkins by adjusting the estimated
drinking water concentrations (EDWC)
from a previous run simulating melons
in Missouri; adjustments accounted for
differences in application rate and row
spacing. Two EDWCs were calculated
for pumpkins: One based on a 36-inch
row spacing, representing pumpkins for
consumption (77.6 ppb); and a second
based on a 60-inch row spacing,
representing decorative pumpkins (46.6
ppb).
EPA had previously evaluated the
corn rootworm rescue treatment at
seven representative sites, representing
use in states with extensive carbofuran
usage at locations more vulnerable than
most in each state in areas corn is
grown. Using measured rainfall values,
and assuming typical rather than
maximum use rates, peak
concentrations for the corn rescue
treatments simulated for Illinois, Iowa,
Indiana, Kansas, Minnesota, Nebraska,
and Texas ranged from 16.6–36.7 ppb
(Ref. 47). Under the revised assessment
to account for the September 2008 use
restrictions, concentrations for corn,
calculated including the proposed spray
drift buffers in Kansas and Texas,
decreased 5.1% and 4.7%, respectively,
from simulations with no buffer from
the previous assessment (Ref. 47). In
Kansas, the 1-in-10-year peak EDWCs
decreased from 33.5 to 31.8 ppb when
a 300-foot buffer was added, and in
Texas, from 29.9 to 28.5 ppb with the
addition of a 66-foot buffer.
For the sunflower use, 12 simulations
were performed for sunflowers, 9 in
Kansas, and 3 in North Dakota. The
North Dakota scenario was used to
represent locations where sunflowers
are grown that are vulnerable to
pesticide movement to surface water
while the Kansas scenario represents
places that are not particularly
vulnerable, based on the limited rainfall
and generally well-drained soils
(hydrologic group B soils) that are found
in that area. Estimated 1-in-10-year
concentrations ranged from 11.6 to 32.7
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
μg/L. When simulating three
applications, one at plant and two foliar
with a 14-day interval between the two
foliar applications and a 66-foot buffer,
the 1-in-10-year peak EDWC for North
Dakota was 22.4 μg/L. In contrast, the
same three applications in Kansas with
a 14-day interval between the foliar
applications and a 300-foot buffer
produced a 1-in-10-year peak EDWC of
20.5 μg/L. The 1-in-10-year peak
EDWCs, assuming that carbofuran is
applied only at plant, were 14.0 and
16.0 μg/L in Kansas and North Dakota
respectively. EPA also evaluated the
impact of pH on carbofuran
concentrations for sunflowers, resulting
in a 10% decrease in 1-in-10-year peak
concentrations assuming high pH in the
reservoir. Spray drift buffers of 66 and
300 feet decreased concentrations 4.7
and 5.1% for corn and 10.0% and
16.0% for sunflowers, respectively, in
comparison to previous labels that had
no spray drift buffer requirements.
Additional details on these assessments
can be found at Reference 84.
These predicted carbofuran water
concentrations are similar or lower than
the peak concentrations reported in the
United States Geological SurveyNational Ambient Water Quality Survey
(USGS–NAWQA) monitoring data. In
addition, these data, which represent
concentrations in surface water prior to
any treatment by a public drinking
water system, are consistent with the
results of the 2002 data on finished
water compiled by EPA’s Office of
Water. Based on samples collected from
1,394 surface water source drinking
water supplies in 16 states, carbofuran
was found at no public drinking water
supply systems at concentrations
exceeding maximum contaminant level
(MCL) of 40 ppb. However, carbofuran
was found at one surface water public
water system in finished (i.e., posttreatment) water at concentrations
greater than 4 ppb (measurements below
this limit were not reported). Sampling
is costly and is conducted typically four
times a year or less at any single
drinking water facility. The overall
likelihood of collecting samples that
capture peak exposure events is,
therefore, low. For chemicals with acute
risks of concern, such as carbofuran,
higher concentrations and resulting risk
is primarily associated with these peak
events, which are not likely to be
captured in monitoring unless the
sampling rate is very high.
There are few surface water field-scale
studies targeted to carbofuran use that
could be compared with modeling
results. Most of these studies were
conducted in fields that contain tile
drains, which is a common practice
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
throughout midwestern states to
increase drainage in agricultural fields
(Ref. 13). Drains are common in the
upper Mississippi river basin (Illinois,
Iowa, and the southern part of
Minnesota), and the northern part of the
Ohio River Basin (Indiana, Ohio, and
Michigan) (Ref. 58). Although it is not
possible to directly correlate the
concentrations found in most of the
studies with drinking water
concentrations, these studies confirm
that carbofuran use under such
circumstances can contaminate surface
water, as tile drains have been identified
as a conduit to transport water and
contaminants from the field to surface
waters.
EPA conducted dietary exposure
analyses based on the modeling
scenarios for the proposed September
2008 label. Exposures from all modeled
scenarios substantially exceeded EPA’s
level of concern (Ref. 12). For example,
a Kansas sunflower scenario, assuming
two foliar applications at a typical 1 lb
active ingredient (a.i.) per acre use rate,
applied at 14-day intervals, estimated a
1-in-10-year peak carbofuran water
concentration of 11.6 ppb. Exposures at
the 99.9th percentile based on this
modeled distribution ranged from 160%
of the aPAD for youths 13 to 19 years,
to greater than 2,000% of the aPAD for
infants. This scenario is intended to be
representative of sites that are less
vulnerable than most on which
sunflowers could be grown. By contrast,
exposure estimates from a comparable
North Dakota sunflower scenario,
intended to represent more vulnerable
sites, estimated a 1-in-10-year peak
concentration of 22.4 ppb. These
concentrations would result in
estimated exposures ranging between
450% aPAD for youths 13 to 19 years,
to 5,500% aPAD for infants. Similarly,
exposures based on a Washington
surface water potato scenario, and using
a 3 lb a.i. acre rate, ranged from 230%
of the aPAD for children 6 to 12 years
to 890% of the aPAD for infants, with
a 1-in-10-year peak carbofuran
concentration of 7.2 ppb. Although
other crop scenarios resulted in higher
exposures, estimates for these two crops
are presented here, as they are major
crops on which a large percentage of
carbofuran use occurs. For example, one
of EPA’s refined exposure analyses is
based on a Nebraska corn rootworm
‘‘rescue treatment’’ scenario, and
assumes a single aerial application at a
typical rate of 1 lb a.i. per acre. The full
distribution of daily concentrations over
a 30-year period was used in the
probabilistic dietary risk assessment.
The 1-in-10-year peak concentration of
PO 00000
Frm 00013
Fmt 4701
Sfmt 4700
59619
the distribution of values for the
Nebraska corn rescue treatment was
22.3 ppb. Estimated dietary exposures
based on these concentrations ratned
from 340% of the aPAD for adults to
3900% of the aPAD for infants. More
details on these assessments, as well as
the assessments EPA conducted for
other crop scenarios, can be found in
References 12, 47, and 67.
4. Aggregate (food and water)
Exposures. EPA conducted a number of
probabilistic analyses to combine the
national food exposures with the
exposures from the individual region
and crop-specific drinking water
scenarios. Although food is distributed
nationally, and residue values are
therefore not expected to vary
substantially throughout the country,
drinking water is locally derived and
consumed and concentrations of
pesticides in source water fluctuate over
time and location for a variety of
reasons. Consequently, EPA conducted
several estimates of aggregate dietary
risks by combining exposures from food
and drinking water. These estimates
showed that, because drinking water
exposures from any of the crops on the
label exceed safe levels, aggregate
exposures from food and water are
unsafe. Although EPA’s assessments
showed that, based on the Idaho potato
scenarios, exposures from ground water
from use on potatoes would be safe,
surface water exposures from carbofuran
use on potatoes far exceed the safety
standard. More details on the individual
aggregate assessments presented below,
as well as the assessments EPA
conducted for other regional and crop
scenarios, can be found in References 12
and 13.
The results of aggregate exposures
from food and from drinking water
derived from ground water in extremely
vulnerable areas (i.e., from shallow
wells associated with sandy soils and
acidic aquifers, such as are found in
Wisconsin), ranged from 780% of the
aPAD for adults, to 9,400% of the aPAD
for infants.
The results of aggregate exposure from
food and water derived from one of the
least conservative surface water
scenarios—Kansas sunflower, with two
foliar applications—ranged from 190%
of the aPAD for adults to 2,100% aPAD
for infants. These estimates reflect the
risks only for those people in
watersheds with characteristics similar
to that used in the scenario, and
assuming that water treatment does not
remove carbofuran. The estimated water
concentrations are comparable to the
maximum peak concentrations reported
in monitoring studies that were not
designed to detect peak, daily
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59620
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
concentrations of carbofuran in
vulnerable locations.
More details on this assessment, as
well as the assessments EPA conducted
for other crop scenarios, can be found in
References 12, 47, and 67. For example,
in the proposed rule, EPA presented the
results from aggregate exposures
resulting from a Nebraska surface water
scenario based on a Nebraska corn
rootworm ‘‘rescue treatment.’’ Estimated
exposures from that scenario ranged
from 330% of the aPAD for youths 13
to 19 years to 3,900% of the aPAD for
infants.
As noted previously, EPA’s food and
water exposure assessments typically
sum exposures over a 24-hour period,
and EPA used this 24-hour total in
developing its acute dietary risk
assessment for carbofuran. Because of
the rapid nature of carbofuran toxicity
and recovery, EPA conducted an
analysis using information about dietary
exposure, timing of exposure within a
day, and half-life of AChE inhibition
from rats to estimate risk to carbofuran
at durations less than 24 hours.
Specifically, EPA has evaluated
individual eating and drinking
occasions and used the AChE half-life to
recovery information (herein called halflife information) to estimate the residual
effects from carbofuran from previous
exposures within the day. The
carbofuran analyses are described in the
2009 aggregate (dietary) memo (Ref. 55).
Using the two FMC time course
studies in rat pups, EPA calculated halflives for recovery of 186 and 426
minutes (Refs. 24 and 25). The two
values provide an indication that halflives to recovery can vary among
juvenile rats. By extension, children are
expected to vary in their ability to
recover from AChE inhibition where
longer recoveries would be associated
with a potentially higher ‘‘persisting
dose’’ (as described below).
This analysis had little impact on the
exposures from food alone. However,
accounting for drinking water
consumption throughout the day and
using the half-life to recovery
information, risk is reduced by
approximately 2–3X. Consequently, risk
estimates for which food and drinking
water are jointly considered and
incorporated (i.e., Food + Drinking
Water) are also reduced considerably—
by a factor of two or more in some
cases—compared to baseline. But even
though the risk estimates from aggregate
exposure are reduced, they nonetheless
still substantially exceed EPA’s level of
concern for infants and children. Using
drinking water derived from the surface
water from the Idaho potato surface
water scenario, which estimated one of
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
the lowest exposure distributions,
aggregate exposures at the 99.9th
percentile ranged from 328% of the
aPAD under the scenario for which
infants rapidly metabolize carbofuran
(e.g., 186 minute half-life), to a high of
473% of the aPAD under the scenario
for which infants metabolize carbofuran
more slowly, (e.g., scenarios in which a
426 minute half life is assumed).
Moreover, even accounting for the
estimated decreased risk from
accounting for carbofuran’s rapid
reversibility, the Agency remains
concerned about the risks from single
eating or drinking events, as illustrated
in the following example, based on an
actual food consumption diary from the
CSFII survey. A 4-month old male nonnursing infant weighing 10 kg is
reported to have consumed a total of
1,070 milliters (ml) of indirect water
over eight different occasions during the
day. The first eating occasion occurred
at 6:30 a.m., when this 4 month old
consumed 8 fluid ounces of formula
prepared from powder. The FCID food
recipes indicate that this particular food
item consists of approximately 87.7%
water, and therefore, 8 ounces of
formula contains approximately 214 ml
(or grams) of indirect water; with the
powder (various nutrients, dairy, soy,
oils, etc.) accounting for the remaining
12.3%. This infant also reportedly
consumed a full 8-ounce bottle of
formula at 12 p.m., 4 p.m., and 8 p.m.
that day. The food diary also indicates
that the infant consumed about 1
tablespoon of water (14.8 ml) added to
prepare rice cereal at 10 a.m., about 2
ounces of water (59.3 ml) added to pear
juice at 11 a.m., another 1⁄2 tsp of water
(2.5 ml) to prepare more rice cereal at
8:30 p.m.; and finally, he consumed
another 4 ounces of formula (107 ml) at
9:30 p.m.
The infant’s total daily water intake
(1,070 ml, or approximately 107 ml/kg/
day) is not overly conservative, and
represents substantially less than the
90th percentile value from CSFII on a
ml water/kg bodyweight (ml/kg/bw)
basis. As noted, carbofuran has been
detected in finished water at
concentrations of 4 ppb. For this 10 kg
body weight infant, an 8-ounce bottle of
formula prepared from water containing
carbofuran at 4 ppb leads to drinking
water exposures of 0.0856 micrograms
of active ingredient/kilogram of
bodyweight (μg ai/kg bw), or 114% of
the aPAD. Based on the total daily water
intake of 1,070 ml/day (no reversibility),
total daily exposures from water at 4
ppb concentration would amount to
0.4158 μg ai/kg bw, or 555% of the
aPAD; this is the amount that would be
PO 00000
Frm 00014
Fmt 4701
Sfmt 4700
used for this person-day in the Total
Daily Approach.
Peak inhibition occurs following each
occasion on which the infant consumed
8 fluid ounces of formula (6 a.m., 12
p.m., 4 p.m. and 8 p.m.); however, the
maximum persisting dose occurs
following the 9:30 p.m. eating occasion,
based on a 186-minute half-life
parameter. This produces a maximum
persisting dose of 0.1457 μg ai/kg bw, or
about 30% of the total daily exposure of
0.4158 μg ai/kg bw derived above, or
expressed as a fraction of the level of
concern, the maximum persisting dose
amounts to about 194% of the aPAD (or
30% of 554%). Note that with drinking
water concentration at 4 ppb, an infant
consuming one 8 oz bottle of formula—
prepared from powder and tap water
containing carbofuran at 4 ppb will
obtain exposures of approximately
114% of aPAD. Since many infants
consume the equivalent of this amount
on a single eating occasion, accounting
for reversibility over multiple occasions
is not essential to ascertain that infants
quite likely have obtained drinking
water exposures to carbofuran
exceeding the level of concern based on
drinking water concentrations found in
public drinking water supplies.
In this regard, it is important to note
EPA’s Eating Occasion Analyses
underestimate exposures to the extent
that they do not take into account carryover effects from previous days, and
because drinking water pesticide
concentrations are randomly picked
from the entire 30-year distribution. As
discussed previously, DEEM-FCID
[FN(TM)] is a single day dietary
exposure model, and the DEEM-based
Eating Occasion Analysis accounts for
reversibility within each simulated
person-day. All of the empirical data
regarding time and amounts consumed
(and corresponding exposures based on
the corresponding residues) from the
CSFII survey are used, along with the
half-life to assess an equivalent
persisting dose that produced the peak
inhibition expected over the course of
that day. This is a reasonable
assumption for food alone; since the
time between exposure events across 2
days is relatively high (compared to the
half-life)—most children (≤9 months)
tend to sleep through the night—and the
time between dinner and breakfast the
following morning is long enough it is
reasonable to ‘‘ignore’’ persisting effects
from the previous day. A single day
exposure model will underestimate the
persisting effects from drinking water
exposures (formula) among infants, and
newborns in particular (<3 months),
since newborns tend to wake up every
2 to 4 hours to feed. Any carry over
E:\FR\FM\18NOR2.SGM
18NOR2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
pwalker on DSK8KYBLC1PROD with RULES2
effects may be important, especially if
exposures from the previous day are
relatively high, since the time between
the last feeding (formula) of the day and
the first feeding of the subsequent day
is short. A single day model also does
not account for the effect of seasonal
variations in drinking water
concentrations, which will make this
effect more pronounced during the high
use season (i.e., the time of year when
drinking water concentrations are high).
Based on these analyses, the Agency
concludes that the current exposure
assessment methods used in the
carbofuran dietary assessment provide
realistic and high confidence estimates
of risk to carbofuran exposure through
food and water.
F. Response to FMC Comments on the
Final Rule
FMC’s comments raised a range of
issues. Those issues are not summarized
here because FMC basically refilled
many of its comments as objections
without modifying them in response to
EPA’s decision in the final rule. In
addition, FMA submitted a an alternate
risk analysis purporting to show that
aggregate carbofuran exposures to
children would be safe. However, FMC
failed to provide the data and details of
that assessment to the Agency. They
also failed to provide several critical
components that served to support key
inputs into that assessment; and for
several of these, EPA was unable to
replicate the claimed results based on
the information contained in the
comments. In the absence of such
critical components, the Agency was
unable to accept the validity or utility
of the analyses, let alone rely on the
results.
Nonetheless, based on the summary
descriptions provided in the registrant’s
comments, EPA concluded that the risk
analyses contained a critical flaw. The
commenters’ determination of safety
rests on the presumption that under real
world conditions, events will always
occur exactly as hypothesized by the
multiple assumptions in their
assessment. For example, the comments
assumed, despite all available evidence
to the contrary, that children would not
be appreciably more sensitive to
carbofuran’s effects than adults. They
assumed that carbofuran’s effects will be
highly reversible, and that children will
be uniformly sensitive, such that the
effects will be adequately accounted for
by the assumption of a 150-minute halflife, despite the fact that children are
not uniformly sensitive. They further
assumed that there would be no carry
over effect from the preceding day’s
exposures for infants. They assumed
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
that the cancellation of use on alfalfa
would reduce carbofuran residues in
milk by over 70%, even though many
cows’ diet consists primarily of corn.
They assumed that residues would
decrease between 19% and 23% as a
result of the buffer requirements on the
September 2008 label, even though the
label does not require the use of all of
the recommended ‘‘best management
practices’’ (e.g., no requirements
regarding swath displacement), and
applicators do not universally use such
practices in the absence of any
requirement. They assumed that average
ground water pH adequately
characterizes the temporal and spatial
heterogeneity common in most areas,
despite the available evidence to the
contrary. Finally, they assumed that the
percent of the crop treated in any
watershed would never exceed 5%,
despite varying pest pressures,
consultant recommendations, and
individual grower decisions. Leaving
aside that EPA believes most, if not all
of these assumptions are not supported
by the available evidence described
throughout the final rule, the probability
of all these assumptions always
simultaneously holding true under real
world conditions is unreasonably low,
and certainly does not approach the
degree of certainty necessary for EPA to
conclude that children’s exposures will
be safe.
Determining whether residues will be
safe for U.S. children is not a theoretical
paper exercise; it cannot suffice to
hypothesize a unique set of
circumstances that make residues ‘‘fit in
the box.’’ There must be a reasonable
certainty that under the variability that
exists under real world conditions,
exposures will be ‘‘safe.’’ EPA’s
assessments incorporate a certain degree
of conservatism precisely to account for
the fact that assumptions must be made
that may not prove accurate. This
consideration is highly relevant for
carbofuran, because as refined as EPA’s
assessments are, areas of uncertainty
remain with regard to carbofuran’s risk
potential. For example, a recent
epidemiological study reported that
45% of maternal and cord blood
samples in a cohort of New York City
residents of Northern Manhattan and
the South Bronx between 2000 and
2004, contained low, but measurable
residues of carbofuran (Ref. 88). The
Agency is currently unable to account
for the source of such sustained
exposures at this frequency.
A further consideration is that the
risks of concern are acute risks to
children. For acute risks, the higher
values in a probabilistic risk assessment
are often driven by relatively high
PO 00000
Frm 00015
Fmt 4701
Sfmt 4700
59621
values in a few exposures rather than
relatively lower values in a greater
number of exposures. This is due to the
fact that an acute assessment looks at a
narrow window of exposure where there
are unlikely to be a great variety of
consumption sources. Thus, to the
extent that there is a high exposure it
will be more likely due to a high residue
value in a single consumption event.
Additionally worrisome in this regard is
that carbofuran is a highly potent (i.e.,
has a very steep dose-response curve),
acute toxicant, and therefore any aPAD
exceedances are more likely to have
greater significance in terms of the
potential likelihood of actual harm. For
all of these reasons, EPA determined
that the existing carbofuran tolerances
did not meet the FFDCA safety
standard, and should therefore be
revoked.
VI. Response to Objections and
Requests for Hearing
A. Overview
Petitioners raised several objections
that correspond to four basic categories
of issues. The first category of objections
and hearing requests relates to
challenges to EPA’s selection of the
appropriate children’s safety factor. In
this category of issues, they raise
primarily two claims: (1) That EPA’s
scientific basis for retaining a 4X safety
factor is flawed, and (2) the statistical
calculations supporting the 4X safety
factor are flawed, and based on faulty
assumptions. The second category of
issues relate to the manner in which
EPA conducted its assessment of the
exposure from carbofuran through
drinking water sources. In this regard,
all of their objections fall within three
basic categories of issues: (1) EPA
should have accounted for a more
realistic percent of the crop treated
(PCT) in its surface water modeling; (2)
EPA’s ground water concentration
estimates are not based on the best
available data, but on obsolete data and
overly conservative assumptions; and
(3) FMC’s new label restrictions and
revised terms of registration will ensure
that drinking water concentrations will
not exceed 1.1 ppb. The third category
of issues relates to the manner in which
EPA conducted its dietary risk
assessment. Under this category, the
objections and hearing requests raise
four primary issues: (1) Petitioners
challenge the way in which EPA’s risk
assessments accounted for individuals
to recover from the effects of carbofuran
between exposures; (2) EPA should have
relied on the carbofuran human study
and therefore use of the default 10X
interspecies factor is inconsistent with
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59622
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
the ‘‘best available data; (3) the import
tolerances by themselves are safe and
EPA should have retained them even if
EPA believed tolerances associated with
the domestic uses were unsafe; and (4)
Petitioners claim that the combined
food and water exposures are safe, based
on FMC’s drinking water estimates of a
1.1 ppb maximum concentration, which
are guaranteed by new label restrictions
submitted as part of objections. Finally,
Petitioners raise one legal objection
unaccompanied by a hearing request.
They argue that EPA lacks authority to
limit issues and supporting information
that can be raised in objections and
hearing to those raised in earlier
comments.
EPA denies each of the Petitioners’
objections as well as their hearing
requests. In the first instance, EPA
denies Petitioners’ objections and their
hearing requests because the objections
are inextricably intertwined with
proposed changes to carbofuran’s FIFRA
registration that were not submitted
until after publication of the final
tolerance revocation rule. Objections to
EPA’s decision based on FIFRA
registration amendments proposed after
EPA’s decision are irrelevant, and thus
immaterial, to a challenge to EPA’s
decision (See Unit VI.C.). Secondly, an
individual analysis of Petitioners’
objections and hearing requests leads to
the same conclusion for the reasons
summarized below.
The Petitioners’ hearing requests fail
to meet the statutory and regulatory
requirements for holding a hearing. In
most cases, EPA has denied the request
on the grounds that the objection is
irrelevant, and therefore immaterial,
with regard to EPA’s final tolerance
revocation regulation. In particular,
many claims are immaterial because
they largely restate the claims in their
combined comments on EPA’s proposed
rule without challenging the substance
or even responding to EPA’s
explanations for the reasons that EPA
declined to adopt the approaches or
otherwise make the revisions suggested
by the Petitioners in their comments.
These claims are irrelevant to the
determinations reached in the final rule.
In several instances, EPA concluded
that Petitioners evidentiary proffer was
inadequate, because the data and
information submitted, even if accurate,
would be insufficient to justify the
factual determination urged, or to
resolve one or more of the issues in their
favor. Further, in many cases, the
evidence submitted constituted mere
allegations and general denials and
contentions, which EPA regulations
expressly provide to be insufficient to
justify a hearing. In addition, many of
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
Petitioners’ claims do not present
genuine and substantial issues of fact
and/or are immaterial to the relief
requested.
On the merits, the majority of
Petitioners’ objections are denied for
substantially the same reasons given in
EPA’s final rule and response to
comments. As noted, many of
Petitioners’ objections are simply their
recycled comments which do not
address the conclusions reached by EPA
in the final rule. To the extent a
response is even needed to such a stale
claim, it is provided in the final rule
and the response to comments.
The remainder of this Unit is
organized in the following manner. Unit
VI.B describes in greater detail the
requirements pertaining to when it is
appropriate to grant a hearing request.
In Unit VI.C, EPA generally denies all of
Petitioners’ objections and hearing
requests. Unit VI.D provides EPA’s
response to the Petitioners legal
objection that EPA lacks the legal
authority to limit the issues and
supporting information that can be
raised in an objection and hearing to
those raised in comments on the
proposed rule. Units VI. G and I provide
Petitioners’ claims regarding EPA’s risk
assessment. EPA’s conclusions on the
hearing requests and objections are
summarized in Unit VI.K.
EPA has adopted a 4-part format in
Units VI.E through I. for explaining its
ruling on each of the subissues EPA
identified in the objections. First, the
Petitioners’ claim and any arguments or
evidence tendered to support that claim
are described. Second, background
information on the claim is provided
including whether and how the claim
was presented in Petitioners’ comments
and, if it was presented, EPA’s reasons
for denying the claim in its final rule
and response to comments. Third, EPA
explains its reasons for denying a
hearing on that claim. Finally, EPA
explains its reasons for denying the
claim on the merits.
B. The Standard for Granting an
Evidentiary Hearing
EPA has established regulations
governing objections to tolerance
rulemakings and tolerance petition
denials and requests for hearings on
those objections. (40 CFR Part 178; 55
FR 50291 (December 5, 1990)). Those
regulations prescribe both the form and
content of hearing requests and the
standard under which EPA is to
evaluate requests for an evidentiary
hearing.
As to the form and content of a
hearing request, the regulations specify
that a hearing request must include:
PO 00000
Frm 00016
Fmt 4701
Sfmt 4700
(1) A statement of the factual issues on
which a hearing is requested and the
requestor’s contentions on those issues;
(2) a copy of any report, article, or other
written document ‘‘upon which the
objector relies to justify an evidentiary
hearing;’’ and (3) a summary of any
other evidence relied upon to justify a
hearing. (40 CFR 178.27).
The standard for granting a hearing
request is set forth in section 178.32.
That section provides that a hearing will
be granted if EPA determines that the
‘‘material submitted’’ shows all of the
following:
(1) There is a genuine and substantial issue
of fact for resolution at a hearing. An
evidentiary hearing will not be granted on
issues of policy or law.
(2) There is a reasonable possibility that
available evidence identified by the requestor
would, if established, resolve one or more of
such issues in favor of the requestor, taking
into account uncontested claims or facts to
the contrary. An evidentiary hearing will not
be granted on the basis of mere allegations,
denials, or general descriptions of positions
and contentions, nor if the Administrator
concludes that the data and information
submitted, even if accurate, would be
insufficient to justify the factual
determination urged.
(3) Resolution of the factual issue(s) in the
manner sought by the person requesting the
hearing would be adequate to justify the
action requested. An evidentiary hearing will
not be granted on factual issues that are not
determinative with respect to the action
requested. For example, a hearing will not be
granted if the Administrator concludes that
the action would be the same even if the
factual issue were resolved in the manner
sought.
(40 CFR 178.32(b)).
This provision essentially imposes
four requirements upon a hearing
requestor. First, the requestor must
show it is raising a question of fact, not
one of law or policy. Hearings are for
resolving factual issues, not for debating
law or policy questions. Second, the
requestor must demonstrate that there is
a genuine dispute as to the issue of fact.
If the facts are undisputed or the record
is clear that no genuine dispute exists,
there is no need for a hearing. Third, the
requestor must show that the disputed
factual question is material—i.e., that it
is outcome determinative with regard to
the relief requested in the objections.
Finally, the requestor must make a
sufficient evidentiary proffer to
demonstrate that there is a reasonable
possibility that the issue could be
resolved in favor of the requestor.
Hearings are for the purpose of
providing objectors with an opportunity
to present evidence supporting their
objections as the regulation states,
hearings will not be granted on the basis
of ‘‘mere allegations, denials, or general
E:\FR\FM\18NOR2.SGM
18NOR2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
descriptions of positions or
contentions.’’ (40 CFR 178.32(b)(2)).
EPA’s hearing request requirements
are based heavily on FDA regulations
establishing similar requirements for
hearing requests filed under other
provisions of the FFDCA (53 FR 41126,
41129 (October 19, 1988)). FDA
pioneered the use of summary
judgment-type procedures to limit
hearings to disputed material factual
issues and thereby conserve agency
resources. FDA’s use of such procedures
was upheld by the Supreme Court in
1972, (Weinberger v. Hynson, Westcott
& Dunning, Inc., 412 U.S. 609 (1973)),
and, in 1975, FDA promulgated generic
regulations establishing the standard for
evaluating hearing requests (40 FR
22950 (May 27, 1975)). It is these
regulations upon which EPA relied in
promulgating its hearing regulations in
1990.
Unlike EPA, FDA has had numerous
occasions to apply its regulations on
hearing requests. FDA’s summary of the
thrust of its regulations, which has been
repeatedly published in the Federal
Register in orders ruling on hearing
requests over the last 24 years, is
instructive on the proper interpretation
of the regulatory requirements. That
summary states:
pwalker on DSK8KYBLC1PROD with RULES2
A party seeking a hearing is required to
meet a threshold burden of tendering
evidence suggesting the need for a hearing.’
[] An allegation that a hearing is necessary to
sharpen the issues’ or fully develop the facts’
does not meet this test. If a hearing request
fails to identify any evidence that would be
the subject of a hearing, there is no point in
holding one.
A hearing request must not only contain
evidence, but that evidence should raise a
material issue of fact concerning which a
meaningful hearing might be held. [] FDA
need not grant a hearing in each case where
an objection submits additional information
or posits a novel interpretation of existing
information. [] Stated another way, a hearing
is justified only if the objections are made in
good faith and if they ‘‘draw in question in
a material way the underpinnings of the
regulation at issue.’’ Finally, courts have
uniformly recognized that a hearing need not
be held to resolve questions of law or policy
(49 FR 6672, 6673 (February 22,
1984); 72 FR 39557, 39558 (July 19,
2007) (citations omitted)).
EPA has been guided by FDA’s
application of its regulations in this
proceeding. Congress confirmed EPA’s
authority to use summary judgmenttype procedures with hearing requests
when it amended FFDCA section 408 in
1996. Although the statute had been
silent on this issue previously, the
FQPA added language specifying that
when a hearing is requested, EPA ‘‘shall
* * * hold a public evidentiary hearing
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
if and to the extent the Administrator
determines that such a public hearing is
necessary to receive factual evidence
relevant to material issues of fact raised
by the objections’’ (21 U.S.C.
346a(g)(2)(B)). This language grants EPA
broad discretion to determine whether a
hearing is ‘‘necessary to receive factual
evidence’’ to objections (H.R. Rep. No.
104–669, at 49 (1996)).
C. General Denial of Objections and
Hearing Requests
Petitioners’ objections and hearing
requests are denied in their entirety as
irrelevant, and therefore immaterial, to
EPA’s determination in the May 15,
2009 final rule that the carbofuran
tolerances were unsafe and could not be
sustained under FFDCA section 408. In
that final rule, EPA assessed the risks
from carbofuran based on existing uses
of carbofuran, as modified by all use
restrictions proposed by FMC. EPA
concluded that the carbofuran
tolerances substantially exceeded the
FFDCA safety standard, particularly as
to infants and children.
Petitioners’ objections and hearing
requests as to that final rule disclose on
their face their irrelevance to the
conclusions reached in the May 15,
2009 final rule. As Petitioners
summarize their objections on the first
page of their submission:
Petitioners disagree that the carbofuran
tolerances are unsafe and argue that the
available scientific data show that there is a
reasonable certainty of no harm to human
health from the continued use of carbofuran
for certain specific uses and related
tolerances under the terms for reregistration
proposed by Petitioners.
(Objections at 1) (footnote omitted)
(emphasis added). As Petitioners’
footnote to this sentence reveals,
however, the proposed terms for FIFRA
reregistration referenced by Petitioners
include significant terms submitted to
EPA on June 29, 2009, 44 days after
publication of the final rule revoking
carbofuran’s FFDCA tolerances. In fact,
the body of Petitioners’ objections show
that FMC’s June 29, 2009 proposed
FIFRA registration amendments are
inextricably intertwined with the claims
made in the objections. Thus,
Petitioners are actually not objecting to
the conclusions in EPA’s final rule;
rather, they are suggesting that EPA
might reach a different result in a
different factual scenario.
Objections, however, must be directed
‘‘with particularity [at] the provisions of
the regulation or order deemed
objectionable.’’ 21 U.S.C. 346a(g)(2). The
key here is that a party must file
particularized objections to—that is,
identify some type of error in—a
PO 00000
Frm 00017
Fmt 4701
Sfmt 4700
59623
specific regulatory decision. In no sense,
however, can it be claimed that EPA
erred, or that there is something
objectionable, in its May 15, 2009 file
rule because EPA did not consider a
proposed revision to the terms of the
carbofuran registration that had not yet
been made. EPA need not shoot at a
moving target, much less a target that is
not in existence. Therefore, Petitioners’
objections are irrelevant, and thus
immaterial, to the May 15, 2009 final
rule; they are based on hypothetical
terms of carbofuran use not before the
Agency as it made its determination in
that final rule.
Moreover, it is not as if Petitioners’
proposed terms for carbofuran use are
simple, straightforward use deletions
that could be immediately effectuated.
While such a proposal is still irrelevant
as a challenge to a prior EPA
determination, such a proposal might
lead EPA to expeditiously modify its
action. Rather, Petitioners have
proposed an unprecedented scheme
involving FMC playing a role as a
middleman between EPA and growers
to ensure that carbofuran use in no one
area exceeds a certain percentage of the
cropped area. FMC has properly filed
proposed amendments to its FIFRA
registration, which would incorporate
these new restrictions on carbofuran use
and EPA will review these proposals
consistent with the substantive and
procedural requirements of FIFRA. At
such time as these new terms of
registration are determined by EPA to
meet the standard for registration, and
not before, would it be appropriate for
EPA to consider whether the tolerance
revoked by the May 15, 2009 rule
should be re-established.
Finally, Petitioners argue that it can
raise its proposed terms of carbofuran
use because EPA cannot limit them from
putting forward new issues in a hearing.
As explained below, EPA believes
Petitioners have misconstrued the law
on this point. However, even assuming
for the sake of argument that Petitioners
are correct that new issues can be raised
at a hearing on objections, Petitioners
admit that any newly raised issues must
meet the standard of relevance. As
explained above, however, objections
based on terms or FIFRA registration
proposed after EPA’s final rule are
irrelevant to the correctness of EPA’s
determination in that final rule.
EPA has nonetheless evaluated each
of Petitioners’ objections and hearing
requests and determined that there are
alternate grounds for denying them. (See
Units VI.E through I). EPA has
undertaken this analysis for all of the
objections despite the fact that it is not
at all clear that those of Petitioners’
E:\FR\FM\18NOR2.SGM
18NOR2
59624
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
pwalker on DSK8KYBLC1PROD with RULES2
claims which appear to be unrelated to
FMC’s recently proposed registration
amendments would either individually
or collectively change EPA’s safety
determination for the carbofuran
tolerances given the relatively high level
of risk estimated for the carbofuran
tolerances in the final revocation rule.
Petitioners have certainly not provided
any road map as to how a safety finding
could be made absent FMC’s recentlyproposed registration amendments. The
failure to make such a showing is
further justification for EPA’s denial of
Petitioners’ objections and hearing
requests.
D. Response to Petitioners’ Objection
That EPA Lacks the Authority To Limit
the Issues That May Be Raised in
Objections and Hearing Requests
1. Response to Legal Issue. Petitioners
claim that EPA lacks the authority to
restrict the issues that may be raised as
part of their objections. Specifically,
they challenge EPA’s interpretation that
the failure to raise issues or provide
information during the comment period
on the proposed rule bars consideration
of such issues or evidence as part of
submitted objections or hearings.
Petitioners make two arguments in
support of this contention: (1) That
neither FFDCA section 408(g) on its face
nor EPA’s regulations implementing
FFDCA section 408(g) limit the issues
that can be raised in objections, or in
any hearing; and (2) that even though
the rulemaking phase is governed by
553 of the Administrative Procedure Act
(APA), the hearing must be held in
accordance with APA sections 556 and
557, which requires that the ‘‘exclusive
record for decision must consist of
testimony and exhibits received at the
hearing, as well as other papers filed in
the hearing proceeding’’ (Obj at 64). On
this basis, the Petitioners conclude that
all of the cases cited in the Final Rule
requiring parties to raise all issues and
information on which they intend to
rely in subsequent proceedings are
inapplicable.
These arguments are premised on
several fundamental misconstructions of
the FFDCA section 408 and the APA.
None of the cases they cite address the
specific question of whether and how
the requirements of section 553 of the
APA apply to FFDCA section 408. And
for many of these cases, Petitioners
misquote the cases, misinterpret the
holdings, or misconstrue language taken
out of context.
Petitioners’ first argument, that
neither section 408(g) nor EPA’s
regulations limit the issues that can be
raised in objections or in any hearing, is
incorrect and misses the point. As
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
discussed at length in the Final Rule,
the provisions of 408(g) are not to be
viewed in isolation, but as part of a
coherent statutory structure inextricably
linked to the FFDCA’s informal
rulemaking procedures and section 553
of the APA. Petitioners concede that
FFDCA section 408 establishes an
informal rulemaking process (Obj at 62–
63). As an informal rulemaking, the
process is governed by section 553 of
the APA and the case law interpreting
these requirements, except to the extent
that section 408 provides otherwise.5 In
this regard, it is well established that the
failure to raise factual or legal issues
during the comment period of a
rulemaking constitutes waiver of the
issues in further proceedings. E.g.,
Forest Guardians v. U.S. Forest Service,
495 F.3d 1162, 1170–1172 (10th Cir.
2007) (Claim held waived where
commenters ‘‘failed to present its claims
in sufficient detail to allow the agency
to rectify the alleged violation’’);
Nuclear Energy Institute v. EPA, 373
F.3d 1251, 1290–1291 (DC Cir. 2004)
(‘‘To preserve a legal or factual
argument, we require its proponent to
have given the agency a ‘fair
opportunity’ to entertain it in the
administrative forum before raising it in
the judicial forum.’’) Native Ecosystems
Council v. Dombeck, 304 F.3d 886, 889–
900 (9th Cir. 2002) (Purpose of
requirement that issues not presented at
administrative level are deemed waived
is to avoid premature claims and ensure
that agency be given a chance to bring
its expertise to bear to resolve a claim);
Kleissler v. U.S. Forest Service, 183 F.3d
196, 202 (3d Cir. 1999) (Policy
underlying exhaustion requirement is
that ‘‘objections and issues should first
be reviewed by those with expertise in
the contested subject area’’); National
Association of Manufacturers v. U.S.
DOI, 134 F.3d 1095, 1111 (DC Cir. 1998)
(‘‘We decline to find that scattered
references to the services concept in a
voluminous record addressing myriad
complex technical and policy matters
suffices to provide an agency like DOI
with a ‘fair opportunity’ to pass on the
issue’’); Linemaster Switch Corporation
v. EPA, 938 F.2d 1299, 1305–1306 (DC
Cir. 1991) (declining to consider in
challenge to final rule, data alluded to
in comments but not submitted during
the comment period, and information
submitted to EPA office that was not
developing the rule).
Moreover, EPA clearly stated in the
proposed rule that the Agency
5 For example, section 408(d) allows the Agency
to proceed to a final rule after publication of a
submitted petition, rather than requiring
publication of a proposal.
PO 00000
Frm 00018
Fmt 4701
Sfmt 4700
considered that the usual requirements
applicable to informal rulemakings
would remain applicable in this
informal rulemaking. The proposal
explicitly noted that ‘‘[i]f you anticipate
that you may wish to file objections on
the final rule, you must raise those
issues in your comments on this
proposal. EPA will treat as waived, any
issue not originally raised in comments
on this proposal’’ (73 FR 44,865 (July
31, 2008)).
The fact that FFDCA section 408 in
certain limited circumstances
supplements the informal rulemaking
with a hearing does not fundamentally
alter the requirements applicable to
informal rulemakings. Nor, as discussed
below, does it convert this into a formal
rulemaking, subject to the exception in
section 553. The FFDCA section 408
establishes a unique statutory structure
with multiple procedural stages, and
delegates to EPA the discretion to
determine the implementation that best
achieves the statutory objectives.
Accordingly, EPA interprets the notice
and comment rulemaking portion of the
FFDCA section 408 process as an
integral part of the FFDCA process,
inextricably linked to the administrative
hearing. The point of the rulemaking is
to resolve the issues that can be
resolved, and to identify and narrow
any remaining issues for adjudication.
Consequently the administrative hearing
does not represent an unlimited
opportunity to supplement the record,
particularly with information that was
available during the comment period,
but that commenters have chosen to
withhold. For example, as discussed at
greater length in Unit VI.E.2, both in
their comments, and again in their
objections, the Petitioners failed to
provide the underlying mathematical
modeling that supported their claim that
the appropriate children’s safety factor
was 1X, rather than 4X. Instead, they
presented only summary results.
Similarly, although the Petitioners
claimed in their comments to have
conducted an alternate analysis showing
that aggregate carbofuran exposures to
children would be safe, they failed to
provide the data and details of that
assessment to the Agency. They also
failed to provide several critical
components that served to support key
inputs into that assessment.
To read the statute otherwise would
be to render the rulemaking portion of
the process entirely duplicative of the
hearing, and thus, ultimately
meaningless. See, e.g., FDA v. Brown &
Williamson Tobacco, 529 U.S. 120, 132–
133 (2000) (Court must interpret statute
as a symmetrical and coherent
regulatory scheme, and fit, if possible,
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
all parts into a harmonious whole.)
APW, AFL–CIO v. Potter, 343 F.3d 619,
626 (2nd Cir. 2003) (‘‘A basic tenet of
statutory construction * * * [is] that a
text should be construed so that effect
is given to all its provisions, so that no
part will be inoperative or superfluous,
void or insignificant, and so that one
section will not destroy another
* * *’’), quoting Silverman v. Eastrich
Mulitple Investor Fund, 51 F.3d 28, 31
(3rd Cir. 1995). The equities of this
construction are particularly strong,
where, as here, the information was (or
should have been) available during the
comment period. See, Kleissler, 183
F.3d at 202 (‘‘[A]dministrative
proceedings should not be a game or a
forum to engage in unjustified
obstructionism by making cryptic and
obscure reference to matters that ‘ought
to be’ considered and then, after failing
to do more to bring the matter to the
agency’s attention, seeking to have that
agency determination vacated’’) citing
Vermont Yankee Nuclear Power Corp. v.
NRDC, 435 U.S. 519, 553–54 (1978). For
example, one of Petitioners’ exhibits is
the drinking water modeling that served
as the basis for the comments submitted
on the proposed rule. The documents
are dated well before the close of the
comment period, and were clearly
available for submission along with the
comments (Exhibit 15). Yet they were
only provided to EPA as part of the
Petitioners’ objections.
Contrary to Petitioners’ contention,
EPA’s interpretation is entirely
consistent with the FFDCA’s language
and structure. The fact that the statute
and regulations allow ‘‘any person’’ to
file objections is immaterial. At issue is
not ‘‘who’’ may raise objections, but
what issues may be raised as part of the
objections to justify a hearing. And on
the relevant question, the statute is clear
that only certain issues—those of
material fact—may be raised in
objections to justify a hearing (21 U.S.C.
346a(g)(2)(B)). EPA’s regulations expand
on this limitation, providing, among
other requirements, that hearings will
not be held on legal or policy issues, nor
on the basis of mere allegations, nor
where EPA concludes that the data and
information submitted, even if accurate,
would be insufficient to justify the
factual determination urged (See 40 CFR
178.32). It is true that FFDCA section
408(g)(2)(A) provides little guidance on
the objections that a party may raise,
requiring only that parties identify the
specific provisions challenged, and state
‘‘reasonable grounds’’ for their
objection. But the relative silence of the
statutory provision does not mean that
EPA is required to allow parties to raise
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
any and all objections; rather it means
that Congress left the question of what
constitutes ‘‘reasonable grounds’’ for
EPA to resolve.
In construing that requirement, EPA
gives weight to the fact that 408(g) is
only one part of a larger, multi-stage,
administrative process, and that the
statute does not support an
interpretation that this one phase be
granted greater significance than the rest
of the process. Also relevant is that
Congress delegated broad discretion to
the Agency to determine whether a
hearing is ‘‘necessary’’ (21 U.S.C.
346a(g)(2)(B)). Accordingly, EPA
believes that whether an objection states
‘‘reasonable grounds’’ is to be measured
against the context of the rulemaking,
and the provisions applicable to hearing
requests.
Fundamentally, FFDCA section 408
delegates broad discretion to EPA, both
to determine how best to harmonize the
statutory process and to determine what
constitutes ‘‘reasonable grounds’’ for
objections. Consequently, the relevant
question is whether EPA’s exercise of
discretion in requiring parties to present
all available factual issues and evidence
during the rulemaking is reasonable. It
is undeniably a reasonable exercise of
discretion to ensure that the rulemaking
is not an opportunity for one party to
waste the time and resources of all
parties—both the government and other
rulemaking participants—by failing to
raise all of their issues or withholding
information for the purpose of
surprising the government at a later
point during the proceeding. See, e.g.,
Vt. Yankee, 435 U.S. at 553–554; United
States v. L.A. Tucker Truck Lines, 344
U.S. 33, 37 (1952) (‘‘courts should not
topple over administrative decisions
unless the administrative body * * *
has erred against objection made at the
time appropriate under its practice’’).
EPA has consistently interpreted
section 408 in this fashion since the
1996 amendments. For example, EPA
previously ruled that a petitioner could
not raise new issues in filing objections
to EPA’s denial of its Original petition.
See 72 FR 39318, 39324 (July 18, 2007)
(‘‘The FFDCA’s tolerance revocation
procedures are not some sort of ‘game,’
whereby a party may petition to revoke
a tolerance on one ground, and then,
after the petition is denied, file
objections to the denial based on an
entirely new ground not relied upon by
EPA in denying the petition.’’). EPA
reasoned that new issues were not
cognizable because they ‘‘not an
objection to the ‘provisions of the * * *
order [denying the petition]’ ’’ (Id.).
Similarly, in a recent decision EPA
denied NRDC’s request for a hearing
PO 00000
Frm 00019
Fmt 4701
Sfmt 4700
59625
because they had failed in their original
petition to raise the claim asserted in
their objection (73 FR 42683, 42696
(July 23, 2008)). EPA noted that
although NRDC did argue in its petition
that EPA cannot make a safety finding
without completing the endocrine
screening program under FFDCA
section 408(p), it did not assert claims
regarding the endocrine data and the
children’s safety factor. Citing its
previous decision, EPA denied NRDC’s
objections and hearing requests as to the
children’s safety factor (Id.). In that
same decision, EPA also denied a
number of hearing requests on the
ground that requestor failed to proffer
supporting evidence; EPA opined that a
failure to offer evidence at an earlier
stage of the administrative proceeding
could not be cured by suddenly
submitting such evidence with a hearing
request. (See 73 FR 42683, 42710 (July
23, 2008) (‘‘Presumably Congress
created a multi-stage administrative
process for resolution of tolerance
petitions to give EPA the opportunity in
the first stage of the proceedings to
resolve factual issues, where possible,
through a notice-and-comment process,
prior to requiring EPA to hold a full
evidentiary hearing, which can involve
a substantial investment of resources by
all parties taking part * * *
Accordingly, if a party were to withhold
evidence from the first stage of a
tolerance petition proceeding and only
produce it as part of a request for a
hearing on an objection, EPA might very
likely determine that such an untimely
submission of supporting evidence
constituted an amendment to the
Original petition requiring a return to
the first stage of the administrative
proceeding (if, consideration of
information that was previously
available is appropriate at all’’).
The two cases Petitioners cite that are
specific to section 408(d) do not alter
this assessment. Neither of those cases
addressed the scope of the evidence that
could be properly raised as part of
objections to justify a hearing. Nor were
the courts examining the extent of EPA’s
authority to impose requirements on the
filing of objections under 408(g). Rather
these courts were evaluating the scope
of the FFDCA’s exclusive review
provisions, and whether the plaintiffs
could bring a challenge to EPA policies
and individual tolerance decisions
without first exhausting the FFDCA’s
petition process. Geertson Farms v.
Johanns, 439 F.Supp.2d 1012, 1022–
1023 (N.D. Ca 2006); NY v. EPA, 350
F.Supp.2d 429, 442–443 (S.D.N.Y.
2004). This issue is not identical to the
questions at issue here: for example, the
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59626
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
court in Geertson Farms held that the
plaintiffs’ procedural and policy
decisions were properly raised initially
before the Agency through the petition
process. 439 F.Supp2d at 442. Yet it is
undeniable that EPA’s regulations
preclude the reliance on policy or legal
issues as a justification for an Agency
hearing.
Nor do the Petitioners’ other cases
compel a different result. The majority
of the Petitioners’ cases concern FFDCA
section 701(e), which differs in several
significant respects from FFDCA section
408. Section 701(e) imposes no
requirements whatsoever on the party
submitting the objection: ‘‘any person
may file objections * * * specifying the
provisions of the order deemed
objectionable, stating the grounds
therefore * * *’’ 21 U.S.C. 371(e)(2).
This section also expressly provides that
FDA must hold a hearing upon request:
‘‘As soon as practicable after such
request for a public hearing, the
Secretary, after due notice, shall hold
such a public hearing for the purpose of
receiving evidence relevant and material
to the issues raised by such objections.’’
21 U.S.C. 371(e)(3). In the face of this
language, it is unsurprising that the
courts held that FDA lacked discretion
to deny a hearing. Further, under
FFDCA section 701(e) the mere filing of
an objection automatically stays the
effectiveness of the challenged
provisions. ‘‘Until final action is taken
upon such objections is taken by the
Secretary under paragraph (3), the filing
of such objections shall operate to stay
the effectiveness of those provisions of
the order to which the objections are
made.’’ 21 U.S.C. 371(e)(3). By contrast,
section 408 grants the Administrator the
discretion to stay the effectiveness of the
regulation if objections are filed. 21
U.S.C. 346a(g)(1). Indeed, the
Petitioners’ own cases specifically
distinguish between section 701(e) and
other FFDCA provisions. See Pactra
Industries v. Consumer Product Safety
Commission, 555 F.2d 677, 685 (9th Cir.
1977) (rejecting FDA argument that
FFDCA section 701 should be read
consistently with FFDCA sections 505
and 507 to allow for summary judgment
procedures).
Petitioners’ second argument is
equally incorrect.6 As an initial matter,
the parties agree that FFDCA 408
establishes a hybrid rulemaking
procedure, with informal rulemaking
initiating, and frequently ending, the
6 As discussed below, it is not clear that a
determination that a hearing, if held, must be held
in accordance with APA sections 556 and 557
precludes EPA from exercising its discretion to
restrict the issues and evidence that may be raised
at this final stage of the administrative process.
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
process (74 FR 23070 (May 15, 2009));
Obj at 62). Hybrid rulemaking is not
formal rulemaking, which is the only
rulemaking to which APA sections 556
and 557 apply. Nevertheless, Petitioners
contend that once objections are raised,
‘‘Congress required the use of a formal
rulemaking procedure involving an onthe-record hearing for resolving factual
disputes.’’ (Obj at 62) Nothing in the
FFDCA section 408 or the APA supports
this interpretation. And the cases cited
in support of this argument are
inapposite or misconstrued.
The APA section 553 on its face
applies to all rulemakings except
‘‘[w]hen rules are required by statute to
be made on the record after opportunity
for an agency hearing’’ (5 U.S.C. 553(c)).
Under this language, APA section 553
will apply unless two requirements are
met: (1) The statute requires an
opportunity for a hearing as part of the
rulemaking, and (2) the hearing is
required to be ‘‘on the record.’’ FFDCA
section 408 hearings are neither
‘‘required,’’ nor mandated to be ‘‘on the
record.’’ The case law is clear that
statutes containing both characteristics
are the hallmark of formal rulemaking,
and that formal rulemaking is the rare
exception. AT&T v. FCC, 572 F.2d 17,
21–23 (2d Cir. 1978) (‘‘The APA
requires trial-type hearings only ‘[w]hen
rules (or adjudications) are required by
statute to be made (or determined) on
the record after opportunity for an
agency hearing.’ ’’) (citations omitted);
Minden Beef Co v. Cost of Living
Council, 362 F.Supp. 298 (D. Neb. 1973)
(examining whether statutory provision
that ‘‘[t]o the maximum extent possible,
the President or his delegate shall
conduct formal hearings * * *’’ makes
hearings mandatory, in determinating
whether formal rulemaking required).
See also, e.g., Girard v. Klopfenstien,
930 F.2d 738, 741 (9th Cir. 1991) (‘‘The
APA does not apply because a
debarment hearing is not required by
statute. The fact that the hearing is ‘on
the record’ does not trigger an
application of the formal adjudication
provisions of section 554 of the APA’’);
Smedberg Machine & Tool v. Donovan,
730 F.2d 1089, 1092–93 (7th Cir. 1984)
(holding section 554 inapplicable to a
proceeding that ‘‘gives the
adminsitrative law judge the discretion,
rather than the obligation to conduct a
review hearing.’’). As discussed below,
in contrast to other sections of the
FFDCA, such as section 701(e), FFDCA
section 408 makes clear that a hearing
is not mandatory upon request, but that
EPA has broad discretion to determine
whether a public hearing is necessary to
receive factual evidence. See, 21 U.S.C.
PO 00000
Frm 00020
Fmt 4701
Sfmt 4700
346a(g)(2)(B), 346a(g)(2)(C). See also,
H.R. Rep. No. 104–669, at 49 (1996).
The Supreme Court made clear in
Florida East Coast Railway v. FLRA, that
the circumstances under which rules are
‘‘required to be made on the record after
opportunity for an agency hearing’’ are
limited to those where Congress clearly
indicates the intent to do so. 410 US
224, 241 (1973). The mere fact that
statute offers an opportunity for an
agency hearing is not sufficient to bring
rulemaking under scope of this
exemption. Id. See also, U.S. v.
Allegheny-Ludlum Steel, 406 U.S. 742
(1972); NRA v. Brady, 914 F.2d 475, 485
(9th Cir. 1990) (No oral hearing required
where statute required Secretary to
‘‘afford interested parties opportunity
for hearing’’ and Agency regulations
reserved right to determine whether oral
hearing warranted); Wisconsin Gas Co v.
FERC, 770 F.2d 1144, 1165–1168 (DC
Cir. 1985) (APA 556 hearing not
required when statute only contained
provisions requiring decision ‘‘after a
hearing’’ and ‘‘substantial evidence’’
standard of judicial review); AT&T v.
FCC, 572 F.2d 17, 21–23 (2d Cir. 1978)
(APA 556 hearing not required when
statute only contained provisions
requiring decision ‘‘after a hearing’’ and
‘‘substantial evidence’’ standard of
judicial review) Philips Petroleum Co v.
FPC, 475 F.2d 842, 851–852 (10th Cir.
1973) (formal rulemaking not required
even though statute required ‘‘full
hearing’’ and Agency traditionally
conducted trial-type adjudicative
hearing).
Unless the statute providing for
agency action prescribes ‘‘hearings on
the record,’’ either in those exact words
or by using similar words to indicate
that Congress specifically intended to
impose the full trial-type requirements
of sections 556 and 557, the statute does
not fall within section 553’s exception.
FL East Coast Railway, 410 US at 241.
While the absence of those words is not
dispositive, ‘‘in the absence of these
magic words, Congress must clearly
indicate its intent to trigger the formal,
on the record hearing provisions of the
APA.’’ City of West Chicago, Illinois v.
NRC. 701 F.2d 632, 641 (7th Cir. 1983)
(citations omitted). See also, e.g.,
National Classification Committee v.
ICC. 765 F.2d 1146, 1150–1151 (DC Cir.
1985) (‘‘Thus under Florida East Coast,
there is a strong presumption that the
procedural guarantees of section 553 of
the APA are sufficient unless Congress
specifically indicates to the contrary’’
citing Vermont Yankee Nuclear Power
Corp v. NRC, 435 U.S. 519 (1978)); AT
& T v. FCC, 572 F.2d at 21–23 (‘‘The
words, ‘on the record’ have become, as
the District of Columbia Circuit has
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
observed, a ‘touchstone test’ for the
applicability of the APA’s trial-type
procedures’’); Philips Petroleum Co, 475
F.2d at 851–852 (‘‘The fact, as
previously noted, that the Gas Act does
not contain the words ‘on the record’
furnishes a strong argument in support
of the Commission’s contention that
informal rulemaking satisfies the
requirements of the APA’’); Minden Beef
Co, 362 F.Supp. at 306–307 (‘‘Requiring
‘formal hearings’ is not identical with
requiring that rules be made on the
record after opportunity for agency
hearing.’’) What is notable is that, in all
cases, the court required clear
expression that Congress specifically
intended to impose full trial-type
requirements.
Thus the question is whether
Congress indicated any intent to entirely
remove the FFDCA section 408 process
from the requirements of 553. The mere
fact that FFDCA section 408 requires
some (or even many) of the procedures
applicable under section 556 and 557
does not resolve the question. See, e.g.,
National Classification Committee v.
U.S., 765 F.2d 1146, 1150–1151 (DC Cir.
1985) (Rejecting argument that formal
rulemaking required on grounds that
‘‘[u]nder Florida East Coast there is a
strong presumption that the procedural
guarantees of section 553 of the APA are
sufficient unless Congress specifically
indicates to the contrary’’); Association
of National Advertisers v. FTC, 627 F.2d
1151, 1165–1168 (DC Cir. 1979) (formal
rulemaking not required, even though
statute ‘‘did order use of procedures not
required in informal rulemaking’’ such
as rights to rebuttal and crossexamination at public hearing.);
American Public Gas Association v.
FPC, 567 F.2d 1016, 1065–1067 (DC Cir.
1977) (Formal rulemaking not required
by statutory provisions requiring ‘‘full
hearing’’ and ‘‘substantial evidence’’
standard of judicial review).
In fact, the language and legislative
history of section 408 provide clear
indication of Congressional intent not to
subject proceedings under these
sections to APA sections 556 and 557.
FFDCA section 408 does not reference
APA sections 556 or 557 (see, e.g., 7
U.S.C. 136d(c)(2)). By contrast, the
previous version of section 408 did
reference APA section 556, and the
deletion of this requirement provides
clear evidence of Congressional intent
not to exempt FFDCA from APA 553.
Prior to the 1996 amendments, section
408(d)(5) of the original act, which
governed the conduct of hearings,
specifically referenced APA 556. (‘‘Any
report, recommendations, underlying
data, and reasons certified to the
Secretary by an advisory committee
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
shall be made part of the record of the
hearing, if relevant and material, subject
to the provisions of section [556] of the
APA.’’). 21 U.S.C. 346(d)(5). Moreover,
the previous version of the statute
contained additional language
consistent with the requirement of
hearings subject to APA sections 556
and 557; for example, the previous
version of section 408(d)(5) repeatedly
makes reference to ‘‘testifying at such
hearing.’’ A further consideration is that
several other provisions of the FFDCA
do explicitly reference APA sections
554 or 556. Compare, 21 U.S.C.
333(g)(3) (‘‘A civil penalty * * * shall
be assessed by the Secretary by an order
made on the record after opportunity for
a hearing provided in accordance with
this subparagraph and section 554 of
title 5’’); 21 U.S.C. 342(f)(1)(C)
(requiring the Secretary, upon any
declaration of imminent hazard under
this section to ‘‘initiate a proceeding in
accordance with sections 554 and 556 of
title 5’’). The fact that Congress chose
not to explicitly reference APA sections
556 or 557 provides a strong indication
that they did not intend to impose such
a requirement on section 408
proceedings. See, e.g., St Louis Fuel and
Supply Co v. FERC, 890 F.2d 446, 449
(DC Cir. 1989) (holding that formal
hearing under APA 554 not required on
that grounds that ‘‘[w]e consider it
significant that, unlike section 7193(c),
other prescriptions in the DOE
Organization Act expressly invoke the
APA’’) (citations omitted).
Nor does any provision of FFDCA
section 408 include the requirement that
the hearing be ‘‘on the record.’’ By
contrast, several other provisions of the
FFDCA include that exact phrase.
Compare, 21 U.S.C. 335a(i) (‘‘The
Secretary may not take action * * *
unless the Secretary has issued an order
for such action made on the record after
opportunity for an agency hearing on
disputed issues of material fact.’’); 21
U.S.C. 335b(b)(1)(A) (‘‘A civil penalty
shall be assessed * * * by an order
made on the record after an opportunity
for an agency hearing * * *’’); 21 U.S.C.
335(c)(b) (‘‘The Secretary may not take
action * * * unless the Secretary has
issued an order for such action made on
the record after opportunity for an
agency hearing on disputed issues of
material fact.’’) Under all rules of
statutory construction, those differences
are presumed to be intentional. Russello
v. United States, 464 U.S. 16, 23 (1983)
(‘‘[W]here Congress includes particular
language in one section of a statute and
omits it in another section of the same
Act, it is generally presumed that
Congress acts intentionally and
PO 00000
Frm 00021
Fmt 4701
Sfmt 4700
59627
purposely in the disparate inclusion or
exclusion’’).
Equally significant is that the
language of section 408 explicitly grants
EPA broad discretion to deny a hearing.
Section 408(g)(2)(B) provides that EPA
shall ‘‘hold a public evidentiary hearing,
if and to the extent the Administrator
determines that such a public hearing is
necessary to receive factual evidence
relevant to material issues of fact raised
by the objections’’ (21 U.S.C.
346a(g)(2)(B)) (emphasis added). This
language grants EPA the discretion to
determine whether the issues raised in
objections are ‘‘material’’ issues of fact.
Further, even where evidence relevant
to an issue of material fact is proffered
(essentially the standard set forth in 40
CFR 178.32), EPA construes the
statutory language as requiring it to hold
a hearing only where it determines it is
necessary to receive proffered evidence.
In other words, the statute grants EPA
the discretion to determine that the
issues could be resolved entirely on the
basis of the existing written record. See
Philips Petroleum, 475 F.2d at 848–849
(Formal rulemaking under APA 556 not
required even though statute required
that hearing be held, but ‘‘Commission
has a very broad discretion in
determining the form of its
proceedings’’).
EPA’s construction is confirmed by
the House Commerce Committee Report
accompanying the final bill, which
states:
New subparagraph (g)(2)(B) allows an
objector to request a public evidentiary
hearing. The Administrator would decide
whether [a] hearing were necessary to receive
factual evidence relevant to material issues of
fact raised by the objections. The Committee
expects EPA to use this discretion fairly and
to grant hearings to responsible parties on all
sides.
H.R. Rep. No. 104–669, at 49 (1996)
(emphasis added). Notably, in an earlier
version of the 1996 amendments, the
House bill provided for a mandatory
hearing during the notice-and-comment
rulemaking stage of an EPA-initiated
proceeding. [H.R. 1627, 104th Cong.
Section 405 (new FFDCA section
408(e)(2)) (‘‘EPA shall provide an
opportunity for a public hearing
* * *’’) (emphasis added). This
requirement was dropped prior to
enactment but the contrast with section
408(g)(2)(B) confirms the discretionary
character of the latter.
If this were not sufficient indication
of Congressional intent, further
evidence is provided by the fact that in
amending section 408, Congress chose
not to adopt the provisions of section
701(e) that Petitioners cite in their
objections. Clearly, Congress could have
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59628
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
adopted the same provisions found in
FFDCA 701(e), or in any of the other
comparable FFDCA provisions
discussed above, but chose not to do so.
EPA agrees that, when a hearing is
warranted, the FFDCA requires an
evidentiary hearing that comports with
the procedures contemplated by
408(g)(2)(B). But that is not the same as
a requirement that section 553 be
inapplicable to the proceedings, or that
any hearing be held in accordance with
APA sections 556 and 557.7 Rather,
section 408’s provisions are consistent
with APA sections 553 (b) and (c),
which recognize the potential for
hearings as part of informal rulemaking:
‘‘Except when notice or hearing is
required by statute, * * * the agency
shall give interested persons an
opportunity to participate in the rule
making through submission of written
data, views, or arguments, with or
without the opportunity for oral
presentation.’’ 5 U.S.C. § 553(b)(c)
(emphasis added).
Finally, Petitioners’ citation to case
law interpreting FFDCA section 701(e)
does not compel a different result.
Petitioners claim that the provisions of
FFDCA 701(e) are ‘‘near identical’’ to
those under section 408, and on this
basis, argue that, ‘‘by analogy’’ these
decisions compel an identical
interpretation of the requirements of
FFDCA section 408 (Obj at 65).
Petitioners are correct that section
701(e) of the FFDCA has been held to
be ‘‘one of those statutes, few in
number, that does require rule-making
hearings to be on the record in
accordance with APA sections 556.’’
Pactra, supra, 555 F.2d 677, 685 (9th
Cir. 1977), citing Florida East Coast
Railway, 410 U.S. at 237–38, (dictum).
But in all other regards, Petitioners are
incorrect.
As previously discussed, there are
several significant differences between
the statutory language of FFDCA
sections 701 and 408 that render
Petitioners’ citation to these cases
inapposite. Hearings are mandatory
upon request under section 701, and the
filing of objections operates to
automatically stay the provisions of the
rule. Section 701(e)(2) requires only that
the objection ‘‘state the grounds
therefore,’’ rather than requiring the a
statement of ‘‘reasonable grounds.’’ See
Pactra at 684 (distinguishing FFDCA
section 701(e) from 507(f) because the
latter requires hearing applicants to
7 EPA’s
regulations currently provide for a trialtype adjudicatory hearing. These regulations were
adopted under the preceding statutory provision,
and EPA has not yet undertaken any effort to revise
the regulations to take into account the revised
provisions of section 408.
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
show ‘reasonable grounds’). Further,
although section 701 does not itself
contain the requirement that the hearing
be ‘‘on the record,’’ the legislative
history of this provision indicates that
Congress intended such hearings to be
‘‘on the record.’’ Pactra, 555 F.2d at
682–684 (detailing FFDCA section 701
legislative history). These characteristics
played a significant role in the court’s
decision that FDA lacked the authority
to deny hearings under section 701(e)
on the basis of summary judgment
proceedings.8 However, as shown
above, the legislative history of section
408 provides a clear indication of a
contrary Congressional intent with
respect to hearings under this section.
Petitioner’s reliance on the
‘‘substantial evidence’’ standard in
FFDCA section 408(i) is equally
misplaced. Incorporation of that
standard into judicial review provisions
alone has been consistently held to be
insufficient to indicate Congressional
intent to impose the full requirements of
APA sections 556 and 557 to a
rulemaking. Wisconsin Gas Co v. FERC,
770 F.2d at 1167 (‘‘The procedures
required to develop this ‘substantial
evidence’ are not necessarily the strict
adversary procedures of sections 556
and 557 of the Administrative
Procedures Act’’); Public Systems v.
FERC, 606 F.2d 973, 979, n. 32 (DC Cir.
1979) (substantial evidence requirement
in Natural Gas Act ‘‘carries no
implications for procedures to be
followed by the Commission in
compiling the record’’); American
Public Gas Association v. FPC, 567 F.2d
1016, 1065–1067 (DC Cir. 1977) (‘‘In our
view, however, this requirement [of the
substantial evidence standard] in the
judicial review provision of the Act
does not dictate the procedure to be
followed, or the nature of the hearing to
be held).
The specific language of 408(i) defines
the standard for the reviewing court; it
does not describe the process by which
the agency hearing is to be conducted.
This is quite different from the language
under 501(c) of the CWA, on which the
DC Circuit relied in holding that
hearings pursuant to APA section 554
were required. Marathon Oil v. EPA,
564 F.2d 1253, 1262–1265 (DC Cir.
1977). The CWA section 501(c) states
‘‘[i]n any judicial proceeding * * * in
which review is sought of a
determination under this chapter
8 Contrary to Petitioners’ allegation, the DC
Circuit has not ‘‘arrived at the same conclusion’’
(Obj at 65). All of the discussion from Independent
Cosmetic Manufacturers and Distributors v. U.S.
Dept of Health, Education, and Welfare presented
in their objections is dicta from a dissenting
opinion. 574 F.2d 553, 572 (DC Cir. 1978).
PO 00000
Frm 00022
Fmt 4701
Sfmt 4700
required to be made on the record after
notice and opportunity for a hearing
* * *’’ 33 U.S.C. 1369(c) (emphasis
added).9 By contrast, FFDCA section
408(i) merely provides that ‘‘[a]s to
orders issued following a public
evidentiary hearing, the findings of the
Administrator with respect to questions
of fact shall be sustained if supported by
substantial evidence when considered
on the record as a whole’’ (21 U.S.C.
346a(i)) (emphasis added). It is also
worth noting that the court expressly
distinguished this case, which dealt
exclusively with an adjudicatory
proceeding, from those circumstances in
which an agency proceeds through
rulemaking. 564 F.2d at 1262, n. 30.
In any event, even if section 556 did
apply to hearings under section 408,
Petitioners cannot avoid the case law
under section 553 and EPA’s
interpretation of the interrelationship
between any hearing granted under
section 408(g)(2) and the rulemaking
preceding it. Petitioners cite to the
general evidentiary provision in section
556(d) that provides that only irrelevant
or immaterial evidence may be excluded
and argue that this generic standard
necessarily defines the scope of a
hearing regardless of the statutory
scheme in which it is embedded.
However, context matters. As the DC
Circuit noted, ‘‘the informal procedures
of section 553 of the APA and the more
formal requirements of sections 556 and
557 are not mutually exclusive.’’
American Public Gas Association, 567
F.2d at 1067. Even the caselaw relied
upon by Petitioners does not suggest
that section 556(d)’s evidentiary
provision trumps all other
considerations. Petitioners cite
primarily to Catholic Medical Center,
Inc. v. NLRB, 589 F.2d 1166, 1170 (2d
Cir. 1978). In that case, the Second
Circuit interpreted section 556(d) as
specifying that ‘‘an agency thus may not
provide for the exclusion of evidence
not protected by a privilege or
countervailing policy . * * *’’ Id.
(emphasis added). Here, EPA has
interpreted its authority to impose such
a countervailing policy. Moreover,
EPA’s interpretation is clearly within
the broad discretion granted it by the
statute and the policy underlying the
interpretation is a reasonable adaptation
of judicial practice with regard to issues
not presented in notice and comment
rulemaking proceedings. Thus,
Petitioners’ technical and formalistic
argument concerning section 556(d),
which ignores the context of the section
408(g)(2) hearing provision, must be
rejected.
Similarly unavailing is Petitioners’
argument concerning section 556(e)’s
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
specification that the ‘‘exclusive record
for decision’’ after a hearing is material
or testimony submitted in the hearing or
hearing proceeding. Petitioners assert
that this provision somehow removes
any limitations on what can be
submitted at the hearing because ‘‘that
‘exclusive record’ is independent of
whatever record may exist in the prior
informal rulemaking * * *.’’ (Obj at 64).
Yet the hearing record is not
‘‘independent’’ of the rulemaking record
in that EPA regulations require that the
rulemaking record be included in the
record of the hearing (40 CFR
179.179.83(a)(1)). Once again,
Petitioners’ argument fails because it
considers section 556 in isolation rather
than taking into account the context of
the entire administrative proceeding in
which the hearing is embedded.
Finally, Petitioners complain that
EPA ‘‘raised a host of new issues and
assertions for the first time in the Final
[rule],’’ and it would be inequitable for
EPA to prevent them from raising
objections on these new assessments.
Petitioners identify ten categories of
‘‘new computations and contentions’’
that they claim raise issues that go
beyond those addressed in their prior
comments. With one exception, all of
these ‘‘new computations and
contentions’’ were revisions to analyses
conducted in response to Petitioners’
comments. Indeed, some of these were
revisions undertaken in response to
Petitioners’ specific request; for
example, the ‘‘new’’ BMD analyses they
identify were: (1) Corrections made in
response to an EPA error identified in
their comments; (2) an extrapolation of
BMD50 s, using the dose-time-response
model, to develop a common point of
comparison between all studies, which
they had claimed was the appropriate
approach; and (3) a calculation
generating a new dose-response model
in order to calculate the BMD50 s for
brain and RBC AChE inhibition, in
response to Petitioners’ claim that
failure to do so was inappropriate (Refs.
24, 25, 85). Since these analyses were
done at their behest, they can hardly
complain that they present new issues
on which they had no opportunity to
comment. The Agency’s underlying
methodologies were the same as those
used for the proposed rule; the analyses
were based on information provided by
the Petitioners and/or to address the
revisions requested as part of the
Petitioners’ comments.
Regarding the remaining analyses:
The ‘‘new exposure estimates for ground
and surface water,’’ as well as the
‘‘revised dietary risk and drinking water
assessments’’ and ‘‘new assessment of
the impact of buffers and setbacks’’ were
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
conducted to accurately reflect the use
under the registration, as modified by
FMC’s cancellation of uses and
additional mitigation measures. The
same is true for the ‘‘new analysis of the
various carbofuran labels;’’ the analysis
related to the labels submitted as part of
the September 2008 comments. The
chlopyrifos studies were raised in
response to the Petitioners’ citation to a
subset of chlorpyrifos data. They
acknowledge that the ‘‘new literature
citations’’ were provided to address one
of their contentions (Obj at 56). The sole
exception relates to EPA’s calculation of
carbofuran-specific half-lives for use in
the dietary risk assessment. As
discussed in Unit VI.G.2, EPA does not
reject Petitioners’ challenge to EPA’s
calculation of the 186-minute half-life
on the basis that it is untimely.10
A fair indication that EPA has not
raised a host of new issues in the final
rule is that, with the exception of the
revised half-lives, Petitioners do not
challenge the substance of any of the
allegedly ‘‘new’’ information. Indeed, as
discussed in the sections below,
Petitioners have in many instances
failed to address any of the explanations
or revised analyses EPA presented in
the final rule.
Ultimately, Petitioners’ complaint
misses the point. EPA does not interpret
the statute and regulations to preclude
the submission of any new information
as part of the objections phase. Such a
position would in fact be inconsistent
with EPA’s own regulations and past
practice, which require that in order to
support a hearing request, a party
submit more than ‘‘mere allegations or
denials’’ (40 CFR 178.32(b)(2)). Rather,
EPA’s interpretation in this regard is
analogous to the determination of
whether a final rule is the logical
outgrowth of the proposal and the
comments. For example, EPA does not
reject Petitioners’ citation to new
studies in support of the contention that
RBC AChE data are generally more
sensitive than PNS tissues on the
grounds that they are untimely. This is
because these studies are simply more
evidence supplementing the issue they
fairly raised in their comments, and are
intended to rebut EPA’s response in the
final rule. Similarly, the submission of
new analyses relating to the ground
water pH in Exhibit 14 is not considered
untimely, as the issues they raise
relating to ground water pH were fairly
raised in comments and discussed
throughout the rulemaking. Ultimately,
10 The Petitioners’ claim that ‘‘EPA provided new
information concerning the raw data collected and
records maintained by ORD in relation to its
toxicology studies’’ is inaccurate. EPA provided no
new information on this topic in the final rule.
PO 00000
Frm 00023
Fmt 4701
Sfmt 4700
59629
EPA’s policy is merely that the
objections phase does not present an
opportunity for parties to begin the
process entirely anew, by raising issues
or information that could have been
fairly presented as comments on the
proposed rule. Nor is the statute’s
additional procedural step an excuse to
withhold information that was clearly
available at the time of the rulemaking.
2. Implications for FMC’s Submission
of New Registration Amendments as
Part of their Objections. On June 29,
2009, in conjunction with their
objections on the final rule, FMC
Corporation submitted a request for EPA
to amend its registration in several
regards. Some of the requested
amendments were further mitigation
measures intended to address
carbofuran’s dietary risks. The most
significant of these was a proposal
intended to ensure that only 2% of any
watershed would be treated with
carbofuran. The proposal would require
that, within five days of applying the
product, all applicators report to FMC
the following information: The location
that the product will be used, crop, use
rate, application method, acreage, and
quantity applied. Based on this
information, FMC would track the
percentage in each watershed.
‘‘Whenever it appears that carbofuran
has been applied to 1.75% of any
watershed,’’ the registrant would report
that information immediately to EPA,
‘‘cease further sales in any county that
overlaps with such a watershed for that
use season, and shall attempt to recall
all unused carbofuran within such
counties by offering to repurchase such
unused product’’ (Exhibit 2).
Additionally, FMC requested that its
registration be amended to require that
‘‘based on watershed boundaries, FMC
* * * prior to each use season, allocate
to its distributors in a manner which
will attempt to ensure that no
distributor receives more carbofuran for
sale than can be accommodated by the
2% watershed area cap in any
watershed supplied by that distributor.’’
In addition, FMC proposed to add
geographic restrictions that would
prohibit use in certain parts of the
country. Specifically, they proposed to
restrict the use of carbofuran on
potatoes to the three states: Idaho,
Oregon, and to select counties in
Washington. They proposed to restrict
use on Sunflowers to only Colorado,
Kansas, Nebraska, and South Dakota, as
well as limited portions of North Dakota
and Oklahoma. Under this proposal, use
on corn would be restricted to Colorado,
Iowa, Illinois, Indiana, Kansas,
Missouri, Nebraska, and limited
counties in Wisconsin. Further, they
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59630
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
proposed to add set-backs (i.e., areas
where carbofuran could not be applied)
ranging between 100 and 1,000 feet from
drinking water wells, depending on the
geographic area. Finally, as part of these
amendments, FMC also requested that
EPA revise its registration to permit use
of carbofuran on pumpkins in Ohio,
Illinois, and Indiana, and to cancel the
use on pumpkins in the southeastern
United States.
As made clear in Unit VI.C., FMC’s
newly-proposed registration
amendments are irrelevant to the prior
determinations made in the final
tolerance revocation rule. Further, as
discussed in Unit VI.D., as a
consequence of the failure to raise these
amendments measures as part of their
comments on the proposal, EPA
considers that all issues arising
exclusively as a result of these proposed
amendments have been waived. There is
no evident reason that FMC could not
have offered these amendments as part
of its September 2008 proposals. All of
the information on which they rely was
available in September of 2008. All of
the risk concerns that the amendments
were intended to address were
discussed at length in EPA’s proposed
rule. Since 2006, EPA has clearly stated
its determination that carbofuran’s
potential to leach into ground water and
to runoff into surface water caused
unacceptable dietary risks. EPA’s
methodologies for evaluating these risks
have not changed since 2006. Indeed,
EPA deferred regulatory action for
several months, subsequent to the
Agency’s determination in 2006 that
carbofuran did not meet either the
FIFRA or FFDCA standard, to allow the
Petitioners time to generate data to
address the exact same issues these
proposals are intended to address. In
their comments on the proposed rule,
Petitioners provided some mitigation
measures intended to address issues
relating to the carbofuran’s leaching and
runoff potential: Well set-backs, buffers,
geographic use restrictions, and aerial
application recommendations.
As previously discussed, EPA
provided clear notice in the proposed
rule that issues that that were not raised
during the comment period would be
considered waived in subsequent stages
of the administrative process (73 FR
44,865). Petitioners were well aware of
this, as they commented that ‘‘EPA’s
requirement to raise all issues in the
comments does not appear to be legally
binding’’ (Ref. 18 at 118). Indeed they
acknowledged that they ‘‘agree that
identifying disputed issues in the
comments is efficient and desirable, and
may help to narrow the issues arising in
subsequent objections and an
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
administrative hearing. Therefore, the
commenters have made a good faith
attempt to raise in these comments the
principal issues of which they are
aware’’ (Id.).
At this stage of the process, the statute
requires the Petitioners to object to the
conclusions and provisions in EPA’s
final rule, not to propose some new
alternate license that they claim would
meet the statutory standards (21 U.S.C.
346a(g)(2)(A) (‘‘any person may file
objections * * * specifying with
particularity the provisions of the
regulation * * * deemed
objectionable’’). In fact, one might fairly
read their proposal as an admission that
the existing license fails to meet the
statutory standards.
A further consideration is that the
question of whether these amendments
can be approved depends on whether
the Agency eventually determines the
amended registration meets the
standards of FIFRA, which include
considerations beyond the dietary risks
evaluated under the FFDCA. Under
FIFRA, the Agency’s review of the
amendments is also subject to a
statutorily mandated schedule
(established as part of the Pesticide
Regulatory Improvement Act (PRIA)).
These are no small matters. In terms of
timing, FMC explicitly acknowledged in
its letter submitting the proposed
amendments that the amendments were
subject to the PRIA review process,
requesting that the actions be subject to
the PRIA 8-month statutory deadline
(which would establish a statutory
deadline of February 2010 for Agency
consideration of FMC’s application). It
is not clear whether FMC is arguing that
its application be accorded a higher
priority than other applications and be
taken out of turn, or whether FMC is
arguing that the consideration of the
objections and request for hearing must
be delayed until the FIFRA review
process is completed. EPA rejects either
position; Petitioners cannot use this
tolerance proceeding to evade FIFRA’s
statutory review scheme, or use that
scheme to delay this tolerance
proceeding.
As noted, although FIFRA
incorporates the FFDCA dietary risk
standard, FIFRA also requires the
Agency to evaluate a much wider scope
of issues in determining whether to
grant new license requirements. For
example, EPA must evaluate the impact
this proposal would have on worker and
ecological risks. In addition, EPA must
carefully evaluate the policy
implications involved in authorizing
Petitioners’ scheme. In this regard, it is
worth noting that FMC’s scheme is a
novel one that raises significant policy
PO 00000
Frm 00024
Fmt 4701
Sfmt 4700
questions that are specific to FIFRA,
such as whether the steps proposed
could be adequately enforced, which
could affect the confidence that
everybody would, in fact, comply with
all the steps, (e.g., who would
investigate whether users have properly
notified FMC of use of the product;
would users have to keep records to
demonstrate to inspectors that they had
appropriately reported use; how would
further sales in a county be prohibited);
and whether the steps themselves are
appropriate tools from a policy
perspective for dealing with risks
associated with the use of a pesticide
(e.g., is it appropriate to require users to
report use to a pesticide manufacturer;
is such reporting subject to approval
under the Paperwork Reduction Act; is
it appropriate public policy to limit
sales in a watershed so that some
growers may have preferential access to
a product; would the scheme encourage
early and potentially unnecessary
purchase of product by users; under
what circumstances, if any, should EPA
approve label and license conditions
that require the extra vigilance that
would be required here of users,
distributors, and state and federal
regulators). Even if this scheme were
determined independently to meet the
FFDCA safety standard, if ultimately
EPA were unable to grant the
amendment based on the other
considerations that it must evaluate
under FIFRA, the unacceptable dietary
risks would still remain. Thus, whether
this scheme could result in a
determination that the dietary risks are
acceptable is not ultimately severable
from the larger FIFRA process. Nor
would it be appropriate to attempt to
resolve FIFRA issues in a hearing under
the FFDCA.
Indeed it is questionable whether
consideration of the proposed
amendments would be appropriate even
under Petitioners’ position that all
objections made in good faith may be
presented at this stage of the proceeding
(Obj at 61). For example, less than six
months prior to their recent submission,
the Petitioners proposed voluntarily
cancellation of all use on pumpkins
except in the Southeastern United
States, alleging that sales data
demonstrated that carbofuran was
needed in the Southeastern U.S. In
response to this amendment, which was
submitted as part of their comments on
the proposed rule, EPA analyzed the
dietary risks based on this proposed use
pattern for the final rule. A request,
mere months later, for additional use on
pumpkins in states with different
geographic and weather conditions and
E:\FR\FM\18NOR2.SGM
18NOR2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
VerDate Nov<24>2008
19:25 Nov 17, 2009
Jkt 220001
justify a hearing, as discussed in the
Units below.
E. Response to Specific Issues Raised in
Objections and Hearing Requests
Relating to EPA’s Children’s Safety
Factor
To more fully understand Petitioners’
objection and hearing request with
regard to EPA’s choice of a 4X
children’s safety factor and EPA’s
responses, a little background is helpful.
Section 408 of the FFDCA imposes a
default additional safety factor for the
protection of infants and children, to
take into account the fact that children
are frequently more sensitive to a
pesticide’s effects than adults. This
default 10X safety factor can only be
revised if the Agency has ‘‘reliable data’’
to demonstrate that the alternative
PO 00000
Frm 00025
Fmt 4701
Sfmt 4725
safety factor—or no safety factor—‘‘will
be safe for infants and children’’ (21
U.S.C. 346a(b)(2)(C)). In determining
whether a different factor is safe for
children, EPA focuses on the three
factors listed in section 408(b)(2)(C)—
the completeness of the toxicity
database, the completeness of the
exposure database, and potential preand post-natal toxicity. In examining
these factors, EPA strives to make sure
that its choice of a safety factor, based
on a weight-of-the-evidence evaluation,
does not understate the risk to children.
(Ref. 79). The Agency’s approach to
evaluating whether sufficient ‘‘reliable’’
data exist to support the reduction or
removal of the statutory default 10X is
described below in Figure 1.
BILLING CODE 6560–50–P
E:\FR\FM\18NOR2.SGM
18NOR2
ER18NO09.000
pwalker on DSK8KYBLC1PROD with RULES2
cancellation of the use in the
Southeastern U.S., may fairly be
considered suspect—an action intended
to delay the revocation process by
forcing the Agency to conduct yet
additional analyses, rather than a goodfaith objection.
For all of these reasons, EPA has
determined that reliance on these
proposed amendments as a basis for
raising objections to the final rule, or for
requesting a hearing is not appropriate.
Nevertheless, EPA evaluated the
individual objections premised on the
newly requested terms and conditions
of registration. And in each case, the
submitted materials relating to these
objections and hearing requests
independently failed to meet the
statutory and regulatory requirements to
59631
59632
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
pwalker on DSK8KYBLC1PROD with RULES2
BILLING CODE 6560–50–C
EPA has consistently required that
data comparing the AChE inhibition in
young rat pups (typically PND11) and
adult rats be submitted on AChEinhibiting pesticides, such as
carbofuran, to determine the extent of
children’s potential sensitivity. The
study measures the levels of AChE
inhibition in both potentially relevant
target tissues: The brain and either the
PNS or red blood cell (RBC), which
serves as a surrogate for the PNS. EPA
required these data from FMC for
carbofuran, and FMC on two occasions
submitted the studies. Both sets of data,
however, were rejected by EPA as
scientifically flawed because they
inaccurately measured the levels of RBC
AChE.
Despite the invalidity of the two FMC
studies as to RBC AChE, EPA still has
certain, limited RBC AChE data and
other PNS-related data on carbofuran
from other studies. These other
carbofuran data indicate the following:
(1) PNS-related effects (tremors) occur
in pups as a result of exposure to
carbofuran at low doses; (2) juveniles
are more sensitive than adults to
carbofuran based on brain measures; (3)
juveniles are more sensitive than adults
to carbofuran based on RBC AChE
measures; and (4) the relative sensitivity
of juveniles compared to adults as to
RBC AChE is significantly greater the
relative sensitivity of juveniles
compared to adults as to brain AChE. It
is also noteworthy that the data in adult
rats showed RBC AChE was generally
more sensitive to carbofuran’s effects
than brain AChE (RBC AChE inhibition
was higher than brain at every dose
except the lowest), although these data
are of limited relevance, because they
were conducted on adult animals rather
than pups, and adult responses are
frequently not predictive of children’s
responses. However, because the
available pup RBC AChE data from
EPA–ORD did not involve testing at
doses that produced a sufficiently low
level of inhibition, the data were not
sufficient to develop a PoD for juveniles
based on RBC AChE.
Accordingly, in making its children’s
safety factor determination for
carbofuran, EPA was faced with three
significant issues: (1) Sufficient data on
carbofuran that are routinely-required
for AChE-inhibiting pesticides to
measure PNS effects was not available;
(2) available data measuring the levels
of AChE inhibition in brain and RBC
indicated that juveniles were more
sensitive than adults to carbofuran and
other carbofuran data indicated that
PNS-related effects could occur in pups
at low dose levels; and (3) although the
VerDate Nov<24>2008
19:25 Nov 17, 2009
Jkt 220001
evidence on carbofuran as to RBC AChE
inhibition in juveniles indicated that
effects on juveniles’ PNS might be the
most sensitive endpoint, there was not
sufficient data to calculate a PoD (for
use in determining the safe dose or
PAD) on these effects. Despite the
incompleteness of the toxicity database
and the evidence indicating the
potential for pre- and post-natal toxicity
at a very sensitive level, which indicate
the need to retain a children’s safety
factor, EPA nonetheless determined
that, because there was limited reliable
data in juveniles, a full statutory default
10X was not necessary to ensure that
children’s exposures would be ‘‘safe.’’
EPA undertook a complex comparison
of the brain and RBC AChE data in
juveniles and determined that the likely
increased level of sensitivity for RBC
AChE inhibition is 4X. EPA thus
concluded that using an additional
children’s safety factor of 4X applied to
the PoD from data on brain AChE
inhibition in juveniles would protect
infants and children.
1. Challenge to EPA’s Scientific Basis
for Retention of a 4X Children’s Safety
Factor. Petitioners object to EPA’s
conclusion that the lack of peripheral
tissue data justifies retention of any
portion of the children’s safety factor.
Petitioners raise two claims in this
regard. First, they allege that a
carbofuran PoD based on brain AChE is
adequately protective of PNS effects.
Second, they claim that RBC AChE
inhibition data are not the best surrogate
for PNS effects when brain data are
available, and therefore, these data are
not an ‘‘appropriate surrogate for PNS
effects’’ and should not have been relied
upon as the basis for retaining any
portion of the safety factor. In support
of these points, Petitioners submit
summaries of the testimony they intend
to offer at a hearing, along with copies
of published studies that they allege
provide evidence of the points raised in
the testimony.
In essence, these two main issues
overlap, particularly with respect to the
evidence submitted. Petitioners rely on
the same studies to support both points.
However, they are presented below
separately as discrete issues in the
interest of clarity. Supplemental to these
two main points, EPA has identified
three separate allegations made by
Petitioners in support of this objection,
which are also analyzed individually in
this section.
a. Objection/hearing request subissue:
Whether a carbofuran PoD based on
pup brain AChE inhibition data alone is
adequately protective of PNS effects.
Petitioners argue that by establishing the
PoD on pup brain AChE inhibition data,
PO 00000
Frm 00026
Fmt 4701
Sfmt 4700
EPA has adequately accounted for all
PNS effects in pups without the need for
an additional children’s safety factor.
They argue that brain data will
adequately protect against PNS effects,
based on the claim that the available
data show that the brain is equally
sensitive or more sensitive than PNS
tissue. In support of this objection,
Petitioners’ submit the evidence
contained in Exhibits 4 and 6. Exhibit
4 consists of a report by Kendall
Wallace, PhD, entitled ‘‘Expert Report:
Carbofuran FQPA Safety Factor,’’ along
with published studies conducted with
OP chemicals, and other NMC
chemicals (Ref. 17, 51, 53, 54, 59, 61, 62,
72). Exhibit 6 consists of a report by
Lucio Costa, PhD, entitled, ‘‘Expert
Report: Carbofuran’s FQPA Safety
Factor and Interspecies Uncertainty
Factor,’’ as well as published literature
studies conducted with chlorpyrifos and
disulfoton, both OP pesticides, and a
single study with propoxur, an NMC
pesticide.
i. Background. In the proposed
tolerance revocation, EPA presented its
rationale for retention of a children’s
safety factor.
As explained in Unit IV.A, EPA uses
a weight of evidence approach to
determine the toxic effect that will serve
as the appropriate PoD (or regulatory
endpoint) for a risk assessment for
AChE inhibiting pesticides, such as
carbofuran (Ref. 78). Neurotoxicity
resulting from carbofuran exposures can
occur in both the central (brain) and
peripheral nervous systems (PNS). In its
weight of the evidence analysis, EPA
reviews data, such as AChE inhibition
data from the brain, peripheral tissues
and blood (e.g., RBC or plasma), in
addition to data on clinical signs and
other functional effects related to AChE
inhibition. Based on these data, EPA
selects the most appropriate effect on
which to regulate; such effects can
include clinical signs of AChE
inhibition, central or peripheral nervous
tissue measurements of AChE inhibition
or RBC AChE measures (Id). Due to the
rapid nature of NMC pesticide toxicity
it is difficult to document effects in the
PNS or even AChE inhibition in the
PNS and thus studies measuring AChE
inhibition in the PNS are very rare for
NMC pesticides. Although RBC AChE
inhibition is not adverse in itself, EPA’s
policy is to use it as a surrogate for
inhibition in peripheral tissues when
peripheral data are not available. As
such, RBC AChE inhibition provides an
indirect indication of adverse effects on
the nervous system (Id.).
There are laboratory data on
carbofuran for cholinesterase activity in
plasma, RBC, and brain from studies in
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
multiple laboratory animals (rat, mouse,
dog, and rabbits). Among these are three
studies that compare the effects of
carbofuran on PND11 rats with those in
young adult rats (i.e., ‘comparative
AChE studies’) (Refs. 1, 2, 66). Two of
these studies were submitted by FMC
and one was performed by EPA–ORD.
An additional study conducted by EPA–
ORD involved PND17 rats (Ref. 63).
The studies in juvenile rats show a
consistent pattern that juvenile rats are
more sensitive than adult rats to the
effects of carbofuran. These effects
include inhibition of brain AChE in
addition to the incidence of clinical
signs of PNS neurotoxicity, such as
tremors, at lower doses in the young
rats. This pattern has also been observed
for other NMC pesticides, which exhibit
the same mechanism of toxicity as
carbofuran (Ref. 81). The 2008 SAP, in
its review of the carbofuran draft NOIC,
concurred with EPA that the brain
AChE data clearly indicate that the
juvenile rat is more sensitive than the
adult rat (Ref. 36).
The Agency does not have any AChE
inhibition data for carbofuran in the
PNS tissue of adult or juvenile animals.
There is data on RBC AChE inhibition,
which is a surrogate for PNS tissue
AChE inhibition, in adult animals at
both high and low doses, and RBC data
in pups, but only at doses causing
greater than 50% AChE inhibition (a
very high level of inhibition). In adults,
the data show that RBC is generally
more sensitive to the effects of
carbofuran than the brain, but that at the
lowest dose tested, brain and RBC have
similar sensitivity. In pups, the
available data at higher doses show that,
like adults, RBC is more sensitive than
brain. For example, the EPA–ORD
studies showed that RBC AChE
inhibition is more sensitive than brain
AChE inhibition in both PND11 and
PND17 pups at the lowest dose tested.
However, the lowest dose (0.1 mg/kg) in
both studies missed the lower portion of
the RBC AChE inhibition dose-response
curve for pups. At the lowest dose, PND
11 pups had approximately 40% brain
and 53% RBC AChE inhibition while
PND17 pups had approximately 25%
brain and 50% RBC AChE inhibition.
Consequently, the Agency does not have
RBC AChE inhibition data in pups at the
low doses (i.e., those that cause only
10% inhibition) that are relevant to risk
assessment to serve as a surrogate for
PNS tissue data.
EPA explained that additional
evidence for the sensitivity of the PNS
to carbofuran’s effects comes from data
in pregnant rats exposed to carbofuran
that showed clinical signs that may be
indicative of peripheral toxicity.
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
Finally, EPA explained that data from
other AChE inhibiting pesticides show
that direct measures of peripheral
nervous system (e.g., lung, heart, and
liver AChE) can be more sensitive than
brain AChE inhibition. To help
illustrate, EPA gave an example of
another chemical for which brain
inhibition alone was not at all
predictive of toxicity, to help explain
why the lack of carbofuran data was so
significant. The example given was
fenamiphos (an OP pesticide), where
cholinergic toxicity (e.g., tremors,
miosis, salivation) was observed
following inhibition of RBC, but not
brain, even up to maximally tolerated
doses (McDaniel and Moser, Ref. 53).
Normally, EPA would regulate based
on the most sensitive endpoint, which
in this case would appear to be the
effects on children’s PNS. However, as
discussed above, EPA lacked the
information that would allow it to
establish a PoD (or regulatory endpoint)
based on the effects on children’s PNS.
EPA therefore established its PoD based
on the AChE inhibition in pup brain.
Generally, by regulating based on pup
data, EPA would directly account for
any additional sensitivity that children
might have, because the safe levels
estimated from these data would be the
levels at which infants and children
would be affected. In such
circumstances, EPA could reduce the
children’s safety factor.
But because EPA lacked the data on
the PNS effects in pups at low doses of
carbofuran, which are most analogous to
the exposures that infants and children
will receive from eating food with
carbofuran residues, the Agency could
not be confident that assessing risk
using brain AChE inhibition would be
protective of potential effects in the PNS
for infants and children. Accordingly,
EPA determined that, even though the
Agency was relying on pup data,
consistent with the statutory mandate
that an additional safety factor be
applied to account for children’s
increased sensitivity in the absence of
information affirmatively demonstrating
that no such safety factor is necessary,
the Agency could not conclude that
removal of the statutory default 10X
would be ‘‘safe for infants and
children.’’ As some information was
available to characterize the effects on
infants and children, EPA concluded
that the full default 10X was
unnecessary, and that it could safely
reduce the factor to 4X.
Petitioners raised many of the same
assertions in their comments on EPA’s
proposed rule that they raise in their
objections. For example, the Petitioners
claimed that because EPA relied on pup
PO 00000
Frm 00027
Fmt 4701
Sfmt 4700
59633
brain data, no additional safety factor
would be necessary to account for
children’s increased sensitivity, because
‘‘brain data are a better surrogate for the
PNS than RBC data.’’ The comments
also contended that RBC data are
problematic in a number of regards, e.g.,
they are more variable. They also argued
that EPA had generally relied
exclusively on brain data for other NMC
pesticides, and that to require an
additional safety factor for carbofuran
based on the lack of RBC AChE data was
inconsistent with those other decisions.
In the final rule and response to
comments EPA responded to all of the
Petitioners’ claims, and
comprehensively restated its reasoning
that the lack of PNS inhibition data
warranted retention of some portion of
the children’s safety factor for
carbofuran (74 FR 68694–68695 (May
15, 2009)). In essence, EPA explained
that Petitioners had not presented any
information that fundamentally altered
the available risk information before the
Agency. Specifically, EPA concluded
that, given that (1) the EPA–ORD data
clearly show that a surrogate measure of
the peripheral nervous system (RBC
AChE) in juvenile rats is more sensitive
to the effects of carbofuran than brain
AChE inhibition; (2) clinical signs
consistent with toxicity to the
peripheral nervous system were seen at
very low doses of carbofuran; and (3)
data from other AChE inhibiting
pesticides show that direct measures of
peripheral nervous system (e.g., lung,
heart, and liver AChE) can be more
sensitive than brain AChE inhibition,
the Agency could not be confident that
assessing risk using brain AChE
inhibition would be protective of
potential effects in the peripheral
nervous system for infants and children.
ii. Denial of hearing request. EPA is
denying Petitioners’ hearing request on
this subissue because the evidence
proffered, even if established, is
insufficient to justify the factual
determination urged (40 CFR
178.32(b)(2)). The totality of the
evidence submitted fails to demonstrate
a reasonable possibility that exclusive
reliance on carbofuran brain data will
be protective, largely because they have
failed to proffer any evidence on several
points that are critical to their argument.
As such, the objection rests on
speculation and mere allegation, and a
hearing will not be granted on this basis
(Id. See, e.g., 73 FR 42708 (July 23,
2008); 57 FR 6667, 6671 (February 27,
1991)).
It is important to remember that to
obtain a hearing on EPA’s children’s
safety factor decision, Petitioners must
proffer more than evidence on whether
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59634
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
EPA erred, Petitioners must proffer
evidence showing there is ‘‘reliable
data’’ supporting the children’s safety
factor they urge. Without the latter, their
objection is immaterial because the
default position is retention of an
additional 10X safety factor.
Accordingly, EPA has evaluated
Petitioners’ proffers on its children’s
safety factor claims in terms of whether
they are sufficient to provide the
‘‘reliable data’’ needed to justify the 1X
safety factor that Petitioners propose.
For purposes of resolving whether the
statute requires the retention of a
children’s safety factor, the critical issue
is whether sufficient data exists to
determine the effects on children’s
peripheral nervous systems from low
doses of carbofuran. None of the
evidence submitted affirmatively
addresses this question. As discussed in
more detail below, the only evidence
proffered in support of this objection
was: (1) A subset of the available
carbofuran data from adult animals; and
(2) data, primarily in adult animals,
from other chemicals to demonstrate
that generally, reliance on brain data
will be protective of PNS effects, and
therefore EPA can assume that the same
will hold true for carbofuran. However,
the Petitioners have failed to submit any
data to demonstrate that the effects seen
in adults will be predictive of the effects
in juveniles. They have also submitted
no evidence specific to carbofuran that
demonstrates the effects of low doses on
children’s peripheral nervous systems.
This is critical because the evidence
they do proffer on other chemicals fails
to establish that as a general matter,
reliance on brain data will always be
protective of the effects on the PNS. The
majority of the evidence in other
chemicals actually proves that reliance
on brain data is frequently not
protective of the effects on the PNS.
And the remainder of the evidence on
this point, taken in the light most
favorable to the Petitioners, provides
only equivocal support for Petitioners.
Such evidence, by itself, is insufficient
to relieve the uncertainty that remains
with respect to carbofuran, based on the
affirmative evidence in carbofuranspecific data, showing that reliance on
brain data may not be protective. And
such evidence, that entirely fail to
address the points that the statute makes
central to a determination of the
appropriate children’s safety factor,
cannot justify a hearing.
When examined more closely, their
overall evidentiary proffer is even less
impressive. As discussed, much of the
evidence was conducted in adult rats.
Indeed the only evidence Petitioners
submitted in support of this objection
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
that was specific to carbofuran’s effects
on the PNS was data in adult rats. No
evidence was submitted to demonstrate
that adult data are generally predictive
of responses in pups. Nor was any
evidence submitted to support the
assumption that pups will respond to
low doses of carbofuran in the same way
as adults. Thus their evidentiary proffer
is effectively based on mere speculation
that adult data will be predictive of pup
responses, which cannot justify a
hearing (40 CFR 178.32(b)(2)). As EPA
previously explained in the proposed
and final rules, responses in adult rats
are not necessarily predictive of, or
relevant to, responses in juveniles since
the metabolic capacity of juveniles is
less than that of adults (73 FR 44864, 74
FR 23046). As such, juvenile rats can be
more sensitive to some toxic agents.
Simply put, studies that only involve
adult animals, therefore, do not provide
information on effects on the young,
which is the focus of the children’s
safety factor. No matter how much
evidence Petitioners can amass showing
that brain AChE is protective of RBC
AChE in adult animals, that does not
relieve the uncertainty concerning
potential sensitivity of PNS tissues in
juvenile animals, particularly when all
of the existing carbofuran data shows
that pups are more sensitive than adults
to the effects of carbofuran, and that
clinical signs consistent with toxicity to
the PNS were seen in pups at very low
doses of carbofuran. Accordingly, in the
absence of carbofuran data in pup PNS
tissues or a surrogate such as RBC data,
the Petitioners’ evidentiary proffer fails
to establish a reasonable possibility that
this issue could be resolved in their
favor. A hearing is not appropriate in
such cases (40 CFR 178.32(b)(2)).
The central tenet of this objection is
that regulating based on the effects in
the CNS will ensure that the PNS is
protected. In this regard, Petitioners do
cite to studies in juvenile animals, but
all of them are conducted with
chemicals other than carbofuran.11
Moreover, the Petitioners’ evidence fails
to demonstrate that the PNS can never
be more sensitive than the CNS, or even
that the PNS is typically less sensitive
than the CNS. Rather, the evidence
shows only that the CNS (brain) is
sometimes more sensitive, and
sometimes less sensitive than the PNS,
depending on the chemical involved.
Because the data do not show a
consistent pattern, it indicates only that
11 Most of the studies were conducted on OP
chemicals, and expressly caution against extending
the results to NMC chemicals such as carbofuran;
a point also raised by Petitioners’ own experts (Ex
4, 6).
PO 00000
Frm 00028
Fmt 4701
Sfmt 4700
the relative sensitivity between the
central and peripheral nervous systems
varies depending on the chemical
involved, which cannot establish that
exclusive reliance on brain data as a
general proposition will always be
protective of PNS effects in pups. Nor
can it establish that reliance on the
brain data will be protective of the PNS
effects in the case of carbofuran.
When data are not available for a
specific chemical, conclusions based on
other chemicals can only be
scientifically supported if it has been
demonstrated that the conclusion is
always true. If, ‘‘in some cases,’’ the
conclusion is not true, then in the
absence of data on the specific
chemical, the conclusion cannot be
made for that chemical, and uncertainty
exists regarding the effects of the
individual chemical. Since there are no
data on the effects of carbofuran in PNS
tissues or RBC data at low doses in
pups, even assuming that they were able
to prove that for the specific chemicals
identified, the CNS is sometimes more
sensitive than the PNS, significant
uncertainty would remain regarding
carbofuran’s effects on the PNS. This is
because the only evidence specific to
the effects of carbofuran on the PNS at
low dose levels that can be used as a
comparison with the brain AChE levels
is the adult RBC data.
This also affects the materiality of this
objection. If the adult RBC AChE data
are not considered, as Petitioners
suggest, no carbofuran-specific data
exists to demonstrate the level of AChE
inhibition in the PNS of either adults or
pups at the low dose levels relevant to
risk assessment. Thus, even assuming
Petitioners could successfully establish
every point they raise in this regard, the
fact still remains that a decision maker
would have no data that provides any
information relating to the potential
effects of carbofuran on a child’s PNS.
Given that FFDCA section 408(b)(2)(C)
compels the application of a 10X safety
factor in the absence of information to
account for the presumptive sensitivity
of children, the lack of any data bearing
on carbofuran’s PNS effects would
require the Agency to apply a 10X safety
factor, rather than the 4X factor applied
in the final rule.
A further flaw in the Petitioners’
evidence is that it is internally
inconsistent. Notwithstanding their
allegations (discussed in subissue b
below) that RBC data are inherently
unreliable and should be discounted in
favor of brain data, the carbofuran adult
RBC data are one of the primary pieces
of evidence proffered to support the
claim that reliance on the carbofuran
pup brain data will protect against all
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
potential PNS effects (Exhibit 4). As
discussed in more detail below, the
Report cites to the carbofuran data with
adult rats to conclude that brain AChE
inhibition correlated closely with RBC
AChE inhibition. ‘‘This was further
substantiated by the study published by
McDaniel et al. (Ref. 54), where they
report that the ‘lowest dose of
carbofuran (0.10 mg/kg) significantly
decreased brain ChE activity but not
RBC ChE or motor activity’ * * *’’ (Id.
at 4, 6). Yet having granted scientific
validity to the adult RBC data, they
must also concede the relevance of the
EPA–ORD carbofuran pup RBC data,
which clearly demonstrate that at every
dose tested, RBC AChE, and therefore
the PNS for which it is a surrogate, is
more sensitive than the brain in juvenile
rats exposed to carbofuran. They raise
no challenge specific to the scientific
validity of the EPA–ORD data, but rely
only on their generic challenge that RBC
data are inherently less reliable than
brain data. No hearing is warranted
based on such evidence. See 49 FR 6672
(February 22, 1984) (challenge to one of
five related studies; in the absence of
any additional data bearing on the
clinical study, the objection constitutes
nothing more than an allegation); 68 FR
46403 (August 5, 2003) (hearing denied
because cited studies only contained
equivocal statements supporting
objector’s position).
Accordingly, the sum of their
evidence is no more than mere
speculation that the effects of
carbofuran exposure in the CNS will be
protective of effects in the PNS. This
falls far short of the ‘‘reliable data’’ on
the safety of infants and children
needed to justify the entire removal of
the 10X children’s safety factor and thus
cannot justify a hearing (40 CFR
178.21(b)(2)). See, e.g., 73 FR 42697
(July 23, 2008) (denying hearing where
the only evidence submitted was
NRDC’s claim that if the DDVP twogeneration rat reproduction study had
been conducted pursuant to the 1998
guidelines it might have shown
endocrine effects at lower doses than
the doses at which DDVP’s
cholinesterase effects were seen on
grounds that this was mere speculation);
57 FR 6667 (February 27, 1992) (hearing
denied to an objector who challenged
FDA’s rejection of a study for only
containing partial histopathological data
on the grounds that ‘‘[s]peculation
regarding data that do not exist cannot
serve as the basis for a hearing’’).
A detailed examination of Petitioners’
evidence follows below.
(a) Testimony intended to show that
brain is the appropriate endpoint.
Petitioners allege that the ‘‘critical effect
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
of concern due to carbofuran is nervous
system AChE. Brain is a direct measure
of such toxic effects, while RBC not
linked to any biological function.’’ On
this basis, they conclude that brain
represents the most appropriate
endpoint for risk assessment.
Essentially this testimony fails to
prove any dispute of material fact. EPA
relied on the carbofuran pup brain
AChE inhibition data to establish
carbofuran’s PoD. The Petitioners have
not argued that PNS effects are
irrelevant. Indeed, their submissions
make clear that effects on the PNS are
appropriate considerations in a risk
assessment; the only point they dispute
is whether brain or RBC data best
account for those effects (Exhibits 4, 6).
Alternatively, if they intend to argue
that RBC data entirely lacks any
scientific validity, this is contradicted in
several places by their other objections
and their own submissions. As
discussed above, the commenters rely
on the adult carbofuran RBC data to
support their claim that reliance on the
pup brain data is adequately protective
of PNS effects. Moreover, they explicitly
acknowledge that reliance on RBC data
is scientifically valid in the context of
the human data (Obj at 13).
Consequently, the submitted materials
are insufficient to justify the factual
determinations urged, and therefore fail
to support a determination that an
evidentiary hearing is warranted (40
CFR 178.32(b)(2)).
(b) Testimony purporting to show that
reliance on brain data is sufficiently
protective of the PNS. The Petitioners
raise several arguments in this regard.
First, they allege that, ‘‘brain responds
rapidly to carbofuran, which readily
passes blood/brain barrier’’ (Obj at 12–
13). Petitioners’ primary point, however,
is that ‘‘the extent of brain inhibition by
carbofuran more accurately compares
with the extent of PNS inhibition, and
therefore brain data are adequately
protective’’ (Id.). In support of this
claim, Petitioners cite to Exhibits 4 and
6, containing a mixture of ‘‘expert
testimony’’ and published studies. None
of the information contained in these
exhibits is sufficient to establish a
reasonable possibility that this issue
could be resolved in their favor.
Petitioners’ first claim simply
reiterates points made in their
comments on the proposed rule. As
explained in the final rule, EPA agrees
that the data show that the brain
responds rapidly to carbofuran, and that
it readily passes the blood/brain barrier.
However, evidence regarding the speed
with which the brain reacts proves
nothing with regard to the relative
sensitivity of PNS tissues (Ref. 85 at 46).
PO 00000
Frm 00029
Fmt 4701
Sfmt 4700
59635
Petitioners have presented nothing that
challenges the substance of EPA’s
response. Consequently, these claims do
not present a live controversy as to a
material issue of disputed fact; both
parties agree on the facts at issue, which
is that the brain responds rapidly to
carbofuran. Moreover, a simple
repetition of comments made on the
proposal without more is insufficient to
warrant a hearing. See, e.g., 73 FR at
42698–42699 (July 23, 2008) (denying
several NRDC hearing requests because
the objections were based on EPA’s
preliminary DDVP risk assessment,
rather than the revised risk assessment
published with the final order); 53 FR
53176 (December 30, 1988) (where FDA
responds to a comment in final rule,
repetition of comment in objections
does not present a live controversy
unless objector proffers some evidence
calling FDA’s conclusion into question);
62 FR 64102, 64105 (December 3, 1997)
(objector claimed that addition of
ethoxyquin invalidated studies; hearing
denied because objector did ‘‘not
dispute FDA’s explanation in the final
rule as to why addition of ethoxyquin
did not compromise the CIVO studies,
and provided no information that would
have altered the agency’s conclusion on
this issue’’).
Petitioners’ second point—that brain
AChE inhibition correlates closely with
PNS inhibition, and demonstrates that
reliance on brain data will be protective
of the PNS—is a disputed material issue
of fact that could warrant a hearing,
except that none of the evidence
submitted in support of this point
presents a reasonable possibility that the
Petitioners could establish the points
alleged. Consequently, they have failed
to demonstrate that a hearing is
warranted on this objection (40 CFR
178.32(b)(2)).
(c) Exhibit 4. This exhibit consists of
a report by Kendall Wallace, PhD,
entitled ‘‘Expert Report: Carbofuran
FQPA Safety Factor,’’ along with
published studies (Ref. 17, 51, 53, 54,
59, 61, 62, 72). The report argues that,
‘‘it is my opinion that for carbofuran,
the evidence indicates that inhibition of
brain AChE is an appropriate surrogate
for PNS AChE inhibition and that there
is reasonable certainty that a PoD for
carbofuran based on brain AChE
inhibition is protective of any adverse
CNS and PNS effects.’’ The only
carbofuran evidence directly cited in
support of this allegation is data
conducted on adult animals, using RBC
AChE data, which they elsewhere try to
discount. This assumes that adults and
pups are similarly sensitive despite the
carbofuran-specific evidence to the
contrary. No evidence is discussed or
E:\FR\FM\18NOR2.SGM
18NOR2
59636
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
pwalker on DSK8KYBLC1PROD with RULES2
submitted to support this assumption.
This therefore constitutes a mere
allegation, which does not justify a
hearing.
None of the published studies
conducted with other chemicals cited in
the Report provide more than equivocal
support for the points above; in fact, in
several instances, the study results
support EPA rather than the
Petitioners.12 The studies contained in
this exhibit fall into two general
categories. The first group of studies
consists of a subset of the chlorpyrifos
literature—which is generally more
relevant to the subissue discussed in the
next objection, arguing that RBC data
are not a good surrogate for the PNS—
rather than demonstrating affirmatively
that brain is a protective surrogate for
the PNS. The second category of studies
is one paper on physostigmine, a
carbamate, that is discussed in the body
of the report. All but one of these
studies was conducted using adult rats.
Marable, et al. (Ref. 51) and Nostrandt
et al. (Ref. 59) are two of the
chlorpyrifos studies Petitioners
submitted as part of the comments on
the proposed rule, and they contain
little evidence to demonstrate that brain
data correlate well with the PNS, and
thus are generally protective of the PNS.
Marable et al. involved chronic
exposures to adult dogs; in addition to
the fact that adult animals were used,
and therefore provide evidence of little
relevance to the question at issue, there
are significant differences between the
results of chronic and acute exposures.
As a result of the repeated exposures,
blood, brain and peripheral tissues were
at steady state, which cannot occur from
an acute exposure, and therefore this
study can provide no information on the
effects from acute exposures. Nostrandt
et al. actually reported that, following a
single low dose of chlorpyrifos, brain
inhibition was less (not greater) than the
inhibition obtained in heart which is
part of the PNS (although higher
inhibition was not seen in the
diaphragm or retina, other parts of the
PNS). At higher doses, the inhibition in
brain and peripheral tissues were more
similar. Thus, this study contradicts the
Petitioners’ claim that brain data will be
protective of all PNS effects. Petitioners
offer no explanation of how the
resubmission of these studies addressed
EPA’s conclusion in the final rule that
12 It is interesting to note that, in Exhibit 4, the
expert actually faults EPA for comparing OP and
NMC pesticides, saying ‘‘Although OP pesticides
inhibit AChE, they are completely different from
carbofuran and other N-methylcarbamates * * *:’’
(Exhibit 4 at 4). Yet the Exhibit includes papers on
effects of chlorpyrifos, an OP, and these papers are
not discussed in the text of the Exhibit.
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
the chlorpyrifos data failed to prove
their claim.
Chen, et al. (Ref. 17), another study of
chlorpyrifos, discussed whether plasma
or RBC AChE should be used to
establish a regulatory endpoint in
humans and compared data from several
animal studies, some of which were
conducted with adults and some with
pups. This is the only study in Exhibit
4 that contains data on pups. The results
of one of the studies reported in Chen,
et al. shows that at the lowest doses,
inhibition was greater in the heart,
which is part of the PNS, than in the
brain (56% and 41% respectively); note
that these are the data in adult rats
reported in Nostrandt et al. (described
above). Based on data from a
developmental study of chlorpyrifos by
Hoberman (Ref. 37), Chen et al. reported
that the doses estimated to produce 50%
inhibition in heart and brain actually
show that in 5-day old pups (both males
and females), the heart is 2–3 times
more sensitive than brain. Thus, this
study contradicts Petitioners’ claim that
brain data will be protective of PNS
effects, since the PNS inhibition was
greater than brain at the lowest doses in
both adults and pups. And in fact, it
supports EPA’s concern that the absence
of data at low doses is significant
because the effects at low doses can
differ significantly from those at higher
doses. The data from Hoberman showed
that at higher doses, ranging from 30–
100 mg/kg, the levels of inhibition in
the brain were higher than the levels in
the PNS (Ref. 37 at 16)—the exact
opposite of what occurred at the lowest
doses.
The second group of studies consists
of data on NMC chemicals. McDaniel et
al. (Ref. 53) and Padilla et al. (Ref. 62)
were cited in support of the claim that
the difference in sensitivity between the
brain and RBC is generally less for NMC
chemicals. These studies were
conducted with adult animals, and so
do nothing to address the question
before the Agency with respect to pups.
These studies merely confirm the
existing carbofuran data in adults,
which shows that at the lowest dose
tested, brain and RBC are essentially the
same.
Somani et al. (Ref. 72) is a study on
another NMC chemical, physostigmine,
in adult animals, cited to support the
claim that ‘‘in adult rats, brain AChE is
somewhat more sensitive than RBC or
peripheral AChE to inhibition by acute
doses of physostigmine.’’ As an initial
matter, it is unclear that this study
provides more than equivocal support
for their claim; the study authors claim
only that the brain ‘‘appears’’ to have
the lowest values. However, even
PO 00000
Frm 00030
Fmt 4701
Sfmt 4700
conceding that this study shows that the
CNS tissues in adult rats are more
sensitive to the effects of physostigmine
than the PNS tissues, the data in this
study is of limited relevance to the issue
at hand, which is the effects in
juveniles. Thus it is ultimately
insufficient to affirmatively support the
Petitioners’ claim.
In sum, based on the evidence
contained in this exhibit, EPA
concludes that there is not a reasonable
probability that the proffered evidence
would resolve the issue in Petitioners’
favor, and that consequently no hearing
is warranted on this basis. First, all but
one of the studies discussed in this
exhibit were conducted with adult
animals, rather than pups. As such, they
provide evidence of little relevance to
the question of whether pups’ PNS are
more sensitive than the CNS. In the
absence of carbofuran PNS data, or pup
RBC data, much of this evidence is
effectively mere speculation about
whether adult data will be predictive of
pup responses, which cannot justify a
hearing (40 CFR 178.32(b)(1)).
(d) Exhibit 6. This exhibit consists of
a report by Lucio Costa, PhD, entitled,
‘‘Expert Report: Carbofuran’s FQPA
Safety Factor and Interspecies
Uncertainty Factor,’’ as well as
published literature studies conducted
with chlorpyrifos and disulfoton, both
OP pesticides, and a single study with
propoxur, an NMC pesticide (Refs. 71,
19, 20, 21, 61, 52, 41, 64, 16). According
to Costa, these studies generally show
that there was similar or greater AChE
inhibition in brain than in the PNS
tissues of heart, ileum, or the
diaphragm, which Petitioners claim
proves that reliance on carbofuran pup
brain AChE inhibition data will
necessarily be protective of all effects in
the PNS (Exhibit 6 at 3). The exhibit
also references a human incident study
(Ref. 50) of carbamate poisoning in early
childhood and in adults, claiming that,
‘‘Lifshitz * * * showed that signs of
adverse effects in the CNS, rather than
PNS, prevailed in young children at the
low dose levels covered by the paper.’’
EPA concludes that there is not a
reasonable probability that the evidence
contained in this exhibit would resolve
the issue in Petitioners’ favor. The
results of these studies fail to
demonstrate the point for which
Petitioners cite them—that brain AChE
is always equally or more sensitive than
PNS AChE, and therefore exclusive
reliance on brain data can be assumed
to be protective. Consequently, the fact
that Petitioners can identify examples of
other chemicals, whether OPs or NMCs,
that sometimes affect the brain more
severely than the PNS does not prove
E:\FR\FM\18NOR2.SGM
18NOR2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
that this will be the case with
carbofuran. Furthermore, in several of
the cited examples the Petitioners
misinterpret the findings, which
actually support EPA’s position.
As explained in EPA’s final rule,
Petitioners are relying on only a subset
of the chlorpyrifos data. The data, when
examined in total, do not support a
conclusion that brain data will always
be protective of PNS effects (74 FR
23054–23055 (May 15, 2009)). But even
relying solely on the studies Petitioners
reference in this exhibit, it is clear that
brain is not always inhibited to the same
degree as peripheral tissues, nor is it
always protective of peripheral tissues.
The data in Padilla et al. (Ref. 61) are
the only chlorpyrifos data that support
a conclusion that reliance on the CNS
data will be protective of the PNS.
However, the Padilla study involved
chronic dosing of rats via the feed, and
as such, cholinesterase measurements
reflected steady-state conditions. This
study cannot provide information
relevant to acute exposure. None of the
other chlorpyrifos studies referenced in
this exhibit support this conclusion. In
Mattson et al. (Ref. 52), and Hunter et
al. (Ref. 41), following a single dose to
pregnant dams, heart and liver tissues
were more inhibited than brain tissues.
Similarly, in Richardson and Chambers
(Ref. 64), where repeated doses were
administered to pregnant dams, at both
the low and high doses, the lung tissue
was more inhibited than the brain tissue
in the one-day old pups. In Carr et al.
(Ref. 16), the results were more
equivocal; in a repeated dosing study
using pups of varying ages, whether
brain or peripheral tissues were most
inhibited depended on the age of the
pups and the dose. Nevertheless, Carr
(2001) showed that brain inhibition
decreased as the age of the pups
increased, even though inhibition in the
heart tissues did not. In other words, the
submitted material only supports a
conclusion that brain is sometimes
inhibited by chlorpyrifos to the same
degree as the peripheral tissues, and in
reality, the studies show that brain is
often inhibited to a lesser extent than
peripheral tissues. This cannot support
a conclusion that reliance exclusively
on brain data will necessarily be
protective in the absence of some
additional carbofuran-specific evidence.
The results are similar for the
disulfoton studies. Schwab et al. (Ref.
71) shows that after both a single dose
and repeated doses, the brain and
peripheral tissues were equally
inhibited. However, these results are
contradicted by Costa et al. (Ref. 19) and
Costa and Murphy (1983), where the
results varied depending on the dosing
and the brain area examined. In Costa
and Murphy (Ref. 21), diaphragm
tissues were more inhibited than brain
tissues after a single dose of disulfoton,
while after repeated doses, brain and
diaphragm tissues were similarly
inhibited. Thus, the relative sensitivity
between CNS and PNS changes with
repeated dosing, and these studies
provide no information on RBC
inhibition with which to compare the
other tissues.
Finally, the Lifshitz study does not
support the claim for which it was cited.
59637
The study presents no data on the dose
levels associated with the poisoning
incidents, and in fact concludes that
there was ‘‘insufficient information to
compare the doses ingested by [adults
and children].’’ However, based on the
symptomology reported (comas, stupor,
and severe hypotoxicity) it is likely that
the doses were high, not low, as the
Report claims. Also, this study cannot
be used to discount PNS effects in
children; a large percentage of the
children clearly showed PNS effects
(myosis, diarrhea). In addition, because
this was a retrospective study of
patients admitted to a hospital intensive
care unit, given the severity of some of
the CNS symptoms, such as comas, it is
not unlikely that even if the subjects
also showed PNS symptoms, they were
not reported. Finally, the study authors’
conclusion was that in children, the
‘‘clinical presentation [of carbamate
poisoning] differs from adult poisoning
manifestations’’ (Ref. 50). Or in other
words, that the effects in adults from
exposure to carbamates such as
carbofuran are not necessarily
predictive of the effects in children. It
is difficult to see how this study could
be fairly argued to support Petitioners’
allegations.
In conclusion, the totality of the
evidence in Exhibits 4 and 6 fail to
support Petitioners’ contention. As
shown in Table 1 below, the majority of
the study results demonstrate that the
PNS is frequently more sensitive than
the CNS. The remainder, taken in the
light most favorable to the Petitioners,
provide merely equivocal support.
TABLE 1—SUMMARY OF PETITIONERS’ STUDIES
Study design
Relative inhibition
Is CNS protective of PNS?
Chlorpyrifos Studies
Single dose, adults .......................
Single dose, pregnant dams ........
Single dose, pregnant dams ........
Richardson and Chambers 2003 ...
Repeated doses to pregnant
dams, measured pups at 1 day
old (not direct dose).
Carr et al. 2001 ..............................
pwalker on DSK8KYBLC1PROD with RULES2
Padilla et al. 2005 ..........................
Mattsson et al. 2000 ......................
Hunter et al. 1999 ..........................
Repeated doses to pups ..............
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
PO 00000
Frm 00031
Fmt 4701
RBC > brain ≈ diaphragm ............
RBC > heart > brain .....................
Liver > brain ..................................
Blood not measured.
Low dose, lung > serum ≈ brain >
heart.
High dose, lung > brain ≈ heart >
serum.
Note, serum has only ≈ 50%
AChE, not true measure of
AChE.
PND6: brain ≈ diaphragm > heart
≈ lung > skeletal muscle ≈
serum.
PND10: heart ≈ hindbrain ≈ diaphragm ≈ lung > skeletal muscle > forebrain ≈ serum.
PND16: heart ≈ lung > brain.
PND20: heart > lung > brain.
PND25: brain > PNS.
Brain inhibition decreased with
age, heart did not.
Sfmt 4700
E:\FR\FM\18NOR2.SGM
Yes (same sensitivity).
No.
No.
No.
Not always, depending on age,
dose, and brain region.
18NOR2
59638
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
TABLE 1—SUMMARY OF PETITIONERS’ STUDIES—Continued
Study design
Nostrandt et al. 1997 (also cited in
Chen et al. 1999).
Hoberman 1998 as cited in Chen
et al. 1999.
Relative inhibition
Is CNS protective of PNS?
Acute dose, adults ........................
RBC > heart > brain > diaphragm
No.
Repeated doses to pregnant
dams, measured in pups at 5
days old (not direct dose).
RBC > heart > brain .....................
No.
Disulfoton Studies
Single dose ...................................
Repeated doses ...........................
Costa et al. 1981 ...........................
Single dose ...................................
Repeated doses ...........................
Costa and Murphy 1983 ................
pwalker on DSK8KYBLC1PROD with RULES2
Schwab et al. 1981 ........................
Repeated doses ...........................
Single dose ...................................
Repeated doses ...........................
Accordingly, Petitioners’ proffer is
facially insufficient because there is no
reasonable possibility that it can
establish a necessary element of
Petitioners’ objection—that there are
‘‘reliable data’’ that show it would be
safe for infants and children to remove
entirely the 10X children’s safety factor.
iii. Denial of objection. The objections
do not address the fundamental issue
that EPA is required by the statute to
resolve: Are there ‘reliable’ data to
support reduction or removal of the
statutory 10X for protection of infants
and children? The statute compels that
EPA may only revise the 10X default
safety factor if, ‘‘on the basis of reliable
data’’ EPA can conclude that the
alternative safety factor will be ‘‘safe’’
(21 U.S.C. 346a(b)(2)(C)). The statute
also requires EPA to account for the
‘‘completeness of the toxicity data’’ in
making this determination (Id). In this
case, the Agency concluded that there
are sufficient data to reduce the 10X
safety factor but there is insufficient
information to justify removing the
factor entirely.
Similar to other AChE inhibiting
pesticides, carbofuran can affect both
the central and peripheral nervous
system. Because the relative sensitivity
of the central and peripheral nervous
system varies among pesticides and the
children’s safety factor should account
for the most sensitive toxicity endpoint,
the Agency considers the availability of
data in both the central and peripheral
nervous systems important in its safety
factor evaluation.
As shown in Figure 1, above, there are
several datasets that evaluate the effects
of carbofuran on the central nervous
system (e.g., brain AChE inhibition) in
VerDate Nov<24>2008
18:41 Nov 17, 2009
Jkt 220001
heart ≈ ileum ≈ brain ....................
brain ≈ ileum > heart
No blood measured
Brain > ileum ................................
Forebrain > ileum > hindbrain ......
Brain ≈ ileum ................................
No blood measured.
Diaphragm > brain ........................
Brain ≈ diaphragm ≈ plasma.
Note, plasma has only ≈ 50%
AChE, not true measure of
AChE.
juvenile rats. There are no AChE data
from peripheral tissues. Lack of
peripheral AChE data is typical of
NMCs due to the rapid reactivation of
AChE. As a matter of science policy, the
Agency typically uses AChE data from
blood, particularly RBCs, as a surrogate
measure for the peripheral nervous
system (Refs. 76, 87). In the case of
carbofuran, RBC AChE data from two
separate studies submitted by FMC are
considered unreliable and unusable in
human health risk assessment (Ref. 83).
Data from EPA’s ORD includes high
quality RBC AChE data, but only high
doses were used in the ORD studies.
Data at the low end of the dose response
curve are not available for assessing the
effects in juvenile rats, which are the
doses relevant for human health risk
assessment. Thus, because reliable data
are available to assess affects on the
CNS and some surrogate data are
available to assess the PNS, the Agency
believes that the children’s safety factor
can be reduced. However, this factor
cannot be completely removed since the
available carbofuran data show that RBC
AChE inhibition in pups is more
sensitive than brain AChE inhibition.
Given that (1) data from other AChE
inhibiting pesticides show that direct
measures of peripheral nervous system
(e.g., lung, heart, and liver AChE) can be
more sensitive than brain AChE
inhibition; (2) a surrogate measure of the
peripheral nervous system (RBC AChE)
is more sensitive in juvenile rats to
carbofuran; and (3) clinical signs
consistent with toxicity to the
peripheral nervous system were seen at
very low doses, the Agency can not be
confident that assessing risk using brain
AChE inhibition is protective of
PO 00000
Frm 00032
Fmt 4701
Sfmt 4700
Yes, similar sensitivity.
Not always, depends on dosing
paradigm and brain region.
Not consistent within same study.
Not always, depends on dosing
paradigm.
potential effects in the peripheral
nervous system for infants and children.
For example, in the first FMC-sponsored
comparative ChE studies (Ref. 4) every
pup at the 0.3 mg/kg dose group
exhibited tremors. The range-finding
portion of the second FMC-sponsored
comparative ChE study (Ref. 1) resulted
in tremors in rats exposed to 0.3 mg/kg
carbofuran (2⁄5 males and 2⁄5 females)
within 15 minutes post-dosing.
Additional evidence for sensitivity of
the PNS comes from carbofuran data in
pregnant rats that showed clinical signs
that may be indicative of peripheral
toxicity. The California Department of
Pesticide Regulation (CDPR) has
calculated a BMD10 and BMDL10 of 0.04
and 0.03 mg/kg/day, respectively, for
mouth smacking and chewing in
pregnant rats exposed to carbofuran.
These signs are early indicators of
toxicity from some cholinesterase
inhibitors (Ref. 56). This is notable for
two reasons. First, cholinergic toxicity
(e.g., tremors, miosis, salivation) may be
observed following inhibition of blood,
but not brain, cholinesterase. This was
the case with fenamiphos (an OP
pesticide), even up to maximally
tolerated doses (Ref. 53). Second, the
BMDL10 from the mouth smacking and
chewing in pregnant rats is similar to
that being used by EPA for brain AChE
in juveniles. The similarity of the CDPR
BMD in adults and EPA’s BMD in
juveniles is striking because all of the
available data show that pups are more
sensitive than adults to carbofuran
toxicity. This therefore suggests that
behavioral effects and/or clinical signs
may be occurring in juvenile animals at
lower doses, but which cannot be
detected, in part due to the challenges
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
with assessing clinical signs in juvenile
rats. As noted by the SAP, this
‘‘limitation reflects the limited range of
toxic signs detectable in very young
pups (p. 54).’’ This provides further
support that the lack of pup data at
lower doses is significant, because the
Agency cannot fully evaluate the
behavioral effects on juvenile animals.
Further support for the Agency’s
concern comes from other clinical
reports of the effects of carbamate
poisoning in children. For example,
Lifshitz reported that all children
presented with CNS symptoms (coma,
stupor), but CNS symptoms were
observed in only 54% and 23% of
children as reported by Zweiner and
Ginsburg (1988) and El-Naggar et al.
2009 (Refs. 91, 26). Peripheral
muscarinic symptoms were the most
commonly reported (73% and 100%)
signs of toxicity in these latter two
reports. These markedly different
findings emphasize that conclusions
cannot be unequivocally drawn from
only one study.
In addition, Petitioners’ own data
show that effects can differ significantly
between high and low doses. In Chen,
for example, the data from Hoberman
showed that at the lowest doses the
levels of inhibition were higher in the
PNS than in the brain, but at higher
doses, the levels were higher in the
brain.
Thus, for a number of reasons, the
Agency has concerns that children’s
PNS may be more sensitive to the effects
of carbofuran than the CNS. This
concern is the basis for retention of a
portion of the children’s safety factor.
The carbofuran RBC data in adult
animals does not resolve this question.
There can be substantial differences in
response between pups and adults, and,
as noted, the data show clearly that
pups are more sensitive to the effects of
carbofuran. It is not unusual for juvenile
rats, or indeed, for infants or young
children, to be more sensitive to
chemical exposures as metabolic
detoxification processes in the young
are still developing. Because pups are
more sensitive than adult rats, data from
pups provide the most relevant
information for evaluating risk to infants
and young children and are thus used
to derive the PoD. In addition, typically
(and this is the case for carbofuran)
young children (ages 0–5) tend to be the
most exposed age groups because they
tend to eat larger amounts of food per
their body weight than do teenagers or
adults.
b. Objection/hearing request subissue:
Reliance on RBC AChE inhibition data
as a surrogate for PNS effects. This
objection also challenges EPA’s decision
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
to retain some portion of the
presumptive 10X children’s safety
factor, rather than remove it entirely. As
explained above, EPA retained a portion
of the presumptive 10X children’s safety
factor because of the absence of
sufficient data on PNS effects in
juveniles and the uncertainty created by
the limited data relevant to the PNS that
showed greater sensitivity in juveniles.
In the previous subissue, Petitioners
argued that in fact there is no
uncertainty created by the lack of low
dose RBC data and the finding of
sensitivity in the RBC AChE data
because brain AChE data is protective of
PNS effects. In this subissue, Petitioners
attempt to buttress their first argument
by claiming that RBC AChE data are not
an ‘‘appropriate surrogate’’ for PNS
effects, and should not have formed the
basis for retention of any portion of the
children’s safety factor.
Petitioners do not argue that RBC data
are entirely irrelevant, but rather that
brain data are ‘‘preferred.’’ They raise
several points in support of this
contention; first, that ‘‘RBC AChE
inhibition data are only preferred for
risk assessment purposes in two
circumstances: (1) Where the PoD is set
using data from human studies where
only RBC data are available or (2) where
data from the relevant target tissues are
unavailable.’’ They allege that, despite
the absence of carbofuran data in the
PNS tissues, brain is preferred in this
case because the brain is ‘‘target tissue’’
from the nervous system, and because
brain data are a ‘‘better predictor’’ of
PNS effects than RBC. As further
evidentiary support, they cite to
evidence from OP studies that RBC
AChE can ‘‘in some cases’’ be inhibited
to a greater degree than either PNS or
brain AChE, and therefore reliance on
RBC AChE data can overstate potential
PNS effects. They also argue that RBC
AChE is more variable and less reliably
measured at low response levels, such
as 10% AChE inhibition. The evidence
in Exhibits 4 and 6 is also proffered in
support of this objection.
i. Background. EPA’s well-established
policy when evaluating cholinesteraseinhibiting compounds is to rely on data
in the target tissue where it is available
(Ref. 76). As noted in the preceding
section, measures of AChE inhibition in
the PNS are rarely collected for NMC
pesticides. And in fact, there are no
carbofuran data measuring effects in
PNS tissues. But in the absence of target
tissue data, as a matter of science policy,
EPA typically uses RBC AChE
inhibition data as an indicator of
possible effects on AChE in the PNS for
number of reasons. (Ref. 76 at 32).
Although RBC AChE inhibition is not
PO 00000
Frm 00033
Fmt 4701
Sfmt 4700
59639
adverse in itself, it is a surrogate for
inhibition in peripheral tissues. As
such, RBC AChE inhibition provides an
indirect indication of adverse effects on
the nervous system (Id.).
Petitioners raised many of the same
issues raised in the objections in their
comments on the proposed rule. For
example, they argued that, ‘‘as a matter
of science policy, brain AChE inhibition
is the preferred endpoint over RBC
AChE inhibition.’’ They also argued that
no physiological function has been
demonstrated for RBC, and RBC AChE
inhibition is not itself an adverse effect.
In the final rule, EPA responded to
each of their comments, but concluded
that no information had been submitted
to justify altering the Agency’s general
policy that reliance on RBC is
appropriate as a surrogate for PNS
effects in the absence of direct
measurements in PNS tissues.
ii. Denial of hearing request. This
subissue does not raise a dispute of
material fact. There is no dispute
regarding many of the facts raised in
this objection: When data in the target
tissue are available, it is preferred over
a surrogate. RBC AChE can be more
variable and less reliably measured at
low response levels than brain AChE.
RBC AChE inhibition can, in some
cases, be more extensive than PNS
AChE inhibition. Equally, there is no
dispute that no physiological function
has been demonstrated for RBC, and
RBC AChE inhibition is not itself an
adverse effect. All of these points are
explicitly recognized in EPA’s
Cholinesterase policy and in the
tolerance revocation rulemaking record,
and relate purely to the ease or wisdom
of relying on these measures rather than
others, as opposed to the scientific
invalidity of such data. The only point
on which there is a dispute is, given that
there is no data in the target tissues of
the PNS, which data—brain or RBC—is
‘‘preferred.’’ The Petitioners expressly
acknowledge this to be the issue: ‘‘There
are other surrogate measures of PNS
AChE that could have been selected by
OPP, such as brain AChE’’ (Exhibit 4 at
5). This is clearly a question of scientific
policy, since both EPA and the
Petitioners agree on the scientific
validity and relevance of RBC AChE
inhibition data. As they expressly
acknowledged in their comments, the
choice of which surrogate to use is a
matter of ‘‘science policy’’ (Ref. 18).
Indeed, Petitioners explicitly concede
the propriety of relying on RBC data
‘‘where data from the relevant target
tissues are unavailable, or when relying
on human data, where RBC AChE
inhibition data are the only data
available (Obj at 13). Hearings are not
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59640
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
appropriate for debating questions of
policy (40 CFR 178.32(b)(1)).
Nor does the proffered evidence
present any other issue that would
warrant a hearing. The evidence
submitted in Exhibits 4 and 6 on this
point only relates to the question of
whether brain data can sometimes
correspond more closely with PNS
effects than RBC AChE data, rather than
the question of whether the RBC data
are scientifically invalid. Or in other
words, the submitted materials relate
only to the point that reliance on RBC
data is unnecessarily conservative,
because sometimes it overestimates the
potential PNS effects, rather than to the
factual question of whether RBC data
bears no relation whatsoever to PNS
effects. Unless Petitioners can show that
RBC AChE is not related to CNS effects
generally or specifically for carbofuran,
or that brain AChE is protective of CNS
effects generally or specifically for
carbofuran, then the mere fact that RBC
AChE may be a conservative, or even
very conservative, indicator of PNS
effects is simply immaterial to the
question of whether there are ‘‘reliable
data’’ to justify removing the
presumptive 10X children’s safety factor
in the absence of sufficient RBC AChE
data. As shown in the discussion of
subissue 1, the Petitioners’ evidence
does not demonstrate that reliance on
juvenile brain data as a surrogate for
effects in the juvenile PNS will
guarantee that the levels chosen on that
basis will be predictive of all PNS
effects from carbofuran, because the
PNS effects occur only at the same or
higher doses than those that produce
effects on the brain AChE—i.e., that the
brain data ‘‘bound’’ all potential PNS
effects. Nor, as discussed below, does
any of Petitioners’ evidence support a
conclusion that RBC AChE is unrelated
to PNS effects.
Indeed, much of the evidence in the
Exhibit 4 and 6 Reports is ultimately an
irrelevance, and thus fails to present a
material factual dispute. Instead of
focusing the stated objection—RBC
AChE is inappropriate marker for CNS
effects—the Reports attempt to link
EPA’s children’s safety factor decision
to findings concerning chlorpyrifos
(Exhibit 4 at 4). In fact, a fair portion of
the Report in Exhibit 6 is dedicated to
a rebuttal of EPA’s conclusion that the
majority of the more recent and more
relevant chlorpyrifos evidence did not
support Petitioners’ contention. EPA,
however, has been clear throughout the
rulemaking that the basis for retention
of a children’s safety factor has been the
absence of carbofuran data to determine
the levels of exposure that will be
protective of children’s PNS, in the
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
context of a statutory provision that
expressly requires EPA to account for
missing data. EPA’s point in discussing
the chlorpyrifos data—which Petitioners
initially raised as relevant—was simply
that it showed that because peripheral
tissues can be more sensitive than
central nervous system tissues, the
absence of data addressing carbofuran’s
effects on the PNS is highly relevant.
Whatever the chlorpyrifos data show
cannot resolve the extent of carbofuran’s
risks. As the Petitioners’ experts
themselves point out, ‘‘Even conceding
that [EPA’s conclusion in the final rule
that peripheral tissues are often shown
to be more sensitive than brain tissue
following exposure to chlorpyrifos] may
be true, it is still unclear how this
would be relevant to carbofuran * * *’’
(Exhibit 6 at 3). Accordingly, this
evidentiary submission fails to
demonstrate that a dispute exists on a
question of material fact.
Finally, their submission provides an
inadequate basis on which to grant a
hearing; because evidence is not
proffered on critical points, the
objection ultimately rests on allegation,
speculation, and general denials (40
CFR 178.32(b)(2)). As discussed in
preceding section, the majority of the
evidence comes from adult data, which
are of limited relevance. Further, and
more significantly, the evidence fails to
demonstrate that brain data always—or
even more frequently than not—
correlates more closely with PNS effects
than RBC AChE data. Instead, the
proffered evidence only demonstrates
that whether brain or RBC data correlate
better with actual PNS effects can vary
depending on the chemical. This,
therefore, cannot resolve the question as
to whether, in the case of carbofuran,
brain AChE data will necessarily
correspond more closely with the PNS.
Finally, as also discussed in the
preceding section, Petitioners’ argument
is internally inconsistent, because they
rely on carbofuran adult RBC AChE data
to support their argument that exclusive
reliance on the brain data will be
protective of potential PNS effects in
pups. No hearing is appropriate where
the proffered evidence fails to prove the
points for which it is offered, or offers
merely equivocal support (See, 73 FR
42705 (July 23, 2008) (hearing denied
because published articles focus on an
issue not applicable to the facts of the
case at hand); 68 FR 46405–46406
(August 5, 2003) (a hearing was denied
because the cited studies only contained
equivocal statements)).
A detailed examination of Petitioners’
evidence follows below:
PO 00000
Frm 00034
Fmt 4701
Sfmt 4700
(a) Exhibit 4. As discussed in the
previous objection, this exhibit consists
of a report, along with published
studies. The Report criticizes EPA for
assuming that RBC AChE inhibition
provides ‘‘a stronger and more
quantitative concordance with the
sensitivity of AChE of the PNS to
inhibition by carbofuran,’’ on the
ground that EPA failed to cite to
evidence to support this inference
(Exhibit 4 at 5). In the absence of such
evidence, the report concludes that,
‘‘one cannot discount the plausibility
that brain AChE may be a more
quantitative and representative
surrogate measure of PNS sensitivity’’
(Id). To support this allegation, the
report argues that the cited NMC data
show that the difference in sensitivity
between brain and RBC shown with
NMC chemicals is less than the
differences seen with OP chemicals,
citing studies by Padilla et al. (Ref. 62)
and McDaniel et al. (Ref. 54). In this
regard, the Report actually misquotes
McDaniel et al. The Report claims that
the paper concluded that there was a
stronger correlation between brain
AChE inhibition and motor activity. The
study actually concluded that there was
little difference between brain AChE
inhibition and RBC AChE inhibitions
(‘‘higher correlation for brain and motor
activity compared to RBC were not
significantly different.’’) (Ref. 54). In any
event, the Report’s equivocal conclusion
that ‘‘one cannot discount the
plausibility’’ that brain AChE might be
the most representative measure of PNS
effect is, on its face, insufficient grounds
to overcome the statutory presumption
for retention of the additional 10X
children’s safety factor in the face of the
evidence of children’s additional
sensitivity to carbofuran, and the lack of
carbofuran data in PNS tissues or in a
surrogate for such tissues, RBC AChE.
Chen et al. (Ref. 17), which was
discussed at length in the earlier
objection, evaluated whether plasma or
RBC AChE should be used to establish
a regulatory endpoint; it did not
evaluate whether brain AChE would be
an appropriate surrogate for PNS effects.
It is true that the authors conclude that
‘‘[i]nhibition of RBC AChE activity is
consistently exhibited at lower dosages
of chlorpyrifos than those required to
result in clinical symptoms of OP
toxicity, or alterations in cognitive
functional responses.’’ However, since
the study authors ultimately concluded
that, ‘‘inhibition of RBC AChE activity
is an appropriate surrogate for
measurement of chlorpyrifos exposure
and provides a conservative endpoint
for establishing appropriate margins of
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
safety for both adults and infants,’’ it is
difficult to see how this could be argued
to provide unequivocal support for
Petitioners’ objections.
Exhibit 6. This exhibit consists of a
report by Lucio Costa, PhD, entitled,
‘‘Expert Report: Carbofuran’s FQPA
Safety Factor and Interspecies
Uncertainty Factor,’’ as well as
published literature studies. The report
discussed the results of several
published studies that they claim
demonstrate that ‘‘where available,
brain AChE inhibition data provide a
superior surrogate’’ to RBC data because
‘‘in some cases RBC AChE may
overestimate PNS AChE inhibition,
while in other cases * * * RBC AChE
inhibition may underestimate actual
AChE inhibition in the PNS.’’ In support
of this allegation, the report references
data from several studies conducted
with chlorpyrifos and disulfoton, both
OP pesticides, and a single study with
propoxur, an NMC pesticide (Refs. 16,
19, 20, 21, 41, 52, 61, 64, and 71).
According to the Report, these studies
generally show that there was similar or
greater AChE inhibition in brain than in
the PNS tissues of heart, ileum, or the
diaphragm, which Petitioners claim
proves that reliance on carbofuran pup
brain AChE inhibition data is more
predictive of all effects in the PNS. The
exhibit also references a human incident
study (Ref. 50) of carbamate poisoning
in early childhood and in adults,
claiming that, ‘‘Lifshitz * * * showed
that signs of adverse effects in the CNS,
rather than PNS, prevailed in young
children at the low dose levels covered
by the paper.’’
In its denial of the hearing request on
the previous issue, EPA examined the
results of the studies in this exhibit at
length, and demonstrated that the
results of the studies failed to support
a conclusion that brain data correlate
more closely to PNS effects than RBC
data. Indeed, in most of these studies,
brain AChE inhibition poorly reflected
the AChE inhibition in PNS tissues. For
example, the Carr et al. study results,
reproduced in Table 1 of Exhibit 6,
showed that for PND 10, 16, and 20 rat
pups, the heart tissue had the greatest
levels of inhibition, and that PND 16
and 20 rat pups had greater levels of
inhibition in lung tissue than in the
brain (Ref. 16 at 3). Further, since the
study was conducted with serum, which
contains no RBC, it is unclear how this
study could prove that brain data are a
better indicator of PNS effects than RBC
data.
The remainder of the report consists
of criticisms of EPA’s conclusions, and
contentions that EPA was inconsistent,
without citation to biological evidence
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
to support these claims. For example,
the Report addresses EPA’s rejection of
the Bretaud study in goldfish on the
grounds that the ‘‘distribution of
carbofuran across fish and mammalian
tissues may be quite different,’’ by
criticizing EPA for failing to provide
‘‘evidence or a citation to support this
point’’ (Exhibit 6 at 1). But they cite to
nothing demonstrating the similarity of
fish and mammalian tissues or
otherwise supporting their proposed
extrapolation across taxa; at this stage of
the administrative process the
obligation is on the Petitioners to come
forward with evidence to call EPA’s
conclusions into question. See, 73 FR
42683, 42706, July 23, 2008 (‘‘NRDC
does no more than state ‘we are aware
of no statistical test’ which would
support EPA’s use of the Gledhill data.
As EPA’s regulations make clear, a mere
‘denial’ of an EPA position is not
enough to satisfy the standard for
granting a hearing.’’); 53 FR 53176,
53199, December 10, 1982 (‘‘Rather than
presenting evidence, [the objector]
asserts that FDA did not adequately
justify its conclusions. Such an
assertion will not justify a hearing.’’).
The report also attempts to dismiss
EPA’s conclusions by complaining that
EPA’s assessment fails to include ‘‘any
analysis of the relationship between
RBC AChE and PNS AChE.’’ This also,
cannot justify a hearing. As has been
previously noted, FMC, who bears the
statutory burden for producing such
data, has failed to provide data in the
PNS that would allow EPA to make the
suggested comparison (See, 73 FR
42683, 42699, July 23, 2008 (hearing
denied where NRDC made no
evidentiary proffer supporting its claim
that each of the factors cited in EPA’s
risk assessment ‘‘poses a serious risk of
understating the risks’’); 70 FR 21619,
April 27, 2005 (objector questioned
exposure assessment and studies relied
on for assessment; hearing denied
because no information presented); 72
FR 39557, 39560, July 19, 2007
(‘‘Although Public Citizen alleged that
the studies that FDA evaluated do not
support the safety of x-rays of 10 MeV
or lower used for inspection of cargo
containers that may contain food, Public
Citizen did not present any evidence
that would have led to a different
conclusion concerning the safety of the
subject additive.’’).
iii. Denial of Objection. EPA’s wellestablished policy when evaluating
blood cholinesterase inhibition is to use
RBC AChE data as an indicator of
possible effects on AChE in the PNS;
EPA adopted this policy for a number of
reasons (Ref. 76 at 32). EPA’s reasoning
PO 00000
Frm 00035
Fmt 4701
Sfmt 4700
59641
here is straightforward. As a biomarker
of exposure, blood AChE inhibition can
be correlated with the extent of
exposure. There is often a direct
relationship between a greater
magnitude of exposure and an increase
in incidence and severity of clinical
signs and symptoms as well as blood
AChE inhibition. In other words, the
greater the exposure, the greater the
amount of AChE inhibition that will be
present in the blood and the greater the
potential for an adverse effect to occur.
RBC measures of AChE inhibition also
provide: (1) Pharmacokinetic evidence
of absorption of the pesticide and/or its
active metabolite(s) into the
bloodstream and systemic circulation;
and (2) pharmacodynamic evidence of
binding to AChE, the neural form of the
target enzyme. Because the interaction
with AChE is widely accepted as a key
event of the mechanism of toxicity for
anticholinesterase pesticides, inhibition
of this AChE in the blood creates the
presumption that a chemical also is
causing inhibition of neural AChE.
Chemicals are absorbed into the blood
and transported to the PNS.
Pharmacokinetically, the blood
compartment and the PNS are ‘‘outside
of’’ the central nervous system, i.e.,
separated from the CNS by the bloodbrain barrier. Thus, RBC measures of
AChE activity are viewed as a better
surrogate for the effects on AChE in the
peripheral nervous system than are
enzyme changes in the CNS. Because
data on AChE inhibition in the PNS
have rarely been gathered in animals,
blood AChE inhibition measures are
generally the only information available
to assess the potential of chemicals to
inhibit AChE in the peripheral nervous
system.
Finally, based on the record, FMC
seemingly intended in the past for RBC
AChE to be used as a surrogate for
peripheral AChE inhibition. In 2005,
FMC submitted a time course study
with plasma and RBC AChE inhibition
following acute exposure to carbofuran
in adult rats. The title of this study is
‘‘The toxicokinetics of peripheral
cholinesterase inhibition from orally
administered carbofuran in adult male
and female CD rats (Ref. 5).’’ Although
this study is entitled ‘‘peripheral
cholinesterase inhibition,’’ there are no
actual measures of peripheral toxicity
(e.g., liver, lung, heart). Instead, RBC
and plasma ChEs are the only measures
included. That report states that
‘‘carbofuran reversibly inhibits
cholinesterase activity by binding to
acetycholinesterase in red blood cells
* * * Carbamylation of cholinesterase
after the association of carbofuran leads
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59642
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
to an accumulation of acetylcholine and
inhibition of nerve function at the
neuronal and neuromuscular synapse.’’
Based on this statement, FMC assumed
at the time of conducting and
submitting this study that measures of
RBC AChE were relevant for predicting
neurotoxicity and for use in risk
assessment. For all of these reasons, the
Petitioners’ objection is denied.
c. Objection/hearing request subissue:
‘‘Lip-smacking’’ as CNS effect.
Petitioners object that EPA’s evidence of
‘‘lip smacking’’ in a carbofuran adult
developmental rat study does not
support concern for potential PNS
effects because lip smacking is more
properly correlated to CNS, rather than
PNS inhibition. In support, the
Petitioners proffer testimony that relies
on four published studies, none of
which was conducted with carbofuran.
The papers describe pharmacological
and physiological analyses of the bases
of ‘‘purposeless chewing movements’’,
‘‘chewing jaw movements’’, ‘‘chewing
motions and tongue protrusions’’, and
‘‘tongue protrusion and gaping’’ seen in
rats dosed with either cholinergic or
dopaminergic drugs.
i. Background. In the proposed rule,
in addition to the data in pups showing
frank PNS effects (tremors), EPA
discussed the results of another
carbofuran study that appeared to be a
possible consequence of PNS inhibition,
to provide further explanation of the
basis for EPA’s concern that carbofuran
could cause adverse PNS effects. The
proposed rule stated that ‘‘[t]here is
indication in a toxicity study where
pregnant rats were exposed to
carbofuran that effects on the PNS are of
concern; specifically, chewing motions
or mouth smacking was observed in a
clear dose-response pattern immediately
following dosing each day’’ (73 FR
44873, July 31, 2008). EPA explained
that the California Department of
Pesticide Regulation calculated a BMD05
and BMDL05 of 0.02 and 0.01 mg/kg/
day, and established the acute PoD
based on this study. The Agency also
explained that ‘‘[t]hese BMD estimates
are notable as they are close to the
values EPA has calculated for brain
AChE inhibition and being used as the
PoD for extrapolating risk to children’’
(73 FR 44873, July 31, 2008). The
similarities of the BMDs in adult and
juvenile rats suggests that toxicity may
be occurring in juvenile animals which
cannot be detected due to the challenges
with assessing clinical signs in juvenile
rats.
The Petitioners did not raise the
allegation contained in their objections
as part of the Petitioners’ comments.
The context in which ‘‘lip smacking’’
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
was addressed was a sentence that
states, ‘‘One issue raised at the FIFRA
SAP meeting was whether ‘lip
smacking’ observed in the adult females
in the developmental toxicity study
were the result of PNS or CNS AChE
inhibition’’ (Ref. 18 at 82). In a footnote
to this allegation, the Petitioners stated
‘‘Moreover, it is impossible to tell from
the study data whether this ‘‘lip
smacking’’ was a PNS or a CNS effect.’’
(Ref. 18 at 82). The Petitioners’
comments focused instead on the
contention that the study was irrelevant
because the dose levels in the study
were higher than the dose levels at
which EPA was regulating for AChE
inhibition (Ref. 18 at 82).
EPA did not respond to the
Petitioners’ description of the
discussion at the SAP, since it correctly
characterized the discussion. However
EPA responded fully to the Petitioners’
comment regarding the dose levels in
the final rule and response to
comments.
ii. Denial of hearing request. There
can be no legitimate argument that this
comment raised the issue in sufficient
detail to allow Petitioners to object that
‘‘lip smacking’’ is more properly
correlated with CNS inhibition, and to
supplement the objection with the
published literature studies they cite
here. See, e.g., Forest Guardians v. US
Forest Service, 495 F.3d 1162, 1170–
1172 (10th Cir. 2007) (Claim held
waived where comments ‘‘failed to
present its claims in sufficient detail to
allow the agency to rectify the alleged
violation’’); National Association of
Manufacturers v. US DOI, 134 F.3d
1095, 1111 (DC Cir. 1998) (‘‘We decline
to find that scattered references to the
services concept in a voluminous record
addressing myriad complex technical
and policy matters suffices to provide
an agency like DOI with a ‘fair
opportunity’ to pass on the issue.’’) For
the reasons discussed in Unit VI.C, EPA
considers the objection and evidence
untimely, and therefore waived. As
such, this objection does not warrant a
hearing.
But in any event, this issue is not
material. EPA’s decision to retain a 4X
children’s safety factor did not rest
exclusively, or even significantly—on
the effects observed in this
developmental study. Rather, EPA
retained the children’s safety factor
based on the lack of data in the PNS
and/or a surrogate at the low end of the
response curve, and the fact that the
available pup RBC data at higher doses
affirmatively indicate that the PNS
appears to be significantly more
sensitive than the CNS (73 FR 44871–
44872; 74 FR 23073–23075). Indeed, it
PO 00000
Frm 00036
Fmt 4701
Sfmt 4700
is clear from both the proposed and
final rules that the results of this study
merely supplemented the Agency’s
bases for concern (73 FR 44871–44872;
74 FR 23073–23075). The Petitioners’
complaint that the effects occurred at
dose levels three times higher than PoD
and therefore do not quantitatively
support the 4X children’s safety factor is
equally immaterial. The record is clear
that EPA relied on comparisons between
the BMD50 estimated for pup brain and
RBC AChE inhibition to derive the 4X
(73 FR 44871–44872; 74 FR 23073–
23075). A hearing can only be based on
a genuine issue of disputed fact. Where
a party’s factual allegations are
contradicted by the record, there is no
genuine dispute (40 CFR 178.32(b)(1))
(See, 73 FR 42683, 42701 July 23, 2008;
57 FR 6667, 6672, February 27, 1992)
(‘‘A hearing must be based on reliable
evidence, not on mere allegations or on
information that is inaccurate and
contradicted by the record.’’).
iii. Denial of objection. The
carbofuran developmental study does
not definitively resolve whether the
effects described were the product of
PNS or CNS AChE inhibition; because
only RBC AChE inhibition data were
collected it is not possible to determine
the degree of CNS inhibition. However,
as the Petitioners acknowledge, chewing
or oral fasciculations, which are the
movements EPA described at the SAP
meeting and in the proposed and final
rules, have often been reported as an
early sign of toxicity produced by
carbamates and OPs in rats (Exhibit 5 at
2). Petitioners also acknowledge that
‘‘oral fasciculations’’ are indeed a
peripheral neuromotor response (Id.)
(‘‘some of the toxicity is peripherally
mediated or an effect on the PNS (for
example, muscle fasiculations and
tremors are due to inhibition of AChE at
the motor endplate of the muscle)’’).
Nevertheless, Petitioners attempt to
confuse the issue by providing several
different descriptions of oral
movements, from lip-smacking to mouth
smacking to mouth movements to
chewing movements, and claiming that
it is clear that these are all CNS effects.
As an initial matter, it is unclear
whether all of the study authors in
Petitioners’ cited literature are referring
to the same phenomenon. It is therefore
unclear whether the oral movements
from the carbofuran developmental
study (which EPA described as ‘‘lipsmacking’’ and ‘‘fasiculations’’) are the
same responses described as ‘‘tongue
protrusion,’’ ‘‘gaping,’’ ‘‘yawning,’’ and
‘‘chewing movements’’ in the
pharmacology papers Petitioners
reference. It is not unlikely that all of
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
the different papers refer to somewhat
different actions; Rupniak et al. (Ref. 68)
were able to produce ‘‘chewing jaw
movements’’ by chronic treatment with
haloperidol, a dopaminergic receptor
antagonist, which suggests that the
movements studied in that paper are not
purely cholinergic. The fact that
anticholinergics could block the
haloperidol-induced dopaminergic
movements shows that this is not a
straightforward physiological response
dealing only with the cholinergic
system. For the same reason, this calls
into question the contention that the
effects are exclusively CNS-related.
Similarly, the claim that the ‘‘the
masticatory response’’ is clearly a CNS
effect is equally misleading and
inaccurate. The report in Exhbit 5
claims that ‘‘[t]he masticatory response
is considered a preliminary index of
convulsive activity and convulsions
have been demonstrated to be caused by
changes in brain chemistry.’’ None of
the papers the Petitioners cited describe
this ‘‘masticatory response’’ in that way.
Instead, those papers all state that this
response is seen at relatively low doses
of these anticholinesterases. By way of
contrast, convulsions are seen at high
doses. The Exhibit also implies that the
‘‘masticatory’’ response and convulsions
are a continuum of the same
phenomemon; however EPA is aware of
no scientific support for this claim, and
Petitioners have provided none.
Petitioners’ objection on this issue is
therefore denied.
The Exhibit also implies that the
‘‘masticatory’’ response and convulsions
are a continuum of the same
phenomemon; however EPA is aware of
no scientific support for this claim, and
Petitioners have provided none.
d. Objection/hearing request subissue:
EPA’s analysis does not rely on Good
Laboratory Practice (GLP)-compliant
studies. Petitioners object that EPA’s
reliance on the ORD data is problematic
because the data were not conducted in
accordance with EPA’s GLP regulations
at 40 CFR part 160.
i. Background. The only data available
on the effects of carbofuran on the pup
PNS are RBC AChE inhibition data from
two studies conducted by EPA–ORD.
These data unequivocally show that pup
RBC AChE is more sensitive than pup
brain AChE. EPA also used these data in
its calculations supporting the 4X
children’s safety factor. In their
comments on the proposed rule,
Petitioners alleged that, ‘‘the Moser
study may not meet minimum criteria
for scientific acceptability.’’ They based
this on a claim that critical data were
unavailable for this study, including: A
complete protocol, analysis of dosing
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
solutions, clinical observations,
standardization of brain and RBC AChE
results in terms of amount per unit of
protein, and quality assurance records
of inspections for the carbofuran portion
of the study. However, no more specific
explanation was provided as how this
purportedly missing data rendered the
data scientifically deficient. EPA
responded in full to these allegations in
the final rule and response to comments
document.
EPA’s regulations at 40 CFR part 160
establish a set of principles that
provides a framework within which
laboratory studies are planned,
performed, monitored, recorded,
reported, and archived. GLP helps
assure EPA that the data submitted are
a true reflection of the results obtained
during the study and can therefore be
relied upon when making risk/safety
assessments. The regulations are
applicable only to studies that support,
or are intended to support applications
for ‘‘research or marketing permits’’ for
pesticides regulated under FIFRA (40
CFR 160.1(a)).
ii. Denial of hearing request. On
several grounds, a hearing on this
subissue is not warranted. First, this
objection fails to identify a dispute of
material fact. There is no dispute that
the EPA–ORD studies were not
conducted in strict accordance with
EPA’s GLP regulations. Nor have
Petitioners identified a substantive flaw
in those studies that they believe
resulted from the lack of compliance
with the regulations, or otherwise
challenged the scientific validity of
those studies. Thus, the only issue
presented is whether EPA should rely
on otherwise scientifically valid studies
that were not conducted in accordance
with its GLP regulations. This is clearly
a legal or policy issue. Hearings are not
appropriate on such issues; issues of
fact, not of law or policy are required to
justify a hearing (40 CFR 178.32(b)(1)).
A further defect is that Petitioners
have submitted no evidence on this
point. In fact, this claim consists of
nothing more than the bare statement
that EPA’s analysis does not rely on
GLP-compliant studies. A hearing will
not be granted on ‘‘mere allegations’’ or
‘‘general contentions’’ (40 CFR
178.32(b)(2)). To the extent the
Petitioners are relying on the
information submitted as part of their
comments on the proposed rule, this
does not cure the defect, since no
substantiating information or other
evidence was presented in support of
their comments. Nor can simple
reiteration of a comment made on the
proposed rule justify a hearing. EPA
responded to these comments in the
PO 00000
Frm 00037
Fmt 4701
Sfmt 4700
59643
final rule, and by ignoring the EPA’s
final rule on this subissue, Petitioners
have failed to lodge a relevant objection.
Both EPA and FDA precedent make
clear that when the agency substantively
responds to comments on the proposal,
the commenter may only keep that issue
alive in its objections by addressing the
agency’s substantive response. See, e.g.,
73 FR 42701 (denying hearing because
NRDC merely repeated its assertion that
the study was not representative from
its petition, rather than objecting to the
basis EPA asserted in its petition denial
for concluding that the study was
representative).
Indeed, this entire objection is not
material. The EPA–ORD data are the
only valid pup RBC data using
carbofuran; in the absence of these data,
EPA would have no data that would
provide relevant information on
carbofuran’s effects on children’s PNS.
Under such circumstances, EPA would
be required to retain the statutory
default 10X, because there would be no
‘‘reliable data’’ on which to base any
other factor.
iii. Denial of objection. The mere fact
that a study is not conducted in
accordance with EPA’s GLP regulations
does not mean that the study is
scientifically invalid, or that EPA is
prohibited from considering the study.
The GLP regulations do not apply to
EPA–ORD generated data, but rather to
studies conducted to ‘‘support
applications for research or marketing
permits for pesticide products’’ (40 CFR
160.1(a)). Moreover, the regulations
establish general practices; they do not
identify the only good laboratory
practices that will result in scientifically
valid data. Other laboratory protocols,
such as that used by EPA–ORD are
equally valid. In recognition of this fact
the regulations do not prohibit EPA
from considering studies that were not
conducted in accordance with EPA’s
GLP regulations, but merely provide
that EPA may refuse to consider such
studies to be ‘‘reliable’’ (40 CFR
160.17(a)).
Nor does compliance with EPA’s GLP
regulations guarantee the validity of the
study’s results. The RBC data from
FMC’s carbofuran CCA studies, which
were conducted in accordance with
EPA’s GLP regulations, were
unanimously determined to be
scientifically invalid by the FIFRA SAP
(Ref. 36).
Any claim that the conduct of the
EPA–ORD studies raised questions as to
their scientific validity is equally
baseless. EPA’s ORD data were reviewed
by the FIFRA SAP, which concluded
that, ‘‘EPA–ORD has provided excellent
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59644
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
data regarding RBC AChE inhibition by
carbofuran’’ (Ref. 36 at 55).
As EPA explained in response to the
Petitioners’ comments, all of the
information the Petitioners claimed was
missing had been previously made
publically available as part of the SAP
review of the carbofuran NOIC, and was
provided again in response to FMC’s
FOIA request. A complete study
protocol, as well as a report of the
quality assurance (QA), technical, and
data reviews of the study, were
available, which demonstrated that the
procedures and documentation are in
accordance with the National Health
and Environmental Effects Laboratory
(NHEERL)/ORD Quality Assurance
Management Plan. Concerning
standardization of brain and RBC AChE
in terms of protein concentration, the
Agency notes that this analysis has not
been performed or provided in all the
studies on the record, including those
sponsored by FMC. However, in the
Moser study (Ref. 56), the AChE activity
was standardized in terms of tissue
weight per ml, so the amount of protein
was consistent across samples, which is
an acceptable and widely used practice.
Further, abnormal (or ‘‘clinical’’)
observations were recorded when they
occurred, although the animals could
not be watched while they were in the
motor activity chambers. Finally, the
registrant is correct that the dosing
solutions for the comparative ChE study
were not analyzed, but ORD performed
this analysis for the adult studies in
McDaniel et al. (Ref. 54), and the
preparation and stability of the
carbofuran samples were confirmed
therein. For these reasons, this objection
is denied.
e. Objection/hearing request subissue:
Consistency of EPA’s approach to
deriving the carbofuran children’s safety
factor—i. Background. The Petitioners
argue that EPA’s approach to deriving
carbofuran’s children’s safety factor is
inconsistent with that Agency’s
approach in deriving the safety factors
for other NMC chemicals. Specifically,
they point to carbaryl, which had a
safety factor of 1X.
Petitioners raised this issue in their
comments on the proposed rule. In the
final rule, EPA explained at length, the
basis for its conclusion that the
available data using carbaryl, provided
by the carbaryl registrant, supported a
finding that a 1X children’s safety factor
would be ‘‘safe’’ (74 FR 23058 and Ref.
85). EPA explained that the different
safety factors established for carbaryl
and carbofuran resulted from
differences in the chemicals themselves,
as reflected by the available data (Id).
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
ii. Denial of hearing request. A
hearing is not appropriate on this
objection because it raises a legal or
policy claim, rather than a dispute as to
a material issue of fact. The claim that
EPA acted inconsistently in assessing
different pesticide chemicals is purely a
legal issue. There is no factual dispute
that EPA established a children’s safety
factor of 1X for carbaryl, and a safety
factor of 4X for carbofuran. The only
dispute concerns whether EPA’s basis
for distinguishing between the two is
reasonable, and this is a legal claim, on
which a hearing is not appropriate (40
CFR 178.32(b)(1)).
In addition, the Petitioners make no
claim other than to reiterate the
allegation made in their comments on
the proposed rule, that EPA’s
assessment of carbofuran is inconsistent
with its assessment of carbaryl.
Consequently, Petitioners’ objection on
this subissue is irrelevant, and therefore
immaterial, with regard to EPA’s final
tolerance revocation regulation because
Petitioners ignored EPA’s extensive
analysis of this issue in the final rule
and refiled their comments on the
proposal as if EPA’s determination in
the final rule did not exist. By ignoring
the EPA’s final rule on this subissue,
Petitioners have failed to lodge a
relevant objection. Nor have they
proffered any evidence in support of
this claim. When EPA responds to a
comment in the final rule, mere
reiteration of the comment in objections
does not present a live controversy
unless the objector proffers some
evidence calling EPA’s objection into
question (See, e.g., 73 FR 42700–42701).
iii. Denial of objection. Carbaryl was
evaluated no differently than
carbofuran. The different children’s
safety factors applied to each chemical
reflects the differences in the chemicals
themselves, as reflected by the data.
It is typical EPA practice to use the
central estimate on the BMD as an
appropriate measure for comparing
chemical potency and the lower limit on
the central estimate (i.e., BMDL) as an
appropriate measure for extrapolating
risk. In the case of carbaryl, the
Petitioners inappropriately focused on
the BMDL10, instead of the BMD10. The
more appropriate comparison is
between the BMD10; the carbaryl brain
BMD10 is 1.46 mg/kg compared with the
RBC BMD10 of 1.11 mg/kg. As such, the
brain to RBC ratio is 1.3X. Therefore, for
carbaryl, the brain and RBC AChE data
are similarly sensitive. When the tissues
are similarly sensitive, the Agency
prefers to use data from the target tissue
(i.e., central or peripheral nervous
system) rather than data from a
PO 00000
Frm 00038
Fmt 4701
Sfmt 4700
surrogate tissue (i.e., RBC). EPA’s
hazard identification for carbaryl states:
‘‘Although the RBC BMDL10 for the more
sensitive PND 11 rat is numerically the
lowest (0.8 mg/kg) of the two compartments,
biologically the RBC BMDL10 is similar to the
brain BMDL10 (1.1 mg/kg). Since the brain is
the target tissue for the NMCs, and the brain
BMDL10 1.1 mg/kg is also protective of the
surrogate and often more variable RBC ChE
measurements (BMDL10 0.8 mg/kg), then the
brain BMDL10 of 1.1 mg/kg is the appropriate
PoD for both children and adults in the
carbaryl risk assessment (Ref. 82).’’
Thus, for carbaryl, biologically the RBC
and brain AChE inhibition were
basically equivalent where brain AChE
inhibition is a direct measure in a target
tissue and RBC AChE inhibition is used
as a surrogate for the peripheral nervous
system. This is quite different from the
situation with carbofuran where a
significant difference was noted
between RBC and brain AChE
inhibition, showing that RBC AChE
inhibition (used as a surrogate for the
PNS) is more sensitive.
The approach used for carbaryl—i.e.,
relying on the central estimate for
purposes of comparison across age
groups, and using biological
compartments and the lower limits for
use as PoDs—is being used by EPA in
its carbofuran risk assessment. In
addition, this approach was used in the
NMC cumulative risk assessments
(CRA) and single chemical risk
assessments for multiple OPs. Thus, the
Agency is, in fact, being consistent in its
hazard identifications among the AChEinhibiting pesticides.
With regard to the carbaryl children’s
safety factor, the available brain and
RBC dose-response data in PND11 pups
include data from the lower end of the
dose-response curves. ORD’s
comparative ChE data with carbaryl
show that at the lowest dose at or near
20% inhibition in brain and RBC AChE
were observed. Although not ideal, the
carbaryl data provide information closer
to the benchmark response of 10%, and
therefore allow for a reasonable
estimation of the BMD10 and BMDL10.
This is distinctly different from ORD’s
data with carbofuran in PND11 and
PND17 pups where the 50% or greater
RBC AChE inhibition was observed at
the lowest dose. Accordingly, the
objection is denied.
2. EPA’s Mathematical Modeling
Underlying the Calculation of a 4X
Children’s Safety Factor. Petitioners
argue that EPA committed numerous
errors in calculating the 4X children’s
safety factor. First, Petitioners allege
that, even assuming that RBC values are
relevant, EPA’s conclusion that the
RBC-related effects in the relevant
E:\FR\FM\18NOR2.SGM
18NOR2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
studies were four times more sensitive
than brain effects is not mathematically
supportable. Referencing statistical
analyses performed by a contractor, they
claim that ‘‘[a]t most, the data support
a 2X safety factor, based on actual
difference between brain and RBC
(ranging between 1 and 1.9).’’
Second, the Petitioners claim that
there are several technical errors in the
way EPA conducted the statistical
modeling that formed the quantitative
support for the 4X children’s safety
factor. They also object that the
mathematical assumptions underlying
EPA’s modeling are not justified and fail
to support the 4X children’s safety
factor. In this regard, they allege that
EPA’s children’s safety factor was based
on calculations that (i) are not based on
‘‘within animal comparisons;’’ (ii) have
been applied incorrectly and
inconsistently to the data, which
exaggerated the difference; (iii) overstate
the evidence for higher relative RBC
sensitivity; and (iv) treated carbofuran
inconsistently as compared to other
NMCs. They claim that by removing the
inconsistencies from EPA’s data, the
data yield a brain/RBC ratio of 1.3,
which confirms Petitioners’ approach.
These five allegations are addressed
separately below.
In support of these claims, the
Petitioners offer allegations on the
points above, referencing two
memoranda from Drs. R. Sielken and C.
Valdez-Flores (Exhibits 7, 8, 9) that
generally describe and summarize the
analyses and modeling they conducted.
The full analyses underlying these
memoranda were not included with the
objections.
pwalker on DSK8KYBLC1PROD with RULES2
a. Objection/Hearing Request Subissue:
Use of Within-Animal Brain to RBC
Inhibition Comparisons To Derive the
Children’s Safety Factor
i. Background. In the proposed rule,
EPA explained its approach to deriving
an alternate to the default 10X
children’s safety factor. This safety
factor was calculated using the ratio of
RBC and brain AChE inhibition, using
the data on administered dose for the
PND11 animals from the EPA–ORD
studies and the FMC studies combined.
In other words, EPA estimated the
BMD50 for PND11 animals for RBC and
brain from each quality study and used
the ratio from the combined analysis,
resulting in a BMD50 ratio of 4.1X. EPA
estimated the RBC to brain potency ratio
using EPA’s data for RBC (the only
reliable RBC data in PND11 animals for
carbofuran) and all available data in
PND11 animals for brain. EPA’s
approach yields a ratio of about 4 fold.
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
EPA also compared the BMD50 ratios
for PND17 pups (who are slightly less
sensitive than 11-day olds) in the EPA–
ORD study, to confirm that the observed
differences in sensitivity between RBC
and brain were not unique to the PND11
data. The result of EPA’s modeling
showed a BMD50 ratio of 3.3 13 between
brain and RBC in the PND17 pups.
In their comments on the proposed
rule, Petitioners presented essentially
the same arguments raised in this
objection. They argued that a more
plausible and straightforward approach
would be to compare the RBC and brain
AChE levels at the same time in the
same rat when these rats are exposed to
carbofuran. The comments claimed that
a statistical evaluation of the
experimental data on AChE inhibitions
in RBC and brain in rats due to
carbofuran exposure had been
performed by Sielken & Associates,
which showed that the percentage
inhibition of RBC AChE in a rat is
almost the same as the percentage
inhibition of brain AChE in the rat.
Although the results of the statistical
analyses were summarized in the
comments, the underlying analyses
were not submitted.
In the final rule, EPA provided a
detailed explanation of its rationale for
rejecting the Petitioners’ approach (74
FR 23055; Ref. 85).
ii. Denial of hearing request. EPA is
denying Petitioners’ request for a
hearing on this objection for two
reasons. First, as in its comments,
Petitioners failed to submit the
underlying modeling conducted in
support of its assertions. Petitioners’
consultant merely asserts that the
results are as presented in his
summarized testimony. In the absence
of the underlying scientific analyses,
these are effectively no more than mere
allegations or general contentions.
Hearings will not be granted on this
basis alone. (40 CFR 178.32(b)(2); see
also 73 FR 42702 (July 23,
2008)(denying NRDC’s hearing request
on objection that EPA’s risk assessment
was inadequate because EPA lacked
data on how pest strips were used in
their homes, because ‘‘NRDC provided
no factual information to support its
claim’’); 68 FR 46403, 46406–46407
(August 5, 2003) (FDA denied a hearing
involving a challenge to FDA’s reliance
on consumption pattern data because
the objector ‘‘did not present any
specific information to dispute P & G’s
consumption pattern data; instead,
[objector] simply asserted that other
13 EPA corrected a technical error identified in
Petitioners’ comments, which resulted in a revised
ratio of 2.6X, for the final rule.
PO 00000
Frm 00039
Fmt 4701
Sfmt 4700
59645
consumption patterns were likely.’’);
accord Community Nutrition Institute v.
Novitch, 773 F.2d 1356, 1363 (DC Cir.
1985) (‘‘Mere differences in the weight
or credence given to particular scientific
studies * * * are insufficient [to show
a material issue of fact for a hearing].’’)).
Second, Petitioners’ hearing request is
inadequate because they do not object to
the basis EPA asserted in the final rule
for rejecting this approach. Specifically,
Petitioners do not challenge EPA’s
conclusion that their suggested
approach is fundamentally flawed in
several regards, nor proffer evidence in
support of that challenge. Petitioners
also do not challenge EPA’s analyses,
showing that the results of their
suggested approach are in fact
consistent with EPA’s conclusions. As a
consequence, Petitioners’ objections are
irrelevant, and therefore immaterial,
with regard to EPA’s final tolerance
revocation regulation. The statute,
however, requires that objections be
filed on the final rule not the proposal.
By ignoring the EPA’s final rule on this
subissue, Petitioners have failed to
lodge a relevant objection. Prior FDA
decisions under its regulations are
instructive here. Objections and hearing
requests were filed in response to a food
additive regulation covering the
irradiation of poultry. (62 FR 64102
(December 3, 1997)). The objector
argued that the addition of an antioxidant (ethoxyquin) to irradiated
chicken prior to the chicken’s use in
animal feeding studies compromised the
studies because the ethoxyquin would
have decreased the level of lipid
peroxides in the chicken to levels found
in chicken that had not been irradiated.
The FDA noted, however, that it had
considered the question of ethoxyquin’s
effect on lipid peroxide levels in the
final rule and determined that while
ethoxyquin can retard the normal
oxidation of chicken fat to peroxides,
ethoxyquin cannot reverse oxidation
that has already occurred. FDA denied
the hearing request reasoning that
because the objector did ‘‘not dispute
FDA’s explanation in the final rule as to
why addition of ethoxyquin did not
compromise the CIVO studies, and
provided no information that would
have altered the agency’s conclusion on
this issue * * * there is no factual issue
that can be resolved by available and
specifically identified reliable
evidence’’ (62 FR 64105). See also 53 FR
53176, 53191 (December 30, 1988) (FDA
denied a hearing request noting that
given FDA’s prior conclusion that the
studies relied upon by the objector were
unreliable, the ‘‘burden shifted to [the
objector] to maintain the viability of its
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59646
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
objection by proffering some
information that called into question the
agency’s conclusion on this matter.’’)).
Similarly, here, Petitioners have not
challenged the basis EPA asserted for
rejecting their suggested within-animal
analyses, nor have they proffered any
information calling into question EPA’s
conclusion.
iii. Denial of objection. EPA notes that
the Petitioners recommended this
approach of comparing the degree of
inhibition for each animal as part of
their presentation to the carbofuran
SAP. EPA also addressed this approach,
comparing RBC to brain in the same
animals, at the SAP and in the
responses to the SAP report (Ref. 83). It
is notable that the SAP did not endorse
this approach (Id.).
EPA’s analyses of the Petitioners’
approach identified several significant
deficiencies. First, the comparison
suggested by the Petitioners would
require that EPA ignore existing data.
This is because only EPA’s study of
PND 11 animals contains both brain and
RBC data, so the comparisons suggested
by the commenter can only be made
using that dataset. However, the dose
levels in that study were so high that the
lower portion of the dose-response
curve was missed. At these higher
doses, there is little difference between
the levels of brain and RBC inhibition.
This phenomenon—i.e., that the relative
sensitivity of RBC compared to brain
appears smaller at higher doses—is also
shown in multiple chlorpyrifos studies
where blood or peripheral measures of
AChE inhibition are more sensitive than
brain at low to mid doses, but the
tissues appear to be similar at higher
doses.
Second, the Petitioners’ approach is
fundamentally flawed. The Petitioners’
suggested alternative relies exclusively
on comparisons between the degree of
inhibition in the treated animals
without any regard to the doses at
which the effects occurred. For
example, one animal may have shown,
on average, 10% inhibition in the brain,
when it demonstrated 20% RBC
inhibition. Under this approach, what
would be relevant would simply be the
ratio of 1:2. But the Agency believes it
is critical to focus on the ratios of
potency, which is the ratio of the doses
in the data that cause the same level of
AChE inhibition. The Agency’s
approach of comparing potencies is
more directly relevant for regulatory
purposes than comparisons of average
inhibition. This is because dose
corresponds more directly to potential
exposures, which is what EPA regulates
(i.e., how much pesticide residue does
a child ingest). By comparison, the
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
Petitioners’ suggested reliance purely on
the average degree of inhibition
provides no information that
corresponds to a practical basis for
regulation.
Finally, the range of ratios of effects
that the Petitioners propose as an
alternative is consistent with range of
potencies that EPA has calculated at
these higher doses, so the Petitioners’
results do not ultimately contradict
EPA’s assessment, which is intended to
account for the effects at lower doses.
Briefly, if the dose-responses for RBC
and brain inhibition were linear, ratios
of inhibition would equal ratios of
BMDs. However, these dose-responses
are not at all linear; rather the available
data demonstrate that brain and blood
dose-responses have somewhat different
shapes. Thus, estimates of relative
effects at particular, relatively high,
doses will not determine the estimated
ratios at lower doses. This is because the
dose-response curves begin to level off
as they reach maximal inhibition (i.e.,
no more inhibition is possible), so, at
high doses, there is almost no difference
between the ratio of brain and RBC
inhibitions. Except at the lowest dose,
which produced 50% AChE inhibition,
where the ratio is slightly greater than
2, the remaining ratios are only slightly
greater than 1. Given the inevitable
statistical noise in these measures, it is
clear that the ratios expected from EPA’s
modeling are substantially similar to the
results the Petitioner finds in its
comparison between individuals.
Accordingly, the Petitioners’ suggested
comparisons at higher doses provide no
evidence of what occurs at lower doses;
and thus provides no evidence that
demonstrates that EPA’s modeling
results at lower doses is inaccurate.
b. Objection/hearing request sub
issue: Scientific validity of EPA’s
approach. The Petitioners object that
EPA’s approach has not been
established as scientifically valid. They
claim that data for other carbamates
suggests that BMD50 s for the carbamates
tend to diverge more than the dose
levels used to select the PoD (i.e., the
BMD10 s). In addition, they criticize
EPA’s approach for incorrectly
assuming that the relationship between
BMD50 s and BMD10 s is linear, which
they claim overstates the potential
differences. They claim that these issues
could be avoided by adopting their
suggested approach of using withinanimal comparisons to determine the
relative sensitivity of RBC and brain
AChE. The evidence submitted in
support of this subissue is the summary
presented in the objection.
i. Background. In the proposed rule,
EPA explained that its comparisons of
PO 00000
Frm 00040
Fmt 4701
Sfmt 4700
the BMD50 s for brain and blood relied
on an assumption that the magnitude of
the difference between RBC and brain
AChE inhibition is constant across dose.
In other words, EPA assumed that the
RBC and brain AChE dose curves are
parallel, even though there are no data
to test this assumption (73 FR 44873). In
their comments, the Petitioners
criticized EPA for this assumption, and
recommended using ‘‘within animal
comparisons’’ to avoid having to make
this assumption. In the final rule, EPA
explained that its decision to rely on
comparisons of BMD50 s rather than
BMD10 s was because the RBC data for
10% inhibition levels was insufficient
to allow the Agency to generate the
necessary estimates. EPA agreed that the
dose-response curves were not parallel
at these lower doses, (i.e., that the
relationship between BMD50 s and
BMD10 s was not linear) but that EPA
lacked any data that would allow it to
make any other assumption. EPA
nevertheless rejected the Petitioners’
suggested approach of relying on
within-animal comparisons, because, as
described in the preceding objection, it
is intrinsically flawed and scientifically
invalid.
ii. Denial of hearing request. A
hearing on this subissue is not
appropriate because Petitioners’ request
is based on mere allegations, general
contentions, and speculation (40 CFR
178.32(b)(2)). No evidence has been
submitted on any of the issues raised in
this objection. Petitioners have provided
no evidence that supports their
assertion that EPA’s assumption that the
dose-response curves will remain
parallel at lower doses overestimates the
ratios. In the absence of data at the low
end of the dose-response curve, which
Petitioners were required to have
developed, there is just as great a
likelihood that EPA’s assumption
underestimates the ratios. Petitioners
have not cited to any data from other
carbamates to support their contention
that BMD50 s tend to diverge more than
BMD10 s; the objection fails to even
identify the carbamate chemicals that
purportedly support this claim. Further,
the claim is untimely, as it was not
raised as part of their comments on the
proposed rule. For the reasons
discussed in Unit VI.D, EPA will not
consider such information in support of
a request to justify a hearing.
In addition, a hearing on this
objection is denied on the ground of
materiality (40 CFR 178.32(b)(1)). In the
absence of EPA’s assumption, EPA
would have no basis for deriving an
alternate children’s safety factor. Thus,
EPA would have to raise the children’s
safety factor from 4X to the statutory
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
default of 10X, rather than to lower the
factor as the Petitioners seek. As
discussed at length in the preceding
objection subissue, the Petitioners’
suggested alternative of within-animal
comparisons is scientifically invalid,
and provides no useful basis for
regulatory action. Accordingly, if
Petitioners establish that available
information does not support EPA’s
assumption that the dose-response
curves are parallel, then EPA is left with
no valid scientific information to
determine the correct dose-response
curve at lower doses, or to establish a
BMD10 (21 U.S.C. 346a(b)(2)(C)).
Because deviation from a 10X children’s
safety factor requires some ‘‘reliable
data’’ on the shape of the dose response
curve for RBC AChE, Petitioners’
objection on EPA’s low dose-response
curve assumptions, in combination with
the failure to provide a valid alternate
approach would result in a higher
children’s safety factor, and a
conclusion that EPA has underestimated
carbofuran’s risks.
iii. Denial of objection. EPA disagrees
that its approach is not scientifically
valid. The models used to develop the
BMD estimates have been repeatedly
reviewed and approved by the SAP
(Refs. 34, 35). The most recent occasion
was the February 2008 carbofuran SAP,
which concluded that ‘‘[t]he doseresponse analysis done by the Agency
for the EPA–ORD PND11 study was
appropriate and led to a very uncertain
BMD10 * * * This [assumed doseresponse] curve fit well in the region
where there were data, but there was no
way to validate it at low doses’’ (Ref. 36
at 54).
EPA acknowledges that it lacks
information to confirm its assumption
that the dose-response curves remain
parallel at lower doses. EPA believes
this is the most reasonable assumption,
given the absence of information at low
doses, since it neither presumes that
RBC inhibition will increase or decrease
at lower doses. Contrary to Petitioners’
naked assertion that EPA’s approach
overestimates the difference, there is no
inherent reason to expect that EPA’s
assumption would overestimate or
underestimate the difference between
BMD50 s and BMD10 s. If indeed data
were to show that EPA’s assumption
overestimated the difference—and
Petitioners have submitted none—it
would only be as a result of the animal
biology, as there is no indication in the
mathematical modeling that it
overestimates the difference in any way.
The mathematical relationship between
BMD50 s and BMD10 s certainly provides
no hint that there might be a bias. In this
regard, it is notable that the February
VerDate Nov<24>2008
17:53 Nov 17, 2009
Jkt 220001
2008 SAP concluded that ‘[w]hat the
Panel observed at the low end [of the
dose-response curve] made it tempting
to assume linearity at this part of the
dose-response curve’’ (Ref. 36 at 55).
Regarding the Petitioners’ claim that
data for other carbamates suggests that
BMD50 s for the carbamates tend to
diverge more than the dose levels used
to select the PoD (i.e., the BMD10 s). EPA
cannot confirm the accuracy of this
allegation, as Petitioners have provided
neither data nor any explanation of a
biological basis to support this claim.
Nor is EPA able to substantiate this
claim based on the information
currently available. However, there is no
a priori reason to expect such a
systematic divergence between ratios of
BMD50’s and ratios of BMD10 s for blood
and brain, based either on biology or the
mathematical relationship between
BMD50’s and BMD10 s. It is actually far
more probable that the variation from
chemical to chemical (due both to real
variation among chemicals and to
statistical sampling noise) would be
large enough to make a conclusive
determination from data difficult.
c. Objection/hearing request sub
issue: Combining data from different
toxicological studies—i. Background. In
its risk assessment, EPA relied on all of
the valid data from the available studies
to calculate the estimates that served as
the PoD, and to calculate the estimates
of BMD50 s that serves as quantitative
support for derivation of the 4X
children’s safety factor.
For purposes of the PoD, the Agency
used a meta-analysis that combined
valid data from all available studies to
calculate the BMD10 and BMDL10 for
pups and adults; this analysis includes
brain data from studies where either
adult or juvenile rats or both were
exposed to a single oral dose of
carbofuran. The quality brain AChE data
from the three studies (2 FMC, 1 EPA–
ORD) conducted with PND11 rats, in
combination, provides data to describe
both low and high doses. By combining
the three studies in PND11 animals
together in a meta-analysis, the entire
dose-response range is covered.
EPA also combined studies in
calculating the 4X children’s safety
factor. EPA derived the ratio of RBC and
brain AChE inhibition using the data on
administered dose for the PND11
animals from the EPA–ORD studies and
the FMC studies combined. In other
words, EPA estimated the BMD50 for
PND11 animals for RBC and brain from
each quality study and used the ratio
from the combined analysis, resulting in
a BMD50 ratio of 4.1X. EPA estimated
the RBC to brain potency ratio using
EPA’s data for RBC (the only reliable
PO 00000
Frm 00041
Fmt 4701
Sfmt 4700
59647
RBC data in PND11 animals for
carbofuran) and all available data in
PND11 animals for brain.
In their comments on the proposed
rule, Petitioners claimed that EPA’s
decision to combine data for different
strains of rats, sexes, experiments,
laboratories, dates, dose preparations,
rat ages, and times between dosing and
AChE measurement, is problematic,
claiming that these differences in study
design severely limit the validity of
EPA’s comparisons. Further, they
alleged that differences in data and
methods EPA used to estimate its
BMD50 (brain) and BMD50 (RBC) caused
EPA to overestimate the difference
between brain and RBC, and thereby
invalidating any comparison of the
estimates. Specifically, Petitioners were
concerned that the datasets from the six
studies EPA used for brain differ not
only because they were from different
studies, but also because the data were
taken at different times ranging from 15
minutes to 4 hours after dosing.
EPA responded to these comments in
full during the rulemaking (74 FR
23055–23057 (May 14, 2009); Ref. 85).
Petitioners referenced these comments
in their objections, but presented no
further argument or evidence on any of
these points. Because Petitioners
originally raised this claim also with
respect to the derivation of EPA’s PoD,
even though they only raise it in this
objection here, the Agency responds to
both points below.
ii. Denial of hearing request. The
Petitioners have not met the
requirements for a hearing on this
subissue. Petitioners have not
challenged the basis EPA asserted for
rejecting their suggested within-animal
analyses, and have therefore failed to
lodge a relevant objection. Both EPA
and FDA precedent make clear that
when the agency substantively responds
to comments on the proposal, the
commenter may only keep that issue
alive in its objections by addressing the
agency’s substantive response (40 CFR
178.32(b)(3)). Nor have they proffered
any evidence that calls the substance of
EPA’s conclusions into question. A
hearing is not warranted on the basis of
mere denials or contentions (40 CFR
178.32(b)(2)). See 73 FR 42698–42699
(When an objector does not challenge
EPA conclusions in the section
408(d)(4)(iii) order but rather challenges
some prior conclusion that was
superseded by the section 408(d)(4)(iii)
order, the objector has not raised a live
controversy as to an issue material to
the section 408(d)(4)(iii) order); 53 FR
53176, 53191 (December 30, 1988) (FDA
denied a hearing request noting that
given FDA’s prior conclusion that the
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59648
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
studies relied upon by the objector were
unreliable, the ‘‘burden shifted to [the
objector] to maintain the viability of its
objection by proffering some
information that called into question the
agency’s conclusion on this matter.’’)).
Second, this objection is not material.
In the case of carbofuran, EPA used a
sophisticated analysis of multiple
studies and datasets to develop the PoD
for the carbofuran risk assessment.
Instead of this analysis, EPA could
simply have followed the general
approach laid out in its BMD policy
(Ref. 100), which is used in the majority
of risk assessments. Under this general
approach, EPA would regulate using the
most sensitive effect, study, and/or
dataset. If the Agency chose not to
combine the data in its analyses, as the
commenters’ suggested, data collected at
or near the peak time of effect (i.e., 30
minutes) would in fact provide the more
relevant datasets. If this more simple
approach were taken, in accordance
with BMD guidance, EPA would select
the lowest BMDL10. Assuming the
commenters’ values were used, EPA
would have selected a PoD of 0.009 mg/
kg/day, instead of the 0.03 mg/kg/day
that EPA is currently using in its risk
assessment. A lower PoD of 0.009 mg/
kg/day would significantly increase
carbofuran’s level of estimated risk.
iii. Denial of objection. In general,
EPA believes that consideration of all
available data is the scientifically more
defensible approach, rather than the
selective exclusion of reliable data. The
Agency’s Draft BMD Guidance says the
following: ‘‘Data sets that are
statistically and biologically compatible
may be combined prior to dose response
modeling, resulting in increased
confidence, both statistical and
biological, in the calculated BMD’’ (Ref.
76). The SAP has reviewed and
approved EPA’s practice of combining
data from studies numerous times (Refs.
34, 35, 36). Most recently, as part of the
carbofuran SAP, the SAP was fully
aware that the Agency was planning to
derive BMD estimates from data sets
using different strains of rats (Ref. 36).
Accordingly, the Agency’s carbofuran
analysis has included all available, valid
data in its analysis.
By contrast, the Petitioners’ suggested
analysis ignores relevant, scientifically
valid data. Their analysis left out the 30minute data from MRID no. 47143705
(Ref. 2), but provided no rationale as to
why it would be appropriate to
selectively exclude data from the time
frame in this study most relevant to the
risk assessment (i.e., peak AChE
inhibition). The Petitioners’ analysis of
the individual datasets from this study
showed that at 30 minutes the females
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
and males provide BMDL10 s of 0.009
mg/kg/day and 0.014 mg/kg/day,
respectively. When the datasets were
combined, inclusion of the 30-minute
timepoint from MRID no. 47143705
decreased the BMDL10 from 0.033 mg/
kg/day to 0.030 mg/kg/day.
Although the Petitioners complain
that EPA’s approach of combining data
across multiple studies is scientifically
inappropriate, the Petitioners
themselves combined the results of
analysis from four datasets in the
information presented with their
comments and referenced in their
objections. Indeed, it is notable that
most of the criticisms raised by the
Petitioners also apply equally to the
Petitioners’ own analysis, as described
in more detail in EPA’s Response to
Comments document (Ref. 85).
The Petitioners are also incorrect that
differences in the data available for
brain and RBC are so great as to
invalidate comparisons of the BMD
estimates. EPA used all the data
available in each case, and used a
hierarchical model to account for
variability of the BMD among
laboratories for the brain endpoint,
which the SAP has explicitly reviewed
and approved numerous times (Refs. 34,
35, 36).
The Petitioners are correct that data
from both sexes were combined for
brain but only male data were used for
RBC. However, EPA first performed an
evaluation of the differences between
the sexes. EPA combined data from
males and females only after showing
that they did not respond differently.14
The only remaining study to examine
AChE activity in RBC in PND11
animals, after FMC’s flawed studies
were eliminated, contained only male
animals. Both BMD50 s for brain and
RBC in adults were based on 15
minutes, the minimum time interval
after dosing when a sample was taken,
in each dataset.15 This is also true for
the brain endpoint in PND11 animals.
However, the only study available of the
RBC endpoint in PND11 animals was
conducted at 40 minutes after dosing,
and did not include a recovery time
course study.
EPA believes that its decision to
combine data for purposes of its BMD50
estimates supporting the children’s
safety factor is equally appropriate, and
14 See pp. 34–35 in the brain document dated
October 25, 2007 for adults, pp. 47–48 in the same
document for PND11 animals; p. 15 in the RBC
document dated October 23 for adults.
15 See Oct. 5, 2007 reports, page 8 (for the values
of the time interval) and page 63 (setting the
parameter delta to the minimum non-zero value for
that interval) in the RBC report, and page 9, and
page 45 for the corresponding report for Brain.
PO 00000
Frm 00042
Fmt 4701
Sfmt 4700
any differences in the way in which the
studies were conducted did not impact
the validity of EPA’s analyses. For
example, one of Petitioners’ complaints
was that it was inappropriate to
combine studies because the data in the
studies were taken at different times,
ranging from 15 minutes to 4 hours after
doses. EPA responded to the allegation
that this was problematic by conducting
the analysis that the Petitioners claimed
should have been done to support this.
As explained in the final rule, although
EPA disagreed with the Petitioners’
contention that this was necessary or
appropriate, EPA conducted the
Petitioners’ suggested analysis, and used
the dose-time-response model to
extrapolate BMD50 s to develop a
common point of comparison between
all studies. Specifically, EPA
extrapolated the PND11 brain analysis
to estimate BMD50 for 40 minutes after
dosing for comparison with the existing
PND11 RBC BMD50, and extrapolated
the PND11 RBC BMD50 to 15 minutes
after dosing for a range of assumed
recovery half-lives, for comparison to
the existing PND11 brain BMD50. The
results are provided in (Refs. 24, 25). In
either approach, the estimate of the RBC
to brain potency ratio in PND11 animals
is increased, and EPA’s safety factor
would correspondingly increase to
reflect that larger difference. For
example, when the PND11 brain BMD50
is extrapolated to 40 minutes, the RBC
to brain potency ratio grows to 4.7 (Ref.
24 at 46), and when the PND11 RBC
BMD50 is extrapolated to 15 minutes,
using a range of estimates for the
recovery half-life of the RBC endpoint,
the RBC to brain potency ratio ranges
from 4.2 to 4.6 (Ref. 24). The Petitioners’
approach would therefore support a
children’s safety factor of 5X rather than
the 4X EPA is currently applying in its
risk assessments. Nevertheless, EPA
continues to believe that its current use
of a 4X factor reflects the most reliable
interpretation of existing quality data.
Although it is true that EPA’s BMD50
for brain was based on data from 6
datasets while the RBC BMD50 was
based on a single study, this is because
scientifically acceptable RBC data are
only available from a single study. As
discussed, the fact that EPA used all
available data sets in its modeling does
not affect the validity of its modeling
(Ref. 76).
For all of the foregoing reasons, this
objection is denied.
d. Objection/hearing request sub
issue: Technical Flaws in EPA’s
statistical comparisons. In their
objections, Petitioners claim to have
found a number of technical errors and
inconsistencies in how the modeling
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
was conducted. Correcting for these
errors, they claim, shows that the BMDs
for brain and RBC data are essentially
the same, which was consistent with the
results of modeling conducted by the
Petitioners when evaluating the
individual animal data. Specifically,
Petitioners allege that the approach EPA
used to estimate BMD50 s for carbofuran
is inconsistent with its ‘‘meta-analysis’’
approach of combining studies. The
Petitioners also argued that EPA’s
modeling failed to account for
significant difference in study
methodologies (e.g., time to sacrifice
following dosing). For example, EPA’s
BMD50 (Brain) is calculated at 15
minutes after exposure starts whereas
EPA’s BMD50 (RBC) is calculated at 40
minutes after exposure starts. EPA’s
BMD50 (brain) is based on 6 studies
whereas EPA’s BMD50 (RBC) is based on
1 study, and the dose-time-response
modeling methodology for combined
studies and EPA’s BMD50 (brain) is
different than the dose-time response
modeling methodology for a single
study and EPA’s BMD50 (RBC).
Petitioners also allege that EPA applied
its dose-time-response model
inconsistently between the brain and
RBC calculations, alleging that the
power was fixed to 1.00 for brain, but
estimated for RBC.’’ They also criticize
the modeling on the grounds that EPA
did not: (1) Account for differences
between the combined datasets; (2)
develop a protocol supporting its
approach; (3) clearly document its
method; (4) accurately document model
parameters; (5) rely on a plausible doseresponse model, or (6) report its data
accurately or transparently. They further
allege that ‘‘removing all of these
inconsistencies in methodology results
in a ratio of 1.3, which corresponds with
the ratio that the Petitioners claim to
have obtained based on their within
animal comparisons.
Petitioners have provided neither
further details of their concerns than the
explanation above, nor any other
evidence to support this objection.
i. Background. EPA addressed all of
the commenters’ claimed
inconsistencies in its final rule and
Response to Comments document (74
FR 23055–23056; Ref. 85 at 61–62). For
the majority of these claimed flaws and
inconsistencies, EPA explained that the
Petitioners had misunderstood EPA’s
analyses, or that the Petitioners’ were
incorrect. However in response to
certain allegations, EPA conducted new
analyses to determine whether the
suggested alternative approaches would
make any significant difference in EPA’s
modeling outcomes.
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
Petitioners have provided little detail
in their objections on the issues they
intend to raise in their testimony; in
most instances, they simply allege that
EPA’s modeling was incorrect. But as
the objections reference the Petitioners’
comments on the proposed rule, EPA
assumes that they intend to raise only
the points previously discussed in their
comments.
ii. Denial of hearing request. The
Petitioners’ request for a hearing on the
issues raised in this objection is denied
on two bases. First, Petitioners have not
challenged the substance of EPA’s
response to their comments or
submitted evidence that calls the
substance of EPA’s conclusions into
question. As previously explained, their
failure to challenge the actual basis of
EPA’s final rule affects the materiality of
the objection and hearing request (40
CFR 178.32(b)(3)). See 73 FR 42698–
42699 (When an objector does not
challenge EPA conclusions in the
section 408(d)(4)(iii) order but rather
challenges some prior conclusion that
was superseded by the section
408(d)(4)(iii) order, the objector has not
raised a live controversy as to an issue
material to the section 408(d)(4)(iii)
order) 53 FR 53176, 53191 (December
30, 1988) (FDA denied a hearing request
noting that given FDA’s prior
conclusion that the studies relied upon
by the objector were unreliable, the
‘‘burden shifted to [the objector] to
maintain the viability of its objection by
proffering some information that called
into question the agency’s conclusion
on this matter.’’)). Further, Petitioners
have not rebutted, or even
acknowledged, the additional analyses
EPA undertook at their suggestion, and
discussed in the final rule, which
ultimately provided further support for
EPA’s position. For example, in
response to the complaint that EPA
should have generated a new doseresponse model in order to calculate the
BMD50 s for brain and RBC, EPA
conducted the suggested calculation,
and under that analysis, the result is the
same as that EPA originally calculated.
Similarly, in response to the complaint
that EPA should have used the dosetime-response model to extrapolate
BMD50 s to develop a common point of
comparison between all studies, EPA
conducted that analysis and described it
in the final rule (74 FR 23055–23056
(May 15, 2009)). The result of this
reanalysis supported a higher children’s
safety factor than EPA’s 4X. But rather
than challenge the new analysis,
Petitioners simply repeat the assertions
made in their comments. Because the
objections on these points fail to
PO 00000
Frm 00043
Fmt 4701
Sfmt 4700
59649
account for EPA’s analyses, the
objections are contradicted by the
record, and accordingly, fail to
demonstrate a factual dispute (40 CFR
178.32(b)(1)). See 73 FR 42698–42699
(Denying NRDC hearing where objection
reiterated claims premised on
conclusions in EPA’s preliminary risk
assessment, rather than objecting to
EPA’s conclusions in the revised
assessment prepared for the petition
denial); 49 FR 6672 (February 22, 1984)
(no hearing if claim based on
demonstrably false premise); 57 FR 6667
(February 27, 1992) (‘‘A hearing must be
based on reliable evidence, not on mere
allegations or on information that is
inaccurate and contradicted by the
record’’).
Second, as in their comments,
Petitioners failed to submit the
underlying modeling they claim to have
conducted in support of their
objections. Petitioners’ consultants
merely assert that the results are as
presented in their summarized
testimony. In the absence of the
underlying scientific analyses, these are
effectively no more than mere allegation
or general contentions. Hearings will
not be granted on this basis. (40 CFR
178.32(b)(2); see also 68 FR 46403,
46406–46407 (August 5, 2003) (FDA
denied a hearing involving a challenge
to FDA’s reliance on consumption
pattern data because the objector ‘‘did
not present any specific information to
dispute P & G’s consumption pattern
data; instead, [objector] simply asserted
that other consumption patterns were
likely.’’); accord Community Nutrition
Institute v. Novitch, 773 F.2d 1356, 1363
(DC Cir. 1985) (‘‘Mere differences in the
weight or credence given to particular
scientific studies * * * are insufficient
[to show a material issue of fact for a
hearing].’’).
iii. Denial of Objection. For all of the
reasons discussed in the final rule and
Response to Comments documents, this
objection is denied. A summary of
EPA’s bases, which were discussed in
detail in both the final rule and
Response to Comments document, is
presented below.
Consistency of EPA approach. In their
comments, the Petitioners’ explained
that the alleged inconsistency with
which they were concerned was that
‘‘EPA attempts to extrapolate a BMD10 to
a BMD50 without refitting the data. That
is, EPA uses the dose-response model
obtained for the BMD10 rather than
obtaining a new model for BMD50.’’
They claimed this was ‘‘especially
troublesome since EPA has expressly
stated that the model obtained for
BMD10 (RBC) is unreliable.’’
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59650
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
The Petitioners’ allegation on this
point is incorrect. The model itself does
not need to change in order to develop
a BMD50. Whether one wants to estimate
the BMD10 or the BMD50, one would use
the same underlying model. EPA simply
developed a mathematical expression to
adjust parameter values for that fitted
model so that, for any given benchmark
response level (in particular, for 10% or
50% inhibition), the corresponding
BMD could be estimated as a parameter
in that model. The same expression
makes it possible to compute a BMD for
any given response level from estimates
based on any other response level.
Mathematically, it is not necessary to
refit the model to the data to estimate
different BMD levels.
However in response to the
comments, EPA conducted their
suggested calculation, and the ratio of
brain to RBC BMD50 s in this new
analysis is the same as the ratio EPA
calculated by using the mathematical
expression (Refs. 24, 25). Both provide
a ratio of brain to RBCs BMD50 of 4X.
Specifically, in the just cited documents
above, the values are for PND11 brain
BMD50 are 0.35 (Ref. 24 at 40) and for
RBC, 0.086 (Ref. 25 at 20), resulting in
a ratio of 4.09.
With regard to the EPA’s purported
statement that the BMD10 model is
unreliable, the Petitioners misconstrued
EPA’s statement. EPA stated that it
cannot reliably estimate the RBC BMD10
and BMDL10 in pups because it lacks
data at low doses, not because its model
is unreliable. Given the greater amount
of data, the estimate for the BMD50 is
substantially better supported, and thus,
less uncertain, than the estimate of the
BMD10.
Differences in study methodologies.
Both BMD50 s for brain and RBC in
adults were based on 15 minutes, the
minimum time interval after dosing
when a sample was taken, in each
dataset.16 This is also true for the brain
endpoint in PND11 animals. However,
the only study available of the RBC
endpoint in PND11 animals was
conducted at 40 minutes after dosing,
and did not include a recovery time
course study.
As noted in the previous objection
response, EPA used the dose-timeresponse model to extrapolate BMD50 s
to develop a common point of
comparison between all studies. Using
that approach would support a
children’s safety factor of 5X rather than
the 4X EPA has applied.
16 See Oct. 5, 2007 reports, page 8 (for the values
of the time interval) and page 63 (setting the
parameter delta to the minimum non-zero value for
that interval) in the RBC report, and page 9, and
page 45 for the corresponding report for Brain.
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
Although it is true that EPA’s BMD50
for brain was based on data from 6
datasets while the RBC BMD50 was
based on a single study, this is because
scientifically acceptable RBC data are
only available from a single study. As
discussed in the preceding objection
response, the fact that EPA used all
available data sets in its modeling does
not affect the validity of its modeling
(Ref. 76).
Inconsistent application of model.
EPA did not apply its model
inconsistently; the difference to which
the Petitioners refers results from the
differences between the available data.
In order to generate an estimate of the
power parameter, data at both extremes
of the dose-response curve are
necessary. Despite the comparatively
greater amount of brain inhibition data,
the brain data did not provide
information at both extremes of the
curve. A value of 1.00 is the standard
default in this situation for all the NMC
dose-response analyses. Moreover,
despite the limited information at the
extremes of the dose-response curve for
estimating power in the brain data, a
power parameter of 1.00 is consistent
with the available brain data. By
contrast, because the available RBC data
provides the necessary information at
higher doses, the power in the RBC data
could be directly estimated and was
significantly less than 1.0.
EPA is unable to comment on the
analyses referenced in the Petitioners’
objections as they failed to provide
them. However, EPA has previously
explained the reasons for rejecting the
suggested analysis based on brain RBC
comparisons within the same animal.
This is discussed at length in the final
rule and response to comments, as well
as Unit VI.E.2.a of this Order.
f. Objection/hearing request sub issue:
Consistency in approach between
carbofuran and other NMC chemicals—
i. Background. In their comments on the
proposed rule, the Petitioners argued
that EPA’s approach to deriving
carbofuran’s children’s safety factor was
inconsistent with its approach to
deriving the safety factors for other
NMC pesticides. They identified only
three specific chemicals: Aldicarb,
oxamyl, and carbaryl. With respect to
aldicarb they argued that although the
relative potency of carbofuran is less
than aldicarb, the uncertainty factors
assigned by EPA presuppose that
carbofuran is ten times more toxic that
aldicarb. They claim that the aldicarb
data show that by all objective measures
of toxicity, aldicarb is nearly twice as
acutely toxic as carbofuran across all
species tested. They further claim that
an alternative approach to relative
PO 00000
Frm 00044
Fmt 4701
Sfmt 4700
rankings of carbamates proposed by the
SAP in its assessment of the NMCs
(which also considered the rate of
recovery) also showed aldicarb having
approximately twice the potency of
carbofuran. They further alleged that the
children’s safety factor for carbaryl was
inconsistent with the safety factor
applied to carbofuran. Finally, the
Petitioners compared the aPAD, aRfD,
and uncertainty factors for oxamyl,
aldicarb, and carbaryl, concluding that
these were inconsistent with EPA’s
conclusions for carbofuran.
EPA responded to these comments in
both the final rule and the
accompanying response to comments
document (74 FR 23058 (May 15, 2009)).
In their objections, Petitioners have
not identified any specific facts that
they believe demonstrate inconsistency.
They merely allege that the ‘‘relative
potency of carbofuran as compared to
other N-methyl carbamates does not
correspond with OPP’s aPAD for
carbofuran relative to those same
compounds.’’
ii. Denial of hearing request. A
hearing is denied on this subissue
because there is no disputed factual
matter for resolution at a hearing. There
is no dispute concerning the children’s
safety factors that EPA applied to the
other carbamates, nor how EPA derived
those safety factors. Thus, the only
question is whether it was reasonable
for EPA to account for the fact that other
chemicals had a greater amount of
toxicity data, and therefore greater
uncertainty, in determining the
appropriate children’s safety factor,
when the statute requires EPA to
account for ‘‘the completeness of the
data’’ (21 U.S.C. 346a(b)(2)(C)). This
question requires the application of a
legal standard to undisputed facts.
Hearings are not appropriate on
questions of law or policy (40 CFR
178.32(b)(1)). See, 73 FR 42706–42707)
(denying NRDC hearing request when
the only question raised was whether a
human study using only adult males
met the regulatory requirement of
‘‘scientifically valid and relevant data’’.
FDA has repeatedly confirmed that the
application of a legal standard to
undisputed facts is a question of law for
which a hearing is not required. (See,
e.g., 68 FR 46403, 46406 n.18, 46408,
46409 (August 5, 2003) (whether facts in
the record show there is a reasonable
certainty of no harm is a question of
law; whether a particular effect is a
‘‘harm’’ is a question of law)).
In addition, Petitioners have not
challenged the substance of EPA’s
response to their comments, but simply
reiterated their comments on the
proposed rule. Accordingly, a hearing is
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
not warranted, as the objection is
subissue is irrelevant, and therefore
immaterial, with regard to EPA’s final
tolerance revocation regulation (40 CFR
178.32(b)(3)). See 73 FR 42698–42699
(July 23, 2008) (When an objector does
not challenge EPA conclusions in the
section 408(d)(4)(iii) order but rather
challenges some prior conclusion that
was superseded by the section
408(d)(4)(iii) order, the objector has not
raised a live controversy as to an issue
material to the section 408(d)(4)(iii)
order; 53 FR 53176, 53191 (December
30, 1988) (where FDA responds to a
comment in the final rule, repetition of
the comment in objections does not
present a live controversy unless the
objector proffers some evidence calling
FDA’s conclusion into question)).
Nor have they submitted evidence
that calls the substance of EPA’s
conclusions into question. Petitioner’s
entire argument concerning this issue is
a single conclusory sentence. A hearing
will not be granted on ‘‘mere
allegations’’ or ‘‘general contentions.’’
(40 CFR 178.32(b)(2)) (See 53 FR 53176,
53199 (December 30, 1998)) (‘‘Rather
than presenting evidence, [the objector]
asserts that FDA did not adequately
justify its conclusions. Such an
assertion will not justify a hearing.’’).
iii. Denial of objection. Although it is
unclear which precise chemicals the
Petitioners believe demonstrate that
EPA was inconsistent, the only ones on
which any allegations were arguably
presented were those identified in their
comments on the proposed rule:
aldicarb, carbaryl, and oxamyl.
Accordingly, EPA denies this objection
for the same reasons that EPA explained
in its final rule and comment responses.
In their comments, the Petitioners
provided information on the oral LD50
in rat and the BMDL10 for AChE in rat
brain or human RBC. The comments
also provided uncertainty factors for the
three NMCs, the respective aRfD 17 or
aPAD 18 and the cumulative risk
assessment oral potency factor. The
LD50 and BMDL10, values provided are
not completely accurate.
The allegations and the supporting
information contained in Petitioners’
comments were inaccurate. For
example, the LD50 values in the oxamyl
RED were 3.1 mg/kg (male) and 2.5 mg/
kg (female), rather than 30 mg/kg as the
Petitioners claimed. Further, the
Agency’s recent hazard assessments of
carbaryl and aldicarb are each
consistent with EPA policies and
practice, as well as with the Agency’s
17 aRfD
is the acute reference dose.
is the acute RfD adjusted for the
Children’s Safety Factor.
18 aPAD
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
approach to the assessment of
carbofuran.
The Petitioners’ assertions regarding
aldicarb were based on an earlier
assessment. At the time the Agency
conducted the assessment to which the
commenters refer, the Agency was
unaware of the difference in sensitivity
between PND17 and PND11 animals.
Since EPA became aware of the
differences, EPA has required the
aldicarb registrant to conduct a CCA
study in PND11 rats; the Agency
anticipates the receipt of this study and
the companion range-finding and time
course studies in 2009. In the absence
of these data, EPA will apply the
statutory default children’s safety factor
to account for the additional sensitivity
of PND11 animals, because the Agency
lacks any ‘‘reliable data’’ that could be
used to derive a reduced factor that EPA
could determine will be ‘‘safe for infants
and children.’’
With regard to the carbaryl children’s
safety factor, the available brain and
RBC dose-response data in PND11 pups
include data from the lower end of the
dose-response curves. ORD’s
comparative AChE data with carbaryl
show that at the lowest dose 20% or
near 20% inhibition in brain and RBC
AChE was observed. Although not ideal,
the carbaryl data provide information
closer to the benchmark response of
10%, which allows for a reasonable
estimation of the BMD10 and BMDL10.
This is distinctly different from ORD’s
data with carbofuran in PND11 and
PND17 pups where 50% or greater RBC
AChE inhibition was observed at the
lowest dose.
Petitioners’ other comparisons are
equally inapposite. The LD50, BMDL10,
and relative potency factor from the
cumulative risk assessment are each
measures of chemical potency. Thus,
these calculations provide reasonable
comparisons of the relative potency of
aldicarb, carbofuran, and oxamyl.
However, the Petitioners’ allegations
were based on comparisons of the
aPAD, aRfD, and uncertainty factors,
which are not measures of potency and
should not be interpreted as such (Ref.
79). The magnitude of the uncertainty
factors is intended to account for
uncertainty in the available data for a
particular chemical. For example, it is
standard practice to apply a 10X
uncertainty factor for extrapolation from
animals to humans when ethically and
scientifically sound human data are not
available for the pesticide of interest.
And this explains the difference in the
uncertainty factors applied to the three
chemicals. Deliberate dosing studies in
human subjects conducted with aldicarb
and oxamyl were reviewed and
PO 00000
Frm 00045
Fmt 4701
Sfmt 4700
59651
accepted by the HSRB for both scientific
validity and ethical conduct. This is not
the case for carbofuran. As discussed
below in Unit VI.G, the HSRB
concluded that the carbofuran study
was not sufficiently scientifically robust
for use in the risk assessment.
Therefore, there is less uncertainty in
the aldicarb and oxamyl risk
assessments since quality data are
available in humans and the
interspecies factor can be reduced or
removed for these chemicals. There are
no comparable data for carbofuran.
Accordingly, this objection is denied.
F. Objections to EPA’s Drinking Water
Exposure Assessments.
Petitioners raise separate objections to
EPA’s estimates of drinking water
exposures from contaminated ground
water and to the estimates from
contaminated surface water. In each
objection, Petitioners argue that, based
on newly proposed restrictions
submitted as part of their objections, the
exposure estimates will be significantly
lower than EPA’s estimates in the final
rule.
1. Objections relating to groundwater
exposure estimates. Petitioners raise
several challenges to the ground water
concentration estimates in the final rule.
They allege that EPA’s estimates are not
based on the best available data, but on
obsolete data and overly conservative
assumptions that are inappropriate
because use has been prohibited in all
areas like those seen in these data. The
objection also claims that the
requirements in the new registration
proposals to require setbacks from all
drinking water wells ranging between
100 and 1,000 feet will ensure that all
potential groundwater exposures will be
below the level of concern. In support
of this objection three analyses were
submitted in Exhibits 12, 13, and 14.
a. Objection/hearing request subissue:
Reliance on the results of the
prospective ground water study (PGW)
and historical monitoring to validate
groundwater exposure estimates. The
Petitioners object that EPA should not
have relied for validation on their PGW
study or historical monitoring data.
They argue that these data are from a
period when use was an ‘‘order of
magnitude greater.’’ Additionally they
allege that all areas like those seen in
the PGW have now been removed from
the carbofuran label, and so the study
results do not accurately reflect current
risks. In support of this objection,
Petitioners reference their comments on
the proposed rule, and Exhibit 12.
i. Background. In the proposed rule,
EPA relied on a drinking water
assessment that used both monitoring
data for carbofuran and modeling
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59652
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
methods (Refs. 13, 42, 44, 47, 67).
Regarding the potential exposure from
contaminated groundwater, the Agency
concluded that drinking water taken
from shallow wells is highly vulnerable
to contamination in areas where
carbofuran is used around sandy, highly
acidic soil, although sites that are less
vulnerable (e.g., deeper aquifer, higher
organic matter) could still be prone to
have concentration exceeding
acceptable exposures. EPA concluded
that the results of its modeling were
consistent with the results of the
available monitoring data, including a
PGW study conducted by FMC in the
1980s, when scaled to reflect the current
lower rates of application (73 FR 44881).
In their comments, the Petitioners
complained that EPA’s reliance on the
PGW was inappropriate because that
study no longer reflected current
conditions. Petitioners also summarized
the results of their ‘‘National Leaching
Assessment’’ which used PRZM and
‘‘databases specifically created to
provide access to all necessary inputs
for a national scale PRZM modeling.’’
They claimed that after accounting for
the use prohibitions on their September
2008 label, the maximum 1-in-10 year
peak concentrations in all potential
carbofuran use areas is 1.2–1.3 ppb,
while expected concentrations in most
areas covered by this assessment are
below 1.0 ppb. Neither the ‘‘National
Leaching Assessment’’ nor the
‘‘National Pesticide Assessment Tool’’
upon which the assessment appears to
have been based, were submitted to EPA
as part of the Petitioners’ comments.
In the final rule, EPA revised the
assessment conducted for the proposed
rule in response to the FMC comments
submitted during the comment period,
which requested cancellation of the use
on a number of crops and imposed a
number of restrictions intended to
address the potential for groundwater
contamination. These restrictions
included use prohibitions in certain
states, and well setbacks. Taking these
into account, ground water
concentrations were estimated for all
remaining crops on carbofuran labels,
using two new Tier 2 scenarios. Based
on a new corn scenario in Wisconsin,
representative of potentially vulnerable
areas in the upper Midwest where use
remained, EPA estimated one-in-ten
year concentrations for ground water
source drinking water of 16 to 1.6 ×
10¥3 ppb, for pH 6.5 and 7,
respectively. Well setback prohibitions
of 50 ft were proposed on the new label
for the flowable and granular
formulations in select counties in
Kentucky (7 counties), Louisiana (1
county), Minnesota (1 county), and
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
Tennessee (1 county). Analysis of the
impact of these setbacks for the use on
corn indicated that the setbacks would
not reduce concentrations significantly
at locations where exposure to
carbofuran in ground water is of
concern because at acid pHs, carbofuran
does not degrade sufficiently during the
travel time from the application site to
the well to substantially reduce the
concentration.
EPA concluded that the results of the
revised corn modeling were consistent
with the PGW. Using higher use rates
than currently permitted, the peak
concentration measured in the PGW
study was 65 ppb; when scaled to
current use rates, the estimated peak
concentration was 11 ppb. The final rule
explained that EPA’s modeling is also
consistent with a number of other
targeted groundwater studies conducted
in the 1980s showing that high
concentrations of carbofuran can occur
in vulnerable areas; the results of these
studies as well as the PGW study are
summarized in References 13 and 67 (74
FR 23079).
ii. Denial of hearing request. For this
hearing request, the Petitioners have
failed to proffer evidence, which would,
if established, resolve a material issue in
their favor. First, Petitioners’
evidentiary proffer does not support
their contention, and consequently, EPA
is unable to conclude that there is a
reasonable possibility that the issue
could be resolved in its favor (40 CFR
178.32(b)(2)). Petitioners’ own experts
relied on the PGW to validate the
modeling submitted in support of this
objection and to demonstrate the safety
of the tolerances. The Executive
Summary of the National Carbofuran
Leaching Assessment states
‘‘[a] model validation study was conducted
in which the results of a prospective
groundwater monitoring (PGW) study
conducted for cabofuran in Maryland from
1981–1983 were compared to the model
simulations that most closely matched the
PGW study site in terms of location, soil
texture, organic carbon content, and pH. The
annual peak concentrations during the
simulation are on the order of 9 to 11 ppb,
which are similar to the measured
concentrations in the PGW study (9 to 10 ppb
after adjusting for application rate). The
validation provides context that the model
predictions are reasonable.’’
(Exhibit 12 at 7). See, e.g., 57 FR 33244
(July 27, 1992) (Studies cited by NRDC
do not provide a basis for the hearing
because they ‘‘support the [FDA]
conclusion in question.’’).
Second, this objection is premised on
inaccurate factual statements that are
directly contradicted by the record. For
example, the objection disregards the
PO 00000
Frm 00046
Fmt 4701
Sfmt 4700
fact that EPA scaled the PGW modeling
to reflect the lower current use rates.
The Petitioners present no challenge to
the methods EPA used to scale the study
results; indeed, it is likely that their
contractor used the same or similar
methodology. Equally, the objection that
EPA relied on ‘‘historical monitoring
data from a period when carbofuran use
was an order of magnitude larger’’ is
simply incorrect (Ref. Obj at 40). The
monitoring results EPA cited in the final
rule were from the 1980s, but the
targeted monitoring studies were
conducted with the same or lower use
rates as those permitted under the
current labeling (74 FR 23085, May 15,
2009). Such a submission is insufficient
to justify a hearing (See, 73 FR 42696
(July 23, 2008)(denying hearing where
objector incorrectly claimed that EPA
had failed to rely on DDVP-specific
information in making its children’s
safety factor determination); 57 FR 6667
(February 27, 1992) (‘‘A hearing must be
based on reliable evidence, not on mere
allegations or on information that is
inaccurate and contradicted by the
record.’’)
Further, the Petitioners’
misrepresentation of EPA’s analyses
also affects the materiality of the hearing
request (40 CFR 178.32(b)(3)). Even if
Petitioners were able to successfully
refute the validity of the PGW study, it
would not affect the validity of the
additional monitoring data cited in the
final rule (74 FR 23079 (May 15, 2009)),
on which EPA also relied to validate its
monitoring. See, 49 FR 6672 (February
22, 1984) (challenge to one of five
related studies; in the absence of any
additional data bearing on the clinical
study, the objection constitutes nothing
more than an allegation).
Finally, the evidentiary proffered with
respect to the Petitioners’ allegation that
all areas with conditions similar to
those found in the PGW have been
removed from the label is insufficient to
warrant a hearing (40 CFR 178.32(b)(2)).
To the extent this allegation is based on
the information presented as part of the
2008 comments, this claim was rebutted
in EPA’s final rule, by the modeling
based on the Wisconsin corn scenario,
and by the lack of any underlying
analyses to support of Petitioners’
comments. As explained in the final
rule, the information provided is
insufficient to allow EPA to confirm the
Petitioners’ contention that there is no
overlap between use and all potentially
vulnerable ground water (74 FR 23061–
23062 (May 15, 2009)).
The evidence submitted along with
this objection does not cure this defect.
The only evidence proffered in this
regard is the Petitioners’ comments on
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
the proposed rule, and the new analysis
submitted in Exhibit 12. As previously
discussed, mere reiteration of comments
made in response to the proposed rule
does not provide an adequate basis for
a hearing, unless the objector proffers
some evidence calling EPA’s conclusion
into question. Consequently, Petitioners’
submission on this issue is irrelevant
and therefore immaterial, with regard to
EPA’s final tolerance revocation (40 CFR
178.32(b)(3)). The analysis in Exhibit 12
appears to be the National Leaching
Assessment described in Petitioners’
comments, but modified to account for
the proposed amendments submitted as
part of the objections. As noted
previously, neither the National
Leaching Assessment nor the model on
which it was based was submitted as
part of the comments. Because the
National Leaching Assessment was
available during the comment period
but was withheld, this information is
considered to be untimely and the
Petitioners have waived the right to rely
on it. For the reasons discussed in Unit
VI.D, EPA therefore will not consider it
as an appropriate basis for justifying a
hearing on its final rule. See 73 FR
42683, 42696 (July 23, 2008); 72 FR
39318, 39324 (July 18, 2007). Further,
for the reasons discussed in Unit VI.C,
EPA has determined that objections and
hearing requests based on the newly
proposed amendments, as well as
evidence or analyses premised on those
amendments, are irrelevant, and
therefore immaterial, to EPA’s
determination in the May 15, 2009 final
rule that the carbofuran tolerances were
unsafe and could not be sustained under
FFDCA section 408. Petitioners are
actually not objecting to the conclusions
in EPA’s final rule; rather, they are
suggesting that EPA might reach a
different result in a different factual
scenario. Objections, however, must be
directed ‘‘with particularity [at] the
provisions of the regulation or order
deemed objectionable’’ (21 U.S.C.
346a(g)(2)).
iii. Denial of objection. EPA denies
this objection on several bases. Based on
the information available, and even
accounting for the September 2008
geographic restrictions, the Agency
cannot confirm the Petitioners’ claim
that use has been prohibited in all areas
with conditions similar to the PGW
study. Based on the information that
was timely submitted, the only
information provided was in map
format. While maps are useful for
interpreting results, maps alone are
insufficient for a thorough evaluation of
the Petitioners’ claim, in part because of
the maps’ spatial resolution. The maps
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
submitted were all on a nation-wide
scale, which does not provide the level
of detail necessary to verify the
combination of paramaters (e.g., soil
textures, pH) at locations identified as
vulnerable. Further, the maps provided
by the Petitioner do not represent all
carbofuran use patterns. For example,
Figure IV–2 on page 42 of the
Petitioners’ comments does not address
the granular use patterns and proposed
label prohibitions. In addition, as a
general matter, none of the previously
submitted assessments provided a
comprehensive analysis of the
distribution of soil and water pHs for
the Midwest, Northwest or any other
region of the country where carbofuran
use would be permitted on the
September 2008 label, or have the
Petitioners provided such an analysis
with their objections.
Further, the available scientific
information does not support their
contentions. EPA examined readily
available data with respect to ground
water and soil pH in order to evaluate
the spatial variability of pH. Data from
the USGS and other readily available
sources do not necessarily encompass
the entire range of ground water pH
values present within a state. This is
especially true for shallow ground water
systems, where local conditions can
greatly affect the quality and
characteristics of the water. Also, pH in
a water body can be higher or lower
than the tabulated average values. In
addition, average ground water pH
values for a given area do not truly
characterize the area’s temporal and
especially spatial heterogeneity. This
can be seen by comparing differences in
pH values between counties within a
state, and by the fact that even within
a county individual wells will
consistently yield ground water with
either above- or below-average pH
values for that county. The ground
water simulations in Reference 84,
Appendix I reflect variability in pH by
modeling carbofuran leaching in four
different soil and subsurface pH
conditions (pH 5.25, 6.5, 7.0, and 8.7),
representing the range in the aquifer
system in that area. This range also
approximates the pH range of natural
waters in general. The results of the
ground water simulations for corn use
showed that a relatively small (0.5)
decrease in pH from 7 to 6.5 resulted in
an increase in the 1-in-10-year peak
concentrations of carbofuran in ground
water of 4 orders of magnitude.
The results of EPA’s revised corn
modeling, based on a new scenario in
Wisconsin, are consistent with the
results of the PGW study developed by
the registrant in Maryland in the early
PO 00000
Frm 00047
Fmt 4701
Sfmt 4700
59653
1980s. Using higher use rates than
currently permitted, the peak
concentration measured in the PGW
study was 65 ppb; when scaled to
current use rates, the estimated peak
concentration was 11 ppb. EPA’s
modeling is also consistent with a
number of other targeted ground water
studies conducted in the 1980s showing
that high concentrations of carbofuran
can occur in vulnerable areas; the
results of these studies as well as the
PGW study are summarized in
References 13 and 67. For example, a
study in Manitoba, Canada assessed the
movement of carbofuran into tile drains
and ground water from the application
of liquid carbofuran to potato and corn
fields. The application rates ranged
between 0.44–0.58 pounds a.i./acre, and
the soils at the site included fine sand,
loamy fine sand, and silt loam, with pH
ranging between 6.5–8.3. Concentrations
of carbofuran in ground water samples
ranged between 0 (non-detect) and 158
ppb, with a mean of 40 ppb (Refs. 13
and 67).
Finally, as discussed above, to the
extent this objection relies on untimely
information and analyses, and on the
newly submitted registration
amendments, the objection is denied as
irrelevant and immaterial.
b. Objection/hearing request subissue:
Accounting for FMC’s label mitigation
measures. Petitioners object that EPA’s
risk assessment relies on ‘‘unrealistic
and overly conservative assumptions
about potential concentrations,’’ and
fails to account for FMC’s label
mitigation measures. They claim that
maximum concentrations of carbofuran
in groundwater are expected to be below
1.1 ppb, based on the new proposed
geographic restrictions and well
setbacks. They allege that, ‘‘only
permeable soils (e.g., greater than 90%
sand and less than 1% organic matter)
with acidic soils and water conditions,
and shallow water tables (e.g., less than
30 feet) are vulnerable to carbofuran
applications.’’ They also claim that
vulnerable groundwater only exists
along eastern seaboard, and in select
counties in the United States, where use
has already been prohibited. They argue
that further confirmation is provided by
the available NAWQA data, which show
that detections of carbofuran are rare,
and occur only at low levels except in
areas where use is now prohibited.
Finally, Petitioners allege that in the
specific regions where carbofuran will
continue to be used under the revised
label, groundwater pH data collected
under the USGS NAWQA program
demonstrate that the average pH is
approximately 7.25, and in most
regions, moving two standard deviations
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59654
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
away from average, which they claim
would capture 95% of all observed
values, results in pHs that are still
greater than 6.0. According to the
Petitioners, under such conditions the
combination of hydrolysis and drinking
water well setbacks would ensure that
any carbofuran that might reach ground
water sources would degrade to only de
minimis concentrations less than or
equal to 1.1 ppb.
In support of this objection,
Petitioners cite the analyses submitted
as part of their comments, and the new
analyses in Exhibits 12, 13, and 14.
Exhibits 12 and 13 contain the revised
modeling of the estimated groundwater
concentrations from carbofuran use,
based on the label restrictions proposed
as part of the objections. Exhibit 14
consists of a statistical summary of
groundwater pH statistics from the
USGS NAWQA database. Means,
standard deviations, and numbers of
groundwater measurements in the
database are summarized by state and
land use within each state.
i. Background. In the proposed rule
EPA concluded that drinking water
taken from shallow wells is highly
vulnerable to contamination in areas
where carbofuran is used around sandy,
acidic soil, although sites that are less
vulnerable (e.g., deeper groundwater,
less coarsely textured soils) could still
be prone to have concentrations
exceeding acceptable exposures (73 FR
44881–44883 (July 31, 2008)). EPA also
described the available NAWQA
monitoring data, and explained the
reasons that the monitoring data tends
to underestimate exposure for acute
risks, such as those carbofuran presents,
and so are not sufficiently robust to be
used as an input into a quantitative risk
assessment or to serve as a lower bound
(73 FR 44880–44881 (July 31, 2008)).
As part of their comments on the
proposed rule, FMC requested that EPA
amend their registration to include a
number of geographic use restrictions
and migitation measures intended to
address the risks to groundwater. In
their comments, Petitioners claimed that
‘‘[g]roundwater sources are vulnerable
to carbofuran leaching only under
certain conditions, namely where
permeable soils (e.g., areas with soils
greater than 90% sand and less than 1%
organic matter), acidic soil and water
conditions, and shallow water tables
predominate (e.g., where ground water
is less than 30 feet).’’ The commenters
claimed that these conditions are rare in
areas where carbofuran would be used
under the new label proposed as part of
their comments. They further asserted
that in ‘‘most states where carbofuran is
used, less than 2% of the entire surface
VerDate Nov<24>2008
17:53 Nov 17, 2009
Jkt 220001
areas possess sandy soil texture’’ and
that ‘‘low pH conditions are not found
in carbofuran use areas allowed under
the registrant’s amended label’’ (Ref. 18
at 33–34). They described, but did not
submit analyses they claimed to have
conducted to demonstrate this. The
summary consisted primarily of maps
depicting areas identified as vulnerable.
On December 24, 2008, FMC again
requested that EPA amend their
registration to include additional
restrictions intended to further mitigate
carbofuran’s risks to groundwater.
In response to the September 2008
proposed label restrictions submitted as
part of the comments, EPA revised its
risk assessment to take into account the
new geographic restrictions, as well as
the proposed risk mitigation measures.
Based on its revised assessment, EPA
explained in the final rule that it
disagreed that the criteria on the
September 2008 label defined 100% of
the conditions where ground water
sources would be vulnerable to
carbofuran leaching. EPA noted that no
comprehensive analysis had been
provided that evaluated how the
Petitioners had reached this conclusion.
As discussed in greater detail in EPA’s
Response to Comments, the information
provided as part of the Petitioners’
comments—primarily maps depicting
areas identified as vulnerable—was not
sufficient to allow the Agency to
evaluate their claim (Ref. 84).
EPA also disagreed that the
commenters provided sufficient
information to support their general
claim that only high pH conditions (pH
above 7) existed in all the areas in
which carbofuran could be used under
FMC’s September 2008 revised label.
EPA presented its assessment of the
newly submitted label in its Response to
Comments document and these issues
were addressed in substantial detail
there (Ref. 84).
EPA did not evaluate the mitigation
measures proposed in the December 24,
2008 submission. The mitigation
measures in that submission were
incorporated into the measures
proposed by the Petitioners as part of
their objections on June 30, 2009.
ii. Denial of hearing request. EPA is
denying the hearing requested on this
objection because, in large measure, if
not entirely, it rests on the newly
submitted mitigation measures
accompanying Petitioners’ objections.
As discussed in Unit VI.C, EPA has
determined that these objections do not
warrant a hearing because they are
irrelevant, and therefore immaterial, to
EPA’s determination in the May 15,
2009 final rule that the carbofuran
tolerances were unsafe and could not be
PO 00000
Frm 00048
Fmt 4701
Sfmt 4700
sustained under FFDCA section 408 (40
CFR 178.32(b)(3)). Petitioners are
actually not objecting to the conclusions
in EPA’s final rule; rather, they are
suggesting that EPA might reach a
different result in a different factual
scenario. Objections, however, must be
directed ‘‘with particularity [at] the
provisions of the regulation or order
deemed objectionable’’ (21 U.S.C.
346a(g)(2)). In addition, for the reasons
discussed in Unit VI.D, EPA has
determined that the new risk mitigation
measures are not appropriately
considered at this stage of the
administrative process, and will not
grant a hearing on this basis.
Petitioners’ objections provide no
further clarification as to what is meant
by their claim that EPA’s assessment
relied on ‘‘unrealistic and overly
conservative assumptions.’’ Therefore,
this objection, and the attendant hearing
request, is denied based on Petitioners’
failure to state with ‘‘particularity * * *
the basis for the objection * * *’’ (40
CFR 178.25(a)(2)). As Petitioners raised
similar allegations in their comments,
EPA has assumed that they intended to
incorporate all of the issues raised in the
comments on the proposed rule.
To the extent this objection relies on
the September 2008 mitigation
measures, EPA denies the hearing
request because the evidentiary proffer
in support of this objection is
insufficient to warrant a hearing. The
record is clear on its face that EPA did
account for the mitigation measures in
its revised risk assessment supporting
the final rule. A hearing can only be
based on a genuine issue of disputed
fact (40 CFR 178.32(b)(1)). Where a
party’s factual allegations are
contradicted by the record, there is no
genuine dispute (73 FR 42701–42702
(July 23, 2008) (Denying NRDC’s hearing
request where EPA had revised its
residential exposure assessment to
address the issue complained of); 57 FR
6667, 6668 (February 27, 1992) (‘‘A
hearing must be based on reliable
evidence, not on mere allegations or on
information that is inaccurate and
contradicted by the record.’’)).
The objection also suffers from a
further defect; many of the allegations in
this objection merely reiterate points
Petitioners had raised in their earlier
comments. For example, EPA addressed
the claim that the NAWQA data from
1993–2006 rarely show detections of
carbofuran, and that in ‘‘almost every
instance’’ the observed concentrations
are low. EPA also addressed the claim
that only areas with permeable soils
(e.g., areas with soils greater than 90%
sand and less than 1% organic matter),
acidic soil and water conditions, and
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
where shallow water tables predominate
(e.g., where ground water is less than 30
feet) present significant risks of
leaching. As previously discussed, mere
reiteration of comments made in
response to the proposed rule does not
provide an adequate basis for a hearing,
unless the objector proffers some
evidence calling EPA’s conclusion into
question (40 CFR 178.32(b)(3)). See, e.g,
73 FR 42701–42702 (July 23, 2008); 53
FR 53176 (December 30, 1988).
The evidence submitted in Exhibits
12–14 does not cure these defects. As a
preliminary matter, much of this
evidence is untimely. The analyses in
Exhibits 12 and 13 appear to be the
National Leaching Assessment
described in Petitioners’ comments, but
modified to account for the proposed
amendments submitted as part of the
objections. As noted previously, neither
the National Leaching Assessment nor
the model on which it was based was
submitted as part of the comments.
Certainly, there is no justification for
Petitioners’ refusal to provide the
analyses that were available during the
comment period. Because the National
Leaching Assessment was available
during the comment period but was
withheld, this information is considered
to be untimely and the Petitioners have
waived the right to rely on it.
Accordingly, as discussed in Unit VI.D,
because this evidence was not presented
as part of the Petitioners’ comments,
EPA considers that the evidence
submitted in support of this objection is
not appropriately considered as a basis
for justifying a hearing on the final rule.
See 73 FR 42683, 42696 (July 23, 2008);
72 FR 39318, 39324 (July 18, 2007). And
in the absence of this evidence, this
portion of the objection consists of mere
allegations and denials, which do not
warrant a hearing (40 CFR 178.32(b)(2)).
But even assuming that the evidence
was appropriately considered, the
evidence is insufficient, even if
established, to justify the factual
determination urged (40 CFR
178.32(b)(3)). Nothing in Exhibits 12–13
provides any information that
substantively differs from the
information summarized in the
comments. Second, even assuming that
the analysis in Exhibit 14 is valid, on its
face the submission states that the
analysis only addresses 95% of the
samples chosen by the study; no
information was provided to explain
how the samples relate to the state or
other geographic area in which
carbofuran would be used. This is
important because NAWQA samples
were not evenly distributed across most
states, but tended to be concentrated in
particular regions; in statistical
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
parlance, the samples were not collected
randomly. The maps in Exhibit 14
clearly demonstrate that the study
samples were not randomly distributed
across the state but were primarily in
the southern and eastern portions of
each state, even though carbofuran use
is not restricted to those portions of the
states. In other words, no evidence was
provided that would allow the Agency
to determine the percentage of the
carbofuran use area represented by the
95% of the samples the Petitioners’
analysis addressed. Nor was any
information provided to document the
significance of the remaining 5% of the
samples that were not captured by their
analysis; for example, although this may
have only represented 5% of the
samples, it is not clear whether this 5%
relates to only 5% of the areas where
carbofuran may be used, or whether it
actually represent a far greater
percentage of the use area.
iii. Denial of objection. EPA denies
this objection on several bases.
The contention that the NAWQA
monitoring data—or indeed any
available carbofuran monitoring data—
provide an adequate basis for
concluding that concentrations will
remain low in the areas where use is
now permitted is incorrect. The
NAWQA program focuses on ambient
water rather than on drinking water
sources, is not specifically targeted to
the high use area of any specific
pesticide, and is sampled at a frequency
(generally weekly or bi-weekly during
the use season) insufficient to provide
reliable estimates of peak pesticide
concentrations in surface water. For
example, significant fractions of the data
may not be relevant to assessing
exposure from carbofuran use, as there
may be no use in the basin above the
monitoring site. Unless ancillary usage
data are available to determine the
amount and timing of the pesticide
applied, it is difficult to determine
whether non-detections of carbofuran
were due to a low tendency to move to
water or from a lack of use in the basin.
As a consequence, the data do not
support relying on the non-detections as
a lower bound, or relying on the
detections as an upper bound. The
program, rather, provides a good
understanding on a national level of the
occurrence of pesticides in flowing
water bodies that can be useful for
screening assessments of potential
drinking water sources, especially for
those assessments concerned with
chronic, rather than acute toxicants.
While there have been additional
groundwater monitoring studies that
included carbofuran as an analyte, there
has been no additional monitoring
PO 00000
Frm 00049
Fmt 4701
Sfmt 4700
59655
targeted to carbofuran use in areas
where aquifers are vulnerable, and the
locations of sampling and the sampling
frequencies generally are not sufficient
to capture peak concentrations of the
pesticide in a watershed or aquifer
where carbofuran is used. Capturing
these peak concentrations is particularly
important for assessing risks from
carbofuran because the toxicity endpoint of concern results from single-day
exposure (acute effects). Pesticide
concentrations in ground water are
generally the result of longer-term
processes and less frequent sampling
can often adequately characterize peak
ground water concentrations. However,
such data must be targeted at vulnerable
aquifers in locations where carbofuran
applications are documented in order to
capture peak concentrations. As a
consequence, monitoring data tends to
underestimate exposure for acute
endpoints.
EPA also disagrees that the
Petitioners’ criteria of soils composed of
90% sand and less than 1% organic
matter, and wells of less than 30 feet
define all of the conditions under which
ground water sources are vulnerable to
carbofuran leaching. No comprehensive
analysis was provided evaluating how
they reached this conclusion. Although
the Petitioners proposed these criteria as
restrictions on the carbofuran label, the
spatial extent of the label restrictions
was not provided. Moreover, as
discussed in greater detail in EPA’s
Response to Comments, the information
provided as part of the Petitioners’
comments (primarily maps depicting
areas identified as vulnerable) was not
sufficient to allow the Agency to
evaluate their claim (Ref. 84). For
example, the percent sand, one of the
criteria used in this analysis, varies
significantly across a field and the
whole range of soil textures may occur
at a county-level. The national map
provided purports to represent this
parameter and several others aggregated
together to identify vulnerable locations.
This national-scale map does not
provide the level of detail needed to
verify the combination of paramters at
locations identified as vulnerable.
While the assertion that soils with 90
percent sand are the most vulnerable to
leaching is in part true, it is misleading.
While many states have only small areas
of sandy soils, several of the states in
which carbofuran would continue to be
used under the Petitioners’ proposals
have quite extensive areas. For example,
according to the Petitioners’ own
assessment of states with high amounts
of carbofuran application (Ref. 6), Texas
had 4.2% of soils classified ‘‘as sand’’,
Michigan had 21.3% and Nebraska had
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59656
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
26.3%. In addition, the Petitioners’
statements imply that soils that are
sandy textured define the universe of
soil textures that are vulnerable to
leaching. It is possible that more finetextured soils, for example sandy loams
or silt loams, could also be sufficiently
permeable to result in carbofuran
leaching as it has not been established
how much of a reduction in leaching
might occur as texture becomes finer.
Furthermore, finer textured soils tend to
have more cracks and root channels and
thus are more prone to preferential flow.
Petitioners’ claims regarding pH
concentrations are also incorrect. As an
initial matter, their analysis fails to
prove that pH values in all use areas
will ensure that concentrations are
below the level of concern because the
analysis in Exhibit 14 is based on a
flawed statistical analysis. The
methodology on which the Petitioners
relied—the use of the mean minus two
standard deviations—to estimate the 5th
percentile (i.e., 95% of the samples
above the value) of the distribution of
ground water pHs in a state depends
strongly on the shape of the
distribution. This method relies on three
assumptions: 1) That the data is
randomly sampled, 2) that the samples
are normally distributed (i.e., a bellshaped distribution), and 3) that the
samples are independent (i.e., the
sampling locations do not share
common characteristics and are not
clustered). The maps in Exhibit 14
clearly demonstrate that the study
samples were not randomly collected
across each state but were primarily in
the southern and eastern portions of the
states, even though carbofuran use is not
restricted to those portions of the states.
For example, Figure 1 in Exhibit 14
clearly shows that the vast majority of
the wells sampled in North Dakota and
South Dakota are in the eastern half of
the state, and in Nebraska in the
southern and eastern parts. Therefore
the wells sampled will not be
representative of the full distribution of
wells in the state. On the second
assumption, the analysis provided by
the Petitioners did not determine
whether the distribution was normal;
the accuracy of percentiles at the tails of
the distribution, such as the 95th
percentile, are very sensitive to the
accuracy of this assumption.
Environmental data are usually not
normally distributed; log-normal
distribution is more typical (Ref. 60). If
the shape of the distribution is not
known, a non-parametric or ‘empirical’
estimation of the percentiles is better
because it does not depend on the same
assumption of normal distribution.
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
Finally, the pH in various wells may or
may not be statistically independent.
Samples taken across the landscape are
usually spatially correlated up to a
certain distance. Beyond that distance,
they are statistically independent.
Unfortunately, this was not determined
as part of this analysis. While pH is
clustered across the state, there is
considerable spatial variability in pH
conditions for both the subsurface and
surface environments. This is especially
true for shallow ground water systems,
where local conditions can greatly affect
the quality and characteristics of the
water. This can be seen by comparing
differences in pH values between
counties within a state, and noting that
even within a county individual wells
will consistently yield ground water
with either above- or below-average pH
values for that county. Furthermore,
even if the statistical calculations was
correct, by definition this evidence
would not support a determination that
groundwater concentrations would
never exceed 1.1 ppb, as 5 percent of the
samples would result in concentrations
that are higher.
In conducting its modeling for the
final rule, EPA examined readily
available data with respect to ground
water and soil pH to evaluate the spatial
variability of pH in Wisconsin. As part
of the final rule, EPA explained that
ground water pH values can span a wide
range; this is especially true for shallow
ground water systems, where local
conditions can greatly affect the quality
and characteristics of the water (higher
or lower pHs compared to average
values). As noted even within counties
in the same state, wells will consistently
yield ground water with either above- or
below-average pH values for that
county. Thus, EPA concluded that
average ground water pH values for a
given area do not truly characterize the
(temporal and especially spatial)
heterogeneity common in most areas.
The actual significance of using a single
pH even if it is a 95th percentile value,
which as described above was not
demonstrated to be accurately
calculated, is not clear. For this reason,
EPA bracketed potential exposure using
a range of pH values.
As further explained in the final rule,
the considerable spatial variability in
pH conditions for both the subsurface
and surface environments is significant
because the pH has a large effect on the
persistence of carbofuran. This is
demonstrated by the results of the
ground water modeling simulations
from the South-Central Wisconsin
scenario, which show that what might
appear as relatively small variations in
soil pH can have a significant impact on
PO 00000
Frm 00050
Fmt 4701
Sfmt 4700
estimates of carbofuran in ground water.
Under more acidic conditions, the
hydrolysis half-life increases from 28
days at pH 7 to years or more at pHs less
than 6. Further, the results of EPA’s
corn ground water simulations
(bounded by the high and low pH
values of the aquifer system underlying
the scenario location) showed that a
relatively small (0.5) decrease in pH
from 7 to 6.5 resulted in an increase by
4 orders of magnitude in the 1-in-10year peak concentration of carbofuran.
The ground water simulations reflect
variability in pH by modeling
carbofuran leaching in four different pH
conditions (pH 5.25, 6.5, 7.0, and 8.7),
representing the range in the Wisconsin
aquifer system. The upper and lower
bound of pH values that EPA chose for
this assessment were measured values
from the aquifer, and the remaining two
values were chosen to reflect common
pH values between the measured values.
Estimated 1-in-10-year peak ground
water concentrations at pH 7 are
1.6×10¥3 ppb; however, the estimated 1in-10-year peak ground water
concentration at pH 6.5 is 16 ppb,
nearly 4 orders of magnitude greater.
EPA explained that, because of
carbofuran’s sensitivity to pH, the
Agency had concerns that any given set
of mitigation measures would not
successfully protect groundwater source
drinking. Data indicate that pH varies
across an agricultural field, and also
with depth (Ref. 49). In particular, the
pH can be different in groundwater than
in the overlying soil. The upper bound
of the carbofuran concentrations
estimated by EPA at pH 6.5 is much
greater than the concentrations the
Petitioners reported in their objections.
EPA’s complete assessment of the 2008
revised label can be found in its
Response to Comments document and
these issues were addressed in more
detail there (Ref. 84).
For all of these reasons, the objection
is therefore denied.
c. Objection/hearing request subissue:
Consistency with groundwater
concentration in NMC–CRA. Petitioners
object that EPA’s estimates in the final
rule are inconsistent with the
groundwater concentration estimates
EPA developed for the NMC (CRA).
However, they do not identify any
specific inconsistency, they simply
make the general allegation. They allege
that, by contrast, their assessment,
which estimated maximum
concentrations of 1.1 ppb, is consistent
with the NMC CRA.
i. Background. The NMC CRA
examined carbofuran at two sites,
northeastern Florida and the Delmarva
Peninsula. In Florida, concentrations
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
were found to be below levels of
concern because of high pH, but in
Delmarva, both in corn and in melon
scenarios EPA estimated that 90% of
daily concentrations could be as high as
20.5 and 25.6 ppb, respectively. In the
proposed and final rules, EPA cited the
modeling conducted for the NMC to
support its estimates. In addition, EPA
used the same methodology used to
develop the estimates for the NMC CRA,
to conduct the modeling for the
additional crops and locations on which
carbofuran use occurs.
Although the Petitioners alleged that
their estimates were consistent with the
NMC CRA in their comments on the
proposed rule, they did not identify any
specific inconsistency between EPA’s
groundwater estimates for the proposed
rule and its estimates for the NMC CRA.
ii. Denial of hearing request. EPA
denies the request for a hearing on this
subissue because there is no disputed
factual matter for resolution. There is no
dispute as to the methodology EPA used
to conduct its modeling in either
assessment. Petitioners have not
identified any specific inconsistency
between EPA’s groundwater exposure
assessment conducted for this rule and
the assessment conducted for the NMC
CRA. Instead, they rely on mere
allegations and denials. As EPA’s
regulations make clear, a mere ‘‘denial’’
of an EPA position is not sufficient to
satisfy the standard for granting a
hearing (40 CFR 178.32(b)(2)). Moreover
the question of whether EPA’s
assessments are consistent requires the
application of a legal standard to
undisputed facts, and is thus a legal or
policy question. Hearings are not
appropriate on questions of law or
policy (40 CFR 178.32(b)(1)). (73 FR
42696–42697) (denying a hearing on
EPA’s decision to reduce the children’s
safety factor, in the absence of data from
the endocrine screening program, on the
ground that the objection constituted a
legal issue). FDA has repeatedly
confirmed that the application of a legal
standard to undisputed facts is a
question of law for which a hearing is
not required. (See, e.g., 68 FR 46403,
46406 n.18, 46408, 46409 (August 5,
2003) (whether facts in the record show
there is a reasonable certainty of no
harm is a question of law; whether a
particular effect is a ‘‘harm’’ is a
question of law)).
Neither does the claim that their
modeling is consistent with the NMC
CRA justify a hearing on this question.
As EPA explained in the final rule, the
values estimated in the modeling
conducted for the NMC CRA are greater
than the 1 ppb that FMC claims is the
maximum expected 1-in-10-year peak
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
concentration. A hearing is not
warranted where the claim is clearly
contradicted by the record (40 CFR
178.32(b)(2)). See, e.g., 57 FR 6667
(February 27,1992) (‘‘A hearing must be
based on reliable evidence, not on mere
allegations or on information that is
inaccurate and contradicted by the
record.’’); 49 FR 6672 (February 22,
1984) (hearing denied where claim was
based on demonstrably false premise).
iii. Denial of objection. As discussed
in the final rule and response to
comments document, the Petitioners’
results are not consistent with the
estimates developed for the NMC CRA.
The NMC CRA examined carbofuran at
two sites, northeast Florida and the
Delmarva Peninsula. In Florida,
concentrations were found to be below
levels of concern because of high pH,
but in Delmarva, both in corn and in
melon scenarios EPA estimated that
90% of daily concentrations could be as
high as 20.5 and 25.6 ppb, respectively.
These values are greater than the 1 ppb
that Petitioners claim is the maximum
expected 1-in-10-year peak
concentration.
2. Objections relating to surface water
exposure estimates—a. Objection/
hearing request subissue: Use of percent
of the crop treated (PCT) in surface
water modeling. The Petitioners object
to the assumption in the surface water
assessments in the final rule that 100%
of the crops in a watershed will be
treated with carbofuran. The Petitioners
argue that actual carbofuran sales data
on a county basis from 2002-present
demonstrate that the current carbofuran
PCT is less than 4.25%. Using this PCT,
and taking into account the recently
submitted ‘‘no application buffers,’’ the
Petitioners allege that the modeling in
Exhibit 15 demonstrates that carbofuran
concentrations in surface water will not
exceed 1.1 ppb, ‘‘which is below the
level of concern.’’
In support of this objection, the
Petitioners reference county level sales
data that were submitted to the Agency
on November 7, 2008, after the close of
the comment period. They also
reference the use tracking system
proposed in their recent registration
amendments (Exhibit 2) and the
modeling contained in Exhibit 15.
i. Background. To conduct an
assessment of a pesticide’s potential to
contaminate surface water, EPA
estimates the percentage of farmland in
a watershed on which a particular crop
is grown (e.g, corn); this is referred to
as the percent cropped area (PCA). EPA
then assumes that 100% of the cropped
area is treated with the pesticide that is
the subject of the assessment. In the
proposed rule, EPA explained that the
PO 00000
Frm 00051
Fmt 4701
Sfmt 4700
59657
reason for its assumption that 100% of
PCA in a watershed is treated is due to
the large uncertainties in the actual PCT
on a watershed-by-watershed basis. EPA
developed an extensive discussion of
the uncertainties in PCT and how they
impact drinking water exposure
assessment in its proposed rule (73 FR
44885 (July 31, 2008)), and in a
background document previously
provided to the SAP considering the
draft carbofuran NOIC (Ref. 45). The
data are generally not available on the
scale necessary to allow for reliable
estimates of pesticide use in a
watershed. Such data are generally
available only on a statewide basis, and
if such estimates are used to account for
PCT, it will underestimate the risks for
some drinking water facilities in the
state, as these estimates represent only
a state-wide average. In some cases this
underestimate can be substantial,
because usage may not be evenly
distributed across the landscape; due to
differences in factors like pest pressure,
local consultant recommendations, and
weather, it may be much higher in some
areas. Further, temporal uncertainties
can result in changes in use that might
be driven by weather, changes in insect
resistance over time, and changes in
agronomic practices. To date, methods
that account for this uncertainty, given
the nature of the available data, have not
been developed. EPA explained that as
a consequence, the Agency could not
accurately estimate a drinking-water
watershed scale PCT that, when used in
a quantitative risk assessment on a
national or regional basis, standing
alone, provides the necessary level of
certainty to allow the Agency to
confidently conclude that exposures
will meet the FFDCA section 408 safety
standard. EPA also described the results
of a sensitivity analysis conducted using
a low PCT estimate.
In their comments on the proposed
rule, the Petitioners criticized the
Agency for this assumption, arguing that
because carbofuran is used on such a
low percentage of crops nationally that
it is unrealistic to assume that such a
large percentage of any individual
watershed would be treated. To support
their claims that the PCT would
generally be below 4%, they referenced
county-level ‘‘use’’ data, but failed to
provide either the data or methodology
on which they relied until after the
close of the comment period.
In the final rule, EPA explained at
length the reasons that the information
provided during the comment was
insufficient to allow the Agency to
reliably estimate a lower PCT for
carbofuran. EPA did not review the
information submitted after the close of
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59658
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
the comment period. However, based on
the information that could be gleaned
from the description in the comments,
EPA explained that the data on which
they relied did not appear to be ‘‘use’’
data, but sales data, and that both the
data and methodology failed to support
the claims made in the Petitioners’
comments. The Agency also described
the results of a sensitivity analysis
conducted to determine the impact that
PCT could have on the risk assessment,
which demonstrated that even assuming
that a low percentage of a watershed is
treated with carbofuran, exposures will
still be unsafe for infants.
ii. Denial of Hearing Request. To the
extent Petitioners’ objection is limited to
EPA’s refusal to use a 4% PCT in
estimating drinking water
concentrations, EPA has concluded that
the objection does not warrant a hearing
because the Petitioners’ objection on
this subissue is irrelevant, and therefore
immaterial, with regard to EPA’s final
tolerance revocation. The Petitioners
have not responded to EPA’s
explanation in the final rule of the
reasons that the information and
methodology on which they relied to
estimate a 4% PCT was flawed. As
discussed in the final rule, EPA had
assumed that the data on which they
were relying was sales data, and so the
resubmission of the information sent in
after the close of the comment period
only confirms that the Agency’s analysis
was correct; it does not rebut EPA’s
substantive concern that such
information is insufficient to support
the conclusions the Petitioners assert. In
essence, the Petitioners ignored EPA’s
extensive analysis of this issue in the
final rule and simply refiled their
comments on the proposal as if EPA’s
determination in the final rule did not
exist. The statute, however, requires that
objections be filed on the final rule not
the proposal. By ignoring EPA’s final
rule on this issue, Petitioners have
failed to lodge a relevant objection.
When an objector does not challenge
EPA’s conclusions in the final rule, but
merely reiterates comments made on the
proposed rule, without submitting some
evidence that calls EPA final rule
conclusions into question, the objector
has not raised a live controversy as to
an issue material to the final rule (See
73 FR 42698–42699 (July 23, 2008)
(denying several NRDC hearing requests
because the objections were based on
EPA’s preliminary DDVP risk
assessment, rather than the revised risk
assessment published with the final
order); 53 FR 53176, 53191 (December
30, 1988) (where FDA responds to a
comment in the final rule, repetition of
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
the comment in objections does not
present a live controversy unless the
objector proffers some evidence calling
FDA’s conclusion into question)).
An additional flaw in this objection is
that the proffered evidence is untimely
and insufficient. Neither the proposed
registration amendments nor the
evidence submitted as part of this
objection, including the modeling in
Exhibit 15, was provided to the Agency
during the comment period. The
modeling in Exhibit 15 was available,
because it was summarized in
Petitioners’ comments; however the
underlying modeling was withheld.
Equally, there is no evident reason that
the sales data could not have been
submitted as part of the Petitioners’
comments. Petitioners relied on this
data to perform analyses completed in
2006–2007, for purposes of the January
2008 SAP review of the draft carbofuran
NOIC, so the information was available
long before their comments needed to be
filed. Accordingly, as discussed in Unit
VI.D, this information is not
appropriately considered as a basis for
justifying a hearing on its final rule.
Moreover, as explained below, because
no evidence was submitted in support
of the newly proposed use tracking
system, reliance on that proposal to
support a low PCT constitutes nothing
more than an allegation. This is not an
adequate basis on which to grant a
hearing (40 CFR 178.32(b)(2)). Finally,
to the extent this objection relies on
Petitioners’ recently proposed risk
mitigation measures, as discussed in
Units VI.C and D, objections and
hearing requests based on these new
risk mitigation measures are not
appropriately considered at this stage of
the administrative process, and are
denied as immaterial (40 CFR
178.32(b)(3)).
iii. Denial of objection. While the
Agency typically uses PCT in
developing estimates of pesticide
residues in food, this is entirely
different than developing estimates of
the percent of a watershed that is treated
for purposes of estimating drinking
water exposures. Food is generally
randomly distributed for sale across the
nation without regard to where it is
grown. This tends to even out any PCT
variations that may arise on local levels.
By contrast, the source of water
consumption (and consequently
exposure) is localized, either in a
private well or a community water
system. The PCT in any watershed will
therefore directly impact the residues to
which people living in that watershed
will be exposed.
For this reason, among others, for
drinking water exposure estimation, the
PO 00000
Frm 00052
Fmt 4701
Sfmt 4700
Agency assumes that 100% of the
cropped area (or 100% PCT) is treated
with the pesticide. EPA also makes this
assumption due to the large
uncertainties in the actual PCT on a
watershed-by-watershed basis. EPA
included an extensive discussion of the
uncertainties in PCT and how they
impact drinking water exposure
assessment in its proposed rule (73 FR
44834) and in a background document
provided to the SAP considering the
draft carbofuran NOIC (Ref. 45). Because
usage is often not evenly distributed
across the landscape, due to differences
in factors like pest pressure, local
consultant recommendations and
weather, it may be much higher in some
areas. Further, temporal uncertainties
can result in changes in use that might
be driven by weather, changes in insect
resistance over time, and changes in
agronomic practices. To date, methods
that account for this uncertainty, given
the nature of the available data, have not
been developed. Consequently, EPA
cannot accurately estimate a drinkingwater watershed scale PCT that, when
used in a quantitative risk assessment
on a national or regional basis, standing
alone, provides the necessary level of
certainty to allow the Agency to
confidently conclude that exposures
will meet the FFDCA section 408 safety
standard.
In most cases, EPA agrees that it is
unlikely that 100% of the crop will be
treated with a single pesticide in most
watersheds, particularly in larger
watersheds. However, for small
watersheds, it is reasonable to assume
that an extremely high percentage of the
crops in the watershed may be treated.
Moreover, EPA has an obligation to
evaluate all legally permitted use
practices under the label, and to ensure
that all such use meets the requisite
statutory standards, not simply to base
its decisions on the practices the
majority might typically use. The
September 2008 proposed label,
submitted during the comment period,
imposes no restriction on the
application of carbofuran related to
whether a particular percent of the
watershed has been treated. Thus, even
with the restrictions on FMC’s
September 2008 labels, it remains
legally permissible for 100% of the
watershed to be treated with carbofuran.
Nor is EPA aware of an enforceable
mechanism to ensure that farmers
applying pesticide to their individual
fields will have the ability to
indendently determine whether a
particular percentage of the watershed
has been treated. There are significant
practical difficulties inherent in
implementing such label directions, as
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
they force individual growers to have
continual knowledge of the variances of
the behavior of other farmers across the
entire watershed. While for small
watersheds that involve only one or two
farms it might be feasible for neighbors
to independently coordinate
applications with respect to adjacent
fields, for larger watersheds or for
smaller watersheds with multiple farms,
the practical difficulties increase
significantly. And as explained below in
Unit VI.F.2.D, significant questions
remain regarding the efficacy of
Petitioners’ proposed use tracking
system.
However, in the final rule, EPA
conducted a sensitivity analysis to
explore the impact of the PCT
assumption on dietary risk using an
assumed 10% PCT, a figure proposed
previously by FMC (74 FR 23065–
23066). The results of that analysis
demonstrated that even at these low
percentages, which may significantly
underestimate exposures, particularly in
small watersheds, carbofuran exposures
from drinking water contribute
significantly to children’s dietary risks.
EPA conducted a similar sensitivity
analysis for the final rule, discussed
below in Unit VI.F.3, which
demonstrates that even assuming that a
low percentage of a watershed is treated,
exposures will still be unsafe for infants.
Since EPA’s 2006 determination that
carbofuran does not meet the safety
standard, FMC has submitted three
assessments that relied in part on what
they refer to as ‘‘county-level usage
data’’ (Refs. 29, 74, and 89). Based on
the information provided with the
objections, the original source of the
‘‘county-level usage data’’ is sales data,
apparently collected at the distributor
level. The Petitioners claim to have
augmented these sales data in an
unspecified manner, by incorporating
information from the distributors, which
was used to allocate carbofuran usage at
the county level. In their comments on
the proposed rule, the Petitioners
provided maps representing county
level and watershed-scale use estimates,
but did not provide the actual usage
estimates in any clearly understandable
format.
The Petitioners did submit these sales
data as part of their objections, but have
provided only a limited description of
how these data were collected and no
description of how they were actually
analyzed or validated; what was
characterized as ‘‘careful and proven
techniques to capture this data’’ were
not described. The method used to
attribute carbofuran sales to counties
was not described. Nor have they
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
explained what is meant by negative
usage estimates.
The Agency agrees that county-level
use data would be useful in generating
reasonable estimates of PCT that might
be appropriately used in drinking water
assessments. However, no usage data
have been provided. Rather, the
Petitioners only provided county-level
use estimates for Illinois, although they
have not submitted the analyses that
presumably are the basis for the
estimates. County-level estimates to
support other risk assessments have not
been submitted by the Petitioners.
Further, the Petitioners have provided
limited characterization of the source
data, noting that these data were derived
from FMC billings and ‘‘EDI data’’, but
they did not provide either the billings
or the EDI data, nor explain how they
were collected.
There are two major problems in
equating sales information with use
information: (1) Mapping the point and
time of sale to the point and time of use
and (2) allocating the amount sold
across the crops on which it can be
used. The submission did not explain
how either of these two problems was
resolved.
The first problem is highlighted by
the fact that for some county/crop/year
combinations in the submitted tables,
estimated usage is negative. Use of a
pesticide clearly cannot be negative, but
sales at a particular point and time can
be negative because buyers can return
unused product. The fact that some
usage estimates are negative suggests
that buyers are returning carbofuran
product purchased in an earlier time
period or from another location. But if
farmers are returning carbofuran
purchased in a previous time period,
any assessment must also account for
the possibility that they also could use
stocks purchased previously. Thus, use
in a given year may be greater than sales
in that year. Similarly, if farmers are
returning carbofuran purchased in
another location, it must be recognized
that they could be using carbofuran
purchased in another location. Thus,
use in any given county or watershed
could be greater than sales in that
locality. That is, regardless of whether
the issue is use over space, time, or
both, the results are that usage will be
underestimated in some localities.
Further, zeroing out the negative values
will not result in appropriate estimates;
the negative usage estimates merely
make the problem manifest. Even total
sales at a point in time may
underestimate actual use.
The second problem arises with the
allocation of product sales across the
crops on which it can be used. The data
PO 00000
Frm 00053
Fmt 4701
Sfmt 4700
59659
provided as part of the objections were
aggregated for all crops, including crops
on which use is no longer allowed, such
as cotton or alfala; the data were not
collected based on the individual crops.
No explanation is provided to indicate
how the Petitioners divided the quantity
sold between the amount used on
cotton, on alfalfa, and on all other crops.
Since part of the purpose of the
Petitioners’ assessment is presumably to
show that eliminating the use on the
cancelled crops, such as alfalfa, will
sufficiently reduce any risks, it is
critical to know how they determined
the amount used on alfalfa as opposed
to other crops, and it is difficult to
imagine how this could be done with
any accuracy. For example, one could
assume that the chemical is used on
equal proportion of all crops, but there
is no basis for such an assumption. It
might not matter if all EPA were
interested in was the total amount used
in an area, but this is not useful for
purposes of assessing the risk on a
smaller scale, such as in the present
case.
The method the Petitioners used to
generate use estimates from the sales
data does not account for the
uncertainties described above nor for
the potential for use to be locally
concentrated due to pest pressures. The
method that is summarily described as
having been used to allocate countylevel usage estimates to watersheds
appears to be similar to a method that
has been used by others to calculate
‘‘best-estimate’’ county-level PCT (Ref.
73) to map nationwide pesticide usage.
However, these methods are not
appropriate for calculating PCTs for
surface drinking water sources or
watersheds that drain to community
water systems, because they do not
adequately account for the uncertainty
in the data at the appropriate spatial
scale. This methodology produces an
estimate that is a measure of central
tendency and, as such, roughly half the
estimated values will underestimate the
PCT. Furthermore, because pesticide
use varies from year to year, and can in
some cases be patchy, with high levels
of use in small areas and little use in
most areas, the underestimates of PCT
can be substantial in small watersheds.
As previously noted, methods for
calculating PCT that account for these
uncertainties have not been developed.
Accordingly, EPA denies this objection.
b. Objection/hearing request subissue:
Results of FMC modeling. The
Petitioners claim that the prior surface
water assessments submitted to the
Agency demonstrated that carbofuran
concentrations in surface water were not
expected to exceed 1.1 ppb. They claim
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59660
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
that these studies provide further
confirmation of the results of the new
modeling conducted to support their
objections, which also concluded that
concentrations would be less than 1.1
ppb. In support of this objection, the
Petitioners reference the previously
submitted studies, along with the
modeling provided in Exhibit 15. The
modeling in Exhibit 15 appears to be the
modeling that was originally
summarized in their comments, but that
the Petitioners withheld. The modeling
was also supplemented to account for
the newly proposed registration
amendments submitted as part of the
objections.
i. Background. In their comments, the
Petitioners alleged that the results of
their modeling showed that
concentrations of carbofuran in surface
water would not exceed 1.1 ppb. The
comments referenced two surface water
assessments that they had submitted to
the Agency prior to the proposed
tolerance revocation: a surface water
assessment based on an Indiana
Community Water System (CWS) (Refs.
89 and 90) and an assessment based on
the Watershed Regressions for
Pesticides (WARP) model. They also
summarized additional surface water
modeling that had been conducted to
support their comments on the
proposed rule, a Nationwide
Community Water System Assessment
(Ref. 57), but did not submit the actual
modeling, or identify or describe in
detail the model on which they relied.
In the final rule, EPA explained the
flaws in all of the Petitioners’
assessments that caused the Agency to
reject the studies’ conclusions. For the
two assessments that had actually been
submitted to the Agency, EPA was able
to definitively explain the flaws. With
respect to the Nationwide CWS
modeling that was summarized in their
comments, EPA evaluated the modeling
based on the information it was able to
glean from the description provided in
the comment discussion.
ii. Denial of hearing request. A
hearing is denied on this subissue
because EPA has concluded that
Petitioners’ objection on this issue is
irrelevant, and therefore immaterial,
with regard to EPA’s final tolerance
revocation regulation (40 CFR
178.32(b)(3)). In the final rule, and in
other rulemaking documents, EPA
provided a detailed explanation of the
bases for its conclusions that the
previously submitted assessments were
invalid (74 FR 23062–23064 (May 15,
2009)). Petitioners have not challenged
EPA’s explanation, nor explained how
the resubmission of the same studies
addressed the substantive issues EPA
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
raised. Because Petitioners ignored
EPA’s extensive analysis of this issue in
the final rule, they have essentially
refiled their comments on the proposal
as if EPA’s determination in the final
rule did not exist. The statute, however,
requires that objections be filed on the
final rule, not on the proposal (21 U.S.C.
346a(g)(2)). By ignoring the EPA’s final
rule on this subissue, Petitioners have
failed to lodge a relevant objection.
Petitioners’ resubmission of the exact
same information does nothing to call
EPA’s conclusion into question, which
is what is required to maintain their
claim at this stage of the proceeding.
When an objector does not challenge
EPA conclusions in the final rule, but
merely reiterates comments made on the
proposed rule without submitting some
evidence that calls EPA final rule
conclusions into question, the objector
has not raised a live controversy as to
an issue material to the final rule. (See
73 FR 42700–42701 (July 23, 2008)
(hearing request denied where NRDC
failed to challenge EPA’s conclusion
that challenged study is consistent with
several other studies, but merely
reiterated assertions from its original
petition that the study is not
representative); 53 FR 53176, 53191
(December 30, 1988) (where FDA
responds to a comment in the final rule,
repetition of the comment in objections
does not present a live controversy
unless the objector proffers some
evidence calling FDA’s conclusion into
question)).
With respect to the modeling
submitted in Exhibit 15, this evidence is
untimely. The modeling submitted in
Exhibit 15 appears to be a fuller
description of Petitioners’ National CWS
Assessment, which was described but
not provided as part of their comments
on the proposed rule. The modeling also
has been revised to account for the
newly proposed risk mitigation
measures. However, even with the
greater detail provided, the information
contained in Exhibit 15 still fails to
address many of the deficiencies EPA
identified in the final rule. For example,
although some further detail has been
provided of how the Petitioners
modeled the vegetated buffer strip, the
complete information EPA would need
to assess the modeling was not
provided; the material provided is
insufficient to understand how the
simulations were performed or how the
simulations were parameterized. Nor
have the Petitioners submitted the
inputs used in modeling estimated
concentration from spray drift. As
discussed in Unit VI.D, because the
modeling in Exhibit 15 was not
PO 00000
Frm 00054
Fmt 4701
Sfmt 4700
provided during the comment period,
and to the extent that the detailed
information EPA identified as lacking in
the final rule has still not been
provided, the evidence submitted in
Exhibit 15 is not appropriately
considered as a basis for justifying a
hearing on its final rule. And in the
absence of this evidence, this objection
consists of mere allegations and general
denials, which are inadequate to justify
a hearing (40 CFR 178.32(b)(2)).
Further, to the extent that this
objection relies on the ‘‘no application
buffers,’’ or the proposed use tracking
system newly submitted as part of their
objections to support the models’
assumption of a low PCT, the hearing
request is denied as irrelevant, and
therefore immaterial, to EPA’s
determination in the May 15, 2009 final
rule, for the reasons discussed in Unit
VI.C. Petitioners are actually not
objecting to the conclusions in EPA’s
final rule; rather, they are suggesting
that EPA might reach a different result
in a different factual scenario.
Objections, however, must be directed
‘‘with particularity [at] the provisions of
the regulation or order deemed
objectionable’’ (21 U.S.C. 346a(g)(2).
And, as explained below, because no
evidence was submitted in support of
the newly proposed use tracking system,
reliance on that proposal to support a
low PCT constitutes nothing more than
an allegation. This is not an adequate
basis on which to grant a hearing (40
CFR 178.32(b)(2)).
iii. Denial of objection. To the extent
this objection relies on Petitioners’
newly submitted registration
amendments, the objection is denied as
immaterial. EPA also denies the
remaining objections because, based on
its review of the submitted modeling,
EPA has concluded all of the modeling
has substantial flaws that render the
model results invalid. EPA has
previously reviewed these assessments,
and provided a detailed explanation of
the reasons for the Agency’s
conclusions, most recently, in the final
rule and the associated response to
comments (74 FR 23060–23064, Ref.
84). EPA’s reasoning is summarized
briefly below.
Indiana CWS Assessment
EPA has previously reviewed the
Indiana surface water assessment, and
has provided comments on that
submission (Ref. 45), many of which
were reiterated at length in the final rule
and response to comments documents
(74 FR 23062–23064, Ref. 84). The
Petitioners originally submitted this
study to demonstrate that ‘‘EPA’s
standard index reservoir scenario
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
overestimates surface water
concentrations compared with expected
concentrations in actual Indiana CWS
where carbofuran is used.’’ The Index
Reservoir is designed to be used as a
screen, and as such, represents
watersheds more vulnerable than most
of those that support a drinking water
facility. It is thus protective of most
drinking water on a national basis. That,
however, does not mean that EPA
believes this scenario overestimates
concentrations for all drinking water
reservoirs. EPA agrees that it is an
appropriate refinement to simulate local
and regional watersheds, and has in fact
done so (Refs. 44, 46, 47, 48, and 84).
However, for the reasons discussed
below, EPA does not believe that the
Petitioners’ assessment demonstrates
that carbofuran concentrations will not
exceed 1.1 ppb in Indiana surface water
sources of drinking water. Even
accepting the Indiana surface water
assessment at face value, the estimated
1-in-10-year peak concentrations at
some facilities were as high as 6.88
μg/L, and these concentrations
substantially exceed the 1.1 ppb
concentration the Petitioners now claim
represent reasonable estimates.
The study also fails to support the
Petitioners’ other conclusions. The
study was originally intended to
demonstrate two points: (1) That the
vulnerability of the Indiana CWS
‘‘brackets’’ the Index Reservoir, and (2)
that the concentrations they estimated
for these locations are significantly less
than EPA estimates. Regarding the
vulnerability of the CWS, the
assessment describes their approach for
modifying the parameters of the Index
Reservoir scenario to represent 15
reservoir-based watersheds in Indiana
cropped in corn. The study indicates the
Petitioners have included data that,
based on EPA’s review of these
submissions, are not available at the
appropriate scale to determine all sitespecific parameters. The Petitioners
modified some of the parameters based
on available data to represent more
localized conditions that are more or
less vulnerable than for the Index
Reservoir. From the description, the
Petitioners’ approach is similar to the
methods that EPA uses to develop new
scenarios, in that soil and weather data
are varied in order to represent different
locations. However, for other
parameters, EPA believes the
modifications are inconsistent with
fundamental assumptions upon which
the modeling is based. In previous
submissions to the Agency, FMC has
described that they have made
modifications to scenarios to reflect
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
local conditions of each CWS in Indiana
by modifying the soil and weather data
and altering the ratio of watershed
drainage area to the reservoir capacity
(Ref. 89). EPA agrees that soil and
weather data can be modified to reflect
conditions at local watersheds.
However, EPA disagrees that altering
the ratio of watershed drainage area to
the reservoir capacity (i.e., the DA/NC)
is a reasonable modification.
The DA/NC parameter is associated
with increased concentrations in
drinking water reservoirs to a certain
point. The Petitioners adjusted their
EDWCs for each drinking water facility
by a factor representing the ratio of the
DA/NC for each reservoir divided by the
DA/NC for the Index Reservoir (which
is 12). EPA does not believe this is
appropriate for two reasons. First, the
relationship between concentrations
and the DA/NC is not strictly linear.
Small DA/NCs imply a small watershed
combined with a large reservoir. As the
DA/NC increases, the relative watershed
size increases, and thus the runoff
volume going into the reservoir also
increases. This is also means the
reservoir’s ability to dilute the runoff
decreases; the result is that
concentrations increase with an increase
in the DA/NC. However, at some point,
the runoff volume exceeds the reservoir
capacity, and rather than increasing the
pesticide concentration, the excess
runoff flows out of the reservoir,
carrying the pesticide with it. Thus,
because pesticide concentrations are not
linearly related to the DA/NC, it is not
appropriate to multiply the model
output by a linear DA/NC adjustment
factor. Secondly, the PRZM model,
which is used to simulate the watershed
for the Index Reservoir, is a field-scale
model. As the watershed size (and the
DA/NC) increases, assumptions upon
which PRZM relies (namely: uniformity
of soils, equal and simultaneous
movement of runoff to the reservoir, and
uniform weather across the watershed)
no longer hold and the model becomes
less valid for simulating the runoff
processes. The geometry of the Index
Reservoir was chosen partly to avoid
these two limitations (Ref. 43).
The study authors also calculated
their own PCA values 19 for this
assessment. EPA uses the maximum
PCA calculated for any HUC8 (8-digit
hydrologic unit code) watershed in
exposure estimates. HUC8s are
cataloging units for a watershed
developed by the USGS and are used as
surrogates for drinking water
watersheds. The process by which PCAs
19 The PCA is the fraction of the drinking water
watershed that is used to grow a particular crop.
PO 00000
Frm 00055
Fmt 4701
Sfmt 4700
59661
were developed and how they are used
by the Agency has been vetted with the
FIFRA SAP (Refs. 30 and 31). The
Agency has developed PCAs for four
major crops—corn, soybeans, wheat,
and cotton—and uses a default PCA
based on all agricultural land for
characterizing other crops. The Agency
has also calculated regional default
PCAs for use in characterizing regional
differences in drinking water exposure.
EPA limited further development of
PCAs for additional crops in response to
the FIFRA SAP peer review, which
concluded that the data were not
available at the appropriate scale to do
so. The Petitioners’ assessment
estimated PCAs for specific watersheds
in Indiana, but did not provide
sufficient detail in their descriptions of
how they calculated those PCAs to
enable EPA to assess their validity.
Regarding the statement that the
concentrations estimated for the study
locations in Indiana are significantly
less than EPA estimates, EPA has
determined that the Petitioners included
an adjustment factor to account for the
percent of a crop that is treated with
carbofuran. As previously discussed,
EPA does not believe that it is
appropriate to base its aggregate risk
estimates on PCT within watersheds.
This is because data and/or methods are
not available that would allow EPA to
develop PCT at the watershed scale with
the necessary level of confidence to
allow EPA to make a safety finding. The
PCT factors that the Petitioners applied
would generate significantly lower
concentrations than those estimated by
EPA.
WARP Assessment
EPA has reviewed the WARP
assessment previously and has provided
comments on the submission (Refs. 45
and 86). The WARP model has not been
fully evaluated for quantitative use in
exposure estimation by the Agency,
although it has been preliminarily
reviewed by the SAP (Ref. 32). EPA
used WARP to select monitoring sites
for the herbicide atrazine, based on
predicted vulnerability of watersheds to
atrazine runoff within the corn/sorghum
growing regions. EPA presented its
approach to the FIFRA SAP in
December 2007. The SAP report
concluded that ‘‘WARP appears to be a
logical approach to identify the areas of
high vulnerability to atrazine exposure,’’
endorsing EPA’s use of this tool only for
atrazine, and for the limited purpose of
designing a monitoring program. The
SAP noted that the most important
explanatory variable with WARP was
use intensity, which underscores the
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59662
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
importance of having the most accurate
data for this parameter.
WARP is a regression model
developed by the USGS to estimate
concentrations of the pesticide atrazine
in rivers and streams. As a regression
model, it is based on monitoring data
from 112 USGS NAWQA monitoring
locations. WARP does not directly
estimate daily concentrations, but
predicts the percent of the time in a
randomly selected year that
concentrations of the pesticide are less
than a specified value, with a specified
level of confidence. USGS attempted to
develop an approach to estimate annual
time series for other pesticides, and
concluded that ‘‘further data collection
and model development may be
necessary to determine whether the
model should be used for areas for
which fewer historical data are available
* * * Because of the relative simplicity
of the time-series model and because of
the inherent noise and unpredictability
of pesticide concentrations, many
limitations of the model need to be
considered before the model can be
used to assess long-term pesticide
exposure risks’’ (Ref. 92).
The Petitioners had previously relied
on their WARP assessment to support
the conclusion that the ‘‘maximum 1-in10-day estimated concentrations of
carbofuran at the 90th percentile level
in Illinois, Indiana, Iowa, and Nebraska
* * * will be less than or equal to
0.3687 ppb.’’ This is erroneous. WARP
does not provide direct estimates of
return frequency, i.e., 1-in-10 days, but
rather percentiles of the expected
distribution of measurements. This may
be similar but not identical to the return
frequency expressed as a percentile,
depending on the number of
measurements used to support the
regression. EPA lacked the information
necessary to determine whether the
contractor calibrated the model
correctly. However, taking the
conclusion at face value, the value the
Petitioners predicted using WARP,
0.3687 ppb, appears to represent the
maximum of the estimated values of the
annual 90th percentile among all the
sites evaluated. Such a site would be
expected to have higher concentrations
than 0.3687 ppb about 37 days a year
(10% of the year). Generally, the 90%
prediction intervals tend to be about
plus or minus an order of magnitude.
Thus, roughly 5% of such sites could
have about 37 days a year greater than
about 3.7 ppb, or over 3-fold higher than
the 1.1.ppb concentrations the
Petitioners now claim will be the
maximum concentrations in surface
water.
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
The Agency also disagrees that the
differences between the Petitioners’ and
EPA estimates are only due to
Petitioners’ use of county-level use
estimates. Most importantly, the
Petitioners relied on estimates of 1-in10-day concentrations, rather than the 1in-10-year peak concentrations
estimates used routinely by EPA. 1-in10-day concentrations are not the
measurement endpoint EPA uses for
human health risk assessment and are
not appropriate for estimating drinking
water exposure. The Agency uses 1-in10-year peak concentrations for
screening level assessments, and the full
time series (typically 30 years) of daily
concentration values for refined
assessments. EPA’s reliance on the 1-in10-year peak concentration has been
reviewed and approved by the FIFRA
SAP (Ref. 30).
A concentration that occurs 1-in-10
days occurs 350 times as often as a 1in-10-year event. Using this value
instead of the one EPA used would
result in significantly lower estimates of
pesticide water concentration and
human exposure. For example, EPA’s
estimate of the 1-in-10-year peak
concentration from the simulation of
corn in Kansas with a 300 ft buffer was
31.8 ppb. By contrast, EPA’s estimate of
the 1-in-10-day concentration from the
same simulation was 4.5. Use of the 1in-10 day concentration to assess dietary
risk would be inconsistent with the
SAP’s advice and EPA’s typical practice,
as well as with EPA’s statutory
requirement to protect human health.
EPA disagrees with the Petitioners’
claim that ‘‘the extreme nature of a 1in-10-year event would result in
dilution effects that cancel out any
increased loading.’’ The Index Reservoir
scenario has been validated against
monitoring collected at the site it was
designed to represent, Shipman City
Lake in Illinois (Ref. 43). This
assessment showed that the 1-in-10-year
event EPA modeled was similar in
magnitude to the peak value of the
pesticide concentrations shown in 5
years of monitoring data collected at
that site. The 1-in-10-year peak
concentration calculated for that
pesticide (not carbofuran), using the
Index Reservoir was 33 ppb, while the
peak value from 5 years of monitoring
was 34 ppb.
EPA cannot determine the validity of
the use intensities assumed for the
Petitioners’ assessment. The source of
county level use data appears to have
been sales data at the distributor level,
similar to the data provided in the
Petitioners’ November 7, 2008
submission. However, as previously
explained, the method chosen to
PO 00000
Frm 00056
Fmt 4701
Sfmt 4700
estimate county level use estimates from
the sales data was not provided. The
county level estimates used in the
assessment for 2002 to 2004 for Illinois
were provided in a table. These
estimates for each county were averaged
over the 3 years for input to the model.
A summary description of how
watershed-scale use estimated from
county level use data was provided, but
because the sales data for the individual
crops and the method that was used to
generate county level estimates were not
available, the validity of this assessment
cannot be evaluated.
Nationwide CWS Assessment
EPA has previously reviewed the
Petitioners’ ‘‘Nationwide CWS
Assessment’’ and provided a response to
the submission as part of the final rule
and Response to comments (Ref. 45). As
a preliminary matter, this assessment
only included use intensity for
reservoir-based systems, and excluded
use intensity for all stream- or riverbased systems from their assessment.
Therefore, this assessment provides no
evidence to demonstrate that carbofuran
can be safely used in stream or riverbased community water systems.
Similar to the Indiana CWS study
discussed above, this study relied on
county-level usage estimates to estimate
use intensity. The National CWS
Assessment concluded that a use
intensity below 2.1 lbs a.i/mi2 would
assure that surface water concentrations
will be below the level of concern.
To evaluate the study, it is therefore
important to understand how the use
intensities were derived. The
Petitioners’ methods have been poorly
described, but EPA has been able to
piece together a general sense of the
methods from the various reports
provided to EPA. To summarize, the
Petitioners relied on sales data to
generate the use intensity estimates, but
the method used to generate the countylevel use estimates from the sales data
is not described. The actual county level
use estimates used in the use intensity
calculations were not provided. There is
a limited description indicating only
that the county level use estimates were
apportioned to different crops, but the
method used to do this was not
provided. The Petitioners appear to
have used an objective method to group
the county-level use estimates into 5
classes, but the method is only briefly
described. Thus, because EPA cannot
determine how use intensity was
estimated, the Agency cannot determine
if the conclusions made in the National
CWS Assessment are justified by the
underlying data.
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
In the absence of this information,
EPA is unable to substantiate the study
conclusion that 75% of the permissible
use areas have a carbofuran use
intensity below 2.1 lbs a.i/mi2—even
assuming that reliance on only 75% of
the use areas would be protective, and
nothing has been submitted to
substantiate that conclusion. Use
intensity maps that were provided with
the Petitioners’ comments appear to
indicate that carbofuran use varies year
by year, and it is not clear for which
year or years, the Petitioners are relying
to support their claim that use intensity
will be below 2.1 lbs a.i/mi2. No further
support for this claim was provided
with the Petitioners’ objections, even
though EPA presented its conclusions in
the final rule.
As noted, the National CWS
Assessment assumed that a use intensity
below 2.1 lbs a.i/mi2 would assure that
surface water concentrations will be
below the level of concern. EPA agrees
that using lower rates of carbofuran will
result in lower exposure. But EPA does
not agree that it has been demonstrated
that a use intensity below 2.1 lbs a.i./
mi2 will assure that surface water
concentrations will be below the
applicable level of concern. The
National CWS Assessment does not
justify such a finding, nor has any other
assessment that has been submitted to
date. The Agency modeled use rates for
carbofuran on corn based on the label
proposed in September 2008, which are
the rates at which farmers are legally
allowed to apply carbofuran, and the
results clearly demonstrate that
estimated exposures will substantially
exceed safe levels. The results of EPA’s
assessments are described in more detail
in Unit V.E. of this order, the final rule
and in Reference 111.
EPA is equally unable to confirm the
study’s claim that the no-application
buffers on the September 2008 labels
will adequately mitigate the risks ‘‘in
areas with historical use intensities
greater than 2.1 lbs a.i./sq. mi.’’ On the
September 2008 labels, FMC included
buffers of 300 feet on water bodies in
Kansas, and 66 feet around water bodies
in other places, but EPA cannot evaluate
how these buffers relate to areas where
carbofuran use intensities exceeded a
specific value, for all of the reasons
stated above. EPA did, however, model
the effects from the buffers proposed on
the September 2008 labels and found
that these buffers reduce exposure by
5.1% (33.5 to 31.8 ppb) for corn in
Kansas with a 300-foot spray drift buffer
and 4.7% (29.9 to 28.5 ppb) for corn in
Texas with a 66-foot spray drift buffer.
However, even with the buffers, EPA’s
analyses clearly demonstrate that
VerDate Nov<24>2008
17:55 Nov 17, 2009
Jkt 220001
estimated exposures will substantially
exceed safe levels. These results are
described in more detail in Unit V.E. of
this order, the final rule, and Reference
84, Appendix I. For all of these reasons,
the objection is denied.
c. Objection/hearing request subissue:
Challenges to EPA use of NAWQA
monitoring data. The Petitioners object
to EPA’s discussion in the final rule of
the extremely high concentrations
detected in Zollner Creek in Oregon.
They argue that reliance on these
concentrations to confirm the results of
EPA’s modeling is not supportable
because Zollner Creek is a small isolated
creek, not a drinking water source, and
that because of its size, is not
representative of potential drinking
water anywhere else. They also argue
that the majority of the concentrations
in the NAWQA data, including those
detected at Zollner Creek, are extremely
low—below the 1.1 ppb they claim is
supported by their modeling. They also
contend that the higher observed
concentrations in the NAWQA
monitoring data are the result of use
patterns that are no longer permitted,
and that allowed a much higher use rate
than is currently permitted.
i. Background. In the proposed rule,
EPA described the available monitoring
data that characterized carbofuran
concentrations in surface water. EPA
described that the highest
concentrations of carbofuran are
reported from a sampling station on
Zollner Creek, which EPA
acknowledged ‘‘is not directly used as a
drinking water source’’ (73 FR 44883).
USGS monitoring at Zollner Creek from
1993 to 2006 detected carbofuran
annually in 40–100% of the samples.
EPA stated that although the majority of
the concentrations detected were in the
sub-part per billion range,
concentrations have exceeded 1 ppb in
8 of the 14 years of sampling (Id.). The
maximum measured concentration was
32.2 ppb, observed in the spring of
2002. EPA compared its modeling
results to the concentrations seen in all
of the USGS monitoring, Safe Drinking
Water Act (SDWA) monitoring, and to
the results of the available field scale
studies. EPA concluded that the
concentrations estimated in its
modeling were consistent with the
results of all of the available monitoring
and studies (73 FR 44883–44884).
In their comments on the proposed
rule, the Petitioners alleged that
comparisons between EPA’s modeling
concentrations and Zollner Creek
detections were inappropriate because
they were based on ‘‘older data [that] are
not reflective of future carbofuran use
areas and/or intensities’’ (Ref. 18 at 55).
PO 00000
Frm 00057
Fmt 4701
Sfmt 4700
59663
In support, they claimed that
‘‘carbofuran was once used at several
nurseries and strawberry farms in the
Zollner Creek watershed at estimated
application rates of up to 15 lbs. a.i./
acre (5 times higher than the maximum
rate on the current label, and 15 times
higher than the most common use
rates)’’ (Id at 56).
In the final rule, EPA explained that
it had not relied solely on Zollner Creek
concentrations to validate its modeling.
EPA again described the results of all
available modeling, which included the
detections at Zollner Creek, but also
included results from all other NAWQA
sites, SDWA post-treatment monitoring,
and the results of field studies. Based on
all of these data, EPA concluded that the
results of the revised modeling
conducted for the final rule was
consistent with the available monitoring
data.
ii. Denial of hearing request. This
subissue does not meet the standard for
a hearing. The objections regarding
Zollner Creek are not material. EPA did
not rely in on the concentrations
detected at Zollner Creek to provide
significant support its assessment.
In the final rule, EPA was clear that
it considered the levels seen at Zollner
Creek to be a rare circumstance:
While available monitoring from other
portions of the country suggests that the
circumstances giving rise to high
concentrations of carbofuran may be rare,
overall, the national monitoring data indicate
that EPA cannot dismiss the possibility of
detectable carbofuran concentrations in some
surface waters under specific use and
environmental conditions.
(74 FR 23081). The final rule was clear
that EPA placed greater reliance on the
concentrations detected in Safe
Drinking Water Act (SDWA) posttreatment monitoring, showing
concentrations ranging between 4 and 7
ppb (74 FR 23079–23080). EPA also
discussed the results of the UK tile
drain studies as supplemental
confirmation of its modeling (74 FR
23082).
Petitioners’ contentions regarding the
NAWQA monitoring also fail to present
a genuinely-disputed issue of material
fact. In both the proposed and final
rules, EPA acknowledged the large
percentage of non-detections and low
concentration levels in the majority of
the NAWQA monitoring data, and
repeatedly explained the reasons that
these data cannot serve as lower or
upper bounds (73 FR 44882–44883; 74
FR 23081). Petitioners do not dispute
those conclusions, or submit evidence
to rebut them. When an objector does
not challenge EPA conclusions in the
final rule, but merely reiterates
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59664
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
comments made on the proposed rule,
without submitting some evidence that
calls EPA final rule conclusions into
question, the objector has not raised a
live controversy as to an issue material
to the final rule. (See 73 FR 42700–
42701 (denying hearing request where
NRDC failed to object to the basis EPA
asserted in its petition denial for
rejecting their original challenge).
Finally, no evidence has been submitted
to support the contention that all of the
higher concentrations exclusively result
from uses or higher use rates that are no
longer permitted. Hearings will not be
granted on mere allegations (40 CFR
178.32(b)(2)).
iii. Denial of objection. Data compiled
in 2002 by EPA’s Office of Water show
that carbofuran was detected in treated
drinking water at a few locations. Based
on samples collected from 12,531
ground water and 1,394 surface water
source drinking water supplies in 16
states, carbofuran was found at no
public drinking water supply systems at
concentrations exceeding 40 ppb (the
MCL). Carbofuran was found at one
public ground water system at a
concentration of greater than 7 ppb and
in two ground water systems and one
surface water public water system at
concentrations greater than 4 ppb
(measurements below this limit were
not reported). Sampling is costly and is
conducted typically four times a year or
less at any single drinking water facility.
The overall likelihood of collecting
samples that capture peak exposure
events is, therefore, low. For chemicals
with acute risks of concern, such as
carbofuran, higher concentrations and
resulting risk is primarily associated
with these peak events, which are not
likely to be captured in monitoring
unless the sampling rate is very high.
Unlike drinking water derived from
private ground water wells, drinking
water from public water supplies
(surface water or ground water source)
will generally be treated before it is
distributed to consumers. An evaluation
of laboratory and field monitoring data
indicate that carbofuran may be
effectively removed (60–100%) from
drinking water by lime softening and
activated carbon; other treatment
processes are less effective in removing
carbofuran (Ref. 81). The detections
between 4 and 7 ppb, reported above,
represent concentrations in samples
collected post-treatment. As such, these
levels are of particular concern to the
Agency. An infant who consumes a
single 8-ounce serving of water with a
concentration of 4 ppb, as detected in
the monitoring, would receive
approximately 130% of the aPAD from
water consumption alone.
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
To further characterize carbofuran
concentrations in surface water (e.g.,
streams or rivers) that may drain into
drinking water reservoirs, EPA analyzed
the extensive source of national water
monitoring data for pesticides, the
USGS NAWQA program. The NAWQA
program focuses on ambient water
rather than on drinking water sources, is
not specifically targeted to the high use
area of any specific pesticide, and is
sampled at a frequency (generally
weekly or bi-weekly during the use
season) insufficient to provide reliable
estimates of peak pesticide
concentrations in surface water. For
example, significant fractions of the data
may not be relevant to assessing
exposure from carbofuran use, as there
may be no use in the basin above the
monitoring site. Unless ancillary usage
data are available to determine the
amount and timing of the pesticide
applied, it is difficult to determine
whether non-detections of carbofuran
were due to a low tendency to move to
water or from a lack of use in the basin.
The program, rather, provides a good
understanding on a national level of the
occurrence of pesticides in flowing
water bodies that can be useful for
screening assessments of potential
drinking water sources.
The national monitoring data indicate
that EPA cannot dismiss the possibility
of detectable carbofuran concentrations
in some surface waters under specific
use and environmental conditions. Even
given the limited utility of the available
monitoring data, there have been
relatively recent measured
concentrations of carbofuran in surface
water systems at levels above 4 ppb and
levels of approximately 1 to 10 ppb
measured in streams representative of
those in watersheds that support
drinking water systems (Ref. 81). Based
on this analysis, and since monitoring
programs have not been sampling at a
frequency sufficient to detect daily-peak
concentrations that are needed to assess
carbofuran’s acute risk, the available
monitoring data, in and of themselves,
are not sufficient to establish that the
risks posed by carbofuran in surface
drinking water are below thresholds of
concern. Nor can the non-detections in
the monitoring data be reasonably used
to establish a lower bound of potential
carbofuran risk through this route of
exposure. Nevertheless, these results are
consistent with the results of EPA’s
surface water modeling (Refs. 12, 47,
67). For all of these reasons, the
Petitioners objection is denied.
d. Objection/hearing request subissue:
New label restrictions and revised terms
of registration. As discussed in Units
VI.C and D, FMC submitted a request to
PO 00000
Frm 00058
Fmt 4701
Sfmt 4700
amend its existing registration to
incorporate a requirement intended to
ensure that no more than 2% of any
watershed will be treated with
carbofuran. Petitioners allege that these
new use restrictions will ensure that
drinking water concentrations will not
exceed 1.1 ppb. In support, the
objection presents a June 30, 2009 letter
describing the restrictions, along with
proposed revisions to the carbofuran
labels.
i. Background. On June 30, FMC
requested that EPA amend its
registration to incorporate a requirement
that, within five days of applying the
product, all applicators report to FMC
the following information: the location
that the product will be used; crop, use
rate, application method, acreage, and
quantity applied. Based on this
information, FMC would track the
percentage in each watershed.
‘‘Whenever it appears that carbofuran
has been applied to 1.75% of any
watershed,’’ the registrant would report
that information immediately to EPA,
‘‘cease further sales in any county that
overlaps with such a watershed for that
use season, and shall attempt to recall
all unused carbofuran within such
counties by offering to repurchase such
unused product’’ (Exhibit 3). In
addition, FMC requested that its
registration be amended to require that
‘‘based on watershed boundaries, FMC
* * * prior to each uses season, allocate
to its distributors in a manner which
will attempt to ensure that no
distributor receives more for carbofuran
for sale than can be accommodated by
the 2% watershed area cap in any
watershed supplied by that distributor.’’
ii. Denial of hearing request. EPA
denies this hearing request on two
grounds. First, discussed in VI.C,
Petitioners’ objections and hearing
requests are denied as irrelevant, and
therefore immaterial, to EPA’s
determination in the May 15, 2009 final
rule that the carbofuran tolerances were
unsafe and could not be sustained under
FFDCA section 408. Petitioners are
actually not objecting to the conclusions
in EPA’s final rule; rather, they are
suggesting that EPA might reach a
different result in a different factual
scenario. Objections, however, must be
directed ‘‘with particularity [at] the
provisions of the regulation or order
deemed objectionable’’ (21 U.S.C.
346a(g)(2)). Further, as discussed in
Unit VI.D, this objection is untimely,
because it was not raised in comments.
Neither this specific proposal, nor any
other proposal regarding a potential
tracking system, was presented to EPA
by the close of the September 29, 2008
comment period. EPA therefore
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
considers this issue waived, and will
not consider this as an appropriate basis
for justifying a hearing on its final rule.
However, there is a further equally
material defect in this hearing request.
The Petitioners have submitted no
evidence to support their allegation that
these proposed requirements would be
effective in ensuring that carbofuran
would be applied to no more than 2%
of any watershed. The only submission
was the description provided in the
June 30 letter (Exhibit 3), and repeated
above. However, this vague description
leaves several critical questions
unanswered. For example, the critical
component of this proposal is a post-use
reporting scheme, with a five-day delay
between use and reporting. Even
assuming that one accepts that reporting
an address would allow for complete
identification of the location within an
individual watershed—a point on which
no evidence has been submitted—no
evidence, or even an explanation, has
been provided to demonstrate how this
after-the-fact reporting requirement will
prevent application to greater
percentages of the watershed. For
smaller watersheds, as discussed in the
final rule, application to only one or two
farms may be sufficient to substantially
exceed 2% of the watershed. In such
cases, since applicators are only
required to report within five days after
application, it is likely that FMC would
not be informed until after the 2% cap
had been exceeded. Further, there will
inevitably be some delay between
FMC’s attempt to repurchase the
product and the reports suggesting (or
confirming) that the cap either has been
or will shortly be exceeded. Given the
inevitable delay, it is not unlikely that
further application would occur before
FMC could even attempt to repurchase
the product. No details whatsoever have
been provided regarding the timing or
mechanism by which this would occur.
Further, this program operates in the
absence of any enforceable use
restriction, and no description of the
means by which this would be enforced
is provided. Although the company
would ‘‘attempt to recall the product’’ or
make it less available by ‘‘attempting’’ to
direct sales to particular
distributorships, in the absence of some
mechanism to prevent sales or use, such
as a permitting process, there is no real
assurance that these voluntary measures
would be effective (Exhibit 3). This is
further complicated by the extremely
low percentages contemplated by this
proposal.
Additionally, this scheme rests on a
variety of assumptions that no evidence
has been submitted to substantiate. For
example, the proposal to restrict sales to
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
distributors in particular watersheds
rests on an assumption that farmers
always purchase products from a
distributor within their watershed. It
also assumes that growers and
distributors will accept FMC’s offer to
repurchase unused stock of the
products, rather than seeking to
stockpile the product for use in the next
growing season.
In the absence of any evidence to
demonstrate the efficacy of these
proposed restrictions, any objection
based on these proposed amendments
constitute no more than mere
allegations or denials. Hearings will not
be granted on such a basis (40 CFR
178.32(b)(2)).
iii. Denial of objection. For the
reasons discussed above, even if it were
appropriate to consider the proposed
registration amendments, EPA is unable
to conclude that those amendments
would ensure that concentrations of
carbofuran in drinking water derived
from surface water will not exceed 1.1
ppb. Accordingly, the objection is
denied.
e. Objection/hearing request subissue:
Consistency with NMC surface water
estimates. Petitioners object to EPA’s
surface water exposure estimates on the
ground that they are inconsistent with
the estimates EPA developed for
purposes of the NMC CRA. Petitioners
further claim that their revised surface
water assessment is consistent with the
EPA estimates in the NMC cumulative
risk assessment. The evidence proffered
for this objection consists of the
modeling in Exhibit 15.
i. Background. In comments on the
proposed rule, the Petitioners
complained that as part of the NMC
CRA, EPA relied on actual ‘‘county-or
multi-county level pesticide use
information, based on agricultural
chemical use surveys’’ to develop its
estimates of potential exposure, rather
than assuming 100% PCT.’’ In the final
rule, EPA provided a lengthy and
detailed explanation of the reasons that
its approach to assessing individual
chemicals and its approach to assessing
the cumulative risks of multiple
chemicals differed (74 FR 23067–23068
(May 15, 2009)).
ii. Denial of hearing request. To the
extent Petitioners base this objection on
the concerns raised in their comments,
EPA denies the hearing request on this
subissue because there is no disputed
factual matter for resolution at a
hearing. There is no dispute that EPA
assumed 100% PCT for carbofuran in its
surface water modeling, nor that EPA
developed lower estimates in the NMC
CRA, that accounted for the percent of
the crop that was likely to be treated
PO 00000
Frm 00059
Fmt 4701
Sfmt 4700
59665
with each individual NMC chemical in
order to more accurately account for the
likelihood of pesticide co-occurrence at
a single drinking water facility. Thus,
the only question is whether EPA’s basis
for adopting a different approach
between the assessment of a single
chemical’s aggregate exposure and the
assessment of the cumulative exposures
from several chemicals is reasonable.
This question requires the application of
a legal standard to undisputed facts.
Hearings are not appropriate on
questions of law or policy (40 CFR
178.32(b)(1)); (73 FR 42706–42707 (July
23, 2008)). FDA has repeatedly
confirmed that the application of a legal
standard to undisputed facts is a
question of law for which a hearing is
not required. (See, e.g., 68 FR 46403,
46406 n.18, 46408, 46409 (August 5,
2003) (whether facts in the record show
there is a reasonable certainty of no
harm is a question of law; whether a
particular effect is a ‘‘harm’’ is a
question of law)).
In addition, Petitioners have not
challenged the substance of EPA’s
response to their comments or
submitted evidence that calls the
substance of EPA’s conclusions into
question (40 CFR 178.32(b)(3)).
Consequently, the Petitioners’ objection
on this issue is irrelevant, and therefore
immaterial, with regard to EPA’s final
tolerance revocation regulation because
Petitioners ignored EPA’s extensive
analysis of this issue in the final rule
and essentially resubmitted their
comments on the proposal as if EPA’s
determination in the final rule did not
exist. The statute, however, requires that
objections be filed on the final rule, not
on the proposal (21 U.S.C. 346a(g)(2)).
By ignoring the EPA’s final rule on this
subissue, Petitioners have failed to
lodge a relevant objection. Both EPA
and FDA precedent make clear that
when the agency substantively responds
to comments on the proposal, the
commenter may only keep that issue
alive in its objections by addressing the
agency’s substantive response. See 73
FR 42698–42699 (When an objector
does not challenge EPA conclusions in
the section 408(d)(4)(iii) order but rather
challenges some prior conclusion that
was superseded by the section
408(d)(4)(iii) order, the objector has not
raised a live controversy as to an issue
material to the section 408(d)(4)(iii)
order; 53 FR 53176, 53191 (December
30, 1988) (where FDA responds to a
comment in the final rule, repetition of
the comment in objections does not
present a live controversy unless the
objector proffers some evidence calling
FDA’s conclusion into question)).
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59666
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
To the extent this objection is simply
an allegation that the results of the
modeling are consistent with the surface
water estimates in EPA’s NMC risk
assessment, the hearing request also
suffers from a fatal flaw. The modeling
is based on the assumption the recently
proposed label restrictions are effective,
and that the PCT will be 2%. Because
the objection and hearing request are
inextricably intertwined with the
Petitioners’ newly submitted proposed
FIFRA registration amendments, the
objection and hearing request are denied
as irrelevant, as discussed in Unit VI.C.
Further, as discussed, no evidence was
submitted to support the assumption
that the newly submitted use tracking
proposal will be effective. The only
evidence submitted in this regard is the
results of the modeling in Exhibit 15,
which as previously discussed is
untimely, and therfore provides an
inappropriate basis for a hearing. This
evidence, therefore, on multiple
grounds is insufficient to support a
reasonable possibility that the issue will
be resolved in the Petitioners’ favor. No
hearing is warranted under such
circumstances (40 CFR 178.32(b)(2)).
iii. Denial of objection. While it is true
that in the NMC assessment EPA used
PCT numbers to estimate the cumulative
exposure from the contamination of
such pesticides in surface water, this
was done in order to more accurately
account for the likelihood of pesticide
co-occurrence at a single drinking water
facility. But this does not mean that use
of PCT is appropriate in conducting an
assessment of aggregate exposure from
carbofuran residues in surface water.
This difference in approach between the
assessment of a single chemical’s
aggregate exposure, and the assessment
of the cumulative exposures from
several chemicals, stems from the
differences in the purpose and scope of
the two assessments. These differences
inevitably require the application of
different methodologies.
In evaluating the acute risks
associated with a single chemical’s
contamination of drinking water, EPA
must consider all of the variations
permitted under the label. Drinking
water exposures are driven by uniquely
local factors; not only is the source of
drinking water local (i.e., a person
drinks water from his or her local water
system, not from a combination of water
systems from across the United States),
but the likelihood and degree of
contamination of any particular, local
drinking water source, whether it is a
reservoir or well, varies widely based on
local conditions (e.g, from local pest
pressures, weather). Given this local
variability, EPA must evaluate how all
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
of the practices permitted under the
label will affect drinking water
exposures, because all are legally
allowed, and farmers may choose any of
them based on their particular
individual local conditions. This means
that even if growers, on a national or
regional basis, do not frequently use a
particular practice, EPA must still
evaluate whether aggregate exposures
from that practice would be safe because
the practice is legally permissible and
may be used due to local conditions.
Thus, for example, even if most growers
tend to apply the chemical only to a
portion of the field, or typically only
apply one-half of the maximum
application rate, EPA must determine
whether use by all or some growers on
the entire field or at the maximum rate
in a local watershed would result in
unsafe drinking water concentrations.
By contrast, it is not feasible to
conduct the identical analysis for a
cumulative assessment of related
chemicals. Since the potential
combinations of variations in pesticide
use practices for the group of pesticides
to be assessed are essentially infinite,
even with computer modeling it would
be impossible to model or evaluate all
of the combinations allowed under the
labels. EPA therefore needed to narrow
its evaluation of the possible
combinations to those deemed ‘‘likely’’
to occur. In contrast to the single
chemical assessment, a cumulative
assessment is intended to develop a
snapshot in time of what is likely
occurring at the moment. Moreover, the
purpose of a cumulative assessment is
to identify major sources of risk that
could potentially accrue due to the
concurrent use of several pesticides that
act through a common mechanism of
toxicity. Thus, EPA is primarily
interested in the subset of circumstances
in which residues from such pesticides
occur concurrently (or co-occur).
In addition, one of the important
attributes of a cumulative risk
assessment is that its scope and
complexity can potentially lead to
inflated estimates of risk due to
compounding conservatisms, which
would reduce the interpretability and
ultimately the utility of the assessments.
Because many data sets need to be
combined, reducing the impact and
likelihood of compounding conservative
assumptions and over-estimation bias
becomes very important in constructing
a reasonable cumulative risk
assessment.
When little or no information is
available to inform potential sources of
exposure, such as a reasonable or
maximum watershed scale PCT, it is
both scientifically and legally
PO 00000
Frm 00060
Fmt 4701
Sfmt 4700
reasonable for a single chemical
assessment to incorporate conservative
assumptions to reflect reasonable worstcase exposure estimates. But in a
cumulative risk assessment, the
incorporation of such conservative
assumptions would imply multiple
simultaneous reasonable worst-case
exposure estimates for each individual
chemical. This is so unlikely that the
results would no longer represent even
a reasonable worst-case estimate of the
likely risks. Consequently, some of the
conservative assumptions appropriately
used in the single chemical risk
assessments are not appropriate or
reasonable for use in a cumulative risk
assessment, and vice versa.
As a result, EPA chose in the NMC to
work with those data that most closely
reflect ‘‘representative’’ exposures, and
developed ‘‘representative’’ estimates of
PCT in regional watersheds. However,
to be clear, the PCT values used in the
NMC assessment do not represent
estimates of 50% of watersheds, or even
the ‘‘average’’ watershed; rather, they
represent values that are expected to be
as likely to be accurate as not, based on
a random selection of watersheds. A
comparable example is the statistic that
the average American family has
approximately 2 children; this may or
may not be true for any individual
family, but there is an equally good
chance that it will be accurate for any
randomly selected family, as that it will
not be accurate. For the cumulative
assessment, EPA is able accept this level
of uncertainty in these estimates,
precisely because it has confidence that
aggregate exposures from the individual
chemicals will be safe, based on the
level of conservatism in the single
chemical assessments. But given the
statute’s mandate to ensure a
‘‘reasonable certainty of no harm,’’ EPA
could not rely on the approach used
under the cumulative assessment in the
absence of the more conservative singlechemical assessment that evaluates the
full range of exposures permitted by the
registration.
Nevertheless, as discussed in the final
rule, in response to FMC’s concerns
EPA performed a sensitivity analysis of
an exposure assessment using a PCT in
the watershed to determine the extent to
which some consideration of this factor
could meaningfully affect the outcome
of the risk assessment. The results
suggest that, even at levels below 10%
CT, exposures from drinking water
derived from surface waters can
contribute significantly to the aggregate
dietary risks, particularly for infants and
children. Accordingly, these
assessments suggest that use of a
reasonably conservative PCT estimate,
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
even if one could be developed, would
not meaningfully affect the carbofuran
risk assessment, as aggregate exposures
would still exceed 100% of the aPAD.
f. Objection/hearing request subissue:
Natural surface water pH conditions.
The Petitioners contend that the low
PCT levels guaranteed by the recent
proposed use tracking system, along
with natural surface water pH
conditions in the areas where use is
permitted under the revised label will
ensure potential exposures are de
minimis. In support they reference the
analysis in Exhibit 16, which they claim
demonstrates that the NAWQA USGS
data show that average surface water pH
is above 7.5 and that ‘‘in most regions,
moving 2 standard deviations away
from average (which would capture
95% of all observed values) results in
pHs that are still greater than 7.5.’’
i. Background. In the proposed rule,
EPA explained that the variation in pH
across the landscape was a significant
uncertainty in EPA’s analysis. The
proposal stated, that ‘‘while it is well
established that carbofuran will degrade
at higher rates when the pH is above 7,
and lower rates when below pH 7, due
to the high variation of pH across the
country for many of the scenarios, a
neutral pH (pH 7) default value was
used to estimate water concentrations
(73 FR 44883). Petitioners raised no
issue regarding surface water pH in their
comments.
ii. Denial of hearing request. EPA
denies this hearing request because the
objection, as well as the proffered
evidence is untimely. EPA clearly
described the potential impact that pH
could have on its estimates, and noted
that this was a significant uncertainty in
its assessment. None of the analyses in
Exhibit 16 were provided as comments
on the proposed rule. Nor were any of
the issues inherent in this objection
raised as comments on the proposal.
Since the proposed rule was clear that
the issue was relevant, and the NAWQA
data were available, Petitioners could
have conducted these analyses and
raised the issue as part of their
comments. Consequently EPA has
determined that the evidence submitted
in support of this objection is not
appropriately considered as a basis for
justifying a hearing on its final rule.
And in the absence of this evidence, the
objection consists of mere allegations
and general denials, which do not
warrant a hearing (40 CFR 178.32(b)(2)).
Further, to the extent the objection and
the evidence in Exhibit 16 rely on use
tracking system and risk mitigation
proposals submitted as part of their
objections, this hearing request is
denied as irrelevant, and therefore
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
immaterial, as discussed in Unit VI.C.
Petitioners are actually not objecting to
the conclusions in EPA’s final rule;
rather, they are suggesting that EPA
might reach a different result in a
different factual scenario. Objections,
however, must be directed ‘‘with
particularity [at] the provisions of the
regulation or order deemed
objectionable’’ (21 U.S.C. 346a(g)(2)). In
addition, for the reasons discussed in
Unit VI.D, any hearing request premised
on the new mitigation measures is
considered untimely, and not
appropriately considered at this stage of
the administrative process as a basis for
granting a hearing under the FFDCA.
EPA is also denying the requested
hearing on the grounds that the
evidence, even if established, is
insufficient to justify the action urged
(40 CFR 178.32(b)(3)). The analyses
presented in Exhibit 16, as the
Petitioners explicitly acknowledge, only
capture 95% of the values; five percent
of exposures are not, per se, de minimis.
Second, just as with the groundwater
pH analyses presented in Exhibit 14, no
information was provided to explain
how the samples relate to the state or
other geographic area in which
carbofuran would be used. This is
important because NAWQA samples
were not evenly distributed across most
states, but tended to be concentrated in
particular regions; in statistical
parlance, the samples were not collected
randomly. In other words, no evidence
was provided that would allow the
Agency to determine the percentage of
the carbofuran use area represented by
the 95% of the samples the Petitioners’
analysis addressed. Nor was any
information provided to document the
significance of the remaining 5% of the
samples that were not captured by their
analysis; for example, although this may
have only represented 5% of the
samples, it is not clear whether this 5%
relates to only 5% of the areas where
carbofuran may be used, or whether it
actually represents a far greater
percentage of the use area. Because this
information, even if established, would
provide an insufficient basis on which
EPA could reasonably conclude that the
drinking water exposures would be
‘‘safe,’’ this issue is not determinative.
iii. Denial of objection. For the
reasons presented above, the Petitioners’
objection is denied. Further, there are
several significant defects with the
analysis in Exhibit 16. First, the analysis
was based on statewide averages, which
ignores the fact that pH is not evenly
distributed, but randomly clustered.
Second NAWQA contained no data for
Kansas (KS), Oklahoma (OK), and South
Dakota (SD); Petitioners simply assert
PO 00000
Frm 00061
Fmt 4701
Sfmt 4700
59667
that the ‘‘given the similarity between
these states and the other High Plains
states, it is reasonable to extend the
observations from Colorado (CO),
Nebraska (NE), and North Dakota (ND)’’
(Exhibit 16 at 4). Although the ‘High
Plains’ states all have extensive areas of
grassland, they also have extensive
geographic soil and climatic
differences—e.g. the Black Hills and
Badlands (SD), Sand Hills (NE), Flint
Hills, Cheyenne Bottoms and Quivira
wetlands (KS), Red Hills and Cross
Timbers region (OK). These differences
are not surprising since the distance
from the Canadian border in ND to OK
is over 1000 miles. Consequently it is
not reasonable to extend observations
from CO, NE, and ND to KS, OK, and
SD.
g. Objection/hearing request subissue:
Effect of existing drinking water
treatment systems. The Petitioners
contend that a review of drinking water
treatment systems in areas under
revised labels indicates that the majority
of the ‘‘total population in affected
states obtain their drinking water from
surface water sources subject to lime
softening or activated charcoal filters.
They allege that ‘‘60% of the total
population in affected states’’ will have
their water treated by methods that will
substantially reduce or entirely remove
carbofuran concentrations. For the
remaining 40%, they claim that a
significant portion use ground water
sources, which are already protected by
the Petitioners’ other mitigation
measures, and the remainder are
protected by the Petitioners’ proposed
use reporting scheme. In support of this
objection, Petitioners rely on the
analysis in Exhibit 17.
i. Background. In the proposed rule,
EPA explained that one of the more
significant uncertainties in EPA’s
analysis was that EPA failed to account
for the potential effect of treatment in
removing carbofuran from finished
drinking water before it is delivered to
the consumer supply system. EPA
explained that an evaluation of
laboratory and field monitoring data
indicate that carbofuran may be
effectively removed (60–100%) from
drinking water by lime softening and
activated carbon; other treatment
processes are less effective in removing
carbofuran (Ref. 81). Although the
Agency was aware of the mitigating
effects of specific treatment processes,
the processes employed at public water
supply utilities across the country vary
significantly both from location to
location and throughout the year, and
therefore EPA was unable to
quantitatively incorporate this factor
into its drinking water exposure
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59668
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
estimates. For example, lime softening
would likely reduce carbofuran
concentrations. That process is used in
3 to 21% of drinking water treatment
systems in the United States (Ref. 14).
Activated carbon has been shown to
also reduce carbofuran concentrations,
but is used in 1 to 15% of drinking
water treatment facilities (Id.).
Petitioners noted this discussion in their
comments, and relied on it to support
their argument that their drinking water
exposure assessments were
conservative, because they did not
account for the effect of treatment (Ref.
18 at 46–55). However they submitted
no comments raising any of the issues
or evidence presented in this objection.
ii. Denial of hearing request. EPA
denies this hearing request on the
grounds that both the objection and the
proffered evidence are untimely. EPA
clearly described the potential impact
that treatment could have on its
estimates. None of the analyses in
Exhibit 17 were provided as comments
on the proposed rule. Nor were any of
the issues inherent in this objection
raised as comments on the proposal.
Since the proposed rule clearly
identified the issue, and the USGS data
were available, the Petitioners could
have conducted these analyses, or at
least raised the issue, as part of their
comments. Consequently, as discussed
in Unit VI.D, EPA has determined that
the evidence submitted in support of
this objection is not appropriately
considered as a basis for justifying a
hearing on its final rule. In the absence
of this evidence, the objection consists
of mere allegations and general denials,
which do not warrant a hearing (40 CFR
178.32(b)(2)). Further, to the extent the
objection and the evidence in Exhibit 17
rely on the new registration proposals
submitted in June 2009 as part of their
objections, this evidence as well is
deemed both immaterial and untimely.
As discussed in Units VI.C and D, the
new risk mitigation measures are not
appropriately considered at this stage of
the administrative process, and no
hearing is warranted on this basis.
EPA is also denying this hearing
request on the grounds the Petitioners’
evidentiary proffer is insufficient to
justify the factual issue urged (40 CFR
178.32(b)(2)). The analysis in Exhibit 17
is based on the percentage of the total
population across all states combined,
not the percentage of the local
populations served by an individual
surface water source—or even the
percentage within each state. Even
assuming that the 60% figure could
legitimately be translated to a state-bystate basis, their own analysis shows
that some percentage of the population
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
in individual states will remain
unprotected. In Colorado, only 24% of
the population obtains their drinking
water from groundwater, and in Illinois,
only 33% of the population obtains
their drinking water from groundwater.
Sixteen percent of Colorado’s
population is not de minimis.
Consequently, even if the analysis were
accurate, it would not provide a
sufficient basis on which to conclude
that exposures from drinking water
would be ‘‘safe.’’
A further consideration in this regard
is that drinking water exposures are
driven by uniquely local factors; not
only is the source of drinking water
local (i.e., a person drinks water from
his or her local water system not from
a combination of water systems from
across the United States), but the
likelihood and degree of contamination
of any particular, local drinking water
source, whether it is a reservoir or well,
varies widely based on local conditions
(e.g., from local pest pressures,
weather). Examining a population
across an entire state—let alone across
several states—is an entirely
inappropriate basis on which to
conclude that drinking water exposures
will be safe.
The evidence submitted therefore
does not support their contention that
60% of the population in ‘‘affected
states’’ obtain their drinking water from
public systems that use the treatment
processes effective at mitigating
carbofuran residues. For example,
Exhibit 17 shows that a major Chicago
surface water drinking water system,
which serves a population of 9,000,000,
has neither lime softening processes nor
filters. Petitioners have submitted no
evidence that this population is
protected. The fact that a small
population remains unprotected is not
outweighed by the fact that a larger
population in another community or
state is protected. Their own evidence
also shows that only 26 of 141 of
community water systems use lime
softening/filters (Exhibit 17 at 4–9),
which supports the conclusion in the
final rule that approximately 20%
facilities have appropriate treatment.
See 57 FR 33244 (7/27/92) (Studies
cited by NRDC do not provide a basis
for the hearing because they ‘‘support
the [FDA] conclusion in question.’’); 57
FR 6667 (2/27/1992) (‘‘A hearing must
be based on reliable evidence, not on
mere allegations or on information that
is inaccurate and contradicted by the
record.’’); 49 FR 6672 (2/22/84) (no
hearing if claim based on demonstrably
false premise).
iii. Denial of objection. For the
reasons discussed above, this objection
PO 00000
Frm 00062
Fmt 4701
Sfmt 4700
is denied. A further consideration is that
treatment does not necessarily remove
all residues. As previously noted, in
both the proposed and final rules EPA
discussed the SDWA monitoring
detections between 4 and 7 ppb, which
represent concentrations in samples
collected post-treatment. As such, these
levels are of particular concern to the
Agency. An infant who consumes a
single 8-ounce serving of water with a
concentration of 4 ppb, as detected in
the monitoring, would receive
approximately 130% of the aPAD from
water consumption alone. An infant
who consumes a single 8-ounce serving
of water with the higher detected
concentration of 7 ppb, as detected in
the monitoring, would receive
approximately 220% of the aPAD from
water consumption alone.
G. Objections to EPA’s Dietary Risk
Assessment
Petitioners raise two related
objections to the way in which EPA
evaluated the aggregate dietary
exposures to carbofuran residues. First
they raise several technical challenges
to the way in which EPA calculated the
two recovery half-lives that were used
in the risk assessment supporting the
final rule to account for the potential for
individuals to recover from the effect of
ingesting carbofuran residues between
exposures. Second, they object to the
fact that in the final rule EPA included
both aggregate exposure estimates that
did not account for the potential for
individuals to recover from the effects
between exposures as well as estimates
that did account for such recovery. In
support the Petitioners cite to Exhibits
9 and 10. Exhibit 9 is a memorandum
prepared by Robert Sielken and Ciriaco
Valdez-Flores. Exhibit 10 is a published
literature study by Elsa Reiner that
presents data on the rates of
spontaneous reactivation of
phosphorylated and carbamylated
cholinesterases.
1. Objection/hearing request subissue:
Inclusion of exposure estimates that do
not incorporate recovery in final rule.
The Petitioners object to the fact that the
final rule presented aggregated exposure
estimates that did not incorporate the
anticipated recovery from carbofuran’s
effects between exposures, in addition
to those that did account for recovery.
They claim that recovery time should be
included in EPA’s ‘‘primary’’ risk
assessment.
i. Background. As discussed in Unit
V, EPA’s standard acute dietary
exposure assessment calculates total
dietary exposure over a 24-hour period;
that is consumption over 24 hours is
summed and no account is taken of the
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
fact that eating and drinking occasions
may spread out exposures over a day.
This total daily exposure generally
provides reasonable estimates of the
risks from acute dietary exposures,
given the nature of most chemical
endpoints. Due to the rapid recovery
associated with some chemical toxicity
(e.g., AChE inhibition), 24-hour
exposure periods may or may not be
appropriate. To the extent that a day’s
eating or drinking occasions leading to
high total daily exposure might be
found close together in time, or to occur
from a single eating event, minimal
AChE recovery would occur between
eating occasions (i.e., exposure events).
In that case, the ‘‘24-hour sum’’
approach, which sums eating events
over a 24-hour period, would provide
reasonable estimates of risk from food
and drinking water. Conversely, to the
extent that eating occasions leading to
high total daily exposures are widely
separated in time (within 1 day) such
that substantial AChE recovery occurs
between eating occasions, then the
estimated risks under any 24-hour sum
approach may be overstated. In that
case, a more sophisticated approach—
one that accounts for intra-day eating
and drinking patterns and the recovery
of AChE between exposure events—may
be more appropriate. This approach is
referred to as the ‘‘Eating Occasions
Analysis’’ and it takes into account the
fact that the toxicological effect of a first
dose may be reduced or tempered prior
to a second (or subsequent) dose.
In the proposed rule, EPA conducted
an Eating Occasion analysis based on
two half-lives: 150 minutes and 300
minutes (73 FR 44887 (July 31, 2008)).
These half-lives were not specific to
carbofuran, but were calculations
derived for the NMC Cumulative Risk
Assessment. EPA concluded that
incorporating these analyses into the
risk assessment had little impact on the
risk estimates from exposures from food
alone, but that risk estimates from
combined exposures from food and
water were reduced by approximately
2–3X (Id). However, because many of
EPA’s risk concerns stemmed from a
single exposure (e.g., one meal) and
because, even when recovery was
accounted for, aggregate exposures far
exceeded safe levels, EPA concluded
that ‘‘risks to carbofuran is indeed not
substantively overestimated using * * *
the 24-hour approach’’ (Id).
In their comments, Petitioners
complained that EPA had failed to
incorporate recovery into their risk
assessment. They further argued that
EPA should calculate the per capita
99.9th percentile based on all person
minutes rather than all person-days. In
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
addition, they submitted an aggregate
dietary risk assessment they had
conducted using a 150-minute half-life
input. They submitted no explanation
for using only the 150-minute half-life
rather than also including estimates
based on the 300-minute half-life that
EPA has used for the proposed rule.
In the final rule EPA explained that it
had conducted a revised Eating
Occasion analysis to evaluate the impact
of carbofuran’s rapid reversibility on its
risk estimates (74 FR 23086 (May 15,
2009)). EPA concluded that
incorporating Eating Occasion Analysis
and the 186-minute or 426-minute
recovery half-lives for carbofuran did
not significantly change the risk
estimates for food exposures alone (74
FR 23086 (May 15, 2009)). EPA
concluded that risk estimates based on
combined food and drinking water
exposures are reduced considerably—by
a factor of two or more in some cases,
but nonetheless still substantially
exceed EPA’s level of concern for
infants and children. EPA also
explained that the Agency remains
concerned about the risks from single
eating or drinking events. Finally, EPA
noted that the Eating Occasion Analyses
underestimate exposures to the extent
that they do not take into account carryover effects from previous days, and
because drinking water concentrations
are randomly picked from the entire 30year distribution (Id at 23087).
ii. Denial of hearing request. EPA is
denying this hearing request on two
grounds. First, the objection fails to
present a disputed issue of material fact.
The record is clear that EPA did
incorporate recovery into its analysis;
indeed, one of Petitioners’ objections
relates to the manner in which EPA
incorporated recovery into its risk
assessment (Obj at 30–33). Rather, their
only challenge is that the final rule
should have only presented risk
estimates that accounted for recovery.
The sole issue is whether it was
reasonable for EPA to have also
communicated aggregate risks that did
not account for recovery, when (1)
EPA’s estimates showed that accounting
for recovery demonstrated that EPA’s
standard 24-hour estimates were not
substantially overstated; (2) EPA’s
approach to accounting for recovery
underestimates some risks; and (3)
EPA’s risk assessments concluded that
infants received unsafe exposures from
a single meal (eating occasion). This is
a policy issue, and hearings are not
appropriate on such (40 CFR
178.32(b)(1)).
Second, the fact that EPA relied on
24-hour aggregate exposures in addition
to analyses that accounted for recovery
PO 00000
Frm 00063
Fmt 4701
Sfmt 4700
59669
is not material. As documented in the
final rule, EPA would still have
concluded that revocation of all
tolerances were warranted on the
grounds that, even accounting for
recovery, aggregate exposures are not
‘‘safe.’’ Even though accounting for
recovery resulted in a 2–3X reduction in
exposure estimates, many of EPA’s
estimates for aggregate exposures ranged
between 2700% aPAD and 9400% aPAD
for infants. Accounting for recovery
does not, therefore, demonstrate that
aggregate exposures will be safe for
infants. Of greater significance in this
regard is EPA’s finding that infants are
at risk from a single exposure. Recovery
is only relevant, by definition, where
the risk is derived from multiple
exposures over time.
iii. Denial of objection. The reason for
not simply adopting the assessment
incorporating recovery time was that the
Agency has concerns that other aspects
of its exposure model tends to
understate exposure. If the assessment
using recovery time had suggested that
carbofuran risks may be acceptable, EPA
would have had to further examine how
exposure was assessed. However,
because both the assessment based on
24-hour exposure and the one
incorporating recovery time showed
carbofuran exposures to be well over the
safe level, EPA concluded that its
exposure assessment was reasonable. As
explained in the final rule,
incorporating Eating Occasion Analysis
and the 186-minute or 426-minute
recovery half-lives for carbofuran
resulted in a reduction in the risk
estimates for which food and drinking
water are jointly considered (i.e., Food
+ Drinking Water) by a factor of two or
more in some cases. But even though
the risk estimates from aggregate
exposure are reduced, they nonetheless
still substantially exceed EPA’s level of
concern for infants and children. Using
drinking water derived from the surface
water from the Idaho potato surface
water scenario, which estimated one of
the lowest exposure distributions,
aggregate exposures at the 99.9th
percentile ranged from 328% of the
aPAD under the scenario for which
infants rapidly metabolize carbofuran
(e.g., 186-minute half-life), to a high of
473% of the aPAD under the scenario
for which infants metabolize carbofuran
more slowly (e.g., scenarios in which a
426-minute half life is assumed). Either
way, the tolerances are unsafe.
Moreover, even accounting for the
estimated decreased risk from
accounting for carbofuran’s rapid
reversibility, for which recovery
between exposures is irrelevant. The
Agency remains concerned about the
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59670
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
risks from single eating or drinking
events, as illustrated in the following
example, based on an actual food
consumption diary from the CSFII
survey. A 4-month old male nonnursing infant weighing 10 kg is
reported to have consumed a total of
1,070 milliters (ml) of indirect water
over eight different occasions during the
day. The first eating occasion occurred
at 6:30 a.m., when this 4 month old
consumed 8 fluid ounces of formula
prepared from powder. The FCID food
recipes indicate that this particular food
item consists of approximately 87.7%
water, and therefore, 8 ounces of
formula contains approximately 214 ml
(or grams) of indirect water; with the
powder (various nutrients, dairy, soy,
oils, etc.) accounting for the remaining
12.3%. This infant also reportedly
consumed a full 8-ounce bottle of
formula at 12 p.m., 4 p.m., and 8 p.m.
that day. The food diary also indicates
that the infant consumed about 1
tablespoon of water (14.8 ml) added to
prepare rice cereal at 10 a.m., about 2
ounces of water (59.3 ml) added to pear
juice at 11 a.m., another 1⁄2 tsp of water
(2.5 ml) to prepare more rice cereal at
8:30 p.m.; and finally, he consumed
another 4 ounces of formula (107 ml) at
9:30 p.m.
The infant’s total daily water intake
(1,070 ml, or approximately 107 ml/kg/
day) is not overly conservative, and
represents substantially less than the
90th percentile value from CSFII on a
ml water/kg bodyweight (ml/kg/bw)
basis. As noted, carbofuran has been
detected in finished water at
concentrations of 4 ppb. For this 10 kg
body weight infant, an 8-ounce bottle of
formula prepared from water containing
carbofuran at 4 ppb leads to drinking
water exposures of 0.0856 micrograms
of active ingredient/kilogram of
bodyweight (μg ai/kg bw), or 114% of
the aPAD from that bottle alone. Based
on the total daily water intake of 1,070
ml/day (no reversibility), total daily
exposures from water at 4 ppb
concentration would amount to 0.4158
μg ai/kg bw, or 555% of the aPAD; this
is the amount that would be used for
this person-day in the Total Daily
Approach.
Peak inhibition occurs following each
occasion on which the infant consumed
8 fluid ounces of formula (6 a.m., 12
p.m., 4 p.m. and 8 p.m.); however, the
maximum persisting dose occurs
following the 9:30 p.m. eating occasion,
based on a 186-minute half-life
parameter. This produces a maximum
persisting dose of 0.1457 μg ai/kg bw, or
about 30% of the total daily exposure of
0.4158 μg ai/kg bw derived above, or
expressed as a fraction of the level of
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
concern, the maximum persisting dose
amounts to about 194% of the aPAD (or
30% of 554%). Note that with drinking
water concentration at 4 ppb, an infant
consuming one 8 oz bottle of formula—
prepared from powder and tap water
containing carbofuran at 4 ppb will
obtain exposures of approximately
114% of aPAD. Since many infants
consume the equivalent of this amount
on a single eating occasion, accounting
for reversibility over multiple occasions
is not essential to ascertain that infants
quite likely have obtained drinking
water exposures to carbofuran
exceeding the level of concern based on
drinking water concentrations found in
public drinking water supplies.
The approach discussed above is used
to evaluate the extent to which the
Agency’s 24-hour approach to dietary
risk assessment overestimates risk from
carbofuran exposure. The results of both
approaches indicate that the risk from
carbofuran is indeed not substantively
overestimated using the current
exposure models and the 24-hour
approach.
In this regard, it is important to note
EPA’s Eating Occasion Analyses
underestimate exposures to the extent
that they do not take into account carryover effects from previous days, and
because drinking water concentrations
are randomly picked from the entire 30year distribution. As discussed
previously, DEEM–FCID is a single day
dietary exposure model, and the DEEMbased Eating Occasion Analysis
accounts for reversibility within each
simulated person-day. All of the
empirical data regarding time and
amounts consumed (and corresponding
exposures based on the corresponding
residues) from the CSFII survey are
used, along with the half-life to assess
an equivalent persisting dose that
produced the peak inhibition expected
over the course of that day. This is a
reasonable assumption for food alone;
since the time between exposure events
across 2 days is relatively high
(compared to the half-life)—most
children (>9 months) tend to sleep
through the night—and the time
between dinner and breakfast the
following morning is long enough it is
reasonable to ‘‘ignore’’ persisting effects
from the previous day. A single day
exposure model will underestimate the
persisting effects from drinking water
exposures (formula) among infants, and
newborns in particular (<3 months),
since newborns tend to wake up every
2 to 4 hours to feed. Any carry over
effects may be important, especially if
exposures from the previous day are
relatively high, since the time between
the last feeding (formula) of the day and
PO 00000
Frm 00064
Fmt 4701
Sfmt 4700
the first feeding of the subsequent day
is short. A single day model also does
not account for the effect of seasonal
variations in drinking water
concentrations, which will make this
effect more pronounced during the high
use season (i.e., the time of year when
drinking water concentrations are high).
Based on these analyses, the Agency
concludes that the current exposure
assessment methods used in the
carbofuran dietary assessment provide
realistic and high confidence estimates
of risk to carbofuran exposure through
food and water.
In summary, there are several factors
that may cause EPA’s exposure/risk
model to either understate or overstate
exposure/risk. It is unreasonable to
present risks only incorporating factors
that tend to reduce exposure/risk
estimates (e.g., recovery time), as
Petitioners suggest. EPA’s approach of
evaluating the impact that these factors
may have on the risk assessment is an
appropriate method of taking all
relevant factors into account.
Petitioners’ objection to EPA’s policy
decision to present acute risks in terms
of 24-hours of exposure is therefore
denied because EPA’s policy approach
here is reasonable.
2. Objection/hearing request subissue:
Technical challenges to EPA’s
calculated half-lives. Petitioners
contend that EPA’s calculation of
carbofuran half-lives of 186 minutes and
426 minutes were flawed, and that the
data instead support the use of a 150minute half-life. Petitioners identify
three specific challenges: (1) Because
one of the time course studies showed
that the time-to-peak effect was one
hour, EPA’s assumption that the timeto-peak effect in each study was 15
minutes is incorrect; (2) EPA included
the control rats in its modeling, which
distorts the estimated recovery half-life
because it incorporates AChE from
animals that were not dosed and did not
need to recover; (3) Biochemically, the
recovery half-lives of all NMC chemicals
should be the same, which supports the
use of a 150-minute half-life. In support
of these claims, Petitioners offered a
summary of written testimony from Drs.
Sielken and Valdez-Flores (Exhibit 9)
and a published study (Exhibit 10).
i. Background. In the proposed rule,
EPA relied on half-lives of 150 minutes
and 300 minutes (73 FR 44887). These
values were calculated for the NMC
cumulative risk assessment and so were
intended to encompass the half-lives for
all of the NMC pesticides.
In the final rule, EPA calculated halflives specific to carbofuran to ensure
that its analyses accurately reflected
carbofuran’s risk. Using the two FMC
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
time course studies in rat pups EPA
calculated half-lives for recovery of 186
and 426 minutes (Id). The two values
were derived from two different studies
using rat pups of the same age (Refs. 24,
25); the two values provide an
indication that half-lives to recovery can
vary among juvenile rats. By extension,
children are expected to vary in their
ability to recover from AChE inhibition
where longer recoveries would be
associated with a potentially higher
‘‘persisting dose.’’
ii. Denial of hearing request. The issue
of the appropriate half-lives for
carbofuran is not material. Petitioners
have proffered no evidence to show that
reliance on a 150-minute half-life rather
than a 186-minute half-life would make
a significant difference to their
estimates. By contrast, in the risk
assessment supporting the final rule,
EPA’s estimates show that the use of a
150-minute or 186-minute half-life
makes little or no difference. For
example, EPA’s estimated exposures
from food alone for children 1–2 were
43% of the aPAD, assuming a 186minute half-life, and 41% of the aPAD,
assuming a 150-minute half-life.
Similarly, for infants, the estimates
ranged from 31% aPAD, assuming a
186-minute half-life, and 30% of the
aPAD, assuming a 150-minute half-life.
For all other age groups, the estimated
exposures were identical, whether one
assumed a 150-minute or 186-minute
half-life.
In any event, Petitioners’ objection
would have ultimately no effect on the
Agency’s conclusion that the carbofuran
tolerances are not ‘‘safe.’’ Given EPA’s
assessments showing that a single
exposure can result in excessive risks to
infants—a conclusion that Petitioners
have not challenged—the extent of
recovery between subsequent exposures
is irrelevant. This conclusion alone
provides an adequate basis to revoke the
carbofuran tolerances. Accordingly,
because the action would be the same
even if the factual issue were resolved
in the manner sought, this request does
not meet the standard for granting a
hearing (40 CFR 178.32(b)(3)).
There is yet a further consideration
affecting the materiality of this
objection. EPA’s recalculation of halflives in the final rule would ordinarily
mean that Petitioners could
appropriately challenge EPA’s
methodology for deriving the revised
half-lives for the first time in their
objections. This is because the
Petitioners would have had no prior
opportunity to challenge the manner in
which these estimates were developed,
as EPA had not previously relied on
carbofuran-specific estimates. However
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
in this case, the Petitioners never
commented on the 300-minute estimate
EPA used in the proposal, nor raised
any issue to challenge the reliance on a
longer half-life to account for the
variation in children’s sensitivity. For
the reasons discussed in Unit VI.D, they
have therefore waived any objection to
use of a 300-minute half-life.
Accordingly, the question of whether
the Petitioners’ half-life of 150-minutes
or EPA’s estimated half-life of 186minutes is immaterial, since the lower
amount of recovery associated with the
longer 300-minute half-life would be
expected to have a far greater impact
than the use of a 186-minute half-life.
EPA is also denying the hearing
request because the evidentiary proffer
in support of this objection is
inadequate. Petitioners have not
provided the underlying analyses
conducted in support of their calculated
half-lives. The remainder of Exhibit 9
consists of contentions that EPA’s
analyses were mistaken. In the absence
of the analyses that support their claim
that the data support a half-life of 150
minutes, Petitioners’ evidentiary proffer
consists of no more than mere
allegations and denials. Hearings will
not be granted on this basis (40 CFR
178.32(b)(2)) (See 73 FR 42706 (July 23,
2008) (‘‘NRDC does no more than state
‘[w]e are aware of no statistical test’
which would support EPA’s use of the
Gledhill data. As EPA’s regulations
make clear, a mere ‘denial’ of an EPA
position is not sufficient to satisfy the
standard for granting a hearing’’)
(citations omitted); 53 FR 53176, 53199
(December 30, 1998) (‘‘Rather than
presenting evidence [the objector]
asserts that FDA did not adequately
justify its conclusions. Such an
assertion will not justify a hearing.’’).
The published paper in Exhibit 10
does not cure this defect. The paper was
submitted to support the claim that the
Petitioners’ 150-minute half-life is
consistent with the ‘‘available literature
on the AChE recovery’’ (Obj at 32). This
evidence is immaterial. The Reiner
paper relates to the reactivation of the
AChE enzyme; however the relevant
issue is not the reactivation of the
cholinesterase enzyme, but the level of
chemical in that target tissue, which this
study does not address. Moreover, this
study concludes that ‘‘[I]t follows from
the data in Tables 1 and 2 that the rate
of spontaneous reactivation cannot be
predicted, but must be separately
determined for each compound and
each enzyme source (Exhibit 10 at 1).
The paper did not include data
specifically on carbofuran, and it is
therefore difficult to see how this could
PO 00000
Frm 00065
Fmt 4701
Sfmt 4700
59671
be argued to support the Petitioners’
half-life of 150-minutes.
iii. Denial of objection subissue. All of
Petitioners’ claims are incorrect.
Appropriate time to peak effect. The
Petitioners claim that the time to peak
effect in the study with MRID 47143704
(Ref. 2) should have been 1 hour instead
of the 15 minutes EPA calculated.
Petitioners chose this value simply by
choosing the data point with the highest
level of inhibition. But this approach is
flawed in a number of regards: First as
a practical matter, using the same
criteria on which the Petitioners rely,
the time to peak effect in MRID
46688913 (Ref. 3) is 15 minutes.
Petitioners have presented no basis for
excluding those results.
More significantly, the Petitioners’
approach fails to account for the
variability of the estimated AChE
activity at each time point. As a point
of background, the level of the highest
inhibition is not something that can be
observed, in the way that motor activity
is observed. To determine inhibition,
samples are taken and measured—the
samples may or may not capture the
highest point of inhibition; the
technician has not external indicia that
will determine the moment of the
‘‘peak.’’ Determining peak inhibition is
estimated based on the available
measurements. But because
measurements are generally variable—
the animals differ and the sampling
itself is not identical, as people cannot
perfectly replicate their actions time
after time—in order to accurately
capture the peak levels, the variability
needs to be accounted for. When, as
here, the individual values are quite
variable, then for a half-life as long as
carbofuran’s, the sampling variability
will make the study means bounce up
and down around a trend line
representing the true recovery rate.
Figure 2 illustrates the sampling
variability of the measured AChE
activity and its relationship to EPA’s
modeling estimates for PND11 pups. In
brief, this plots observed versus
predicted for all the data. Each little
point is an individual animal, while the
time-group mean is the larger version of
the same plotting symbol. The vertical
lines are the 95 percent confidence
intervals for each mean, the vertical
lines. The diagonal line in each figure
is the identity line—i.e., the line all the
data would fall on if there were no
variability and the model were perfect.
Normally, one would expect some
random scatter about the identity line.
In such a case, simply visually picking
the time with the lowest mean, which
is what the Petitioners have done, will
E:\FR\FM\18NOR2.SGM
18NOR2
59672
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
Inclusion of data from control
animals. It is standard scientific practice
to include concurrent control animals
(i.e., animals that are not dosed with the
test substance) as part of any
experimental design. The purpose of
controls is to determine the effects of
the inevitable, unexpected, and
uncontrolled variations in experimental
practice, such as the biological variation
between individual living animals.
EPA’s model simply used control levels
to establish a baseline against which to
evaluate the recovery of the treated
animals. For example, as discussed
above, measurements of AChE activities
may change, and that concurrent
controls are set up so that the same nondose-related factors that affect treated
animals will also affect control animals.
Thus, EPA measured activity and
computed inhibition based on measures
of activity in treated animals and
concurrent control animals. Thus, if the
control animals showed that measured
levels of AChE typically varied by 5
percent, if the dosed animal showed
inhibition levels of 20 percent, EPA
would consider that only 15 percent of
the inhibition would be related to the
chemical exposure. EPA did not
estimate a half-life of recovery for the
control animals and incorporate that
into the estimated half-lives, which
seems to be the Petitioners’ allegation.
Biochemically, the recovery half-lives
of all NMC chemicals should be the
same. Although the Petitioners’ claim
that the recovery rate of AChE inhibited
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
by carbamate compounds is dictated by
the commonly-shared NMC carbamyl
group is theoretically plausible, in
reality, it is not supported by the data
on the NMC compounds. EPA had
originally hoped, based on the same
mechanistic argument Petitioners make,
that half-lives would be the same across
all NMCs, thus greatly simplifying the
cumulative risk assessment. It turned
out, though, in the NMC data sets
analyzed for the NMC cumulative risk
assessment, that estimated recovery
half-lives changed (generally, they got
longer) as dose increased, which is
counter to the results that would be
predicted from the Petitioners’ simple
mechanistic argument (Ref. 81).
Ultimately, this is due to the fact that
the relevant question is not the abstract
reactivation of the cholinesterase
enzyme, but the level of chemical in the
living animal’s target tissue, which is a
function both of the pharmacokinetics
of the NMC (i.e., the rate at which the
chemical is absorbed, distributed among
tissues, and eliminated) in the animal
and the rate of hydrolysis of the leaving
group off the AChE molecule. These
parameters vary at least somewhat for
the different carbamates, accounting for
the differences in half-lives between the
NMC pesticides.
H. Objection to EPA’s Decision Not To
Rely on Carbofuran Human Study
Petitioners object to EPA’s reliance on
a default 10X interspecies factor, which
accounts for the uncertainties inherent
in extrapolating from animal data to the
PO 00000
Frm 00066
Fmt 4701
Sfmt 4700
anticipated effects in humans. They
argue, for several reasons, that EPA
should have instead used a 3X
interspecies factor. All of their
arguments, however, depend on EPA
consideration of an oral carbofuran
dosing study conducted in humans.
EPA did not rely on the cited human
study because it found, taking into
account the advice of the HSRB, that the
study was scientifically invalid. EPA’s
Human Research rule prohibits EPA
from considering scientifically invalid
human studies (40 CFR 26.1701). In
their objections, Petitioners argue that
the HSRB’s, and presumably EPA’s,
evaluation of the scientific validity of
the human study was flawed because (1)
the human study was not considered in
light of the animal data on carbofuran;
(2) insufficient weight was given prior
independent reports on the value of the
Arnold study which reached the
opposite conclusion from the HSRB; (3)
the ‘‘technical’’ concerns raised by the
HSRB are addressed by ‘‘the data within
the study’’ and that these ‘‘technical’’
deficiencies do not render the Arnold
study unreliable.
1. Background. There are three
intentional dosing human studies
conducted with carbofuran that were
conducted by J.D. Arnold in 1976, 1977,
and 1978. One study was an oral
ingestion toxicity study and two studies
were intended to evaluate toxicity from
dermal exposure (Refs. 7, 8, 9). The oral
study conducted with carbofuran was
carried out in nine healthy male
E:\FR\FM\18NOR2.SGM
18NOR2
ER18NO09.001
pwalker on DSK8KYBLC1PROD with RULES2
not be a very reliable way to estimate
the time to peak effect.
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
volunteers using an ascending dose
schedule and single doses of 0.05, 0.1
and 0.25 mg/kg (Ref. 7). The two dermal
toxicity studies were found to have
significant ethical deficiencies and the
EPA’s Human Studies Review Board
recommended against their use. The
Petitioners do not challenge the
decision to disregard these studies.
As previously noted, EPA did not rely
upon any of the existing intentional
dosing human toxicity study deriving an
acceptable level of exposure for
carbofuran. Instead, EPA relied on data
conducted with rats, and applied the
default 10 × interspecies factor to
account for the potential uncertainty in
extrapolating from animal data. EPA’s
decision not to rely on the Arnold
studies was made pursuant to its
Human Research rule. As explained in
Unit III.B, that rule establishes different
ethical standards for the review of
completed human studies depending on
whether they were initiated before or
after the effective date of the rule on
April 7, 2006. For an intentional human
exposure study such as the Arnold
studies, that was initiated prior to April
7, 2006, EPA is barred, subject to a very
limited exception, from relying on it if
there is clear and convincing evidence
that the conduct of the research was
fundamentally unethical or significantly
deficient with respect to the ethical
standards prevailing at the time the
research was conducted (40 CFR
26.1704, 26.1706). Further, the rule
limits the human research that can be
relied upon by EPA to ‘‘scientifically
valid and relevant data’’ (40 CFR
26.1701). Finally, because the Arnold
study was conducted with the purpose
of identifying or measuring a toxic
effect, EPA is required by the rule to
submit its determination regarding these
issues to an independent expert
advisory body known as the Human
Studies Review Board (‘‘HSRB’’) for
review. These procedures were followed
with regard to the Arnold study.
The HSRB reviewed the Arnold oral
and dermal carbofuran human studies at
its May, 2006 meeting (Refs. 7, 8, 9). The
Board found numerous technical
deficiencies regarding the conduct of
the oral study and that overall, the
weaknesses of the studies far outweigh
the strengths. These deficiencies
included: (1) There was no justification
or rationale for the selection of doses
used in any of the three studies. (2) The
sample size was very small (typically
two subjects per dose or condition) with
few or no controls (no more than two
control subjects in any study). Such a
design prevented evaluation of
statistical significance for any parameter
measured in the studies. (3) The values
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
obtained for RBC and plasma
cholinesterase levels were highly
variable. Factors that contributed to this
variability included the small sample
size, the inclusion of only a single
baseline sample collected immediately
prior to dosing used to compare all postdosing samples, the small number of
control subjects, and an uncommon
method for analytical determination of
cholinesterase activities. The
contribution of potential laboratory
error cannot be ruled out. (4) Plasma
cholinesterase levels were highly
variable in all studies so as to preclude
any useful interpretation. In general,
plasma cholinesterase levels were not
consistent with changes in RBC
cholinesterase activities. (5) One subject
who presented with abnormal vestibular
mechanisms in the pre-dose evaluation
was used in the oral study and showed
serious symptoms after treatment. (6)
Subjects were allowed to smoke during
the study period.
In response to a specific request from
the Agency, the Board provided
additional analysis concerning the
potential for the data in human subjects
for carbofuran to be applied to: (1) The
calculation of a benchmark dose
(BMD10) and identification of the
BMD10L (lower confidence limit); (2) the
identification of a NOAEL or LOAEL for
effects or (3) the comparison to other
species for possible adjustments to
uncertainty factor for the cumulative
assessment. The HSRB provided the
following additional perspective relative
to the Agency’s question:
The utility of the human studies with
carbofuran was limited by the very small
sample size used in all of the studies. The
Agency proposed to use the RBC
cholinesterase data for determination of the
BMDL10. However, under conditions where
the group size was only two, it would be
imperative to have highly accurate, valid,
reliable and consistent measures of RBC
cholinesterase activity in both control and
carbofuran-treated subjects. This rigor was
simply not achieved in the human studies.
Rather, RBC cholinesterase activities were
compared to a single baseline value, were
highly variable across subjects, including
controls, and did not show any consistency
with plasma cholinesterase levels. As such,
although EPA scientists calculated a BMDL10
from the time course of changes in RBC
cholinesterase values in the nine subjects
evaluated in the oral study, the HSRB
concluded that the accuracy and reliability of
this calculation was limited by the technical
shortcomings noted for the study. Therefore,
the HSRB reiterated its recommendation that
the BMDL10 calculated by the Agency from
the human data should not be used.
In a similar manner, the small sample size,
compounded by the lack of consistent
changes in cholinesterase activities in all
studies, the inappropriate methods used for
PO 00000
Frm 00067
Fmt 4701
Sfmt 4700
59673
dermal application of the compound in the
dermal studies and the inclusion of at least
one subject who presented with abnormal
vestibular function in a pre-dose assessment
limited the general utility of the data.
Collectively, the weaknesses in the conduct
and outcomes of the carbofuran human
studies cast doubt on the utility of the data
for identifying a NOAEL or LOAEL or for
comparing across species in consideration of
the interspecies uncertainty factor for the
cumulative risk assessment. Thus the
majority of HSRB members agreed the human
oral data should not be used to identify a
NOAEL or LOAEL, and there was unanimous
agreement that the human dermal data
should also not be used for these evaluations.
The HSRB concluded that while these
studies were informative, due to the
numerous technical issues regarding the
conduct of the oral study, overall, the
weaknesses of the studies far outweigh
the strengths. Describing the studies as
‘‘poor science,’’ the HSRB
recommended against the use of the oral
study conducted with carbofuran in
human subjects for the single chemical
assessment or in informing the
interspecies uncertainty factor for the
cumulative assessment.
In their comments opposing EPA’s
proposal to revoke carbofuran
tolerances, Petitioners essentially raised
the same arguments they present in
their objections.
In responding to Petitioners’
comments, EPA explained that it agreed
with the HSRB’s conclusions that the
studies were scientifically flawed, and
that, therefore, under the Human
Research rule, EPA was barred from
considering them (Ref. 85 at 9).
2. Denial of hearing request. The
critical issue here is EPA’s
determination under the Human
Research rule that the Arnold study was
scientifically invalid. All of Petitioners’
arguments concerning the choice of the
interspecies safety factor rely on EPA’s
consideration of the Arnold study. As
noted above, Petitioners make three
arguments as to why EPA erred in its
determination. For the reasons
discussed below, none of those
arguments satisfy the regulatory
standard for granting a hearing. Further,
as explained in Unit VI.H.3., Petitioners’
objections to EPA’s determination have
no merit. Thus, there is no need to
consider Petitioners’ more general
arguments about EPA’s decision to use
a 10X interspecies factor in assessing
carbofuran’s risk.
Petitioners’ first argument as to why
EPA erred in its determination that the
Arnold study was scientifically invalid
is that EPA failed to consider the animal
data on carbofuran in assessing the
scientific quality of the Arnold study.
This claim is not material and thus not
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59674
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
appropriate for a hearing (40 CFR
178.32(b)(3)). Under the Human
Research Rule, the relevant question is
whether the Arnold study is
scientifically valid, not whether
consideration of the Arnold study in
conjunction with the animal data could
justify a lower interspecies factor. EPA,
and the HSRB, found the Arnold study
to be flawed at its core—due primarily
to its small sample size and the high
variability in measurement of AChE
inhibition—and no amount of data from
other studies in animals can cure these
defects in the Arnold study. Thus,
Petitioners’ claim here is irrelevant and
immaterial to EPA’s decision.
Ultimately, Petitioners’ objection is a
challenge to the policy established in
the Human Research rule that EPA will
not routinely consider all human data.
They contend that ‘‘[s]ince [human] data
exist for carbofuran, they should have
been used to select the interspecies
uncertainty factor.’’ However, this
policy question is not open for debate
under the terms of the Human Research
rule. And more importantly, such a
question does not provide a basis for a
hearing (40 CFR 178.32(b)(1)).
Second, Petitioners argue that
insufficient weight was given the prior
independent reports on the Arnold
study. However, the weight EPA should
give under the Human Research rule to
pre-rule independent reviews as
opposed to the conclusions of the
HSRB—the body established by the rule
for the purpose of aiding EPA’s
implementation of it—is a legal/policy
question and not a factual one. Hearings
will not be granted on legal/policy
issues (40 CFR 178.32(b)(1)).
Finally, Petitioners’ claims that EPA
and the HSRB identified merely
‘‘technical’’ deficiencies in the Arnold
study and that these deficiencies are
‘‘address[ed]’’ by ‘‘data within the study
itself’’ and, therefore, do not render the
study ‘‘unreliable’’ are no more than
mere allegations and thus provide an
insufficient basis for the granting of a
hearing (40 CFR 178.32(b)(2)).
Petitioners have proffered no evidence
regarding the ‘‘technical’’ nature of the
deficiencies in the Arnold study or how
the deficiencies in sample size or
variability are addressed within the
study. Moreover, the record is clear that
the deficiencies in the study are
fundamental in nature and a hearing
will not be granted on bald objections
that are contradicted by the record (73
FR 42696 (July 23, 2008) (hearing
denied when objection was contradicted
by record and no evidence proffered in
support)).
3. Denial of objection. Petitioners
have offered no response to EPA’s
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
explanation for accepting the HSRB’s
reasoning as to the weaknesses of the
studies that rendered them scientifically
invalid. Specifically, Petitioners do not
address the HSRB’s conclusion, adopted
by EPA, that ‘‘the weaknesses in the
conduct and outcomes of the carbofuran
human studies cast doubt on the utility
of the data for * * * comparing across
species in consideration of the
interspecies uncertainty factor.’’ Nor do
Petitioners offer any reason as to why
the HSRB’s conclusion is not
‘‘justifiable’’ in light of the individual
peer review reports from Drs. Brimijoin,
Chambers, and Pope. Actually, there are
several very good reasons for EPA to
place primary weight on the HSRB’s
report compared to the three individual
reports from Drs. Brimijoin, Chambers,
and Pope prepared in 1997. First, the
prior reports were not produced under
the rubric of the Human Research rule,
which has a different scope of inquiry
than a traditional peer review. Second,
Drs. Brimijoin, Chambers, and Pope
made their recommendation regarding
use of the Arnold study for a RfD in the
context of a very different overall
database for carbofuran. A significant
number of new toxicity studies have
been submitted since 1997. Third, Drs.
Brimijoin, Chambers, and Pope all noted
the severe deficiencies in the Arnold
study but proposed that they be dealt
with through the use of additional safety
factors. Given these considerations it
was reasonable for EPA to place primary
reliance on the HSRB’s report.
The bulk of Petitioners’ argument
concerning EPA’s determination on the
scientific validity of the Arnold study is
devoted to suggesting that the HSRB’s
review of the Arnold study was
somehow ‘‘inadequate’’ because two
members of the HSRB (Drs. Brimijoin
and Chambers) were recused from the
review due to their prior participation
in a prior independent peer review.
Petitioners also assert that the HSRB
was hampered because EPA ‘‘never
informed the HSRB that it could call
upon these experts for questioning or
information regarding their prior peer
review of the human studies, nor was it
informed of—or provided with—those
prior reviews.’’
These claims are wholly without
merit. As laid out in a letter responding
to FMC’s complaint regarding the
recusal of Drs. Brimijoin and Chambers
from the HSRB review of the carbofuran
human studies, the recusal was entirely
appropriate, and consistent with EPA’s
policies and regulations. The facts
outlined in that letter also demonstrate
that the HSRB’s review was in no way
restricted or hampered by the limited
recusal of the two Board members.
PO 00000
Frm 00068
Fmt 4701
Sfmt 4700
First, the HSRB was fully apprised of
the earlier peer review reports. EPA
relied on the reports because EPA’s
position before the HSRB was that the
Arnold study should be found to meet
the standard of the Human Research
rule and would be useful in establishing
points of departure for the carbofuran’s
single chemical assessment and in
informing the interspecies uncertainty
factor for the NMC CRA. It was clearly
in EPA’s interest that the HSRB be made
aware of the earlier reports. In fact, the
background materials provided to the
Board included the peer review reports
by Drs. Brimijoin, Chambers, and Pope,
and the Agency’s Weight-of-theEvidence presentation to the HSRB
which noted the contributions of these
reviewers. Further, both the peer review
reports and EPA’s Weight-of-Evidence
presentations were included in the
public docket for the HSRB review. To
the extent that the HSRB was still
somehow unaware of the prior reports,
FMC clearly referenced them in both its
written and oral comments to the Board.
Second, EPA’s determination on the
recusal of Drs. Brimijoin and Chambers
was clearly consistent with Agency
policy and well with EPA’s discretion.
The EPA’s Peer Review Handbook (3rd
Edition) (Ref. 80) provides guidance
about peer review processes of the
Agency. Of particular relevance is the
Handbook’s guidance regarding
independent peer reviewers. While the
Handbook notes that there is no
prohibition against using the same peer
reviewer more than once on the same
product, it nevertheless advises that ‘‘it
is preferable to use different people each
time to provide a broader perspective
(Ref. 80 at 13). Further the Handbook
advises that the review of experts who
‘‘have participated substantially in the
development of a product * * * may
not qualify as unbiased, independent
peer review * * *’’ (Id.). Therefore,
EPA concluded that, under the
circumstances, a question could be
raised regarding the impartiality of Drs.
Brimijoin and Chambers from the
particular matter under review by the
HSRB. Further support on this point can
be found in the regulations at 5 CFR
2635.502(a)(2), and in the preamble to
the original regulation (56 FR 33778
(July 23, 1991)).
In light of these considerations, EPA
addressed the appearance issue
regarding Drs. Brimijoin and Chambers
by determining whether authorization
by the Agency designee should be
invoked (see, 5 CFR 2635.502(d)). Three
factors were particularly relevant to the
determination of Drs. Brimijoin and
Chambers (see, 5 CFR 2635.502(d)(4),
(5), and (6)): the sensitivity of the
E:\FR\FM\18NOR2.SGM
18NOR2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
pwalker on DSK8KYBLC1PROD with RULES2
matter, the difficulty of reassigning the
matter to another employee, and
adjustments that may be made in the
employee’s duties that would reduce or
eliminate the likelihood that a
reasonable person would question the
employee’s impartiality. After
considering these factors, the Agency
decided the prudent course was be to
recuse Drs. Brimijoin and Chambers
from the HSRB carbofuran discussion
but to authorize limited, as needed,
participation.
As documented in Dr. William
Farland’s May 1, 2006 memorandum
entitled, ‘‘Ethics Determination for
Participation at the May 2–3, 2006 EPA
Human Studies Review Board Meeting’’
(Ref. 39), EPA authorized the HSRB to
ask Drs. Brimijoin and Chambers
clarifying questions regarding their 1997
review, in the event that the HSRB
deemed it necessary as part of their
deliberations. At no point during the
meeting did any of the HSRB’s members
indicate in any way that they wanted to
consult with their recused colleagues.
Nor did any of the members state that
they wanted clarification on any point
associated with the study.
For all of the above reasons,
Petitioners’ objection on this point is
denied.
I. Objections to Revocation of Import
Tolerances
Petitioners object to EPA’s revocation
of the tolerances for imported foods
along with the tolerances associated
with domestic uses. Petitioners allege
that the revocation of the import
tolerances is not supported by the
available data because EPA’s own risk
assessments conclude that, when
considered separately from the domestic
uses, the residues from imported foods
covered by these tolerances are ‘‘safe.’’
Petitioners further argue that EPA ‘‘has
not asserted any claim or rationale in
the Final Order justifying its
conclusions that the import tolerances
are unsafe’’ and therefore the revocation
is unjustified.
1. Background. In the proposed rule,
EPA explained that its finding that
aggregate exposure from all of the
existing uses of carbofuran is not safe
does not necessarily mean that no
individual tolerance or group of
tolerances could meet the FFDCA
408(b)(2) safety standard and be
maintained (73 FR 44865 (July 31,
2008)). Rather, to the extent parties
wanted to retain a particular subset of
existing tolerances, the onus was on
commenters to identify those uses and
to submit information to demonstrate
that the tolerance(s) meet the statutory
standard. Indeed, EPA specifically
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
identified the import tolerances as a
subset that might meet the safety
standard (Id.).
No one submitted any comments
alleging the need to retain individual
tolerances for purposes of imports, or
indicated an intention to seek to
maintain those tolerances. The only
subset of tolerances that commenters
suggested was safe was the subset
identified by the Petitioners, which
included the import tolerances along
with four domestic food uses.
In the final rule, EPA analyzed the
aggregate exposures from the subset of
tolerances the Petitioners sought to
retain, and concluded that the aggregate
residues from food covered by those
tolerances and from residues in drinking
water are unsafe (74 FR 23084–23088).
2. Denial of hearing request. A
hearing is denied on this subissue
because there is no disputed factual
matter for resolution at a hearing. As the
objection notes, EPA and Petitioners’
risk assessment both concluded that the
residues from imported food alone fell
within the risk cup (Obj. at 52–54). The
only issue this objection raises is
whether EPA should have
independently determined to retain a
subset of the tolerances that Petitioners
sought to maintain. This is a legal issue,
and hearings are not appropriate on
such issues (40 CFR 178.32(b)(1)). (See
73 FR 42696–42697 (July 23, 2008)
(denying NRDC’s request for a hearing
on objection that children’s safety factor
could not be reduced in absence of
endocrine screening data). FDA also has
repeatedly confirmed that the
application of a legal standard to
undisputed facts is a question of law for
which a hearing is not required. (See,
e.g., 68 FR 46403, 46406 n.18, 46408,
46409 (August 5, 2003) (whether facts in
the record show there is a reasonable
certainty of no harm is a question of
law; whether a particular effect is a
‘‘harm’’ is a question of law)).
In addition, Petitioners failed to raise
this issue as part of their comments on
the proposed rule, and never requested
retention of only the import tolerances.
Accordingly, as discussed in Unit VI.D,
EPA considers this issue to have been
untimely raised, and therefore waived.
(See, 73 FR 42,696 (July 23, 2008)
(denying NRDC’s hearing request on
claims not presented in their original
petition); 72 FR 39318, 39324 (July 18,
2007) (ruling that parties may not raise
new issues in filing objections to EPA’s
denial of original petition)).
3. Denial of Objection. Petitioners
incorrectly allege that EPA provided no
rationale for the revocations of the
import tolerances. In the final rule, EPA
clearly found that the aggregate
PO 00000
Frm 00069
Fmt 4701
Sfmt 4700
59675
exposures to carbofuran residues from
all remaining uses, when combined
with residues found in drinking water,
were unsafe (74 FR 23084–23088 (May
15, 2009).
EPA can only maintain tolerances that
it can determine will be ‘‘safe’’ within
the meaning of section 408(b)(2)(A)(ii).
In making this determination, EPA must
consider aggregate exposures from
‘‘dietary exposure under the tolerance
and all other tolerances in effect for the
pesticide chemical residue, and
exposure from other non-occupational
sources’’ (21 U.S.C. 346a(b)(2)(D)(vi)).
At the time of the final rule, EPA
evaluated the safety to the public from
all dietary exposures to residues of
carbofuran, which included not only the
import tolerances, but also from
residues on foods associated with
domestic registrations and from residues
in drinking water contaminated by the
domestic uses. Indeed, until domestic
use ceases—or at least until EPA has a
reasonable basis to believe that it will
cease—the Agency has no discretion to
ignore the exposures from those uses.
And revocation of the tolerances
themselves does not necessarily resolve
the issue, given the circumstances here.
Until the registrations are cancelled,
residues from contaminated drinking
water, which is the primary contributor
to the risks, must be included in EPA’s
risk assessment (Id).
The consequence of this requirement
is that, when one tolerance is unsafe, all
tolerances are equally unsafe until
aggregate exposures have been reduced
to acceptable levels. Accordingly, in
circumstances where aggregate
exposures exceed the risk cup, there are
potentially multiple variations of the
potential subset of tolerances that might
meet the safety standard. FFDCA section
408 does not compel EPA to determine
the appropriate subset that would meet
the safety standard. EPA is compelled
‘‘to revoke or modify a tolerance if
[EPA] determines it is not safe,’’ but the
statute grants EPA the discretion to
determine how to proceed where more
than one tolerance is unsafe. EPA’s
general policy in such situations is not
to independently select the subset that
meets the standard, but to rely on the
pesticide registrant and the public to
determine which of the various subsets
of tolerances are of sufficient
importance to warrant retention. There
are a number of reasons EPA adopted
this policy; it would be an unreasonable
burden for the Agency to evaluate every
possible combination of tolerances that
might fit within the risk cup. In
addition, if there were multiple different
combinations that might within the risk
cup, it is not clear that any party would
E:\FR\FM\18NOR2.SGM
18NOR2
59676
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
pwalker on DSK8KYBLC1PROD with RULES2
agree that EPA had selected the
appropriate combination of tolerances.
This is particularly relevant, since EPA
relies on individual entities to maintain
the tolerance, by continuing to submit
necessary data to demonstrate the
continuing safety of the covered
residues.
J. Summary of Reasons for Denial of
Petitioners’ Objections and Hearing
Requests
1. General Denial. All of Petitioners’
objections and hearing requests are
denied because they are irrelevant, and
thus immaterial, to EPA’s final
regulation revoking carbofuran
tolerances. The lack of relevance stems
from Petitioners’ decision to object not
to the safety decision EPA made in its
final revocation regulation but to
instead argue that EPA should reach a
different decision based on FMC’s
proposed changes to the carbofuran
registration that were submitted to EPA
44 days after the regulation published in
the Federal Register. These proposed
registration changes are central to and
inextricably intertwined with the
contention that underlies all of
Petitioners’ objections—that the
carbofuran tolerances are safe, because
in order to retain the contested
tolerances, Petitioners must succeed on
all of their objections. There exist
statutory and regulatory procedures
under FIFRA for FMC to pursue an
amended carbofuran registration. As
part of seeking an amended registration,
FMC may petition to reestablish the
revoked carbofuran tolerances.
However, it is not proper to object to a
final FFDCA tolerance revocation
regulation based on the assertion that
subsequently-filed, and as of yet
unapproved FIFRA registration
amendments, may change the risk
picture under the FFDCA.
FMC has had ample opportunity prior
to issuance of the final tolerance
revocation regulation to amend its
FIFRA registration, whether during the
comment period on the proposed rule,
the extended reregistration process, or
the public process initiated as part of
the NOIC for carbofuran. And FMC has
requested a number of modifications to
its registrations during that time period.
Yet, FMC has waited until EPA issued
a final revocation regulation finding that
carbofuran tolerances are unsafe,
particularly as to infants and children,
before filing its latest series of proposed
FIFRA registration amendments. For
this FFDCA proceeding, that is too late.
The FFDCA commands that EPA ‘‘shall
modify or revoke a tolerance if the
Administrator determines it is not safe’’
(21 U.S.C. 346a(b)(2)(A)(i)). The statute
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
also places EPA under a special
injunction to protect infants and
children from the risks of pesticides (21
U.S.C. 346a(b)(2)(C)). EPA has made a
final determination that carbofuran
tolerances are unsafe and further
determined that that lack of safety falls
hardest on infants and children.
Petitioners had the statutory right under
FFDCA to challenge the accuracy of
EPA’s safety finding on carbofuran
tolerances. FMC also has the statutory
right under FIFRA to request
amendment of its registration. What
Petitioners may not do is prolong the
FFDCA tolerance revocation process by
challenging EPA’s safety determination
based on proposed FIFRA registration
changes that were not before EPA at the
time of its final revocation decision.
2. Alternate Grounds for Denial.
Despite the fact that Petitioners’
objections and hearing requests are
facially defective for reliance on newlyproposed FIFRA registration
amendments, EPA has carefully
examined each of Petitioners’ objections
and hearing requests and found that, in
every instance, there are alternate
grounds for denial. Those grounds are
summarized below.
There are multiple problems with
Petitioners’ hearing requests. Many of
these problems stem from the
Petitioners’ decision to withhold
analyses and information from the
notice-and-comment rulemaking portion
of this proceeding. Thus, despite EPA’s
clear warning that issues not raised in
comments on the proposed rule, and
information not submitted in that same
timeframe, would be considered
waived, Petitioners included several
new issues, and numerous documents
and analyses for the first time with their
objections although they were clearly
available earlier. Petitioners also have,
for the most part, ignored how EPA
responded to the comments they did
submit in the notice-and-comment
rulemaking, and instead have often
merely recycled their earlier comments
as objections without addressing the
reasons why EPA found them lacking in
the first instance. This strategy,
unfortunately for Petitioners, is fatal to
many of their hearing requests and
objections. EPA will not grant hearings
on issues that have been waived, on
issues where supporting documents
were untimely submitted, or on claims
that have become stale in that EPA
addressed them in the final rule and
Petitioners have not responded by
clarifying where disputed issues still
remain.
It is not as if Petitioners lacked
warning that EPA would take such an
approach. Not only did EPA clearly
PO 00000
Frm 00070
Fmt 4701
Sfmt 4700
state in the proposed rule that
comments and information must be
submitted in the comment period to be
preserved but in 2007 EPA denied a
hearing to a party who treated the
notice-and-comment rulemaking
process in a similarly cavalier fashion.
In that instance, the party in question,
like Petitioners, filed objections that
largely mirrored its earlier submissions
to the Agency without taking into
account how EPA’s final action had
altered the nature of issues in dispute
(See, e.g., 73 FR 42693 (‘‘NRDC’s
objections largely restate the claims in
its petition. Significantly, NRDC does
not acknowledge or respond to the
DDVP dietary and residential risk
assessments made in response to the
NRDC petition.’’)). Such objections and
hearing requests were denied for a lack
of materiality (73 FR 42698–42699
(‘‘When an objector does not challenge
EPA conclusions in the section
408(d)(4)(iii) order but rather challenges
some prior conclusion that was
superseded by the section 408(d)(4)(iii)
order, the objector has not raised a live
controversy as to an issue material to
the section 408(d)(4)(iii) order.’’).
a. Children’s Safety Factor Objection.
In support of their objection on the
children’s safety factor, Petitioners put
forward several arguments; EPA
summarizes below the various reasons
for rejecting Petitioners’ hearing
requests and objections on each
argument. Given the voluminous
number of arguments asserted by
petitioners in support of this objection,
it is easy to lose track of the fact that all
of the arguments relate to a single
decision by EPA—the decision to
reduce the presumptive 10X children’s
safety factor to 4X, rather than to 1X or
2X as the Petitioners desire.
(i) Subissue: Are brain AChE
measures in juveniles adequately
protective of CNS effects in juveniles?
EPA based its determination to reduce
the children’s safety factor to 4X on the
ratio of sensitivity shown between
carbofuran’s effects on RBC AChE and
brain AChE in juvenile rats. It is EPA’s
general policy to rely on RBC AChE as
a surrogate for effects on the PNS but
Petitioners failed to provide adequate
RBC AChE data in juveniles to fully
characterize the dose level of concern
for PNS effects in infants and children.
Petitioners claim EPA was wrong from
the start. They claim that once EPA
determined it had adequate data on
brain AChE, the RBC data was irrelevant
because brain AChE is an adequatelyprotective surrogate for PNS effects.
Petitioners’ hearing requests and
objections on this issue are denied for
identical reasons: the available evidence
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
identified by petitioners is ‘‘insufficient
to justify the factual determination
urged’’ (40 CFR 178.32(b)(2)). The
critical issue with regard to EPA’s
children’s safety factor decision is
whether EPA has reliable data to ensure
that residues of carbofuran in food will
not cause adverse effects on infants and
children’s PNS. Petitioners claim that
carbofuran data on brain AChE in
juveniles is such reliable data. However,
the evidence they proffer to support
such an assertion is facially insufficient.
Primarily, Petitioners cite data involving
comparisons of brain AChE and PNS
effects in adult animals. But evidence
from adult animals is beside the point;
the question is whether brain AChE in
juveniles is protective of the PNS in
juveniles. For at least 25 years, EPA has
required toxicity tests be performed
with pre- and post-natal animals as well
as adult animals because young animals
can be more sensitive and affected in a
different manner than adults. Further,
the only studies Petitioners cite that
compared brain AChE in juveniles with
PNS effects in juveniles, were
conducted using other pesticides. For
good reason, EPA requires that
pesticides be individually tested in
toxicity studies. Moreover, the majority
of the data cited by Petitioners in other
chemicals actually fails to demonstrate
that the brain is more sensitive than the
PNS, and the remainder of the evidence
is, at best, merely equivocal on this
point.
To reiterate, if EPA chooses to select
a children’s safety factor different than
10X, it bears the statutory burden of
showing that reliable data support its
determination that the selected factor is
safe for infants and children. Thus,
Petitioners, in seeking to establish that
EPA erred by not selecting an even
lower children’s safety factor for
carbofuran (in fact, no such factor at all),
similarly bear the burden of showing
that there are reliable data for the
proposition that juvenile brain AChE
data for carbofuran are protective of
PNS effects in children. Petitioners’
equivocal and largely irrelevant proffer
cannot meet that standard, particularly
where EPA is lacking data it has
traditionally-required on cholinesteraseinhibiting pesticides to protect against
PNS effects, and the data EPA does have
on measures of PNS effects indicate that
effects on the juvenile PNS occur at
lower doses than effects on brain AChE.
(ii) Subissue: Are RBC AChE measures
adequately reliable evidence of CNS
effects? As a corollary to their claim that
brain AChE measures are adequately
protective of PNS effects, Petitioners
also argue that RBC is not an
appropriate surrogate for CNS effects in
VerDate Nov<24>2008
17:53 Nov 17, 2009
Jkt 220001
most circumstances. A hearing is not
warranted on this subissue because
Petitioners’ evidentiary proffers either
concern matters of undisputed fact (e.g.,
RBC AChE inhibition is not an adverse
effect, RBC AChE can be variable at low
doses) or inadequate and irrelevant data
on other pesticides. Further, Petitioners’
claim basically reduces to an argument
over which is the ‘‘preferred’’ surrogate
for PNS effects in the absence of data
directly measuring such effects. Thus,
this subissue is an argument about
science policy and EPA’s regulations are
clear that hearings will not be held on
policy matters. Even more problematic
to Petitioners’ hearing request on this
subissue is its lack of materiality.
Having failed in the previous subissue
to proffer sufficient evidence to show
carbofuran brain AChE data in juveniles
is protective of carbofuran’s effect on
the PNS in juveniles, Petitioners’
attempt to attack EPA’s basis for
addressing carbofuran’s effects on the
PNS in juveniles can only undercut
Petitioners’ ability to demonstrate the
safety of the carbofuran tolerances. With
the demise of Petitioners’ brain AChE
argument, EPA’s analysis of the RBC
AChE data is the only remaining basis
for reducing the children’s safety factor.
If Petitioners are successful in showing
that RBC AChE data are not a reliable
measure of PNS effects in juveniles,
EPA would have no reliable data on
such impacts and would be required to
retain the full children’s safety factor.
As such, Petitioners’ claim is
immaterial; even if the claim were
upheld, it would not justify the ultimate
relief sought by Petitioners.
As to Petitioners’ objection to EPA’s
science policy decision to use RBC
cholinesterase as a surrogate for PNS
effects, EPA explains in detail in Unit
VI.E, the biological basis for its policy
decision, the multitude of data
supporting its approach, and the
frequent consultations with the SAP
concerning the wisdom of using such an
approach. The equivocal data submitted
by Petitioners does not raise a serious
question regarding EPA’s policy. In any
event, as noted with regard to the
hearing request, this subissue lacks
materiality in that success on this
subissue by Petitioners would retard
rather than advance their challenge to
EPA’s action.
(iii) Subissue: Is ‘‘lip-smacking’’ a
CNS or PNS effect? Petitioners object
that EPA’s evidence of ‘‘lip smacking’’
in a carbofuran adult developmental rat
study does not support concern for
potential PNS effects because lip
smacking is more properly correlated to
CNS, rather than PNS inhibition. A
hearing is denied on this issue because
PO 00000
Frm 00071
Fmt 4701
Sfmt 4700
59677
Petitioners did not raise this issue in its
comments on the proposed tolerance
revocation. A hearing on this issue is
also inappropriate because the issue is
immaterial. EPA’s decision that a 4X
children’s safety factor is appropriate
did not rest exclusively—or even
significantly—on the effects observed in
this developmental study. Rather, EPA
retained the children’s safety factor
based on the lack of data in the PNS
and/or a surrogate at the low end of the
response curve, and the fact that the
available pup RBC data at higher doses
affirmatively indicate that the PNS
appears to be significantly more
sensitive than the CNS.
Petitioners’ objection on this subissue
is denied because both parties agree that
muscle fasiculations, which are the
movements EPA described at the SAP
meeting and in the proposed and final
rules, are PNS-mediated effects. Further,
it is unclear that the effects described in
the studies Petitioners submitted are
actually the same effects seen in the
carbofuran study; other factors in the
studies suggest that the movements
being studied are not purely cholinergic,
which calls into question whether the
effects are the same. For the same
reason, this calls into question the
contention that the effects are
exclusively CNS-related. Finally, the
cited studies fail to support Petitioners’
remaining contentions. Since it is
unclear that the studies actually
describe the same effects, and
Petitioners have failed to demonstrate
that the effects are exclusively CNSrelated, the evidence does not, therefore,
rebut EPA’s conclusions regarding the
movements described in the carbofuran
study.
(iv) Subissue: Did EPA err by relying
on studies not conducted pursuant to
EPA’s GLP regulations? Petitioners
claim that EPA’s reliance on the ORD
data is problematic because the data
were not conducted in accordance with
EPA’s GLP regulations at 40 CFR part
160. Petitioners have not cited any
evidence suggesting there is a
substantive problem with the ORD data
or made any arguments to such effect.
Thus, this subissue presents only a legal
question and legal questions are not
appropriate grounds for a hearing. EPA
denies Petitioners’ objection on this
point because EPA regulations make
clear its GLP regulations only apply to
studies in support of a pesticide
registration or tolerance (40 CFR
160.1(a), 160.3). In any event, noncompliance with the GLP regulations
does not automatically disqualify a
study from EPA consideration but rather
goes to reliability (40 CFR 160.17(a)).
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59678
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
(As noted, Petitioners have made no
claim that the ORD data is not reliable.).
(v) Subissue: Was EPA’s selection of a
4X children’s safety factor consistent
with EPA’s approach to other carbamate
pesticides? Petitioners object that EPA
was inconsistent in retaining a 4X
children’s safety factor for carbofuran
given that EPA removed the children’s
safety factor for other carbamates. A
hearing is not appropriate on this
subissue because it presents a purely
legal question. There is no dispute
regarding the facts of EPA’s decision in
each case, the only question is whether
EPA acted appropriately on carbofuran
given its decision on the children’s
safety factor for other carbamate
pesticides, such as carbaryl. The
objection is denied because EPA’s
decisions in each case were consistent;
EPA applied a different children’s safety
factor to carbofuran than to the other
carbamate pesticides based on the
different facts in each case. For
example, the data showed that carbaryl
differed significantly from carbofuran in
terms of each chemical’s relative
sensitivity in juveniles with regard to
brain and RBC AChE inhibition. For
carbofuran, EPA concluded that RBC
AChE inhibition in juveniles was more
sensitive than brain AChE inhibition in
juveniles by a factor of 4X. For carbaryl,
the AChE inhibition in brain and RBC
of juveniles was essentially equal.
(vi) Subissue: Did EPA err in not using
within-animal brain to RBC AChE
inhibition comparisons to derive the
children’s safety factor? EPA derived an
alternate to the default 10X children’s
safety factor based on the ratio of RBC
and brain AChE inhibition. In their
comments on the proposed rule,
Petitioners criticized this approach,
arguing that EPA should have compared
the RBC and brain AChE inhibition
levels at the same time in the same rat
when these rats are exposed to
carbofuran. Petitioners claimed to have
done such an analysis and that the
analysis showed that within rat
inhibition levels in brain and RBC AChE
were roughly equivalent. Although the
results of the statistical analyses were
summarized in the comments, the
underlying analysis was not submitted.
In the final tolerance revocation
regulation, EPA extensively reviewed
the ‘‘within animal’’ approach and
rejected it as fundamentally flawed in
several regards. Additionally, EPA
noted that EPA’s review of the
Petitioners’ suggested approach showed
that it produced results, which are in
fact consistent with EPA’s conclusions.
In their objections, Petitioners do not
respond to EPA’s rejection of the within
animal approach in the final tolerance
VerDate Nov<24>2008
17:53 Nov 17, 2009
Jkt 220001
revocation rule either by explaining
their disagreement with EPA’s critique
or proffering evidence to counter EPA’s
conclusion. Rather, Petitioners simply
resubmitted essentially the same
comments they provided on the
proposed rule. Petitioners also again
failed to submit the underlying analysis
supporting their within animal
calculations.
A hearing on this subissue is not
appropriate for two reasons. First,
Petitioners’ repeated failure to submit
the analysis supporting their claim
reduces this objection to a mere
allegation. Under EPA’s regulations,
hearings will not be granted on the basis
of mere allegations. More importantly,
Petitioners’ objection on this subissue is
irrelevant, and therefore immaterial,
with regard to EPA’s final tolerance
revocation regulation because
Petitioners ignored EPA’s extensive
analysis of this subissue in the final rule
and refiled their comments on the
proposal as if EPA’s determination in
the final rule did not exist. The statute,
however, requires that objections be
filed on the final rule, not on the
proposal. By ignoring the EPA’s final
rule on this subissue, Petitioners have
failed to lodge a relevant objection. Both
EPA and FDA precedent make clear that
when the agency substantively responds
to comments on the proposal, the
commenter may only keep that issue
alive in its objections by addressing the
agency’s substantive response. In other
words, the final rule is the focal point
for determining whether issues remain
that must be resolved by the objection
and hearing process. Any other
approach relegates the notice-andcomment rulemaking stage of the
revocation process to a meaningless
exercise.
Petitioners’ objections on this
subissue are denied as irrelevant to the
conclusions reached in the final rule.
The final rule explains why Petitioners’
arguments are without a basis, and
Petitioners have failed to address that
explanation. For essentially the same
reasons, EPA denies the objection.
For essentially the same reasons, EPA
denies the hearing request and objection
designated above as Objection/hearing
request sub issue: Technical Flaws in
EPA’s statistical comparisons.
Petitioners’ objection and hearing
request on this subissue consist of mere
reiteration of the comments submitted
in response to the proposed tolerance
revocation. The final rule explained the
reasons that Petitioners’ arguments are
flawed, and the objections are denied
for the same reasons.
(vii) Subissue: Is EPA’s approach to
comparing brain and RBC AChE
PO 00000
Frm 00072
Fmt 4701
Sfmt 4700
inhibition in juveniles due to carbofuran
exposure scientifically valid? Petitioners
allege that EPA’s approach to
calculating the relative sensitivity
between AChE inhibition in brain and
RBC in juveniles is not scientifically
valid. EPA derived the ratio of RBC and
brain AChE inhibition using the data on
administered dose (measured in terms
of BMD50) for PND11 animals. In
addition, the Petitioners criticize EPA
for incorrectly assuming that the
relationship of the dose response curve
between BMD50s and BMD10s is linear,
which they claim overstates the
potential differences. In support of the
claim that EPA’s approach overstates
the differences, Petitioners argue that
data suggests that BMD50s for brain and
RBC AChE inhibition for the carbamates
tend to diverge more than the dose
levels that cause the low levels of AChE
inhibition used to select the PoD (i.e.,
the BMD10s), which demonstrates that at
levels causing lower levels of inhibition,
no safety factor is necessary. Petitioners’
argument is that the 4X ratio EPA
calculated based on the BMD50 is
unnecessarily protective, because the
difference between brain and RBC at the
doses causing lower levels of inhibition
(i.e., 10%), which are the levels at
which EPA is regulating, would not be
significant.
Petitioners’ hearing request on this
subissue is denied for two reasons. First,
Petitioners proffered no evidence on any
carbamate, much less carbofuran, in
support of their claim that BMD50s for
the carbamates tend to diverge more
than the BMD10s or that the response
curve between BMD50s and BMD10s is
not linear. A hearing will not be granted
on the basis of mere allegations. Second,
Petitioners’ claims are immaterial
because unless Petitioners can show
what the relationship is between the
response curves for BMD50s and BMD10s
(an assertion they have not even made),
a showing that EPA’s assumption of
linearity is incorrect can only force EPA
to abandon the 4X children’s safety
factor in favor of the default 10X value.
The objection that EPA’s modeling is
scientifically invalid is denied. EPA’s
modeling has been repeatedly reviewed
and approved by the SAP, including
most recently with respect to the
modeling of carbofuran’s dose-response
curves. There is no indication in the
modeling that EPA’s assumption of
parallel dose-response curves overstates
the difference, and given the absence of
data supplied by Petitioners in support
of this objection, the objection is denied.
(viii) Subissue: Did EPA err by
combining data from different
toxicological studies in calculating the
estimates of BMD50s that serves as
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
quantitative support for derivation of
the 4X childrens’ safety factor? In its
risk assessment, EPA relied on all of the
valid data from the available studies to
calculate the estimates that served as the
PoD, and to calculate BMD50s used in
choosing the children’s safety factor. In
their comments on the proposed rule,
Petitioners claimed that EPA’s decision
to combine data for different strains of
rats, sexes, experiments, laboratories,
dates, dose preparations, rat ages, and
times between dosing and AChE
measurement, is problematic, claiming
that these differences in study design
severely limit the validity of EPA’s
comparisons and caused EPA to
overestimate the difference between
brain and RBC AChE inhibition. EPA
responded to these comments in full
during the rulemaking (74 FR 23052–
23053; Ref. 85). Petitioners referenced
their earlier comments in their
objections, but presented no further
evidence on any of these points. Nor in
their objections and request for hearing
did Petitioners address EPA’s
explanation set forth in the final rule.
A hearing is not appropriate on this
subissue because Petitioners have not
challenged the basis EPA asserted in the
final rule for rejecting their concerns nor
have they proffered any evidence that
calls the substance of EPA’s conclusions
into question. A hearing is not
warranted on the basis of mere denials
or contentions, nor when the
commenter simply reiterates comments
raised in response to the proposed rule
(40 CFR 178.32(b)(1) and (2)).
Additionally, this hearing request is
rejected for lack of materiality. If EPA
abandoned its sophisticated analysis of
multiple studies and datasets and
simply followed the general approach
laid out in its BMD policy, EPA would
have chosen a significantly lower BMD
dramatically raising EPA’s risk
estimates.
Petitioners’ objection on this subissue
is denied because Petitioners have not
responded to the explanation EPA
provided in the final rule supporting its
meta-analysis of multiple studies.
Consistent with Agency guidance, EPA
believes that consideration of all
available data is the scientifically more
defensible approach, rather than the
selective exclusion of reliable data.
Petitioners’ objection on this point is
particularly weak given that their
analysis also combines various data sets
and only arrives at a higher estimate of
the BMD by selectively excluding,
without explanation, the data most
pertinent to assessing carbofuran’s acute
affects.
b. Drinking Water Exposure
Objection—In large part, Petitioners’
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
objections to EPA’s assessment of
carbofuran levels in drinking water are
inextricably intertwined with their
recently-proposed registration
amendments which attempt to create a
scheme whereby carbofuran use would
be limited in individual watersheds. As
explained above (see Unit VI.F.2.a),
objections based on these recentlyproposed registration amendments are
irrelevant to EPA’s determination in the
final tolerance revocation rule.
Nonetheless, in Unit VI.F, EPA
exhaustively evaluated all of the
arguments put forward in Petitioners’
drinking water objection and explained
why a hearing was not appropriate on
any of these arguments and why, on the
merits, the arguments were without
basis. Below EPA has summarized its
reasoning.
The first four subissues below pertain
to EPA’s assessment of the carbofuran
groundwater exposure assessment and
the last eight address the surface water
assessment. In this regard, it is
important to note that, in order to
determine that a tolerance for a
particular use will be safe, EPA must be
able to determine that anticipated
concentrations in both surface water
and ground water resulting from that
use will be safe.
(i) Subissue: Did EPA err in relying on
the results of the prospective ground
water study (PGW) and historical
monitoring to validate groundwater
exposure estimate? The Petitioners
object that EPA should not have relied
for validation on their PGW study or
historical monitoring data. They argue
that these data no longer reflect current
use patterns and that all areas like those
seen in the PGW have now been
removed from the carbofuran label.
A hearing is not appropriate on this
subissue because the Petitioners have
failed to proffer evidence, which would,
if established, resolve a material issue in
their favor. First, Petitioners fail to take
into account the clear record evidence
that EPA scaled the PGW modeling to
reflect the lower current use rates.
Second, Petitioners are simply incorrect
to claim that EPA ‘‘validated’’ its
quantitative groundwater assessment
based on historic monitoring data that
are not reflective of current application
rates. The targeted monitoring data used
for validation were based on application
rates that are identical or lower than the
current use rates. Third, the majority of
Petitioners’ evidence is untimely, and to
the extent Petitioners’ are claiming that
the PGW and other targeted monitoring
data are not reflective of FMC’s June 29,
2009 proposed registration
amendments, that claim is irrelevant to
the current proceeding. Finally,
PO 00000
Frm 00073
Fmt 4701
Sfmt 4700
59679
Petitioners’ evidentiary proffer on the
PGW is internally contradictory given
that Petitioners’ own experts relied on
the PGW to validate the modeling
submitted in support of this objection.
The objection on this subissue is
denied because timely evidence and
reasoning submitted by Petitioners is
contradictory, non-probative, or flatly
contradicted by the record.
(ii) Subissue: Does EPA’s assessment
of carbofuran levels in ground water
account for all of FMC’s label mitigation
measures and ‘‘rely on unrealistic and
overly conservative assumptions about
potential concentrations’’? In this
objection, the Petitioners allege that
maximum concentrations of carbofuran
in groundwater are expected to be below
1.1 ppb, based on their proposed
geographic restrictions and well
setbacks. EPA believes Petitioners’
objection and hearing request on this
subissue is inextricably intertwined
with FMC’s recently-submitted FIFRA
registration amendments and thus the
objection is denied as irrelevant on that
account.
Nonetheless, to the extent possible
EPA has attempted to evaluate this
objection based on the label mitigation
measures submitted and adopted prior
to issuance of the final tolerance
revocation rule and ruled on it on that
basis. EPA denies the objection and its
associated hearing request because
Petitioners have again failed to object to
EPA’s final rule. It is clear from the
record that EPA’s final rule and risk
assessment did account for all of the
risk mitigation measures submitted as
part of the September 2008 comments.
Petitioners have not raised any
substantive challenge to the manner in
which EPA’s modeling addressed those
measures. In addition, Petitioners’
objections provide no further
clarification as to what is meant by their
claim that EPA’s assessment relied on
‘‘unrealistic and overly conservative
assumptions.’’ Therefore, this objection,
and the attendant hearing request, is
denied based on Petitioners’ failure to
state with ‘‘particularity * * * the basis
for the objection * * *.’’(40 CFR
178.25(a)(2)). As Petitioners raised
similar allegations in their comments,
EPA has assumed that they intended to
incorporate all of the issues raised in the
comments on the proposed rule.
However, EPA addressed these
assertions in the final rule. Because
Petitioners have once again ignored the
explanations provided in the final rule,
this objection and hearing request are
denied as immaterial.
(iii) Subissue: Is EPA’s assessment of
the levels of carbofuran in groundwater
appropriate given the manner in which
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59680
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
EPA assessed groundwater exposures in
the NMC CRA? Petitioners object that
EPA’s estimates in the final rule are
inconsistent with the groundwater
concentration estimates EPA developed
for the NMC CRA. However, they do not
identify any specific inconsistency, they
simply make the general allegation.
They allege that, by contrast, their
assessment, which estimated maximum
concentrations of 1.1 ppb, is consistent
with the NMC CRA.
EPA denies the request for a hearing
on this sub-issue because there is no
disputed factual matter for resolution
(i.e., the manner in which EPA assessed
groundwater exposure for carbofuran
and for the NMCs is a matter of record);
rather, the objection poses the legal
question of whether it was appropriate
for EPA to assess groundwater exposure
for carbofuran and the NMCs in a
different manner. Further, because
Petitioners have not identified any
specific inconsistency between the two
groundwater exposure assessments, it
constitutes nothing more than a mere
allegation or denial. As EPA’s
regulations make clear, a mere ‘‘denial’’
of an EPA position is not sufficient to
satisfy the standard for granting a
hearing (40 CFR 178.32(b)(2)). Finally,
the claim that their modeling is
consistent with the NMC CRA does not
justify a hearing on this question. As
EPA explained in the final rule, the
values estimated in the modeling
conducted for the NMC CRA are greater
than the 1.1 ppb level that FMC claims
is the maximum expected 1-in-10-year
peak concentration. A hearing is not
warranted where the claim is clearly
contradicted by the record (40 CFR
178.32(b)(2)).
On the merits, Petitioners’ objection is
denied because the results of
Petitioners’ groundwater assessment are
not consistent with the estimates
developed for the NMC CRA. The NMC
CRA examined carbofuran at two sites,
northeast Florida and the Delmarva
Peninsula. In Florida, concentrations
were found to be below levels of
concern because of high pH, but in
Delmarva, both in corn and in melon
scenarios EPA estimated that 90% of
daily concentrations could be as high as
20.5 and 25.6 ppb, respectively. These
values are far greater than the 1.1 ppb
that Petitioners claim is the maximum
expected 1-in-10-year peak
concentration.
(iv) Did EPA err in not using PCT data
in assessing surface water exposure?
The Petitioners object to the assumption
in the surface water assessments in the
final rule that 100% of the crops in a
watershed will be treated with
carbofuran. The Petitioners argue that
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
actual carbofuran sales data on a county
basis from 2002-present demonstrate
that the current carbofuran PCT is less
than 4.25%. Using this PCT, and taking
into account the recently submitted ‘‘no
application buffers,’’ the Petitioners
allege that the modeling in Exhibit 15
demonstrates that carbofuran
concentrations in surface water will not
exceed 1.1 ppb, ‘‘which is below the
level of concern.’’ In support of this
objection, the Petitioners reference
county level sales data that were
submitted to the Agency after the close
of the comment period. They also
reference the use tracking system
proposed in their recent registration
amendments (Exhibit 2) and the
modeling contained in Exhibit 15.
Because this subissue is inextricably
intertwined with Petitioners’ recentlyproposed FIFRA registration
amendments, it is denied as irrelevant.
To the extent Petitioners’ objection on
this subissue is limited to EPA’s refusal
to use a 4% PCT in estimating drinking
water concentrations in individual
watersheds based on the information
provided as part of their comments on
the proposed rule, this objection and
hearing request are also denied as
immaterial. The Petitioners have failed
to respond to EPA’s explanation in the
final rule that the information and
methodology on which they relied to
estimate a 4% PCT was fundamentally
flawed, and to submit any evidence
calling the basis of EPA’s response into
question (40 CFR 178.32(b)(3)).
Additionally, the proffered evidence
here is untimely. The sales data and
methodology used to generate use
estimates, as well as the modeling in
Exhibit 15, were not submitted during
the comment period on the proposed
rule even though the information was
clearly available to Petitioners (40 CFR
178.32(b)(2)).
Petitioners’ objection on this subissue
is denied because the proffered
evidence is untimely and, even if
considered, insufficient. Although EPA
does use reliable data on pesticide usage
in estimating exposure levels in food,
this approach has limited applicability
in drinking water assessments due to
the differences in the sources of food
and water for consumers. The food
market in the United States is national
in scope but the sources of drinking
water are primarily local. Thus, while
differences in the usage of pesticides
across the country will average out in
estimating pesticide exposure from
food, such averaging is not applicable to
estimating pesticide exposure in
drinking water—i.e., a person’s drinking
water exposure is generally always from
the same watershed. Moreover, the
PO 00000
Frm 00074
Fmt 4701
Sfmt 4700
information that Petitioners submitted
on PCT was not usage data—the type of
information normally used in estimating
PCT for food—but sales data. The link
between sales data and the location of
use is tenuous. Given that EPA lacks the
information to allow EPA to generally
use PCT information in estimating
drinking water exposure, and the poor
quality of information Petitioners
submitted on usage (i.e. county-level
sales data), EPA concludes it could not
make an exposure estimate on
carbofuran in drinking water with
sufficient confidence to meet the
FFDCA’s reasonable certainty of no
harm standard.
(v) Subissue: Do the results of FMC
surface water modeling establish that
carbofuran levels will not exceed 1.1
ppb? The Petitioners claim that the prior
surface water assessments submitted to
the Agency and a new assessment
incorporating FMC’s newly-proposed
FIFRA registration amendments
demonstrate that carbofuran
concentrations in surface water are not
expected to exceed 1.1 ppb. Because
this subissue is inextricably intertwined
with Petitioners’ recently-proposed
FIFRA registration amendments, it is
denied as irrelevant. Nonetheless, EPA
has carefully evaluated all of
Petitioners’ allegation to determine if
any of their claims meet the standard for
a hearing or are otherwise meritorious.
A hearing is also denied on this subissue because Petitioners’ objection on
this subissue is irrelevant, and therefore
immaterial, with regard to EPA’s final
tolerance revocation regulation.
Petitioners have not responded to EPA’s
extensive analysis of these studies,
which included an explanation for the
Agency’s conclusion that they were
significantly flawed, presented in the
final rule. The statute, however, requires
that objections be filed on the final rule
not the proposal. By ignoring EPA’s
final rule on this subissue, Petitioners
have failed to lodge a relevant objection.
Both EPA and FDA precedent make
clear that when the agency substantively
responds to comments on the proposal,
the commenter may only keep that issue
alive in its objections by addressing the
agency’s substantive response (40 CFR
178.32(b)(3)). Similarly, the Petitioners’
new assessment directly relies on FMC’s
newly-proposed FIFRA registration
amendments and is thus irrelevant to
this proceeding. Their new assessment
is also untimely in that it primarily
appears to be a fuller description of
Petitioners’ National CWS Assessment,
which was described, but not provided
as part of their comments on the
proposed rule (40 CFR 178.32(b)(2)).
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
EPA has outlined the substantial
flaws in the previously-submitted
assessments in the final tolerance
revocation rule and in Unit VI.F, above.
For the all the reasons cited therein, this
objection is denied.
(vi) Did EPA inappropriately rely on
NAWQA monitoring data in assessing
carbofuran levels in surface water? The
Petitioners object to EPA’s discussion in
the final rule of the high concentrations
detected in Zollner Creek in Oregon and
claim that EPA inappropriately relied
on NAWQA monitoring data in
estimating surface water exposure levels
of carbofuran. A hearing on this issue is
denied because there are no material
factual issues in dispute. The extent to
which EPA discussed the Zollner Creek
data as part of its discussion of
monitoring results from all other
NAWQA sites, SDWA post-treatment
monitoring, and the results of field
studies is clear on the record. The
record is also clear regarding the degree
of reliance EPA placed on monitoring
data in estimating carbofuran levels in
surface water. The objection on this
subissue is denied because it was
reasonable for EPA to consider NAWQA
data in assessing the likelihood that
carbofuran residues may be present in
surface water. Moreover, the record is
clear that, even though EPA considered
the NAWQA data, it placed primary
emphasis on the carbofuran levels
detected in post-treatment SDWA
monitoring.
(vii) Should EPA consider FMC’s
newly-proposed terms of registration for
carbofuran? The objection is denied
because it is based on FMC’s newly
proposed revisions to its carbofuran
registration that were submitted after
publication of the final tolerance
revocation rule and is thus irrelevant to
this proceeding. An additional ground
for denial of this objection and hearing
request is that Petitioners proferred no
evidence to support their allegation that
these proposed requirements would be
effective in limiting carbofuran
exposure to the extent claimed
(viii) Should EPA have used the NMC
CRA surface water estimates in
assessing exposure to carbofuran in
surface water? Petitioners object to
EPA’s surface water exposure estimates
on the ground that they are inconsistent
with the estimates EPA developed for
purposes of the NMC CRA. This hearing
request is denied because there are no
factual matters in dispute; rather, the
only question is a legal one of whether
it was inappropriate for EPA to use
different approaches to assessing surface
water exposure for the carbofuran
surface water assessment and the
cumulative assessment of surface water
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
exposure for NMCs (40 CFR
178.32(b)(1)). In addition, this issue was
raised in Petitioners’ comments on the
proposed revocation. In the final
revocation, EPA explained how the
substantial differences between a
cumulative risk assessment for a class of
pesticides and a risk assessment for a
single pesticide necessitate different
approaches. Petitioners have not
challenged the substance of EPA’s
response to their comments or
submitted evidence that calls the
substance of EPA’s final rule
conclusions into question, and the
objection and associated hearing request
is therefore immaterial (40 CFR
178.32(b)(3)). Finally, on multiple
grounds, Petitioners’ evidentiary proffer
is insufficient to support a conclusion
that there is a reasonable possibility that
the issue could be resolved in their
favor. Petitioners’ objection on this
subissue is denied for essentially the
same reasons explained in the final
tolerance revocation.
(ix) Has EPA taken natural surface
water pH conditions into account? The
Petitioners contend that the PCT levels
guaranteed by the recently proposed use
tracking system, along with natural
surface water pH conditions in the areas
included under the revised label will
ensure that potential exposures are de
minimis. Because this objection is
inextricably intertwined with FMC’s
newly-proposed FIFRA registration
amendments, it is denied as irrelevant
to this proceeding.
Even assuming Petitioners’ allegation
concerning soil pH can be separated
from the proposed registration
amendments, Petitioners’ claims are
insufficient to justify the action urged
(40 CFR 178.32(b)(3)). Petitioners admit
that their pH analyses explicitly only
capture 95% of surface waters. Because
EPA cannot ignore the other 5% of
surface water, this information, even if
established, would provide an
insufficient basis on which EPA could
reasonably conclude that the drinking
water exposures would be ‘‘safe.’’
Additionally, the proffered evidence for
this objection is untimely because
although the effects of pH were clearly
discussed in the proposed rule,
Petitioners’ claim and the analyses
supporting it were not submitted during
the comment period.
For the same reasons, the Petitioners’
objection is denied.
(x) Has EPA taken the effect of
existing drinking water treatment
systems into account? The Petitioners
contend that, in the areas where
carbofuran use is allowed under revised
labels, the majority of the total
population is protected from carbofuran
PO 00000
Frm 00075
Fmt 4701
Sfmt 4700
59681
by water treatment systems and that the
rest of the population is protected by
Petitioners’ newly-proposed FIFRA
registration amendments. Because this
objection is inextricably intertwined
with FMC’s newly-proposed FIFRA
registration amendments, it is denied as
irrelevant to this proceeding.
Separating out the allegations that are
independent from the new registration
amendments, EPA denies this hearing
request on the grounds that Petitioners’
claims are insufficient to justify the
action urged (40 CFR 178.32(b)(3)) in
that they would fail to justify a
conclusion that the carbofuran
tolerances are safe. The fact that the
majority of people are protected is
irrelevant if major identifiable
subpopulations are not. Further, both
the objection and the proffered evidence
are untimely because Petitioners’ claims
and analyses supporting them were not
submitted during the comment period.
For the same reasons, this objection is
denied.
c. Recovery Time Objection—(i)
Subissue: Has EPA overstated risk
through its approach to considering
recovery time to the effects of
carbofuran? For carbofuran, EPA
estimated acute dietary exposure for the
acute risk assessment by summing
exposure over a 24-hour period. Because
humans are likely to recover in a
relatively short time period from any
single carbofuran exposure, EPA also
undertook a more sophisticated
exposure assessment that took recovery
time into effect. This more sophisticated
analysis was not substituted for the 24hour assessment approach but rather
was used to evaluate whether the 24hour approach substantially overstated
risk. The reason for not simply adopting
the assessment incorporating recovery
time was based on concerns that other
aspects of its exposure model tend to
understate exposure. If the assessment
using recovery time had suggested that
carbofuran risks may be acceptable, EPA
would have further examined how
exposure should be assessed. However,
because both the assessment based on
24-hour exposure and the one
incorporating recovery time showed
carbofuran exposures significantly
exceed the safe level, EPA concluded
that its exposure assessment was
reasonable. Further supporting this
conclusion was the fact that various
other analyses showed that a single
eating occasion could result in excessive
risk to infants. Petitioners have objected
to this approach claiming that recovery
time should be included in EPA’s
‘‘primary’’ risk assessment.
EPA is denying this hearing request
on two grounds. First, the objection fails
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
59682
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
to present a disputed issue of material
fact because EPA did incorporate
recovery time into its analysis. Rather,
Petitioners’ only challenge is to whether
EPA should have only presented risk
estimates that accounted for recovery.
This is a policy issue, and hearings are
not appropriate on such (40 CFR
178.32(b)(1)).
Second, the fact that EPA relied on
24-hour aggregate exposures in addition
to analyses that accounted for recovery
is not material, because even though
accounting for recovery resulted in a
2–3X reduction in exposure estimates,
many of EPA’s estimates for aggregate
exposures ranged between 2700% aPAD
and 9400% aPAD for infants.
Accounting for recovery does not,
therefore, demonstrate that aggregate
exposures will be safe for infants. Of
greater significance in this regard is
EPA’s finding that infants are at risk
from a single exposure. Recovery is only
relevant, by definition, where the risk is
derived from multiple exposures over
time.
Petitioners’ objection to EPA’s policy
decision to present acute risks in terms
of 24 hours of exposure is denied
because EPA’s policy approach here is
reasonable. For the reasons explained in
Unit VI.G, there are several factors that
may cause EPA’s exposure/risk model to
either understate or overstate exposure/
risk. It is unreasonable to present risks
only incorporating factors that tend to
reduce exposure/risk estimates (e.g.,
recovery time), as Petitioners suggest.
EPA’s approach of evaluating the impact
that these factors may have on the risk
assessment is an appropriate method of
taking all relevant factors into account.
(ii) Subissue: Did EPA err in
calculating carbofuran half-lives? In the
proposed rule, EPA used half-lives of
150 minutes and 300 minutes, based on
calculations derived for the NMC CRA.
In the final rule, EPA calculated halflives specific to carbofuran to ensure
that its analyses accurately reflected
carbofuran’s risk. Petitioners contend
that EPA’s calculation of carbofuran
half-lives of 186 minutes and 426
minutes were flawed, and that the data
instead support the use of a 150-minute
half-life.
Petitioners’ hearing requests on this
subissue are denied for two reasons.
First, Petitioners have not provided the
underlying analyses conducted in
support of their claims that the
appropriate half-life for carbofuran is
150 minutes, rather than the 186 or 426
minutes that EPA calculated.
Petitioners’ evidentiary proffer thus
consists of no more than mere
allegations and denials. Hearings will
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
not be granted on this basis (40 CFR
178.32(b)(2)).
Further, the issue of the appropriate
half-lives for carbofuran is not material.
Petitioners have proffered no evidence
to show that reliance on a 150-minute
half-life rather than a 186-minute halflife would make a significant difference
to their estimates. By contrast, in the
risk assessment supporting the final
rule, EPA’s estimates show that the use
of a 150-minute or 186-minute half-life
makes little or no difference. In
addition, EPA’s final risk assessment
found that infants are at risk from a
single exposure. Recovery is only
relevant, by definition, where the risk is
derived from multiple exposures over
time.
EPA denies Petitioners’ objection on
this subissue because the evidence
submitted fails to establish their
allegations, or to rebut the data and
analyses discussed in the final rule.
d. Human Study Objection—Issue:
Did EPA reasonably conclude that a
human toxicity study with carbofuran
was barred from EPA consideration by
the Human Research Rule? In
conducting its dietary risk assessment
for carbofuran, EPA relied on toxicity
data conducted with rats, and applied
the default 10X interspecies factor to
account for the potential uncertainty in
extrapolating from animal data to
humans. Petitioners object to the
decision to use a 10X interspecies factor
claiming that data from a human
toxicity study (Arnold) provides a basis
for reducing this factor to 3X. However,
EPA has previously determined that the
Arnold study lacks scientific validity
and thus may not be considered by the
Agency under EPA’s Human Research
rule. That decision was based on the
advice of the HSRB, which found the
Arnold study to constitute ‘‘poor
science’’ (Ref. 38 at 11).
Although Petitioners have made a
number of arguments in support of
adopting a 3X interspecies factor, all of
the arguments rely on consideration of
the Arnold study. Thus, as a
preliminary matter, Petitioners must
show that a hearing is appropriate based
exclusively on whether EPA erred in
determining that the Arnold study
cannot be considered under the Human
Research rule or, that even if a hearing
is not warranted, that EPA’s decision
under the Human Research rule was
incorrect.
Petitioners have proffered no
evidence that merits a hearing on EPA’s
application of the Human Research rule
to the Arnold study. As an evidentiary
proffer, Petitioners claim (1) that review
of the Arnold study under the Human
Research rule was too narrow in that it
PO 00000
Frm 00076
Fmt 4701
Sfmt 4700
did not consider the Arnold study in
light of the animal data; (2) that
insufficient weight was given prior
independent reports on the value of the
Arnold study; (3) that the ‘‘technical’’
concerns raised by the HSRB are
addressed by ‘‘the data within the
study’’ and that these ‘‘technical’’
deficiencies do not render the Arnold
study unreliable. The first proffer is not
material because the availability of
animal data does not address the
validity of the Arnold human study. At
bottom, this issue involves a challenge
to the policy underlying the Human
Research rule that allows only limited
consideration of human toxicity studies.
A hearing is not appropriate on such a
policy issue, nor on the Human
Research rule itself. Petitioners’ second
proffer is a legal/policy question
regarding the weight to be accorded to
existing peer review reports. No hearing
is required on such issues. To the extent
the third proffer even constitutes a
proffer of ‘‘evidence,’’ it fails because it
is nothing more than a mere allegation.
Petitioners have supplied no
information as to how the HSRB’s
‘‘technical’’ concerns are resolved by the
study itself.
Viewed on their merits, these claims
do not convince EPA that it erred in
determining that the Arnold study did
not meet the Human Research rule
because it lacked scientific validity.
EPA concluded, based on the advice of
the HSRB, that, because the Arnold
study had an extremely small sample
size (2 persons per dose) and highly
variable measurement of RBC and
plasma AChE, it had no scientific value.
The claim by Petitioners that somehow
the Arnold study could be rehabilitated
by considering it in the context of
carbofuran animal data misunderstands
the issue. The question under the
Human Research rule is whether the
human study at issue is scientifically
valid. Here, EPA found the Arnold
study to be flawed at its core. Animal
data on carbofuran are simply irrelevant
to the problems with sample size and
AChE measurement in the Arnold
study. As to the earlier reports on the
Arnold study, Petitioners have provided
no reason as to why these should
outweigh the HSRB’s conclusion
concerning whether the Arnold study
met the Human Research rule standard.
The earlier reports were completed well
before the Human Research rule was
promulgated and thus could not have
addressed the rule’s requirements.
Further, the earlier reports identified the
same defects, but concluded that the
Arnold’s study’s flaws could be
addressed by the use of additional safety
E:\FR\FM\18NOR2.SGM
18NOR2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
factors—an option not available under
the Human Research rule. In such
circumstances, it was reasonable for
EPA to give primary weight to the HSRB
findings. Petitioners’ claim that the
HSRB only identified ‘‘technical’’
problems with the Arnold study and
that the study itself addresses the
HSRB’s concerns is without basis. The
flaws in the Arnold study are not
technical but fundamental, and cannot
be explained away. Finally, Petitioners’
allegations that EPA hampered the
HSRB’s consideration of the prior peer
review reports and that EPA’s recusal
decision was somehow improper are
contradicted by the record. Accordingly,
the objection is denied.
e. Import Tolerance Objection—Issue:
Did EPA err by failing to retain the
carbofuran tolerances that apply solely
to imported food. Whether EPA had
some type of independent duty to retain
carbofuran tolerances for the imported
foods bananas, rice, coffee, and
sugarcane despite its finding that
aggregate exposure to carbofuran is
unsafe, is a legal question. Hearings are
not held on legal issues. Having found
that aggregate exposure to carbofuran is
unsafe, EPA was clearly warranted, if
not required, to revoke all tolerances.
For the policy reasons identified above,
(see Unit VI.I), when aggregate risk to a
pesticide is unsafe, EPA defers to
interested parties to decide in the first
instance what tolerances, if any, they
wish to retain. Although explicitly
invited to do so, no person submitted a
comment on the proposed revocation
that identified the import tolerances as
a subset of tolerances that were asserted
to be safe, and that the commenter
wished to retain. Accordingly, this
objection is denied.
pwalker on DSK8KYBLC1PROD with RULES2
K. Conclusion
For all of the reasons set forth above,
EPA denies the Petitioners’ objections
and their requests for a hearing on those
objections.
VII. Regulatory Assessment
Requirements
As indicated previously, this action
announces the Agency’s final order
regarding objections filed under section
408 of FFDCA. As such, this action is an
adjudication and not a rule. The
regulatory assessment requirements
imposed on rulemaking do not,
therefore, apply to this action.
VIII. Submission to Congress and the
Comptroller General
The Congressional Review Act, (5
U.S.C. 801 et seq.), as added by the
Small Business Regulatory Enforcement
Fairness Act of 1996, does not apply
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
because this action is not a rule for
purposes of 5 U.S.C. 804(3).
IX. References
EPA has established an official record
for this rulemaking. The official record
includes all information considered by
EPA in developing this proposed rule
including documents specifically
referenced in this action and listed
below, any public comments received
during an applicable comment period,
and any other information related to this
action, including any information
claimed as CBI. This official record
includes all information physically
located in docket ID number EPA–HQ–
OPP–2005–0162, as well as any
documents that are referenced in the
documents listed below or in the
docket. The public version of the official
record does not include any information
claimed as CBI.
Objections to the Final Order
Revoking Tolerances for Carbofuran,
and Request for Public Evidentiary
Hearing, submitted by National Potato
Council, National Corn Growers
Association, National Cotton Council,
National Sunflower Association, and
FMC Corporation. June 30, 2009. EPA–
HQ–OPP–2005–0162–0578.
Exhibit 1
• FMC’s letter of 9–29–08 and
accompanying label amendments.
Exhibit 2
• FMC’s letter of 12–24–08 and
accompanying label amendments.
Exhibit 3
• FMC’s letter of 6–30–09 and
accompanying label amendments.
Exhibit 4
• Expert Report: Carbofuran’s FQPA
Safety Factor and Interspecies
Uncertainty Factor by K. Wallace (6 p.)
• 13 published articles on pesticide
effect on cholinesterase activity.
Exhibit 5
• Central Nervous System as the
Primary Target for Carbofuran’s Effects
on Lip Smacking by Neal, Williams, &
Lamb (3 p.)
• 10 published articles on effects of
cholinergic stimulation.
Exhibit 6
• Expert Report: Carbofuran FQPA
Safety Factor by K. Wallace (8 p.)
• 9 published articles on HBC versus
brain cholinesterase inhibition.
Exhibit 7
• Dose Response Modeling Issue in
Carbofuran by Sielken: AChE and BMD
Ratios
PO 00000
Frm 00077
Fmt 4701
Sfmt 4700
59683
Exhibit 8
• Dose Response Modeling Issue in
Carbofuran by Sielken: Statistical
Comparison of AChE Inhibition in RBC
and Brain in Rats Exposed to
Carbofuran.
Exhibit 9
• Dose Response Modeling Issue in
Carbofuran by Sielken: OPP’s Estimates
of the Half-Life of AChE Recovery.
Exhibit 10
• Reiner, 1971. Spontaneous
Reactivation of Phosphorylated and
Carbamylated Cholinesterases Bulletin
WHO 44, 109–112.
Exhibit 11
• Carbofuran Dietary Risk
Assessment. 2009. (Exponent Inc., for
FMC)
Exhibit 12
• Williams, Cheplick, Engle, Fawcett
and Hoogeweg. 2009. National
Carbofuran Leaching Assessment. Vol 1.
Waterborne Environmental Inc., Engel
Consulting, and Fawcett Consulting for
FMC.
Exhibit 13
• Williams, Cheplick, Engle, Fawcett
and Hoogeweg. 2009. National
Carbofuran Leaching Assessment. Vol 2.
Setback Analysis. Waterborne
Environmental Inc., Engel Consulting,
and Fawcett Consulting for FMC.
Exhibit 14
• Memorandum. From: Hoogeweg
and Williams, Waterborne, Inc., To:
Fuge, Latham and Watkins, LLP. June
30, 2009. Subject: Groundwater pH in
selected states.
Exhibit 15
• Williams, Fawcett and Engle. 2009.
The Development and Evaluation of a
Carbofuran Management Plan to Protect
Drinking Water Derived from Surface
Water Sources. Waterborne
Environmental Inc., for FMC.
Exhibit 16
• Memorandum. From: Hoogeweg
and Williams, Waterborne, Inc., To:
Fuge, Latham and Watkins, LLP. June
30, 2009. Subject: Surface water pH in
selected states.
Exhibit 17
• Memorandum. From: Williams,
Waterborne, Inc., To: Fuge, Latham and
Watkins, LLP. June 30, 2009. Subject:
Water Treatment Assessment in
Carbofuran Use States.
E:\FR\FM\18NOR2.SGM
18NOR2
59684
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
Exhibit 18
• Petition of the National Corn
Grower’s Association, the National
Sunflower Association, the National
Potato Council, and FMC Corporation to
Defer the Effective Date of Certain
Tolerance Revocations for Carbofuran.
pwalker on DSK8KYBLC1PROD with RULES2
References
1. Acute oral (gavage) dose range-finding
study of cholinesterase depression from
carbofuran technical in juvenile (day 11) rats.
Hoberman, 2007. MRID 47143703
(unpublished FMC study) EPA–HQ–OPP–
2007–1088–0062.
2. Acute oral (gavage) time course study
and final report of cholinesterase depression
from carbofuran technical in adult and
juvenile (day 11 postpartum) rats. Hoberman,
2007. MRID 47143704, 05 (unpublished FMC
studies) EPA–HQ–OPP–2007–1088–0063 and
–0066.
3. Acute time-course study of carbofuran
technical administered by gavage to adult
and postnatal day 11 male and female CD
(Sprague-Dawley) rats: Tyl, Marr, and Myers.
2005. (Unpublished study received Nov. 14,
2005; prepared by RTI International, RTP,
NC; submitted by FMC Corp., Philadelphia,
Pa.; FMC Study No: A2005–5982. MRID
46688913. EPA–HQ–OPP–2005–0162–0058.
4. Acute dose-response study of carbofuran
technical administered by gavage to adult
and postnatal day 11 male and female CD
(Sprague-Dawley) rats: Tyl and Myers. 2005.
MRID 46688914. EPA–HQ–OPP–2005–0162–
0078.
5. Anderson, S. A. (2002). The
Toxicokinetics of Peripheral Cholinesterase
Inhibition from Orally Administered
Carbofuran in Adult Male and Female CD
Rats. (Unpublished study received May 15,
2002; prepared by Toxicokinetics Laboratory,
RTP, NC; submitted by FMC Corp.,
Philadelphia, Pa.; FMC Study No: A2001–
5379. MRID 456757–01.
6. An Investigation into the Potential for
Carbofuran Leaching to Ground Water Based
on Historical and Current Use Practices.
Submitted by FMC Corporation,
Philadelphia, PA.: Report No. PC–0363.
MRID 47221602. EPA–HQ–OPP–2007–1088–
0022.
7. Arnold, J.D. (1976) Evaluation of the
Safe Exposure Levels to Carbamate,
Administered Orally to Healthy Adult
Normal Male Volunteers. (Unpublished study
received Oct. 24, 1979 under 279– 2712;
prepared by Quincy Research Center,
submitted by FMC Corp., Philadelphia, Pa.;
CDL:241303–B) Accession no. 241303. MRID
00092826. EPA–HQ–ORD–2006–0310–0020.
8. Arnold, J.D. (1977) Carbamate
(Carbofuran) Human Dermal Study. Final
rept. (Unpublished study received Oct. 24,
1979 under 279–2712; prepared by Quincy
Research Center, submitted by FMC Corp.,
Philadelphia, Pa.; CDL:241303–C), Accession
no. 241303. MRID 00092827. EPA–HQ–ORD–
2006–0310–0020.
9. Arnold, J.D. (1978) Comparison of
Cholinesterase Inhibition and Effects of
Furadan 4F and FMC 35001 4 EC (ACT
152.03). Rev. final rept. (Unpublished study
received Oct. 24, 1979 under 279–2712;
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
prepared by Quincy Research Center,
submitted by FMC Corp., Philadelphia, Pa.;
CDL:241305–A) Accession no. 241305, MRID
no. 00092829. EPA–HQ–ORD–2006–0310–
0020.
10. Benjamins, J.A. and McKhann, G.M.
(1981) Development, regeneration, and aging
of the brain. In: Basic Neurochemistry, 3rd
edition. Edited by Siegel, G.J., Albers, R.W.,
Agranoff, B.W., and Katzman, R. Little,
Brown and Co., Boston. pp 445–469.
11. Bretaud S, Toutant JP, Saglio P. 2000.
Effects of carbofuran, diuron, and
nicosulfuron on acetylcholinesterase activity
in goldfish (Carassius auratus). Ecotoxicol
Environ Saf. 2000 Oct.; 47(2):117–24.
12. Carbofuran Acute Aggregate Dietary
(Food and Drinking Water) Exposure and
Risk Assessments for the Reregistration
Eligibility Decision (T. Morton, 7/22/08,
D351371). EPA–HQ–OPP–2005–0162–0508.
13. Carbofuran Environmental Risk
Assessment and Human Drinking Water
Exposure Assessment for IRED. March 2006.
EPA–HQ–OPP–2005–0162–0080.
14. Carbofuran. HED Revised Risk
Assessment for the Reregistration Eligibility
Decision (RED) Document (Phase 6). (PC
090601) D 330541, July 26, 2006. EPA–HQ–
OPP–2005–0162–0307.
15. Carbofuran. HED Revised Risk
Assessment for the Notice of Intent to Cancel.
(PC 090601) D 347038, January 2007. EPA–
HQ–OPP–2007–1088–0034.
16. Carr, Chambers, Guarisco, Richardson,
Tang, and Chambers. 2001. Effects of
repeated oral postnatal exposures to
chlorpyrifos on open-field behavior in
juvenile rats. Toxicol. Sci. 59: 260–267.
17. Chen, W.L., Sheets, Nolan and Mattson.
1999. Human red blood cell
acetylcholinesterase inhibition as the
appropriate and conservative surrogate
endpoint for establishing chlorpyrifos
refernce dose. Regul. Toxicol. ′Pharmacol. 29,
15–22.
18. Comments in Opposition to Proposed
Tolerance Revocations for Carbofuran.
(September 29, 2008). Submitted by the
National Potato Council, National Corn
Growers Association, National Cotton Coucil,
National Sunflower Association, and FMC
Corporation. EPA–HQ–OPP–2005–0162–
0547.1.
19. Costa, Hand, Schwab, and Murphy.
1981a. Reduced [3H] quinuclidinyl benzilate
binding to muscarinic receptors in
disulfoton-tolerant mice. Toxicol. Appl.
Pharmacol. 60: 441–450.
20. Costa, Hand, Schwab, and Murphy.
1981b. Tolerance to the carbamate insecticide
propoxur. Toxicology. 21: 267–278.
21. Costa and Murphy. 1983.
Unidirectional cross-tolerance between the
carbamate insecticide propoxur and the
organophosphate disulfoton in mice. Fund.
Appl. Toxicol. 3: 483–488.
22. Davison, A.N. and Dobbing, J. (1966)
Myelination as a vulnerable period in brain
development. Br. Med. Bull. 22: 40–44.
23. Dobbing, J. and Smart, J.L. (1974)
Vulnerability of developing brain and
behaviour. Br. Med. Bull. 30: 164–168;
24. Dose-Time Response Modeling of Rat
Brain AChE Activity: Carbofuran Gavage
Dosing: BMD50s for PND11 animals, January
14, 2009. EPA–HQ–OPP–2005–0162–0571.
PO 00000
Frm 00078
Fmt 4701
Sfmt 4700
25. Dose-Time Response Modeling of Rat
RBC AChE Activity: Carbofuran Gavage
Dosing: BMD50s for PND11 Animals, January
14, 2009. EPA–HQ–OPP–2005–0162–0570.
26. El-Naggar AEl-R, Abdalla MS, ElSebaey AS, Badawy SM. (2009) Clinical
findings and cholinesterase levels in children
of organophosphates and carbamates
poisoning. Eur. J. Pediatrics 168: 951–956.
27. Engel, Bernard, Richard S. Fawcett, and
W. Martin Williams. 2008. Comments to the
FIFRA Scientific Advisory Panel—Volume V.:
The Water Risk Assessment for Carbofuran.
From Carbofuran Scientific Advisory Panel
Meeting, Feb. 5–8, 2008, Docket ID Number:
EPA–HQ–OPP–2007–1088 FMC Corporation,
Agricultural Products Group Written
Comments.
28. EPA Response to the Transmittal of
Meeting Minutes of the FIFRA Scientific
Advisory Panel Meeting Held February 5–8
2008 on the Agency’s Proposed Action under
FIFRA 6(b) Notice of Intent to Cancel
Carbofuran (E. Reaves, A. Lowit, J. Liccione
7/2008 D352315). EPA–HQ–OPP–2005–
0162–0505.
29. Fawcett, R., B. Engel, W. Williams.
2007. An Investigation into the Potential for
Carbofuran Leaching to Ground Water Based
on Historical and Current Product Uses.
(MRID 47221602) Project Number PC/0363.
32 p. EPA–HQ–OPP–2005–0162–0454.1
30. FIFRA SAP (1998) ‘‘A set of Scientific
Issues Being Considered by the Agency in
Connection with Proposed Methods for
Basin-scale Estimation of Pesticide
Concentrations in Flowing Water and
Reservoirs for Tolerance Reassessment.’’
Final Report from the FIFRA Scientific
Advisory Panel Meeting of July 29–30, 1998
(Report dated September 2, 1998). Available
at: https://www.epa.gov/scipoly/sap/meetings/
1998/july/final1.pdf.
31. FIFRA SAP (1999) ‘‘Sets of Scientific
Issues Being Considered by the
Environmental Protection Agency Regarding
Use of Watershed-derived Percent Crop Areas
as a Refinement Tool in FQPA Drinking
Water Exposure Assessments for Tolerance
Reassessment.’’ Final Report from the FIFRA
Scientific Advisory Panel Meeting of
February 5–7, 2002 (Report dated May 25,
1999). SAP Report 99–03C. Available at:
https://www.epa.gov/scipoly/sap/meetings/
1999/may/final.pdf.
32. SAP. 2001a. REPORT: FIFRA Scientific
Advisory Panel Meeting, September 29, 2000,
held at the Sheraton Crystal City Hotel,
Arlington, Virginia. Session VI–A Set of
Scientific Issues Being Considered by the
Environmental Protection Agency Regarding:
Progress Report on Estimating Pesticide
Concentrations in Drinking Water and
Assessing Water Treatment Effects on
Pesticide Removal and Transformation: A
Consultation. SAP Report No 2002–2.
33. FIFRA SAP. (2002a). ‘‘Methods Used to
Conduct a Preliminary Cumulative Risk
Assessment for Organophosphate
Pesticides.’’ Final Report from the FIFRA
Scientific Advisory Panel Meeting of
February 5–7, 2002 (Report dated March 19,
2002). FIFRA Scientific Advisory Panel,
Office of Science Coordination and Policy,
Office of Prevention, Pesticides and Toxic
Substances, U.S. Environmental Protection
E:\FR\FM\18NOR2.SGM
18NOR2
pwalker on DSK8KYBLC1PROD with RULES2
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
Agency. Washington, DC. SAP Report 2002–
01.
34. FIFRA Science Advisory Panel (SAP).
2005a. ‘‘Final report on N-Methyl Carbamate
Cumulative Risk Assessment: Pilot
Cumulative Analysis.’’ Final Report from the
FIFRA Scientific Advisory Panel Meeting of
February, 2005 (Report dated September 2,
1998). Available at: https://www.epa.gov/
scipoly/sap/2005/february/minutes.pdf.
35. FIFRA Science Advisory Panel (SAP).
2005b. ‘‘Final report on Preliminary N–
Methyl Carbamate Cumulative Risk
Assessment.’’ Final Report from the FIFRA
Scientific Advisory Panel Meeting of July 29–
30, 1998 (Report dated September 2, 1998).
Available at: https://www.epa.gov/scipoly/
sap/2005/august/minutes.pdf.
36. FIFRA Science Advisory Panel (SAP).
2008. ‘‘Final report on the Agency’s Proposed
Action under FIFRA 6(b) Notice of Intent to
Cancel Carbofuran.’’ Report from the FIFRA
Scientific Advisory Panel Meeting of
February, 5–8 2008 (Report dated September
2, 1998). Available at: https://
www.epa.govscipoly/sap/meetings/2008/
february/carbofuransapfinal.pdf.
37. Hoberman, A. M. (1998).
Developmental Neurotoxicity Study of
Chlorpyrifos Administered Orally via Gavage
to Crl:CDBR VAF/Plus Presumed Pregnant
Rats. EPA—MRID No. 44556901. Dow
Chemical Co., Midland, MI.
38. HSRB Meeting Minutes. June 1, 2006.
Minutes of the United States Environmental
Protection Agency (EPA) Human Studies
Review Board (HSRB) May 2–3, 2006 Public
Meeting Docket Number: EPA–HQ–ORD–
2006–0310. https://www.epa.gov/osa/hsrb/
files/meeting-materials/may-2-3-2006-publicmeeting/mayminutesfinal.pdf.
39. HSRB Memorandum: Farland to HSRB
Board. May 1, 2006 ‘‘Ethics Determination for
Participation at the May 2–3, 2006 EPA
Human Studies Review Board Meeting.’’
40. HSRB Report. July 7, 2006.
Memorandum from Fisher to Gray. Subject:
May 2–3, 2006 EPA Human Studies Review
Board Meeting Report. https://www.epa.gov/
osa/hsrb/files/meeting-materials/may-2-32006-public-meeting/final7706.pdf.
41. Hunter, D. L., Lassiter, T. L., and
Padilla, S. 1999. Gestational exposure to
chlorpyrifos: comparative distribution of
trichloropyridinol in the fetus and dam.
Toxicol. Appl. Pharmacol. 158, 16–23.
42. Issue Paper for the FIFRA SAP Meeting
on Carbofuran: Human Health Risk
Assessment Reregistration Eligibility Science
Chapter for Carbofuran, Environmental Fate
and Effects Chapter. March 2006. EPA–HQ–
OPP–2007–1088–0031.
43. Jones, R. David, Sidney Abel, William
Effland, Robert Matzner, and Ronald Parker.
1998. Proposed Methods for Basin-scale
Estimation of Pesticide Concentrations in
Flowing Water and Reservoirs for Tolerance
Reassessment: Chapter IV., An Index
Reservoir for Use in Assessing Drinking
Water Exposure. Presentation to the FIFRA
Science Advisory Panel, July 29–30, 1998.
44. Jones, R. David. 2007a. Additional
chemographs for potatoes and cucurbits for
drinking water exposure assessment in
support of the reregistration of carbofuran.
Internal EPA Memorandum to Jude
VerDate Nov<24>2008
16:17 Nov 17, 2009
Jkt 220001
Andreasen and Danette Drew dated October
23, 2007. EPA–HQ–OPP–2005–0162–0486.
45. Jones, R. David. 2007b. Summary
Evaluation of Recently Submitted FMC Water
Exposure Studies. (DP 347901) Internal EPA
Memorandum to Jude Andreasen dated
December 26, 2007. Available in the federal
docket at www.regulations.gov at EPA–HQ–
OPP–2007–1088–0016.
46. Jones, R. David (2008a) (5/1/2008).
Additional refinements for estimations of
drinking water exposure from carbofuran use
on corn. (DP 351653). EPA–HQ–OPP–2005–
0162–0569.
47. Jones, R. David. 2008b. Additional
Refinements of the Drinking Water Exposure
Assessment for the Use of Carbofuran on
Corn and Melons. (DP 353714) Internal EPA
Memorandum to Jude Andreasen and
Thurston Morton, dated June 23, 2008. EPA–
HQ–OPP–2005–0162–0510.
48. Jones, R. David. (2008c) Updated
Refinements of the Drinking Water Exposure
Assessment for the Use of Carbofuran on
Corn and Melons, 8/18/2008. (DP 355584)
Internal EPA Memorandum to Jude
Andreasen and Thurston Morton, dated
August 18, 2008. EPA–HQ–OPP–2005–0162–
0516.
49. Lauzon, John D., Ivan P. O’Halloran,
David J. Fallow, A. Peter von Bertoldi, and
Doug Aspinall. 2005. Spatial Variability of
Soil Test Phosphorus, Potassium, and pH of
Ontario Soils. Agronomy Journal 97:524–532.
50. Lifshitz, Shahak, Bolotin, and Sofer.
1997. Carbamate Poisoning in Early
Childhood and in Adults. Clinical
Toxicology. 35: 25–27.
51. Marable BR, Maurissen JP, Mattsson JL,
Billington R. 2007. Differential sensitivity of
blood, peripheral, and central cholinesterases
in beagle dogs following dietary exposure to
chlorpyrifos. Regul Toxicol Pharmacol. 2007
Apr;47(3):240–8.
52. Mattsson, J. L., Maurissen, J. P., Nolan,
R. J., and Brzak, K. A. 2000. Lack of
differential sensitivity to cholinesterase
inhibition in fetuses and neonates compared
to dams treated perinatally with chlorpyrifos.
Toxicol Sci 53, 438–46.
53. McDaniel K.L. and Moser V.C. (2004)
Differential profiles of cholinesterase
inhibition and neurobehavioral effects in rats
exposed to fenamiphos or profenofos.
Neurotoxical Teratol. 26:407–415.
54. McDaniel K.L., Padilla S., Marshall
R.S., Phillips P.M., Podhorniak L., Qian Y.,
Moser V.C. (2007) Comparison of acute
neurobehavioral and cholinesterase
inhibitory effects of N-methyl carbamates in
rats. Toxicol. Sci. 98, 552–560.
55. Morton, T., 4/29/09, D358037,
Carbofuran Acute Aggregate Dietary (Food
and Drinking Water) Exposure and Risk
Assessments for the Reregistration Eligibility
Decision.
56. Moser V.C. (1995) Comparisons of the
acute effects of cholinesterase inhibitors
using a neurobehavioral screening battery in
rats. Neurotoxical Teratol 17: 617–625.
57. National Assessment of the Relative
Vulnerability of Community Water Supply
Reservoirs in Carbofuran Use Areas.
Performed by Waterborne Environmental
Inc., Leesburg, VA and Engel Consulting,
West Lafayette, IN. Submitted by FMC
PO 00000
Frm 00079
Fmt 4701
Sfmt 4700
59685
Corporation, Philadelphia, PA. WEI Report
No. 528.01–B, FMC Report No. PC–0387.
MRID 47272301. EPA–HQ–OPP–2007–1088–
0024.
58. National Resources Inventory 1992,
cited in USGS 2002, ‘‘Herbicide
Concentrations in the Mississippi River
Basin—the importance of chloracetanilide
degradates.’’ R.A. Rebich, R.H. Coupe,
E.M.Thurman.
59. Nostrandt, A.C., Padilla, S., and Moser,
V.C. (1997). The relationship of oral
chlorpyrifos effects on behavior,
cholinesterase inhibition, and muscarinic
receptor density in rat. Pharmacol. Biochem.
Behav. 58, 15–23.
60. Ott, Wayne R. 1995. Environmental
Statistics and Data Analysis. CRC Press. Boca
Raton, Florida.
61. Padilla S, Marshall RS, Hunter DL,
Oxendine S, Moser VC, Southerland SB,
Mailman RB. 2005. Neurochemical effects of
chronic dietary and repeated high-level acute
exposure to chlorpyrifos in rats. Toxicol Sci.
2005 Nov;88(1):161–71.
62. Padilla S., Marshall R.S., Hunter D.L.,
and Lowit A. 2007. Time course of
cholinesterase inhibition in adult rats treated
acutely with carbaryl, carbofuran,
formetanate, methomyl, methiocarb, oxamyl,
or propoxur. Toxicology and Applied
Pharmacology, 219; 202–209.
63. PND17 BMDs and BMDLs and recovery
half-lives for the effects of carbofuran on
brain and blood AChE (PND17_DR.pdf).
EPA–HQ–OPP–2007–1088–0047.
64. Richardson, J., and Chambers, J. (2003).
Effects of gestational exposure to chlorpyrifos
on postnatal central and peripheral
cholinergic neurochemistry. J Toxicol
Environ Health A 66, 275–89.
65. Richardson, J., and Chambers, J. 2005.
Effects if repeated oral postnatal exposure to
chlorpyrifos on cholinergic neurochemistry
in developing rats. Toxicol Sci 84, 352–59.
66. Report on cholinesterase sensitivity
study of carbofuran: Adult and PND11 MRID
47289001 (ORD study). EPA–HQ–OPP–2007–
1088–0065.
67. Revised Drinking Water Assessment in
Support of the Reregistration of Carbofuran
(PC Code 090601) (R. David Jones, 9/5/07
D3424057). EPA–HQ–OPP–2005–0162–0485.
68. Rupniak, NM, Jenner, P and Marsden,
CD. 1983. Cholinergic manipulation of
perioral behaviour induced by chronic
neuroleptic administration to rats.
Psychopharmacology 79 (2–3): 226–230.
69. Screening Level analysis of the small
business impacts of revoking carbofuran
tolerances. (Wyatt, T.J. July 2008) 28 pgs.
EPA–HQ–OPP–2005–0162–0506.
70. Setzer W. October 5, 2007. Dose-time
response modeling of rat brain AChE activity:
Carbofuran gavage dosing. 64 pgs. EPA–HQ–
OPP–2007–1088–0053.
71. Schwab, Hand, Costa and Murphy.
1981. Reduced Muscarinic Receptor Binding
in Tissues of Rats Tolerant to the Insecticide
Disulfoton. Neurotoxicology. 2: 635–647.
72. Somani, S. M. and Dube, S. N. 1989.
In vivo dose response relationship between
physostigmine and cholinesterase activity in
RBC and tissues of rat. Life Science 44, 1907–
1915.
73. Thelin, Gail P., and Leonard P.
Gianessi. 2000. Method for Estimating
E:\FR\FM\18NOR2.SGM
18NOR2
59686
Federal Register / Vol. 74, No. 221 / Wednesday, November 18, 2009 / Rules and Regulations
pwalker on DSK8KYBLC1PROD with RULES2
Pesticide Use for County Areas of the
Conterminous United States. U.S. Geological
Survey Open-File Report 00–250.
Sacramento, California, 2000. Available at:
https://water.usgs.gov/nawqa/pnsp/pubs/
ofr00250.
74. Trask, Jennifer R., and Joshua Amos.
2005. Watershed Regressions for Pesticides
(WARP) for Carbofuran in Illinois
Watersheds. Prepared by Waterborne
Environmental Inc., Leesburg, VA. WEI
362.07. (MRID 46688915) Submitted by FMC
Corporation, Philadephia, PA FMC Study
#P3786. EPA–HQ–OPP–2005–0162–0061.
75. USEPA (2000a) ‘‘Assigning Values to
Nondetected/Nonquantified Pesticide
Residues in Human Health Dietary Exposure
Assessments.’’ March 23, 2000. Available at:
https://www.epa.gov/pesticides/trac/science/
trac3b012.pdf.
76. USEPA. (2000b). ‘‘Benchmark Dose
Technical Guidance Document.’’ Draft report.
Risk Assessment Forum, Office of Research
and Development, U.S. Environmental
Protection Agency. Washington, DC. EPA/
630/R–00/001.
77. USEPA. (2000c) ‘‘Choosing a Percentile
of Acute Dietary Exposure as a Threshold of
Regulatory Concern.’’ March 16, 2000.
Available at: https://www.epa.gov/pesticides/
trac/science/trac2b054.pdf.
78. USEPA. (2000d). ‘‘The Use of Data on
Cholinesterase Inhibition for Risk
Assessments of Organophosphorous and
Carbamate Pesticides.’’ August 18, 2000.
Available at: https://www.epa.gov/pesticides/
trac/science/cholin.pdf.
79. USEPA. (2002). ‘‘Office of Pesticide
Programs’ Policy on the Determination of the
Appropriate FQPA Safety Factor(s) For Use
in Tolerance Assessment.’’ Available at:
https://www.epa.gov/oppfead1/trac/science/
determ.pdf.
80. USEPA Peer Review Handbook 3rd
Edition. 2006. Prepared for the U.S.
Environmental Protection Agency by
Members of the Peer Review Advisory Group,
for EPA’s Science Policy Council https://
www.epa.gov/peerreview/.
81. USEPA (2007a). ‘‘Revised N–Methyl
Carbamate Cumulative Risk Assessment U.S.
Environmental Protection Agency, Office of
VerDate Nov<24>2008
17:53 Nov 17, 2009
Jkt 220001
Pesticide Programs,’’ September 24, 2007.
Available at: https://www.epa.gov/oppsrrd1/
REDs/nmc_revised_cra.pdf.
82. USEPA (2007b). Carbaryl. HED Chapter
of the Reregistration Eligibility Decision
Document (RED). PC Code: 056801, DP
Barcode: D334770. 28 June 2007. EPA–HQ–
OPP–2007–0941–0003.
83. U.S. Environmental Protection Agency.
2008a. EPA response to the transmittal of
meeting minutes of the FIFRA Scientific
Advisory Panel Meeting held February 5–8
on the Agency’s proposed action under
FIFRA 6(b) Notice of Intent to Cancel
Carbofuran (3–26–08). E. Reaves et al., July
22, 2008, DP 352315. EPA–HQ–OPP–2005–
0162–0505.
84. USEPA (2009a) Jones, R. David, Reuben
Baris, and Marietta Echeverria. 2009.
Response to comments on EPA’s proposed
tolerance revocations for carbofuran
specifically related to drinking water
exposure assessment. Internal EPA
memorandum to Jude Andreasen dated April
29, 2009. D362182. EPA–HQ–OPP–2005–
0162–0565.
85. USEPA (2009b) Response to Comments
in Opposition to Proposed Tolerance
Revocations for Carbofuran Docket EPA–HQ–
OPP–2005–0162’’ submitted by the National
Potato Council, National Corn Growers
Association, National Cotton Council,
National Sunflower Association, and FMC
Corporation (September 29, 2008). April 29,
2009. EPA–HQ–OPP–2005–0162–0567.
86. Watershed Regressions for Pesticides
(WARP) Model Estimates for Carbofuran in
Illinois Watershed. Performed by Waterborne
Environmental, Inc., Leesburg, VA. WEI
362.07. Submitted by FMC Corporation,
Philadelphia, PA. Report No. P–3786. MRID
46688915. EPA–HQ–OPP–2007–1088–0021.
87. WHO JMPR, 1999. FAO/WHO Joint
Meeting on Pesticide Residues. Report of the
1998 FAO/WHO Joint Meeting on Pesticide
Residues. Food and Agriculture
Organization-United Nations. Rome, Italy.
https://www.fao.org.
88. Whyatt, R., Barr, D., Camann, D.,
Kinney, P., Barr, J., Andrews, H., et al.
(2003). Contemporary-use pesticides in
personal air samples during pregnancy and
PO 00000
Frm 00080
Fmt 4701
Sfmt 4700
blood samples at delivery among urban
minority mothers and newborns.
Environmental Health Perspectives, vol. 111,
num. 5, pp. 749–756.
89. Williams, W. M., (2007a) B. Engel, S.
Dasgupta, and C. G. Hoogeweg. An In-Depth
Investigation to Estimate Surface Water
Concentrations of Carbofuran within Indiana
Community Water Supplies. (MRID
47221603) Performed by Waterborne
Environmental, Inc., Leesburg, VA, Engel
Consulting, and Fawcett Consulting.
Submitted by FMC Corporation,
Philadelphia, PA. WEI No 528.01, FMC
Report No. PC–0378. EPA–HQ–OPP–2005–
0162–0453.
90. Williams, W. M. (2007b) B. Engel, J.
Amos, and C. G. Hoogeweg. National
Assessment of the Relative Vulnerability of
Community Water Supply Reservoirs in
Carbofuran Use Areas. (MRID 47272301)
Performed by Waterborne Environmental,
Inc.and Engel Consulting. Submitted by FMC
Corporation, Philadelphia, PA. EPA–HQ–
OPP–2005–0162–0463.
91. Zwiener RJ, Ginsburg CM. (1988)
Organophosphate and carbamate poisoning
in infants and children. Pediatrics 81:121–
126.
92. Vecchia, A.V. and Crawford, C. G.
(2006). Simulation of Daily Pesticide
Concentrations From Watershed
Characteristics and Monthly Climatic Data
USGS Scientific Investigations. USGS Report
2006–5181. 60 pgs.
List of Subjects in 40 CFR Part 180
Environmental protection,
Administrative practice and procedure,
Agricultural commodities, Pesticides
and pests, Reporting and recordkeeping
requirements.
Dated: October 30, 2009.
Debra Edwards,
Director, Office of Pesticide Programs.
[FR Doc. E9–27261 Filed 11–17–09; 8:45 am]
BILLING CODE 6560–50–P
E:\FR\FM\18NOR2.SGM
18NOR2
Agencies
[Federal Register Volume 74, Number 221 (Wednesday, November 18, 2009)]
[Rules and Regulations]
[Pages 59608-59686]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-27261]
[[Page 59607]]
-----------------------------------------------------------------------
Part II
Environmental Protection Agency
-----------------------------------------------------------------------
40 CFR Part 180
Carbofuran; Order Denying FMC's Objections and Requests for Hearing;
Final Rule
Federal Register / Vol. 74 , No. 221 / Wednesday, November 18, 2009 /
Rules and Regulations
[[Page 59608]]
-----------------------------------------------------------------------
ENVIRONMENTAL PROTECTION AGENCY
40 CFR Part 180
[EPA-HQ-OPP-2005-0162; FRL-8797-6]
Carbofuran; Order Denying FMC's Objections and Requests for
Hearing
AGENCY: Environmental Protection Agency (EPA).
ACTION: Order.
-----------------------------------------------------------------------
SUMMARY: In this order, EPA denies objections to, and requests for
hearing on, a final rule revoking all pesticide tolerances for
carbofuran under section 408(d) of the Federal Food, Drug, and Cosmetic
Act (FFDCA). The objections and hearing requests were filed on June 30,
2009, by the National Corn Growers Association, National Sunflower
Association, National Potato Council, and FMC Corporation
(``Petitioners'').
DATES: This final order is effective November 18, 2009.
ADDRESSES: EPA has established a docket for this action under docket
identification (ID) number EPA-HQ-OPP-2005-0162. To access the
electronic docket, go to https://www.regulations.gov, and search for the
docket number. Follow the instructions on the regulations.gov Web site
to view the docket index or access available documents. All documents
in the docket are listed in the docket index available in
regulations.gov. Although listed in the index, some information is not
publicly available, e.g., Confidential Business Information (CBI) or
other information whose disclosure is restricted by statute. Certain
other material, such as copyrighted material, is not placed on the
Internet and will be publicly available only in hard copy form.
Publicly available docket materials are available in the electronic
docket at https://www.regulations.gov, or, if only available in hard
copy, at the OPP Regulatory Public Docket in Rm. S-4400, One Potomac
Yard (South Bldg.), 2777 S. Crystal Dr., Arlington, VA. The Docket
Facility is open from 8:30 a.m. to 4 p.m., Monday through Friday,
excluding legal holidays. The Docket Facility telephone number is (703)
305-5805.
FOR FURTHER INFORMATION CONTACT: Jude Andreasen, Pesticide Re-
evaluation Division (7508P), Office of Pesticide Programs,
Environmental Protection Agency, 1200 Pennsylvania Ave., NW.,
Washington, DC 20460-0001; telephone number: (703) 308-9342; e-mail
address: andreasen.jude@epa.gov.
SUPPLEMENTARY INFORMATION:
I. General Information
A. Does this Action Apply to Me?
In this document EPA denies objections and hearing requests by the
National Corn Growers Association, National Sunflower Association,
National Potato Council, and FMC Corporation (``Petitioners'')
concerning EPA's final rule revoking all pesticide tolerances for
carbofuran. This action may also be of interest to agricultural
producers, food manufacturers, or pesticide manufacturers. Potentially
affected entities may include, but are not limited to:
Crop production (NAICS code 111).
Animal production (NAICS code 112).
Food manufacturing (NAICS code 311).
Pesticide manufacturing (NAICS code 32532).
This listing is not intended to be exhaustive, but rather provides
a guide for readers regarding entities likely to be affected by this
action. Other types of entities not listed in this unit could also be
affected. The North American Industrial Classification System (NAICS)
codes have been provided to assist you and others in determining
whether this action might apply to certain entities. If you have any
questions regarding the applicability of this action to a particular
entity, consult the person listed under FOR FURTHER INFORMATION
CONTACT.
B. How Can I Access Electronic Copies of this Document?
In addition to accessing an electronic copy of this Federal
Register document through the electronic docket at https://www.regulations.gov, you may access this Federal Register document
electronically through the EPA Internet under the Federal Register
listings at https://www.epa.gov/fedrgstr. You may also access a
frequently updated electronic version of EPA's tolerance regulations at
40 CFR part 180 through the Government Printing Office's pilot e-CFR
site at https://www.gpoaccess.gov/ecfr.
C. Acronyms
The following is a list of acronyms used in this order:
AChE--Acetylcholinesterase
aPAD--Acute Population Adjusted Dose
BMD--Bench Mark Dose
BMDL--Bench Mark Dose Level
CCA--Comparative Cholinesterase Assay
CNS--Central Nervous System
CRA--Cumulative Risk Assessment
CSFII--Continuing Survey of Food Intakes by Individuals
CWA--Clean Water Act
CWS--Community Water System
DEEM-FCID--Dietary Exposure Evaluation Model-Food Commodity Intake
Database
ECG--Electrocardiogram
EDWC--Estimated Drinking Water Concentration
EPA--Environmental Protection Agency
FACA--Federal Advisory Committee Act
FDA--Food and Drug Administration
FIFRA--Federal Insecticide, Fungicide, and Rodenticide Act
FFDCA--Federal Food, Drug, and Cosmetic Act
FQPA--Food Quality Protection Act of 1996
HSRB--Human Studies Review Board
HUC-8--8-digit hydrologic unit code
IRED--Interim Reregistration Eligibility Decision
LD50--Lethal Dose for 50% of a population
LOAEL--Lowest Observable Adverse Effect Level
NAWQA--National Water Quality Assessment Program
NHEERL--National Health and Environmental Effects Laboratory
NMC CRA--N-Methyl Carbamate Cumulative Risk Assessment
NOAEL--No Observable Adverse Effect Level
NOIC--Notice of Intent to Cancel
NRDC--National Resources Defense Council
OP--Organophosphate
ORD--Office of Research and Development
PAD--Population Adjusted Dose
PCA--Percent Cropped Area
PCT--Percent Crop Treated
PDP--Pesticide Data Program
PND--Post-Natal Day
PNS--Peripheral Nervous System
PoD--Point of Departure
ppb--parts per billion
ppm--parts per million
PRZM-EXAMS--Pesticide Root Zone Model-Exposure Analysis Model System
RBC--red blood cell
RED--Reregistration Eligibility Decision
RfD--Reference Dose
SAP--Scientific Advisory Panel
SDWA--Safe Drinking Water Act
USDA--United States Department of Agriculture
USGS--United States Geological Survey
WARP--Watershed Regression for Pesticides
II. Introduction
A. What Action Is the Agency Taking?
Exposure to the pesticide carbofuran resulting from existing legal
uses is unsafe--unsafe for the general
[[Page 59609]]
population, and particularly unsafe for infants and children. EPA
reached this conclusion in 2006 after an exhaustive multi-year review
of the data on carbofuran as part of its effort to determine whether
carbofuran should be reregistered under the Federal Insecticide,
Fungicide, and Rodenticide Act (``FIFRA''), and whether the tolerances
allowing carbofuran residues on certain foods met the revised safety
standard in section 408 of the FFDCA. This multi-year review included
multiple opportunities for public participation, including no less than
four formal public comment periods. Following EPA review of yet more
carbofuran data submitted by FMC, the carbofuran registrant, and the
review of EPA's science findings by the FIFRA Scientific Advisory Panel
(SAP)--an independent scientific peer review panel--EPA again reached
the same conclusion in its July 31, 2008 proposal to revoke the
carbofuran tolerances (73 FR 44864 (July 31, 2008)). In response to
this proposed revocation, FMC submitted comments challenging many of
EPA's science findings and also requesting the cancellation of the
registration of carbofuran on several crops and the restriction of
where, and the manner in which, carbofuran could be used in the United
States on its remaining registered crop sites. Finding FMC's science
arguments to be flawed and its proposed amendments to the carbofuran
registration to be insufficient, EPA finalized the rule revoking
carbofuran tolerances on May 15, 2009 (74 FR 23046 (May 15, 2009)).
Pursuant to the procedures of the FFDCA, on June 29, 2009
objections to the final revocation rule were filed by the National Corn
Growers Association, National Sunflower Association, National Potato
Council, and FMC Corporation (``Petitioners''). The Petitioners also
requested a hearing on their objections. Coupled with these objections,
FMC filed on the same day yet another series of proposed amendments to
its carbofuran registration. These proposed modifications contained new
application and geographic restrictions as well as an unprecedented
non-governmental scheme for preventing the use of carbofuran in any one
area of the country above a small percentage of that area's
agricultural acreage. The Petitioners relied on these proposed
carbofuran registration amendments as central to, and inextricably
intertwined with, their objection to EPA's prior determination in the
final rule that carbofuran tolerances are unsafe. Specific challenges
raised by the Petitioners involved EPA's decision on the appropriate
level of the additional safety factor to protect infants and children,
EPA's estimate of carbofuran levels in drinking water, EPA's
consideration of the time needed to recover from exposure to
carbofuran, and EPA's refusal to consider a human toxicity study
conducted with carbofuran.
Today's order denies all of the Petitioners' objections and
requests for hearing. A principal flaw in the Petitioners' objections
is that they have objected to EPA's determination in the final rule on
the safety of carbofuran based on the FIFRA registration amendments
that FMC filed with EPA 45 days after the safety determination was
made. As such, the Petitioners' objections are irrelevant, and thus
immaterial, to the determination EPA made in the final rule. FMC has
the statutory right under FIFRA to request amendment of its carbofuran
registration. What Petitioners may not do is prolong the FFDCA
tolerance revocation process by challenging EPA's safety determination
based on proposed FIFRA registration changes not before EPA at the time
of its final revocation decision.
It should be noted that EPA's decision on the carbofuran tolerances
is not a determination on FMC's proposed registration amendments. FMC
may continue to pursue these amendments and also the re-establishment
of carbofuran tolerances in light of the amendments. Further, FMC may
seek administrative review, and potentially an administrative hearing,
with regard to any adverse decision issued by EPA on its proposed
amendments. But that process must be played out in the future, a future
in which any decision about the safety of carbofuran is made prior to
the re-introduction of carbofuran residues in food and water, rather
than concurrent with the continued exposure of infants and children to
levels of carbofuran residues that EPA has found to be unsafe.
Despite the fact that a central aspect of the Petitioners'
objections is based on a flawed conception of the objection process
(i.e., the notion that the objection process presents the opportunity
for a complete reformulation of the matter in dispute, rather than a
chance for a review of the accuracy of EPA's earlier determination),
EPA has undertaken a comprehensive analysis of the merits of each of
the Petitioners' objections and hearing requests. That analysis shows,
as is exhaustively set out in Unit VI, that none of the Petitioners'
requests for hearing meets the regulatory standard for granting a
hearing and none of the Petitioners' objections has merit. There are
numerous reasons for these conclusions, but two related themes running
throughout EPA's analysis are the Petitioners' failure to timely raise
issues or submit supporting documents during the public comment process
on the proposed rule and the Petitioners' failure to object to how EPA,
in the final rule, resolved the issues the Petitioners did raise in the
comment process. EPA considers issues untimely raised to be waived--as
EPA clearly warned at the proposal stage--and finds recycled comments
on the proposed rule to be irrelevant to the detailed determinations
made in the final rule. The rulemaking phase of the revocation process
has a purpose, and parties treat it lightly at their peril. Finally,
EPA notes that an additional problem with the Petitioners' objections
is that once the newly proposed registration amendments are stripped
from the objections, it is not at all clear that any remaining issues,
even if concluded in the Petitioners' favor, would result in lowering
carbofuran's estimated risks--which EPA has estimated as far exceeding
the safety standard--to an acceptable level. For all of these reasons,
the Petitioners' objections and hearing requests are denied.
B. What Is the Agency's Authority for Taking This Action?
EPA is taking this action pursuant to the authority in FFDCA
section 408(g)(2)(C), which requires the Agency to issue a final order
resolving the objections to its final rule, issued pursuant to
408(b)(1)(b), 408(b)(2)(A), and 408(e)(1)(A). 21 U.S.C. 346a(b)(1)(b),
(b)(2)(A), (e)(1)(A), (g)(2)(C).)
III. Statutory and Regulatory Background
In this Unit, EPA provides background on the relevant statutes and
regulations governing the Petitioners' objections and requests for
hearing as well as on pertinent Agency policies and practices.
A. FFDCA/FIFRA and Applicable Regulations
1. In general. EPA establishes maximum residue limits, or
``tolerances,'' for pesticide residues in food under section 408 of the
FFDCA (21 U.S.C. 346a). Without such a tolerance or an exemption from
the requirement of a tolerance, a food containing a pesticide residue
is ``adulterated'' under section 402 of the FFDCA and may not be
legally moved in interstate commerce (21 U.S.C. 331,
[[Page 59610]]
342). Monitoring and enforcement of pesticide tolerances are carried
out by the U.S. Food and Drug Administration (``FDA'') and the U.S.
Department of Agriculture (``USDA''). Section 408 was substantially
rewritten by the Food Quality Protection Act of 1996 (``FQPA''), which
added the provisions discussed below establishing a detailed safety
standard for pesticides, additional protections for infants and
children, and the process for establishing or revoking tolerances (Pub.
L. 104-170, 110 Stat. 1489 (1996)).
EPA also regulates pesticides under the Federal Insecticide,
Fungicide, and Rodenticide Act (``FIFRA'') (7 U.S.C. 136 et seq.).
While the FFDCA authorizes the establishment of legal limits for
pesticide residues in food, FIFRA requires the approval of pesticides
prior to their sale and distribution (7 U.S.C. 136a(a)), and
establishes a registration regime for regulating the use of pesticides.
FIFRA regulates pesticide use in conjunction with its registration
scheme by requiring EPA review and approval of pesticide labels and
specifying that use of a pesticide inconsistent with its label is a
violation of federal law (7 U.S.C. 136j(a)(2)(G)). In the FQPA,
Congress integrated action under the two statutes by requiring that the
safety standard under the FFDCA be used as a criterion in FIFRA
registration actions as to pesticide uses that result in dietary risk
from residues in or on food (7 U.S.C. 136(bb)), and directing that EPA
coordinate, to the extent practicable, revocations of tolerances with
pesticide cancellations under FIFRA. (21 U.S.C. 346a(l)(1)).
2. Safety standard for pesticide tolerances. Section
408(b)(2)(A)(i) of the FFDCA requires EPA to modify or revoke a
tolerance if EPA determines that the tolerance is not ``safe'' (21
U.S.C. 346a(b)(2)(A)(ii)). Section 408(b)(2)(A)(ii) of the FFDCA
defines ``safe'' to mean that ``there is a reasonable certainty that no
harm will result from aggregate exposure to the pesticide chemical
residue, including all anticipated dietary exposures and all other
exposures for which there is reliable information.'' This includes
exposure through drinking water and in residential settings, but does
not include occupational exposure. Section 408(b)(2)(D) directs EPA, in
making a safety determination, to:
Consider, among other relevant factors--* * *
(vi) Available information concerning the aggregate exposure levels
of consumers (and major identifiable subgroups of consumers) to the
pesticide chemical residue and to other related substances, including
dietary exposure under the tolerance and all other tolerances in effect
for the pesticide chemical residue, and exposure from other non-
occupational sources;
EPA must also consider, in evaluating the safety of tolerances,
``safety factors which * * * are generally recognized as appropriate
for the use of animal experimentation data.'' (21 U.S.C.
346a(b)(2)(D)(ix).)
Risks to infants and children are given special consideration.
Specifically, section 408(b)(2)(C) states that EPA:
Shall assess the risk of the pesticide chemical based on--* * *
(II) Available information concerning the special susceptibility
of infants and children to the pesticide chemical residues,
including neurological differences between infants and children and
adults, and effects of in utero exposure to pesticide chemicals;
(21 U.S.C. 346a(b)(2)(C)(i)(II) and (III)). This provision also
creates a presumptive additional safety factor for the protection of
infants and children. Specifically, it directs that ``[i]n the case of
threshold effects, * * * an additional tenfold margin of safety for the
pesticide chemical residue and other sources of exposure shall be
applied for infants and children to take into account potential pre-
and post-natal toxicity and completeness of the data with respect to
exposure and toxicity to infants and children'' (21 U.S.C.
346a(b)(2)(C)). EPA is permitted to ``use a different margin of safety
for the pesticide chemical residue only if, on the basis of reliable
data, such margin will be safe for infants and children'' (Id.). The
additional safety margin for infants and children is referred to
throughout this order as the ``children's safety factor.''
3. Procedures for establishing, amending, or revoking tolerances.
Tolerances are revoked by rulemaking under the unique procedural
framework set forth in the FFDCA. Section 408(e) of the FFDCA, 21
U.S.C. 346a(e), authorizes EPA to modify or revoke tolerances on its
own initiative.
In issuing a regulation on its own initiative, EPA must first
publish a notice of proposed rulemaking, and must generally provide at
least 60 days to allow the public to comment on the proposed
regulation. After considering comments submitted during this comment
period, EPA issues a final rule.
Once EPA issues a final rule, any person may file objections with
EPA and, if desired, request an evidentiary hearing on those objections
(21 U.S.C. 346a(g)(2)). Objections must specify ``with particularity
the provisions of the regulation * * * deemed objectionable and stating
reasonable grounds therefore'' (21 U.S.C. 346a(g)(2)(A); 40 CFR
178.25(a)). Objections and hearing requests must be filed within 60
days (Id.). The statute provides that EPA shall ``hold a public
evidentiary hearing if and to the extent the Administrator determines
that such a public hearing is necessary to receive factual evidence
relevant to material issues of fact raised by the objections'' (21
U.S.C. 346a(g)(2)(B)). EPA regulations make clear that hearings will
only be granted where it is shown that there is ``a genuine and
substantial issue of fact;'' the requestor has identified evidence
``which, if established, will resolve one or more of such issues in
favor of the requestor,'' and the issue is ``determinative'' with
regard to the relief requested (40 CFR 178.32(b)). After consideration
of any objections, EPA must issue a final order stating the action
taken in response to each objection, including a determination as to
whether any hearing is appropriate (21 U.S.C. 346a(g)(2)(C)). The final
order also establishes any revisions to the final regulation EPA deems
to be warranted based on the objections. Id. EPA's final order on the
objections is subject to judicial review in the Court of Appeals,
within 60 days of the publication of the order (21 U.S.C. 346a(h)(1)).
4. Tolerance reassessment and FIFRA reregistration. EPA revoked the
carbfuran tolerances to implement the Agency's findings made during the
reregistration and tolerance reassessment processes.
The FQPA required that EPA reassess the safety of all pesticide
tolerances existing at the time of its enactment. (21 U.S.C. 346a(q)).
EPA was given 10 years to reassess the approximately 10,000 tolerances
in existence in 1996. In this reassessment, EPA was required to review
existing pesticide tolerances under the new ``reasonable certainty that
no harm will result'' standard set forth in section 408(b)(2)(A)(i).
(21 U.S.C. 346a(b)(2)(A)(i)). This reassessment was substantially
completed by the August 3, 2006 deadline. Tolerance reassessment was
generally handled in conjunction with a similar program involving
reregistration of pesticides under FIFRA. (7 U.S.C. 136a-1).
Reassessment and reregistration decisions were generally combined in a
document labeled a Reregistration Eligibility Decision (RED).
[[Page 59611]]
B. EPA's Human Research Rule
EPA decisions regarding the use of human studies in pesticide
regulatory decisions are governed by the Protection for Subjects in
Human Research final rule (``Human Research rule''), which
significantly strengthened and expanded protections for subjects of
human research (71 FR 6138 (February 6, 2006)). The framework of the
Human Research rule rests on the basic principle that EPA will not, in
its actions, rely on data derived from unethical research. The rule
divides studies involving intentional dosing of human subjects into two
groups: ``new'' studies--those initiated after April 7, 2006 (the
effective date of the rule)--and ``old'' studies--those initiated
before April 7, 2006. The Human Research Rule forbids EPA from relying
on data from any ``new'' study, unless EPA has adequate information to
determine that the research was conducted in substantial compliance
with the ethical requirements contained therein (40 CFR 26.1705). These
ethical rules are derived primarily from the ``Common Rule,'' (40 CFR
part 26), a rule setting ethical parameters for studies conducted or
supported by the federal government. In addition to requiring informed
consent and protection of the safety of the subjects, among other
things, the rule specifies that ``[r]isks to subjects [must be]
reasonable in relation to * * * the importance of the knowledge that
may reasonably be expected to result [from the study].'' (40 CFR
26.1111(a)(2)). In other words, a study would be judged unethical if it
did not have scientific value outweighing any risks to the test
subjects.
As to ``old'' studies, the Human Research Rule forbids EPA from
relying on such data if there is clear and convincing evidence that the
conduct of the research was fundamentally unethical or significantly
deficient with respect to the ethical standards prevailing at the time
the research was conducted (40 CFR 26.1704). EPA has indicated that in
evaluating ``the ethical standards prevailing at the time the research
was conducted'' it will consider the Nuremburg Code, various editions
of the Declaration of Helsinki, the Belmont Report, and the Common
Rule, as among the standards that may be applicable to any particular
study (71 FR at 6161). Further, reflecting the concern that
scientifically invalid data are ``always unethical,'' (71 FR at 6160),
the rule limits the human research that can be relied upon by EPA to
``scientifically valid and relevant data'' (40 CFR 26.1701).
Whether the data are ``new'' or ``old,'' the Human Research rule
forbids EPA from relying on data from any study involving intentional
exposure of pregnant women, fetuses, or children subject to a very
limited exception (40 CFR 26.1703, 1706).
To aid EPA in making scientific and ethical determinations under
the Human Research rule, the rule established an independent Human
Studies Review Board (HSRB) to review both proposals for new research
(new studies) and reports of completed human research (old studies) on
which EPA proposes to rely (40 CFR 26.1603). The rule directs that the
HSRB shall be comprised of non-EPA employees ``who have expertise in
fields appropriate for the scientific and ethical review of human
research, including research ethics, biostatistics, and human
toxicology'' (40 CFR 26.1603(a)). If EPA decides to rely on the results
from ``old'' research conducted to identify or measure a toxic effect,
EPA must submit the results of its assessment to the HSRB for
evaluation of the ethical and scientific merit of the research (40 CFR
26.1602(b)(2)).
EPA has established the HSRB as a federal advisory committee under
the Federal Advisory Committee Act (FACA) to take advantage of ``the
benefits of the transparency and opportunities for public
participation'' that accompany a FACA committee (71 FR at 6156). The
HSRB, as appointed by EPA, contains approximately 16 distinguished
experts in the fields of bioethics, biostatistics, human health risk
assessment and human toxicology, primarily from academia (Ref. 10).
IV. EPA's Approach to Dietary Risk Assessment
EPA performs a number of analyses to determine the risks from
aggregate exposure to pesticide residues. A short summary is provided
below to aid the reader. For further discussion of the regulatory
requirements of section 408 of the FFDCA and a complete description of
the risk assessment process, see https://www.epa.gov/fedrgstr/EPA-PEST/1999/January/Day-04/p34736.htm.
To assess the risk of a pesticide tolerance, EPA combines
information on pesticide toxicity with information regarding the route,
magnitude, and duration of exposure to the pesticide. The risk
assessment process involves four distinct steps: (1) Identification of
the toxicological hazards posed by a pesticide; (2) determination of
the exposure ``level of concern'' for humans; (3) estimation of human
exposure; and (4) characterization of human risk based on comparison of
human exposure to the level of concern.
A. Hazard Identification and Selection of Toxicological Endpoint
1. In General. Any risk assessment begins with an evaluation of a
chemical's inherent properties, and whether those properties have the
potential to cause adverse effects (i.e., hazard identification). EPA
then evaluates the hazards to determine the most sensitive and
appropriate adverse effect of concern, based on factors such as the
effect's relevance to humans and the likely routes of exposure.
Once a pesticide's potential hazards are identified, EPA determines
a toxicological level of concern for evaluating the risk posed by human
exposure to the pesticide. In this step of the risk assessment process,
EPA essentially evaluates the levels of exposure to the pesticide at
which effects might occur. An important aspect of this determination is
assessing the relationship between exposure (dose) and response (often
referred to as the dose-response analysis). In evaluating a chemical's
dietary risks EPA uses a reference dose (RfD) approach, which involves
a number of considerations including:
A `point of departure' (PoD)--the value from a dose-
response curve that is at the low end of the observable data and that
is the dose that serves as the `starting point' in extrapolating a risk
to the human population;
An uncertainty factor to address the potential for a
difference in toxic response between humans and animals used in
toxicity tests (i.e., interspecies extrapolation);
An uncertainty factor to address the potential for
differences in sensitivity in the toxic response across the human
population (i.e., intraspecies variability); and
The need for an additional safety factor to protect
infants and children, as specified in FFDCA section 408(b)(2)(C).
EPA uses the chosen PoD to calculate a safe dose or RfD. The RfD is
calculated by dividing the chosen PoD by all applicable safety or
uncertainty factors. Typically in EPA risk assessments, a combination
of safety or uncertainty factors providing at least a hundredfold
(100X) margin of safety is used: 10X to account for interspecies
extrapolation and 10X to account for intraspecies variability. Further,
as required by FFDCA section 408(b)(2)(C), in evaluating the dietary
risks for pesticide chemicals, an additional safety factor of 10X is
presumptively applied to protect infants and children, unless reliable
data support selection of a different
[[Page 59612]]
factor. In implementing FFDCA section 408, EPA also calculates a
variant of the RfD referred to as a Population Adjusted Dose (PAD). A
PAD is the RfD divided by any portion of the children's safety factor
that does not correspond to one of the traditional additional
uncertainty/safety factors used in general Agency risk assessment. The
reason for calculating PADs is so that other parts of the Agency, which
are not governed by FFDCA section 408, can, when evaluating the same or
similar substances, easily identify which aspects of a pesticide risk
assessment are a function of the particular statutory commands in FFDCA
section 408. For acute assessments, the risk is expressed as a
percentage of a maximum acceptable dose or the acute PAD (i.e., the
acute dose which EPA has concluded will be ``safe''). As discussed
below in Unit V.C., dietary exposures greater than 100 percent of the
acute PAD are generally cause for concern and would be considered
``unsafe'' within the meaning of FFDCA section 408(b)(2)(B). Throughout
this document general references to EPA's calculated safe dose are
denoted as an acute PAD, or aPAD, because the relevant point of
departure for carbofuran is based on an acute risk endpoint.
2. Acetylcholinesterase Inhibition. Carbofuran is a member of the
class of pesticides called N-methyl carbamates (NMCs). The primary
toxic effect caused by NMCs, including carbofuran, is neurotoxicity
resulting from inhibition of the enzyme acetylcholinesterase (AChE).
The toxicity profile of these pesticides is characterized by rapid time
to onset of effects followed by rapid recovery (minutes to hours).
Consistent with its mechanism of action, toxicity data on AChE
inhibition from laboratory rats provide the basis for deriving the PoD
for carbofuran.
AChE inhibition is a disruption of the normal process in the body
by which the nervous system chemically communicates with muscles and
glands. Communication between nerve cells and a target cell (i.e.,
another nerve cell, a muscle fiber, or a gland) is facilitated by the
chemical, acetylcholine. When a nerve cell is stimulated it releases
acetylcholine into the synapse (or space) between the nerve cell and
the target cell. The released acetylcholine binds to receptors in the
target cell, stimulating the target cell in turn. As EPA has explained,
``the end result of the stimulation of cholinergic pathway(s) includes,
for example, the contraction of smooth (e.g., in the gastrointestinal
tract) or skeletal muscle, changes in heart rate or glandular secretion
(e.g., sweat glands) or communication between nerve cells in the brain
or in the autonomic ganglia of the peripheral nervous system.'' (Ref.
78 at 10).
AChE is an enzyme that breaks down acetylcholine and terminates its
stimulating action in the synapse between nerve cells and target cells.
When AChE is inhibited, acetylcholine builds up prolonging the
stimulation of the target cell. This excessive stimulation potentially
results in a broad range of adverse effects on many bodily functions
including muscle cramping or paralysis, excessive glandular secretions,
or effects on learning, memory, or other behavioral parameters.
Depending on the degree of inhibition these effects can be serious,
even fatal.
EPA's cholinesterase inhibition policy statement explains EPA's
approach to evaluating the risks posed by AChE-inhibiting pesticides
such as carbofuran (Ref. 78 at 10). The policy focuses on three types
of effects associated with AChE-inhibiting pesticides that may be
assessed in animal and human toxicological studies: (1) Physiological
and behavioral/functional effects; (2) AChE inhibition in the central
and peripheral nervous system; and (3) AChE inhibition in red blood
cells and blood plasma. The policy discusses how such data should be
integrated in deriving an acceptable dose (RfD/PAD) for a AChE-
inhibiting pesticide.
After clinical signs or symptoms, AChE inhibition in the nervous
system provides the next most important endpoint for evaluating AChE-
inhibiting pesticides. Although AChE inhibition in the nervous system
is not itself regarded as a direct adverse effect, it is ``generally
accepted as a key component of the mechanism of toxicity leading to
adverse cholinergic effects'' (Id. at 25). As such, the policy states
that it should be treated as ``direct evidence of potential adverse
effects'' and ``data showing this response provide valuable information
in assessing potential hazards posed by antiAChE pesticides'' (Id.).
Unfortunately, useful data measuring AChE inhibition in the peripheral
nervous system tissues has only been relatively rarely captured by
standard toxicology testing, particularly for the NMC compounds. For
central nervous system effects, however, more recent neurotoxicity
studies ``have sought to characterize the time course of inhibition in
* * * [the] brain, including brain regions, after acute and 90-day
exposures'' (Id. at 27).
AChE inhibition in the blood is one step further removed from the
direct harmful consequences of AChE-inhibiting pesticides. According to
the policy, inhibition of blood AChEs ``is not an adverse effect, but
may indicate a potential for adverse effects on the nervous system''
(Id. at 28). The policy states that ``[a]s a matter of science policy,
blood AChE data are considered appropriate surrogate measures of
potential effects on peripheral nervous system AChE activity in
animals, for central nervous system (``CNS'') AChE activity in animals
when CNS data are lacking and for both peripheral and central nervous
system AChE in humans'' (Id. at 29). The policy notes that ``there is
often a direct relationship between a greater magnitude of exposure [to
a AChE-inhibiting pesticide] and an increase in incidence and severity
of clinical signs and symptoms as well as blood AChE inhibition'' (Id.
at 30). Thus, the policy regards blood AChE data as ``appropriate
endpoints for derivation of reference doses or concentrations when
considered in a weight-of-the-evidence analysis of the entire database
* * *'' (Id. at 29). Between AChE inhibition measured in red blood cell
(``RBC'') or blood plasma, the policy states a preference for reliance
on RBC AChE measurements because plasma is composed of a mixture of
acetylcholinesterase and butyrylcholinesterase, and inhibition of the
latter is less clearly tied to inhibition of acetylcholinesterase in
the nervous system (Id. at 29, 32).
EPA has relied on a benchmark dose (BMD) approach for deriving the
PoD from the available rat toxicity studies. A BMD is a point estimate
along a dose-response curve that corresponds to a specific response
level. For example, a BMD10 represents a 10% change from the
background; 10% is often used as a typical value for the response of
concern (Ref. 76). Generically, the direction of change from background
can be an increase or a decrease depending on the biological parameter
and the chemical of interest. In the case of carbofuran, inhibition of
AChE is the toxic effect of concern. Following exposure to carbofuran,
the normal biological activity of the AChE enzyme is decreased (i.e.,
the enzyme is inhibited). Thus, when evaluating BMDs for carbofuran,
the Agency is interested in a decrease in AChE activity compared to
normal activity levels, which are also termed ``background'' levels.
Measurements of ``background'' AChE activity levels are usually
obtained from animals in experimental studies that are not treated with
the pesticide of interest (i.e., ``negative control'' animals).
In addition to the BMD, a confidence limit was also calculated.
Confidence limits express the uncertainty in a BMD that may be due to
sampling and/or
[[Page 59613]]
experimental error. The lower confidence limit on the dose used as the
BMD is termed the BMDL, which the Agency uses as the PoD. Use of the
BMDL for deriving the PoD rewards better experimental design and
procedures that provide more precise estimates of the BMD, resulting in
tighter confidence intervals. Use of the BMDL also helps ensure with
high confidence (e.g., 95% confidence) that the selected percentage of
AChE inhibition is not exceeded. From the PoD, EPA calculates the RfD
and aPAD. Specific to carbofuran and the other NMCs, EPA the FIFRA SAP
has reviewed and supported the statistical methods used to derive the
BMD and BMDLs on multiple occasions (Refs. 34, 35, 36).
In the Agency's BMD analysis for carbofuran, EPA used a response
level of 10% brain AChE inhibition; this value represents the estimated
dose where AChE is inhibited by 10%, compared to untreated animals. For
the last several years EPA has used the 10% value to regulate AChE
inhibiting pesticides, including organophosphorous pesticides (OPs) and
NMCs. For a variety of toxicological and statistical reasons, EPA chose
10% brain AChE inhibition as the response level for use in BMD
calculations. EPA analyses have demonstrated that 10% is a level that
can be reliably measured in the majority of rat toxicity studies; is
generally at or near the limit of sensitivity for discerning a
statistically significant decrease in AChE activity across the brain
compartment; and is a response level close to the background (Refs. 34,
35).
B. Estimating Human Dietary Exposure Levels
Pursuant to section 408(b) of the FFDCA, EPA has evaluated
carbofuran's dietary risks based on ``aggregate exposure'' to
carbofuran. By ``aggregate exposure,'' EPA is referring to exposure to
carbofuran by multiple pathways of exposure. EPA uses available data
and standard analytical methods, together with assumptions designed to
be protective of public health, to produce separate estimates of
exposure for a highly exposed subgroup of the general population, for
each potential pathway and route of exposure. For acute risks, EPA then
calculates potential aggregate exposure and risk by using probabalistic
\1\ techniques to combine distributions of potential exposures in the
population for each route or pathway. For dietary analyses, the
relevant sources of potential exposure to carbofuran are from the
ingestion of residues in food and drinking water. The Agency uses a
combination of monitoring data and predictive models to evaluate
environmental exposure of humans to carbofuran.
---------------------------------------------------------------------------
\1\ Probabilistic analysis is used to predict the frequency with
which variations of a given event will occur. By taking into account
the actual distribution of possible consumption and pesticide
residue values, probabilistic analysis for pesticide exposure
assessments ``provides more accurate information on the range and
probability of possible exposure and their associated risk values''
(Ref. 77). In capsule, a probabilistic pesticide exposure analysis
constructs a distribution of potential exposures based on data on
consumption patterns and residue levels and provides a ranking of
the probability that each potential exposure will occur. People
consume differing amounts of the same foods, including none at all,
and a food will contain differing amounts of a pesticide residue,
including none at all.
---------------------------------------------------------------------------
1. Exposure from Food. The level of human exposure to pesticide
residues in food is a function of both the pesticide residues in food
and the amount of food consumed. Data on the residues of carbofuran in
foods are available from a variety of sources. One of the primary
sources of data comes from federally-conducted surveys, including the
Pesticide Data Program (PDP) conducted by the USDA. Further, market
basket surveys, which are typically performed by registrants, can
provide additional residue data. These data generally provide a
characterization of pesticide residues in or on foods consumed by the
U.S. population that closely approximates real world exposures because
they are sampled closer to the point of consumption in the chain of
commerce than field trial data, which are generated to establish the
maximum level of legal residues that could result from maximum
permissible use of the pesticide. In certain circumstances, when EPA
believes the information will provide more accurate exposure estimates,
EPA will rely on field trial data (see below in Unit VI.E.1).
EPA relies on USDA's Continuing Survey of Food Intake by
Individuals (CSFII) for information on food consumption by the US
population as well as 32 subgroups based on age, gender, ethnicity, and
region. The latest CSFII was conducted in 1994-1996 and 1998. The 1998
survey was a special survey required by the FQPA to supplement the
number of children survey participants. DEEM-FCID also contains
``recipes'' that convert foods as consumed (e.g., pizza) back into
their component raw agricultural commodities (e.g., wheat from flour,
or tomatoes from sauce, etc.). This is necessary because residue data
are generally gathered on raw agricultural commodities rather than on
finished ready-to-eat food. Data on residue values for a particular
pesticide and the RfD or PADs for that pesticide are inputs to the
DEEM-FCID computer program to estimate exposure and risk.
The DEEM-FCID computer program estimates exposure by combining data
on human consumption amounts with residue values in food commodities.
DEEM-FCID also compares exposure estimates to appropriate RfD or PAD
values to estimate risk. EPA uses DEEM-FCID to estimate exposure for
the general U.S. population as well as for 32 subgroups based on age,
sex, ethnicity, and region. DEEM-FCID allows EPA to process extensive
volumes of data on human consumption amounts and residue levels in
making risk estimates. Matching consumption and residue data, as well
as managing the thousands of repeated analyses of the consumption
database conducted under probabilistic risk assessment techniques,
requires the use of a computer.
For carbofuran's assessment, EPA used DEEM-FCID to calculate risk
estimates based on a probabilistic distribution. DEEM-FCID combines the
full range of residue values for each food with the full range of data
on individual consumption amounts to create a distribution of exposure
and risk levels. More specifically, DEEM-FCID creates this distribution
by calculating an exposure value for each reported day of consumption
per person (``person/day'') in CSFII, assuming that all foods
potentially bearing the pesticide residue contain such residue at a
value selected randomly from the exposure data sets. The exposure
amounts for the thousands of person/days in the CSFII are then
collected in a frequency distribution. EPA also uses DEEM-FCID to
compute a distribution taking into account both the full range of data
on consumption levels and the full range of data on potential residue
levels in food. Combining consumption and residue levels into a
distribution of potential exposures and risk requires use of
probabilistic techniques.
The probabilistic technique that DEEM-FCID uses to combine
differing levels of consumption and residues involves the following
steps:
(1) Identification of any food(s) that could bear the residue in
question for each person/day in the CSFII;
(2) Calculation of an exposure level for each of the thousands of
person/days in the CSFII database, based on the foods identified in
Step 1 by randomly selecting residue values for the foods from
the residue database;
(3) Repetition of Step 2 one thousand times for each
person/day; and
[[Page 59614]]
(4) Collection of all of the hundreds of thousands of potential
exposures estimated in Steps 2 and 3 in a frequency
distribution.
The resulting probabilistic assessment presents a range of
exposure/risk estimates.
2. Exposure from water. EPA may use field monitoring data and/or
simulation water exposure models to generate pesticide concentration
estimates in drinking water. Monitoring and modeling are both important
tools for estimating pesticide concentrations in water and can provide
different types of information. Monitoring data can provide estimates
of pesticide concentrations in water that are representative of the
specific agricultural or residential pesticide practices in specific
locations, under the environmental conditions associated with a
sampling design (i.e., the locations of sampling, the times of the year
samples were taken, and the frequency by which samples were collected).
Although monitoring data can provide a direct measure of the
concentration of a pesticide in water, it does not always provide a
reliable basis for estimating spatial and temporal variability in
exposures because sampling may not occur in areas with the highest
pesticide use, and/or when the pesticides are being used and/or at an
appropriate sampling frequency to detect high concentrations of a
pesticide that occur over the period of a day to several days.
Because of the limitations in most monitoring studies, EPA's
standard approach is to use simulation water exposure models as the
primary means to estimate pesticide exposure levels in drinking water.
Modeling is a useful tool for characterizing vulnerable sites, and can
be used to estimate peak pesticide water concentrations from
infrequent, large rain events. EPA's computer models use detailed
information on soil properties, crop characteristics, and weather
patterns to estimate water concentrations in vulnerable locations where
the pesticide could be used according to its label (69 FR 30042, 30058-
30065 (May 26, 2004)). These models calculate estimated water
concentrations of pesticides using laboratory data that describe how
fast the pesticide breaks down to other chemicals and how it moves in
the environment at these vulnerable locations. The modeling provides an
estimate of pesticide concentrations in ground and surface water.
Depending on the modeling algorithm (e.g., surface water modeling
scenarios), daily concentrations can be estimated continuously over
long periods of time, and for places that are of most interest for any
particular pesticide.
EPA relies on models it has developed for estimating pesticide
concentrations in both surface water and ground water. Typically EPA
uses a two-tiered approach to modeling pesticide concentrations in
surface and ground water. If the first tier model suggests that
pesticide levels in water may be unacceptably high, a more refined
model is used as a second tier assessment. The second tier model for
surface water is actually a combination of two models: The Pesticide
Root Zone Model (PRZM) and the Exposure Analysis Model System (EXAMS).
The second tier model for ground water uses PRZM alone.
A detailed description of the models routinely used for exposure
assessment is available from the EPA OPP Water Models Web site: https://www.epa.gov/oppefed1/models/water/index.htm. These models provide a
means for EPA to estimate daily pesticide concentrations in surface
water sources of drinking water (a reservoir) using local soil, site,
hydrology, and weather characteristics along with pesticide application
and agricultural management practices, and pesticide environmental fate
and transport properties. Consistent with the recommendations of the
FIFRA SAP, EPA also considers regional percent cropped area factors
(PCA) which take into account the potential extent of cropped areas
that could be treated with pesticides in a particular area. The PRZM
and EXAMS models used by EPA were developed by EPA's Office of Research
and Development (ORD), and are used by many international pesticide
regulatory agencies to estimate pesticide exposure in surface water.
EPA's use of the percent cropped area factors and the Index Reservoir
scenario was reviewed and approved by the FIFRA SAP in 1999 and 1998,
respectively (Refs. 30, 31).
In modeling potential surface water concentrations, EPA attempts to
model areas of the country that are vulnerable to surface water
contamination rather than simply model ``typical'' concentrations
occurring across the nation. Consequently, EPA models exposures
occurring in small, highly agricultural watersheds in different growing
areas throughout the country, over a 30-year period. The scenarios are
designed to capture residue levels in drinking water from reservoirs
with small watersheds with a large percentage of land use in
agricultural production. EPA's models take into account that pesticide
residues in water fluctuate daily, seasonally, and yearly as a result
of the timing of pesticide applications, the vulnerability of the water
supply to pesticide loading through runoff, spray drift and/or
leaching, and changes in the weather. Concentrations are also affected
by the method of application, the location and characteristics of the
sites where a pesticide is used, the climate, and the type and degree
of pest pressure.
EPA uses the output of daily concentration values from tier two
modeling as an input to DEEM-FCID, which combines water concentrations
with drinking water consumption information in the daily diet to
generate a distribution of exposures from consumption of drinking water
contaminated with pesticides. These results are then used to calculate
a probabilistic assessment of the aggregate human exposure and risk
from residues in food and drinking water.
3. Aggregate Exposure Analyses. Using probabilistic analyses, EPA
combines the national food exposures with the exposures derived for
individual region and crop-specific drinking water scenarios to derive
estimates of aggregate exposure. Although food is distributed
nationally, and exposures to pesticide residues are therefore not
expected to vary substantially throughout the country, drinking water
is locally derived and consumed and there can be significant variations
in pesticide levels in local watersheds due to geographic, climatic,
and other factors. To be protective of all population subgroups, EPA
uses modeled estimates from vulnerable watersheds in calculating
aggregate exposure.
EPA's standard acute dietary exposure assessment calculates total
dietary exposure over a 24-hour period; that is consumption over 24
hours is summed and no account is taken of the fact that eating and
drinking occasions may spread out exposures over a day. This total
daily exposure generally provides reasonable estimates of the risks
from acute dietary exposures, given the nature of most chemical
endpoints. Due to the rapid recovery associated with carbofuran
toxicity (AChE inhibition), 24-hour exposure periods may or may not be
appropriate. To the extent that a day's eating or drinking occasions
leading to high total daily exposure might be found close together in
time, or to occur from a single eating event, minimal AChE recovery
would occur between eating occasions (i.e., exposure events). In that
case, the ``24-hour sum'' approach, which sums eating events over a 24-
hour period, would provide reasonable estimates of risk from food
[[Page 59615]]
and drinking water. Conversely, to the extent that eating occasions
leading to high total daily exposures are widely separated in time
(within one day) such that substantial AChE recovery occurs between
eating occasions, then the estimated risks under any 24-hour sum
approach may be overstated. In that case, a more sophisticated
approach--one that accounts for intra-day eating and drinking patterns
and the recovery of AChE between exposure events--may be more
appropriate. This approach is referred to as the ``Eating Occasions
Analysis'' and it takes into account the fact that the toxicological
effect of a first dose may be reduced or tempered prior to a second (or
subsequent) dose.
Thus, rather than treating a full day's exposure as a one-time
``bolus'' dose, as is typically done in the Agency's assessments, the
Eating Occasion analysis uses the actual time of eating or drinking
occasion, and amounts consumed as reported by individuals to the USDA
CSFII. The actual CSFII-recorded time of each eating event is used to
``separate out'' the exposures due to each eating occasion; in doing
so, this ``separation'' allows the Agency to distinguish between each
intake event and account for the fact that at least some partial
recovery of AChE inhibition attributable to the first (earlier)
exposure occurs before the second exposure event. For chemicals for
which the toxic effect is rapidly reversible, the time between two (or
more) exposure events permits partial to full recovery from the toxic
effect from the first exposure and it is this ``partial recovery'' that
is specifically accounted for by the Eating Occasion Analysis. More
specifically, an estimated ``persisting dose'' from the first exposure
event is added to the second exposure event to account for the partial
recovery of AChE inhibition that occurs over the time between the first
and second exposures. The `persisting dose' terminology, and this
general approach were originally suggested by the FIFRA SAP in the
context of assessing AChE inhibition from cumulative exposures to OP
pesticides (Ref. 33).
C. Selection of Acute Dietary Exposure Level of Concern
Because probabilistic assessments generally are based on a
realistic range of residue values to which the population may be
exposed, EPA's starting point for estimating exposure and risk for such
aggregate assessments is the 99.9th percentile of the population under
evaluation, which represents one person out of every 1000 persons. When
using a probabilistic method of estimating acute dietary exposure, EPA
typically assumes that, when the 99.9th percentile of acute exposure is
equal to or less than the aPAD, the level of concern for acute risk has
not been exceeded. By contrast, where the analysis indicates that
estimated exposure at the 99.9th percentile exceeds the aPAD, EPA would
generally conduct one or more sensitivity analyses to determine the
extent to which the estimated exposures at the high-end percentiles may
be affected by unusually high food consumption or residue values. To
the extent that one or a few values seem to ``drive'' the exposure
estimates at the high end of exposure, EPA would consider whether these
values are reasonable and should be used as the primary basis for
regulatory decision making (Ref. 77).
V. Carbofuran Background and Regulatory History
A. Tolerance Reassessment and Pesticide Reregistration
In July 2006, EPA completed a refined acute probabilistic dietary
risk assessment for carbofuran as part of the tolerance reassessment
program under section 408(q) of the FFDCA and pesticide reregistration
under section 4 of FIFRA. The assessment was conducted using Dietary
Exposure Evaluation Model-Food Commodity Intake Database (DEEM-
FCIDTM, Version 200-2.02), which incorporates consumption
data from the United States Department of Agriculture's (USDA's)
Nationwide Continuing Surveys of Food Intake by Individuals (CSFII),
1994-1996 and 1998, as well as carbofuran monitoring data from USDA's
Pesticide Data Program \2\ (PDP), estimated percent crop treated
information, and processing/cooking factors, where applicable. The
assessment was conducted applying an additional 500-fold safety factor
that included a 5X children's safety factor, pursuant to section
408(b)(2)(C). That refined assessment showed acute dietary risks from
carbofuran residues in food significantly above EPA's level of concern
(Ref. 14). Based in part on the results of that assessment, EPA
concluded that carbofuran failed to meet the revised safety standard in
FFDCA section 408(b) and the standard for FIFRA reregistration.\3\
---------------------------------------------------------------------------
\2\ USDA's Pesticide Data Program monitors for pesticides in
certain foods at the distribution points just before release to
supermarkets and grocery stores.
\3\ Although not relevant to this proceeding, in addition to
determining that use of carbofuran resulted in unacceptable dietary
risks, EPA concluded that use of carbofuran did not meet the
standard for FIFRA registration based on unacceptable occupational
and ecological risks.
---------------------------------------------------------------------------
The tolerance reassessment and FIFRA reregistration process for
carbofuran contained numerous opportunities for public participation.
These included public comment periods on the preliminary ecological
risk assessment (June-August 2005), the preliminary human health risk
assessment (September-November 2005), the revised combined risk
assessment (March-May 2006), and the interim Registration Eligibility
Document (RED) (August-November 2006). EPA received over 200 comments
(plus a letter campaign supporting carbofuran with 2,896 signatories)
to the 2006 RED. FMC submitted extensive comments throughout the
process (including, but not limited to, a comment of 62 pages plus 13
attachments totaling over 900 pages on August 23, 2005, a letter with
20 attachments on November 11, 2005, 46 pages of comments on January
26, 2006, 78 pages of comments on February 17, 2006, a 15-page letter
with 8 attachments on May 22, 2006, over 200 pages on May 24, 2006, and
other submissions. Following issuance of the RED in August 2006, FMC
stated that they would be submitting new data to refute EPA's
ecological and human health risk concerns, as well as EPA's benefits
assessments. Twenty-three submissions with studies and analyses were
submitted in 2007, all of which EPA reviewed. FMC submitted 175 pages
of comments to the proposed tolerance revocations jointly with the NPC,
NCGA, NCC, and NSA on 9/29/09. The Agency has also met numerous times
with FMC, growers, and other stakeholders regarding carbofuran.
One particular aspect of the risk assessment process that involved
substantial public participation opportunities was EPA's review of the
human toxicology studies performed with carbofuran. In making a
determination on whether these studies met the standards of the Human
Research rule, EPA, as required, sought the advice of the HSRB. The
HSRB review process includes the opportunity for the public both to
submit written comments and to make an oral presentation to the HSRB.
FMC gave both written and oral comments at the HSRB meeting, which was
held May 2-4, 2006. FMC also submitted written comments on the final
HSRB report on the meeting.
[[Page 59616]]
B. Draft Notice of Intent to Cancel Carbofuran Registrations
In January 2008, EPA published a draft Notice of Intent to Cancel
(NOIC) all carbofuran registrations, based in part on carbofuran's
dietary risks. As mandated by FIFRA, EPA solicited comments from the
FIFRA Scientific Advisory Panel (SAP) on its draft NOIC.\4\ As part of
that process, EPA presented its dietary risk assessment of carbofuran
to the FIFRA SAP, and requested comment on key issues in the risk
assessment: The Agency's approach to selecting the point of departure
and the children's safety factor. FMC and the remaining Petitioners
participated in this meeting, making substantial presentations to the
SAP. As described in the proposal, the Agency believes that the Panel's
responses unambiguously support the Agency's approach with regard to
carbofuran's hazard identification and hazard characterization (73 FR
44875 (July 31, 2008)). In addition, EPA believes that, on balance, the
application of a 4X children's safety factor is consistent with the
SAP's advice. Additional detail on the SAP's advice and EPA's responses
can be found at Ref. 83.
---------------------------------------------------------------------------
\4\ The draft NOIC was based on all of carbofuran's combined
risks--dietary, occupational, and ecological. Because some non-food
use registrations remain, EPA anticipates issuing the NOIC
subsequent to undertaking the activities required to revoke the
carbofuran tolerances to cancel these remaining uses.
---------------------------------------------------------------------------
C. Proposed Revocation of Carbofuran Tolerances
Having considered the comments from the SAP, EPA initiated the
process to revoke all carbofuran tolerances, publishing a proposed
revocation on July 31, 2008 (73 FR 44,864 (July 31, 2008) (FRL-8378-
8)). EPA proposed to revoke all of the existing tolerances for residues
of carbofuran on the grounds that aggregate exposure from all uses of
carbofuran fails to meet the FFDCA section 408 safety standard (Id).
Based on the contribution from food alone, EPA calculated dietary
exposures to carbofuran exceed EPA's level of concern for all of the
more sensitive subpopulations of infants and children. At the 99.9th
percentile, aggregate carbofuran dietary exposure from food and
drinking water from contaminated ground water was estimated to range
from 1100% of the aPAD for adults, to greater than 10,000% of the aPAD
for infants, the population subgroup with the highest estimated dietary
exposure (Ref. 12). Similarly, aggregate dietary exposures from food
and drinking water from surface water, based on contamination from use
on corn in Nebraska, ranged from 340% of the aPAD for adults, to 3,900%
aPAD for infants. EPA also determined that, based on actual residue
levels measured in food in commerce, individual children consuming
typical amounts of a single food item received unsafe levels of
carbofuran. For example, based on the level of residues detected on in
the food supply, a child between 3-5 years, who consumed \1/2\ cup of
cantaloupe, would receive a dose ranging between 180% and 7,200% of the
aPAD. Finally, the proposal discussed a number of sensitivity analyses
the Agency had calculated in order to further characterize the
potential risks to children. Every one of these sensitivity analyses
determined that estimated exposures significantly exceeded EPA's level
of concern for children.
EPA held a 60-day comment period on the proposed revocation rule.
In the proposed rule, EPA made clear that if any person had concerns
with EPA's proposed revocation, those concerns must be raised during
the comment period to be preserved. Specifically, EPA stated:
In addition to submitting comments in response to this proposal,
you may also submit an objection at the time of the final rule. If
you anticipate that you may wish to file objections to the final
rule, you must raise those issues in your comments on this proposal.
EPA will treat as waived, any issue not originally raised in
comments on this proposal. Similarly, if you fail to file an
objection to the final rule within the time period specified, you
will have waived the right to raise any issues resolved in the final
rule. After the specified time, issues resolved in the final rule
cannot be raised again in any subsequent proceedings on this rule.
(73 FR at 44865).
D. Petitioners' Comments on the Proposed Rule
The comment period for the proposed rule clos